[go: up one dir, main page]

EP2499146A1 - Tricyclic pyrazol amine derivatives - Google Patents

Tricyclic pyrazol amine derivatives

Info

Publication number
EP2499146A1
EP2499146A1 EP10775841A EP10775841A EP2499146A1 EP 2499146 A1 EP2499146 A1 EP 2499146A1 EP 10775841 A EP10775841 A EP 10775841A EP 10775841 A EP10775841 A EP 10775841A EP 2499146 A1 EP2499146 A1 EP 2499146A1
Authority
EP
European Patent Office
Prior art keywords
het
denotes
ethyl
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10775841A
Other languages
German (de)
French (fr)
Other versions
EP2499146B1 (en
Inventor
Pascale Gaillard
Isabelle Jeanclaude-Etter
Vincent Pomel
Eric Sebille
Seenisamy Jeyaprakashnarayanan
Mathilde Muzerelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono SA filed Critical Merck Serono SA
Priority to EP10775841.9A priority Critical patent/EP2499146B1/en
Publication of EP2499146A1 publication Critical patent/EP2499146A1/en
Application granted granted Critical
Publication of EP2499146B1 publication Critical patent/EP2499146B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Definitions

  • the invention relates to compounds of formula (I) and related formulae, their use as medicament and their use for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other diseases like cancers.
  • Phosphoinositide 3-kinases have a critical signalling role in cell proliferation, cell survival, vascularization, membrane trafficking, glucose transport, neurite outgrowth, membrane ruffling, superoxide production, actin reorganization and chemotaxis (Cantley, 2000, Science, 296, 1655-1657).
  • PI3K is given to a family of lipid kinases which, in mammals, consists in eight identified PI3Ks that are divided into three sub-families according to their structure and their substrate specificity.
  • Class I group of PI3Ks consists in two sub-groups, Class IA and Class IB.
  • Class IA are a family of heterodimeric lipid kinases consisting in a 85 kDa regulatory unit (responsible for protein -protein interactions via the interaction of Src homology 2 (SH2) domain with phosphotyrosine residues of other proteins) and a catalytic sub-unit of 1 10kDa that generate second messenger signals downstream of tyrosine kinases, thereby controlling cell metabolism, growth, proliferation, differentiation, motility and survival.
  • Three catalytic forms p1 10a, p1 10 ⁇ and p1 10 ⁇
  • five regulatory isoforms ⁇ 85 ⁇ , ⁇ 85 ⁇ , ⁇ 55 ⁇ , p55a and p50a
  • Class IB are stimulated by G protein ⁇ sub-units of heterodimeric G proteins.
  • the only characterized member of Class IB is ⁇ 3 ⁇ ( ⁇ 1 10 ⁇ catalytic sub-unit complex with a 101 -kDa regulatory protein, p101 ).
  • Class 1A PI3Ks comprises ⁇ , ⁇ and ⁇ isoforms, which are approximately of 1 10 kDa and characterized by the presence of a C-terminal C2 domain.
  • Class III PI3Ks includes the phosphatidylinositol specific 3-kinases.
  • the evolutionary conserved isoforms p1 10a and ⁇ are ubiquitously expressed, while ⁇ and ⁇ are more specifically expressed in the haematopoetic cell system, smooth muscle cells, myocytes and endothelial cells (Vanhaesebroeck et al., 2001 , Annu. Rev. Biochem., 70, 535- 602). Their expression might also be regulated in an inducible manner depending on the cellular-, tissue type and stimuli as well as disease context.
  • PI3Ks are enzymes involved in phospholipid signalling and are activated in response to a variety of extra-cellular signals such as growth factors, mitogens, integrins (cell-cell interactions) hormones, cytokines, viruses and neurotransmitters and also by intra-cellular cross regulation by other signalling molecules (cross-talk, where the original signal can activate some parallel pathways that in a second step transmit signals to PI3Ks by intracellular signalling events), such as small GTPases, kinases or phosphatases for example.
  • extra-cellular signals such as growth factors, mitogens, integrins (cell-cell interactions) hormones, cytokines, viruses and neurotransmitters and also by intra-cellular cross regulation by other signalling molecules (cross-talk, where the original signal can activate some parallel pathways that in a second step transmit signals to PI3Ks by intracellular signalling events), such as small GTPases, kinases or phosphatases for example.
  • Phosphatidylinositol is the basic building block for the intracellular inositol lipids in eukaryotic cells, consisting of D-myo-inositol-1 -phosphate (InsI P) linked via its phosphate group to diacylglycerol.
  • the inositol head group of Ptdlns has five free hydroxy groups and three of these are found to be phosphorylated in cells in different combinations.
  • Ptdlns and its phosphorylated derivatives are collectively referred as inositol phospholipids or phosphoinositides (Pis). Eight PI species have been documented in eukaryotic cells
  • Pis all reside in membranes and are substrates for kinases, phosphatases and lipases.
  • PI3Ks phosphorylate the 3-hydroxyl group of the inositol ring in three different substrates: phosphatidylinositol (Ptdlns), phosphatidylinositol-4-phosphate (PI(4)P) and phosphatidylinositol-4,5-biphosphate (PI(4,5)P2), respectively generating three lipid products, namely phosphatidylinositol 3-monophosphate (PI(3)P), phosphatidylinositol 3,4- bisphosphate (PI(3,4)P2) and phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3.
  • Ptdlns phosphatidylinositol
  • P(4)P phosphatidylinositol-4-phosphate
  • PI(4,5)P2 phosphatidylinositol-4,5-biphosphate
  • Class I PI3Ks The preferred substrate for Class I PI3Ks is PI(4,5)P2.
  • Class II PIKs have a strong prefererence for Ptdlns as substrate over PI(4)P and PI(4,5)P2.
  • Class III PI3Ks can only use Ptdlns as substrate in vivo and are likely to be responsible for the generation of most PI(3)P in cells (Vanhaesebroeck et al., 2001 , above).
  • the phosphoinositides intracellular signalling pathway begins with the binding of a signalling molecule (extracellular ligands, stimuli, receptor dimidiation, transactivation by heterologous receptor (e.g. receptor tyrosine kinase) to a G-protein linked transmembrane receptor integrated into the plasma membrane resulting in the activation of PI3Ks.
  • a signalling molecule extracellular ligands, stimuli, receptor dimidiation, transactivation by heterologous receptor (e.g. receptor tyrosine kinase) to a G-protein linked transmembrane receptor integrated into the plasma membrane resulting in the activation of PI3Ks.
  • PI3Ks convert the membrane phospholipid PI(4,5)P2 into PI(3,4,5)P3 which in turn can be further converted into another 3' phosphorylated form of phosphoinositides by 5'-specific phosphoinositide phosphatases, thus PI3K enzymatic activity results either directly or indirectly in the generation of two 3'-phosphoinositide sub-types that function as second messengers in intra-cellular signal transduction (Toker et al., 2002, Cell Mol. Life Sci. 59(5) 761 -79).
  • the second messengers of phosphorylated products of Ptdlns is involved in a variety of signal transduction pathways, including those essential to cell proliferation, cell differentiation, cell growth, cell size, cell survival, apoptosis, adhesion, cell motility, cell migration, chemotaxis, invasion, cytoskeletal rearrangement, cell shape changes, vesicle trafficking and metabolic pathway (Stein, 2000, Mol. Med. Today 6(9) 347-57).
  • Chemotaxis the directed movement of cells toward a concentration gradient of chemical attractants, also called chemokines is involved in many important diseases such as inflammation/auto- immunity, neurodegeneration, angiogenesis, invasion/metastasis and wound healing
  • PI3-kinase activation is therefore believed to be involved in a range of cellular responses including cell growth, differentiation, migration and apoptosis (Parker et al., 1995, Current Biology, 5, 577-99; Yao et al., 1995, Science, 267, 2003-05).
  • Class I PI3Ks e.g. Class IB isoform ⁇ 3 ⁇
  • Class IB isoform ⁇ 3 ⁇ are dual-specific kinase enzymes, i.e. they display both lipid kinase activity (phosphorylation of phospho-inositides) as well as protein kinase activity, as they are able to induce the phosphorylation of other protein as substrates, including auto-phosphorylation as intramolecular regulatory mechanism.
  • PI3Ks appear to be involved in a number of aspects of leukocyte activation.
  • a p85- associated PI3-kinase activity has been shown to physically associate with the cytoplasmic domain of CD28, which is an important co-stimulatory molecule for the activation of T-cells in response to antigen.
  • CD28 interleukin-2
  • T cell growth factor Fraser et al., 1991 , Science, 251 , 313-16.
  • Mutation of CD28 such that it can no longer interact with PI3-kinase leads to a failure to initiate IL-2 production, suggesting a critical role for PI3-kinase in T cell activation.
  • PI3Ks Cellular processes in which PI3Ks play an essential role include suppression of apoptosis, reorganization of the actin skeleton, cardiac myocyte growth, glycogen synthase stimulation by insulin, TNFa-mediated neutrophil priming and superoxide generation, and leukocyte migration and adhesion to endothelial cells.
  • ⁇ 3 ⁇ relays inflammatory signals through various G(i)- coupled receptors (Laffargue et al., 2002, Immunity 16(3) 441 -51 ) and its central to mast cell function, stimuli in context of leukocytes, immunology includes cytokines, chemokines, adenosines, antibodies, integrins, aggregation factors, growth factors, viruses or hormones for example (Lawlor et al., 2001 , J. Cell. Sci., 1 14 (Pt 16) 2903-10).
  • Two compounds, LY294002 and Wortmannin (cf.hereinafter) have been widely used as PI3- kinase inhibitors. These compounds are non-specific PI3K inhibitors, as they do not distinguish among the four members of Class I PI3-kinases.
  • IC50 values of Wortmannin against each of the various Class I PI3-kinases are in the range of 1 -10 nM and IC50 values for LY294002 against each of these PI3-kinases are about 15-20 ⁇ (Fruman et al., 1998, Ann. Rev. Biochem., 67, 481 -507), also 5-10 ⁇ on CK2 protein kinase and some inhibitory activity on phospholipases.
  • Wortmannin is a fungal metabolite which irreversibly inhibits PI3K activity by binding covalently to the catalytic domain of this enzyme. Inhibition of PI3K activity by wortmannin eliminates the subsequent cellular response to the extracellular factor (Thelen et al., 1994, Proc. Natl. Acad. Sci. USA, 91 , 4960-64). Experiments with wortmannin, show that PI3K activity in cells of hematopoietic lineage, particularly neutrophils, monocytes, and other types of leukocytes, is involved in many of the non-memory immune response associated with acute and chronic inflammation.
  • PI3K inhibitors for example, LY294002
  • cytotoxic agents e.g. paclitaxel
  • p1 10 ⁇ is expressed predominantly in cells of hemopoeitic origin such as leukocytes.
  • PI3K8-null mice To assess the role of the delta isoform of the p1 10 catalytic subunit of PI3Ks, PI3K8-null mice have been developed (Jou et al., 2002, Molecular and Cellular biology, 22(4), 8580-8591 ) and their specific immunological phenotype has been well characterized (Vanhaesebroeck et al., 2005, Trends in Biochemical Sciences, 30(4), 194-204).
  • Mast cells have emerged as a unique immune cell that could participate in a variety of inflammatory diseases in the nervous system (e.g. multiple sclerosis), skin, joints as well as cardiopulmonary, intestinal and urinary systems (Theoharides et al., 2004, J. of
  • PI3K pathway in some widely spread diseases stresses the need to develop inhibitors, including selective inhibitors, of PI3K isozymes, in order that the functions of each isozyme can be better characterized.
  • PI3K inhibitors have been developed: thiazole derivatives (WO 2005/021519; and WO 04/078754), thiazolidine derivatives (WO 2004/007491 and WO 2004/056820) and
  • the present invention provides new tricyclic pyrazol derivatives and their used as Pi3K modulators.
  • compounds of Formula (I) which are suitable for the treatment and/or prevention of disorders related to phosphoinositide-3- kinases, PI3Ks, such as PI3K alpha or PI3K gamma or PI3K delta or PI3K beta.
  • thichromane compounds which are able to modulate, especially inhibit the activity or function of phosphoinositide-3-kinases, PI3Ks in disease states in mammals, especially in humans.
  • disorders selected from auto-immune, inflammatory disorders, cardiovascular diseases, neurodegenerative disorders, bacterial and viral infections, allergy, asthma, pancreatitis, multi-organ failure, kidney diseases, platelet aggregation, cancer,
  • the present invention provides compounds of Formula (I) which are selective of the delta isoform of PI3K over the other isoforms.
  • kit or a set comprising at least one compound of Formula (I), preferably in combination with immunomodulating agents.
  • the kit consists of separate packs of:
  • the present invention provides compounds of Formula ( )
  • X 2 , X5 are independently from one another nitrogen or carbon atoms
  • U denotes an aromatic 6-membered ring having optionally 1 , 2 or 3 nitrogen atoms, including X 5 , or an unsaturated or aromatic 5-membered ring having 1 to 3 heteroatoms selected from N, S or O, including the meaning of X 5 ,
  • Z denotes an unsaturated or aromatic 5-membered heterocyclic ring having 2 nitrogen atoms, including the meaning of X 2 .
  • T denotes S, SO or SO ' : 2
  • R 1 denotes H, A, Hal, CN, N0 2 , N(R 6 ) 2 , OR 6 , Ar, Het, Y, -NR 6 COR 6 , CON(R 6 ) 2 ,
  • NR 6 COAr NR 6 COHet, COHet, -NR 6 S0 2 R 6 , C0 2 R 6 , including C0 2 Y,
  • R 2 denotes H, Ar, Het, A, Cyc,
  • R 3 denotes H, Y,
  • R 4 denotes H, Y, (CH 2 ) n Ar, (CH 2 ) n Cyc, (CH 2 ) n Het, (CH 2 ) n OY, (CH 2 ) n NHY,
  • R 5 denotes H, Y or Ar, when R 5 is Y and r is 2, two R 5 groups may be linked
  • R 6 is H, A, Cyc or Ar.
  • u is 0, 1 , 2, 3, or 4, preferably 0 or 1 ,
  • r 0, 1 or 2
  • Ar denotes a monocyclic or fused bicyclic, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF 3 , N0 2 , CN, perfluoroalkyl, A, OR 6 , N(R 6 ) 2 , COR 6 , -C0 2 R 6 , CON(R 6 ) 2 , COHet, -NHCOR 6 , -NHS0 2 A, -NHS0 2 Ar, - NHS0 2 -N(R 6 ) 2 , N(H) 1-q A q COR 6 , N(H) 1-q A q S0 2 -N(H) 2-m (A) m , -N(H) 1-q A q CON(H) 2 .
  • OR 6 -(CH 2 ) n -N(R 6 )S0 2 A, -(CH 2 ) n -N(R 6 )S0 2 R 6 , Het 2 , -(CH 2 ) n -Het 2 , -(CHY) n - Het 2 ; denotes a monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 , 2, 3 or 4 N, O and/or S atoms and eventually comprising a S0 2 or a CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF 3 , N0 2 , CN, perfluoroalkyl, A, OR 6 , N(R 6 ) 2 , COR 6 , -C0 2 R 6 , CON(R 6 ) 2 , -NHCOR 6 , -NHS0 2 A, -NHS0
  • Cyc denotes a saturated or unsaturated carbocyclic ring having 3 to 8 carbon atoms, which is unsubstituted, mono-substituted, di-substituted or tri- substituted by Hal, OCF 3 , N0 2 , CN, perfluoroalkyi, A, OR 6 , N(R 6 ) 2 , COR 6 , CON(R 6 ) 2 , -NHCOR 6 , -NHS0 2 A, -NHS0 2 R 6 , -NHS0 2 -N(H) 2-m (A) m , N(H) 1- q A q COR 6 , N(H) 1-q A q S0 2 -N(H) 2-m (A) m , -N(H) 1-q A q CON(H) 2-m (A) m , -COOR 6 , - S0 2 A, -S0 2 Ar, -S0 2 N(H) 2-m
  • Y denotes a branched or linear alkyl having 1 to 8 carbon atoms.
  • Hal denotes F, CI, Br or I, q is O or l , m is 0, 1 or 2, n is 1 , 2, 3, or 4 and pharmaceutically acceptable derivatives, solvates, tautomers, salts, hydrates and stereoisomers thereof, including mixtures thereof in all ratios.
  • U is an aromatic 6-membered ring having optionally 1 or 2 nitrogen atoms, including the meaning of X 5 ,
  • X 5 is a carbon atom
  • X 2 is a carbon atom
  • X 2 and X 5 are carbon atoms
  • U is an aromatic 6-membered ring having optionally 1 or 2 nitrogen atoms
  • Z is an unsaturated or aromatic 5-membered heterocyclic ring having 2 nitrogen atoms.
  • X-i is CR 3 wherein R 3 is as defined above.
  • T is S0 2 .
  • X 2 and X 5 are carbon atoms
  • U is an aromatic 6-membered ring having optionally 1 nitrogen atoms
  • Z is an unsaturated or aromatic 5-membered heterocyclic ring having 2 nitrogen atoms
  • T is S0 2
  • Xi is CR 3 wherein R 3 is as defined above.
  • R 1 , R 2 , R 3 , R 4 , T are as defined above.
  • U 1 , U 2 , U 3 , and U 4 denote CR 1 or one or two of U 1 , U 2 , U 3 and U 4 are independently N, and the remaining are CR 1 , or one of U 1 and U 4 is S, U 2 -U 3 form together a group CR 1 and the remaining is CR 1 , or one of U 1 and U 4 is S, U 2 -U 3 form together a group CR 1 and the remaining is N, or denotes the following group
  • U 1 denotes N
  • U 2 -U 3 form together a group CR 1
  • U 4 is CR 1
  • X 5 is N
  • Z, X 1 , X 2 , R 2 , T, are as above defined.
  • R 2 is Ar
  • R 2 is Het or Cyc.
  • R 2 contains 1 or 2 chiral centers.
  • the present invention provides compounds of Formula (la * )
  • X ⁇ X 2 , X 5 , R 4 , T, R 1 , Z, U, r and u are as defined above and
  • M denotes a saturated or unsaturated 4-, 5-, 6-, 7- or 8-membered ring optinally containing 1 to 3 heteroatoms selected from N, S and O,
  • R' denotes Hal, OCF 3 , N0 2 , CN, perfluoroalkyl, A, OR 6 , N(R 6 ) 2 , COR 6 , -C0 2 R 6 ,
  • the invention provides compounds of Formula (I):
  • R 2 denotes H, Ar, Het, A, Cyc
  • R 4 denotes H, Hal, Y, (CH 2 ) n Ar, (CH 2 ) n Cyc, (CH 2 ) n Het, (CH 2 ) n OY, (CH 2 ) n NHY, (CH 2 ) n NH 2 ,
  • R 3 denotes H, Y,
  • R 5 denotes H, Y or Ar, when R 5 is Y and r is 2, two R 5 groups may be linked together to provide with the morpholine group a bridged system.
  • R 1 denotes H, A, Hal, CN, N0 2 , N(R 6 ) 2 , OR 6 , Ar, Het, Y, -NR 6 COR 6 , CON(R 6 ) 2 , - NR 6 COAr, NR 6 COHet, COHet, -NR 6 S0 2 R 6 , C0 2 R 6 , including C0 2 Y,
  • T denotes S, SO or S0 2 .
  • r denotes 0, 1 or 2
  • Ar denotes a monocyclic or fused bicyclic, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF 3 , N0 2 , CN, perfluoroalkyl, A, OR 6 , N(R 6 ) 2 , COR 6 , -C0 2 R 6 , CON(R 6 ) 2 , COHet, -NHCOR 6 , -NHS0 2 A, -NHS0 2 Ar, - NHS0 2 -N(R 6 ) 2 , N(H) 1-q A q COR 6 , N(H) 1-q A q S0 2 -N(H) 2-m (A) m , -N(H) 1-q A q CON(H) m(A) m , -S0 2 A, -S0 2 Ar, -S0
  • Het denotes a monocyclic or bicyclic saturated, unsaturated or aromatic
  • heterocyclic ring having 1 , 2, 3 or 4 N, O and/or S atoms which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF N0 2 , CN, perfluoroalkyl, A, OR 6 , N(R 6 ) 2 , COR 6 , -C0 2 R 6 , CON(R 6 ) 2 , -NHCOR 1 -NHS0 2 A, -NHS0 2 R 6 , -NHS0 2 -N(H) 2-m (A) m , N(H) 1-q A q COR 6 , N(H) 1-q A q S0 2 - N(H) 2-m (A) m , -N(H) 1-q A q CON(H) 2-m (A) m , -S0 2 A, -S0 2 Ar, -S0 2 N(H) 2-m (A) m , CO
  • Hal denotes F, CI, Br or I, is 0 or 1 .
  • m 0, 1 or 2
  • n is 1 , 2, 3, or 4
  • the present invention provides compounds of Formula (I) wherein U 1 , U 2 , U 3 , and U 4 denote CR 1 wherein 2 or 3 of the R 1 groups are H, preferably 3 R 1 goups are H.
  • the present invention provides compounds of Formula (I) wherein U 1 , U 2 , U 3 , and U 4 denote CH.
  • the present invention provides compounds of Formula (I) wherein one of U 1 and U 4 is S, U 2 -U 3 form together a group CR 1 and the remaining is CR 1 .
  • the present invention provides compounds of Formula
  • R 2 denotes H, Ar, Het, A, Cyc,
  • R 3 , R 4 denote independantly from one another H, Y, (CH 2 ) n Ar, (CH 2 ) n Cyc, (CH 2 ) n Het
  • R 5 denotes H, Y or Ar
  • U 1 , U 2 , U 3 , and U 4 denote CR 1 or one or two of U 1 , U 2 , U 3 and U 4 are independently
  • R 1 denotes H, A, Hal, CN, N0 2 , N(R 6 ) 2 , OR 6 , Ar, Het, Y, -NR 6 COR 6 , CON(R 6 ) 2 T denotes S, - SO or -S0 2 .
  • r denotes 0, 1 or 2
  • Ar denotes a monocyclic or fused bicyclic, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF 3 , N0 2 , CN, perfluoroalkyl, A, OR 6 , N(R 6 ) 2 , COR 6 , -C0 2 R 6 , CON(R 6 ) 2 , COHet, -NHCOR 6 , -NHS0 2 A, -NHS0 2 Ar, - NHS0 2 -N(R 6 ) 2 , N(H) 1-q A q COR 6 , N(H) 1-q A q S0 2 -N(H) 2-m (A) m , -N(H) 1-q A q CON(H) 2- m (A) m , -S0 2 A, -S0 2 Ar, -S
  • Het denotes a monocyclic or bicyclic saturated, unsaturated or aromatic
  • heterocyclic ring having 1 , 2, 3 or 4 N, O and/or S atoms which is
  • Cyc denotes a saturated carbocyclic ring having 1 to 8 carbon atoms, which is unsubstituted, mono-substituted, di-substituted or tri-substituted by Hal, OCF 3 N0 2 , CN, perfluoroalkyl, A, OR 6 , N(R 6 ) 2 , COR 6 , CON(R 6 ) 2 , -NHCOR 6 , - NHS0 2 A, -NHS0 2 R 6 , -NHS0 2 -N(H) 2-m (A) m , N(H) 1-q A q COR 6 , N(H) 1-q A q S0 2 - N(H) 2-m (A) m , -N(H) 1-q A q CON(H) 2-m (A) m , -COOR 6 , -S0 2 A, -S0 2 Ar, -S0 2 N(H) 2- m (A)
  • Y denotes a branched or linear alkyl having 1 to 8 carbon atoms.
  • R 6 is H, A, Cyc or Ar.
  • Hal denotes F, CI, Br or I, q is O or l , m is 0, 1 or 2, n is 1 , 2, 3, or 4 and pharmaceutically acceptable derivatives, solvates, tautomers, salts, hydrates and stereo isomers thereof, including mixtures thereof in all ratios.
  • R 1 , R 2 , R 5 , r and T are as above defined, and pharmaceutically acceptable derivatives, solvates, tautomers, salts, hydrates and stereoisomers thereof, including mixtures thereof in all ratios.
  • the invention relates to compounds of formula (A2)
  • R 1 , R 2 , R 5 and r are as above defined, and pharmaceutically acceptable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.
  • the invention relates to the compounds of formula (A3),
  • Q is Ar, Cyc, alkyl having 1 to 8 carbon atoms, or Het, and wherein R 1 , R 3 , R 4 , are as above defined,
  • the invention relates to the compounds of formula (A4),
  • R 1 , R 3 , R 4 , R 5 , T and r are as above defined, and wherein R 7a and R 7b are independently from one another selected from H, Y, A, Hal, N0 2 , CN, OR 6 , N(R 6 ) 2 , COR 6 , - C0 2 R 6 , CON(R 6 ) 2 , COHet, -NHCOA, -NHS0 2 A, -NHS0 2 -N(R 6 ) 2 , N(H) 1-q A q COA, N(H) 1- q A q S0 2 -N(H) 2-m (A) m , -N(H) 1-q A q CON(H) 2-m (A) m , -S0 2 A, -S0 2 N(H) 2-m (A) m , -S0 2 Het, -(CH 2 ) n - N(R 6 ) 2 , -(CH 2 )
  • the invention relates to compounds of Formula (A5):
  • R 1 , R 2 , R 3 , R 4 , R 5 , T and r are as above defined and wherein W is H, Y, Q, - (CH 2 ) P Q, -(CH 2 )pN(R 6 ) 2j -(CH 2 ) P OR 6 ,
  • p is 1 , 2 or 3 and Q is Ar, Cyc, or Het;
  • the present invention provides compounds of Formula (A6) or (A7):
  • R 10 denotes perfluoroalkyl, A, COR 6 , -C0 2 R 6 , CON(R 6 ) 2 , COHet, -S0 2 A, -S0 2 Ar, - S0 2 N(H) 2-m (A) m , -S0 2 Het, -(CH 2 ) n -N(R 6 ) 2 , -(CH 2 ) n -OR 6 , -(CH 2 ) n -N(R 6 )S0 2 A, -(CH 2 ) n -
  • R 6 , Y, A, m, n, Het and Het 2 are as above defined.
  • R 10 denotes A, Het 2 , -(CH 2 ) n -Het 2 , or -(CHY) n -Het 2 .
  • R 10 denotes a branched or linear alkyl having 1 to 6 C-atoms, wherein one or more, preferably 1 to 3 H-atoms may be replaced by Hal, Ar, Het, Cyc, OR 6 , -CN, wherein R 6 is a linear or branched alkyl having 1 to 6 carbon atoms. and pharmaceutically acceptable derivatives, solvates, tautomers, salts, hydrates and stereoisomers thereof, including mixtures thereof in all ratios.
  • the compound B1 is excluded from the compounds of the invention.
  • Me refers to a methyl group
  • Et refers to an ethyl group
  • the formula (I), (I * ) and related formulae also encompasses mixtures of the compounds of the formula (I), ( ) and related Formulae, for example mixtures of two diastereomers or enantiomers, for example in the ratio 1 :1 , 1 :2, 1 :3, 1 :4, 1 :5, 1 :10, 1 :100 or 1 :1000.
  • AlkyI denotes a carbon chain having 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , or 12 carbon atoms.
  • AlkyI preferably denotes methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1 -, 2- or 3-methylbutyl, 1 ,1 -, 1 ,2- or 2,2-dimethylpropyl, 1 -ethylpropyl, hexyl, 1 -, 2-, 3- or 4-methylpentyl, 1 ,1 -, 1 ,2-, 1 ,3-, 2,2-, 2,3- or 3,3- dimethylbutyl, 1 - or 2-ethylbutyl, 1 -ethyl-1 -methylpropyl, 1 -ethyl-2-methylpropyl, 1 ,1 ,2- or 1 ,2,2-trimethylprop
  • Cycloalkylalkylene or "cycloalkylalylen group” denotes a carbon chain having 1 to 6 carbon atoms wherein 1 H atom is substituted by a cycloalkyl group.
  • Cycloalkylalkylene preferably denotes cyclopropylmethylene, cyclobutylmethylene, cyclopentylmethylene, cyclo- hexylmethylene or cycloheptylmethylene.
  • Perfluoroalkyl denotes an alkyl chain having 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms, and wherein all the hydrogen atoms are replaced by F atoms. Perfluoroalkyl more preferably denotes CF 3 . Hal preferably denotes F, CI or Br.
  • Amino or “amino group” denotes the group -NR'R" where each R', R" is independently hydrogen, Y, Ar, Het, Cyc or A. R and R , together with the nitrogen atom to which they are attached, can optionally form a Het group. R' and R", together with the nitrogen atom to which they are attached, preferrably form a 5-membered unsaturated or aromatic
  • heterocyclic ring having 1 , 2, 3, or 4, heteroatoms selected in the group of N, O, and S.
  • Ar preferably denotes a monocyclic or bicyclic, aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by F, CI, Br, CF 3 , OCF 3 , N0 2 , CN, A, OR 6 , N(H) 2-m (A) m , -CON(R 6 ) 2 , COHet, -NHCOA, C0 2 A, - S0 2 A, -S0 2 N(H) 2-m (A) m , -S0 2 Het, -(CH 2 ) n -N(R 6 )S0 2 A,
  • R a and R b denote independently from one another H, Hal, N0 2 , A, CN, N(R 6 ) 2 , - NR 6 COA , -NR 6 C0 2 A , -OR 6 , -C0 2 A, -CON(R 6 ) 2 , -COHet, -S0 2 N(H) 2-m (A) m , -NHS0 2 A, (CH 2 ) n -N(R 6 )S0 2 A, -S0 2 A, -S0 2 Het, Het, Ar, or Cyc,
  • R 6 , A, Ar, Het, Cyc and m are as above defined.
  • Examples of the preferred Ar groups are selected from the following groups:
  • Het preferably denotes monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 or 2 heteroatoms selected from N, O and S, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by alkyl having 1 to 8 carbon atoms, Hal, CF 3 , OCF 3 , N0 2 , CN, OR 6 , N(R 6 ) 2 , CON(R 6 ) 2 , -C0 2 A, -S0 2 A, -S0 2 N(H) 2-m (A) m , COHet, -S0 2 Het, - (CH 2 ) n -OR 6 , -(CH 2 ) n -N(R 6 ) 2 .
  • Het is preferably the group wherein h is 0, 1 or 2, preferably
  • R a and R b are as above defined.
  • R a and R b denote independently from one another one of the following groups: Y, H, Hal, N0 2 , CN, -(CH 2 ) n -NH-S0 2 Y, -0(CH 2 ) n -N(H) 2-m (Y) m , -NH(CH 2 ) n -N(H) 2-m (Y) m , - NH(CH 2 ) n -OH, -NH(CH 2 ) n -OY, -0-(CH 2 ) n -OH, -0-(CH 2 ) n -OY, OH, OY, -(CH 2 ) n -OY, -(CH 2 ) n - OH, -(CH 2 ) n -N(H) 2-m (Y) m , -NHCOY, -NHC0 2 Y, -CF 3 , Het 2 , -(CH 2 )
  • the group -(CH 2 ) n -Het 2 preferably denotes , wherein n is as above defined. Preferrably n is 2.
  • Y preferably denotes a branched or linear alkyl having 1 to 6 carbon atoms.
  • T preferably denotes SO or S0 2 .
  • Cyc preferably denotes a saturated carbocyclic ring having 1 to 8 carbon atoms, which is unsubstituted, mono-substituted, or di-substituted by alkyl having 1 to 8 carbon atoms, alkoxy having 1 to 8 carbon atoms, Hal, CF 3 , OCF 3 , N0 2 , CN, perfluoroalkyl, OH, NH 2 , COH, C0 2 H, CONH 2 , -(CH 2 ) n -OR 6 , whereby R 6 and n are as above defined.
  • Cyc denotes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and
  • R 3 and R 4 preferably denote H or Y.
  • both R 3 and R 4 denote H.
  • R 3 also denotes (CH 2 ) n Ar, (CH 2 ) n Cyc, (CH 2 ) n Het, (CH 2 ) n OY, (CH 2 ) n NHY, (CH 2 ) n NH 2 .
  • R 4 is preferably Y, (CH 2 ) n Ar, (CH 2 ) n Cyc, (CH 2 ) n Het, (CH 2 ) n OY, (CH 2 ) n NHY, (CH 2 ) n NH 2
  • R 1 preferably denotes H, OR 6 , Hal, CN, N0 2 , -(CH 2 ) n -N(R 6 ) 2 , -0(CH 2 ) n -N(R 6 ) 2 , -NR 6 -(CH 2 ) n - N(R 6 ) 2 , -NR 6 -(CH 2 ) n -OR 6 , -NR 6 -C0 2 R 6 , -NR 6 -COR 6 .
  • R 1 is H or Hal.
  • R 2 is preferably selected from H, a linear or branched CrC 6 -alkyl or one of the following groups:
  • R 6 denotes H or A.
  • the invention provides compounds of Formula (I) wherein R 5 is H.
  • the invention provides compounds of formula (I) wherein one of U 1 , U 2 , U 3 and U 4 is N and the remaining are CR 1 whereby R 1 is as above defined.
  • the invention provides compounds of formula (I) wherein R 2 denotes H, Y, Ar, Het or Cyc, R 3 and R 4 are both H.
  • the present invention provides compounds of Formula (I) wherein R 2 denotes H, Y, Ar, Het or Cyc, R 3 and R 4 are both H, T is S0 2 .
  • the present invention provides compounds of Formula (I) wherein R 2 denotes H, Y, Ar, Het or Cyc, R 3 and R 4 are both H, T is S0 2 , and Ui, U 2 , U 3 and U 4 are CR 1 .
  • the invention relates to compounds of Formula (I), (I * ) and related Formulae, selected from the following group.
  • the structures contain one or more stereogenic centers, the respective structure is depicted in an arbitrary absolute configuration.
  • These structures also include the respective structure having the opposite stereochemistry and the corresponding racemate:
  • the compounds according to the general Formula (I) may be obtained by several processes using both solution-phase and/or solid-phase chemistry protocols. Examples of synthetic pathways for the preparation of compounds according to the general Formula (I) are described herebelow. Optimum reaction conditions may vary with particular reactants or solvents used, but such conditions can be determined by the person skilled in the art, using routine optimization procedures.
  • R 5 , g, R 4 , R 2 , R 1 , T, U, Z, X-i , X 2 , X 5 , u and r are as above defined and wherein V denotes H or Y.
  • the compounds according to Formula (I) may be prepared following the synthetic pathways described in the general scheme 1.
  • compounds of Formula (I) may be prepared from the corresponding derivatives of Formula (lb), by one or two alkylation reaction with R 3 -X (and possibly R 4 -X) where X is a leaving group such as a halogen or a sulfonate group and wherein R 3 and R 4 are as defined above.
  • Preferred conditions consist in the treatment of compounds of Formula (lb) with a base such as NaH followed by addition of alkyl or benzyl halide in a suitable solvent such as THF at room temperature.
  • Compounds of Formula (lb) may be prepared from the corresponding derivatives of Formula (lib), wherein R 2 is as above defined and V denotes H or Y which is as defined above, either directly by reaction of compounds of Formula (lib) where V is Y with an amine, or via the hydrolysis of the ester (lib) into an acid wherein V is H and subsequent coupling with an amine.
  • V denotes H or Y which is as defined above
  • compounds of formula (lb) can be obtained using usual conditions for the formation of an amide starting from a carboxylic acid and an amine by using coupling agents such as DCC, DIC, EDC, HATU or via the formation of an acid chloride or an activated ester.
  • Preferred conditions consist in the treatment of compounds of Formula (lib) with a solution of propane phosphonic acid anhydride 50% in EtOAc followed with the addition of morpholine derivatives (D), wherein R 5 and r are as defined above, in the presence of a base such as triethylamine in a suitable solvent such as THF at room temperature.
  • Another preferred condition is the pre-treatment of amine derivative D with AICI 3 or AIMe 3 followed by the addition of compounds of formulae (lib) where V is an alkyl group in a suitable solvent such as DCM or THF at a temperature between 0°C to 50°C.
  • the corresponding carboxylic acid can be obtained by hydrolysis of the corresponding esters using reagents such as, but not limited to, LiOH, NaOH or KOH in solvents such water, alcohol, THF, dioxane, or mixture thereof.
  • Compounds (lib) may be prepared from compounds of Formula (I la) by alkylation reaction with R 2 -X wherein X is a halogen or a sulfonate group.
  • Preferred conditions consist in the treatment of compounds of formula (I la) with an alkyl halide in the presence of a base such as potassium carbonate, in a suitable solvent such as acetonitrile at a temperature between room temperature and 60°C.
  • An alternative pathway for the synthesis of compounds of Formula (lb) consists in alkylating compounds of Formula (la) with R 2 -X wherein X is a halogen or a sulfonate group.
  • Preferred conditions consist in the treatment of compounds of formula (la) with an alkyl halide in the presence of a base such as potassium carbonate in a suitable solvent such as acetonitrile at a temperature between room temperature and 60°C.
  • Compounds of Formula (la) may be prepared from the corresponding derivatives of Formula (I la), wherein R 2 and V are as defined above, either directly by reaction with a morpholine derivative D, or via the hydrolysis of the ester (lib) into an acid wherein V is H and
  • compounds of formula (la) can be obtained using usual conditions for the formation of an amide starting from a carboxylic acid and an amine by using coupling agent such as DCC, DIC, EDC, HATU or via the formation of an acid chloride or an activated ester.
  • Preferred conditions consist in the treatment of compounds of Formula (lib) with 50% propane phosphonic acid anhydride in EtOAc followed with the addition of morpholine derivative D, wherein R 5 and r are as defined above, in a suitable solvent such as THF, at room
  • Another preferred condition is the pre-treatment of amine derivative D with AICI 3 or AIMe 3 followed by the addition of compounds of formulae (lib) where V is an alkyl group in a suitable solvent such as DCM or THF at a temperature between 0°C to 50°C.
  • the corresponding carboxylic acid can be obtained by hydrolysis of esters using reagents such as, but not limited to, LiOH, NaOH or KOH in solvents such water, alcohol, THF, dioxane, or mixture thereof.
  • Compounds of Formula (lla) and Formula (lib) may be prepared from compounds of Formula (III) by cyclization with hydrazine, substituted hydrazines, and protected hydrazines, e.g. hydrazine having a PG group,wherein R 2 is as defined above, respectively (scheme 2).
  • Hydrazine derivatives VII may or may not be protected by a protecting group such as a Boc group.
  • Preferred conditions consist in the treatment of compounds (III) with hydrazine derivatives in a presence of an acid such as acetic acid in a suitable solvent such as methanol or ethanol at reflux.
  • Another preferred condition is the treatment of compounds (III) with Boc-hydrazine derivatives in a presence of an acid such as HCI in a suitable solvent such as ethanol at reflux.
  • Compounds of Formula (III) may be prepared from compounds of Formula (IV) by reaction with V-OCOCO-X, wherein V and X are as defined above, in the presence of a base.
  • the base is a metal alkoxide.
  • Preferred conditions consist in the treatment of compounds (IV) with butyl lithium and then V-OCOCO-X in a suitable solvent such as THF, MTBE or Toluene at a temperature between -78°C and room temperature.
  • V- OCOCO-X is the diethyl oxalate.
  • Other preferred conditions consists in the treatment of compounds (IV) with sodium ethoxide and then diethyloxalate in a suitable solvent such as toluene or MTBE at a temperature between 0°C and room temperature.
  • Compounds of Formulae (I), (la), (lb), (lla) and (lib) may be converted to alternative compounds of Formulae (I), (la), (lb), (lla) and (lib) respectively, using suitable
  • Preferred conditions consist in the treatment of compounds (V) by oxalyl chloride and by tin (IV) chloride in a suitable solvent such as dichloromethane at a temperature between 0°C and room temperature.
  • Other preferred conditions consist in the treatment of compounds (V) with polyphosphoric acid at a temperature ranging from 80°C to 120°C.
  • Compounds of formulae (IV) wherein Ui, denote N and U 2 , U 3 and U 4 denote CR 1 may be obtained either from commercial sources or following procedure described in Journal of Heterocyclic Chemistry, 37(2), 379-382; 2000.
  • Compounds of Formula (V), wherein Ui, U 2 , U 3 and U 4 are as defined as above, may be prepared from compounds of Formula (VI) by alkylation.
  • Preferred conditions consist in the treatment of compounds of formula (VI) by G 4 -CH 2 CH 2 CO-G 3, wherein G 4 is halogen and G 3 is OH or OY, whereby Y is as above defined, in the presence of a base such as potassium carbonate in a suitable solvent such as dimethylformamide at a temperature of 60°C.
  • Preferred conditions consist in the treatment of compounds of formulae (IX) with aryl halide, preferably iodine derivatives, in the presence of copper iodide and Cs 2 C0 3 in a suitable solvent such as DMSO at a temperature between 50°C and 100°C.
  • aryl halide preferably iodine derivatives
  • Compounds of formulae (Vila), wherein G 1 CHG 2 represents R 2 may be prepared from compounds of formulae (VIII) by a reduction reaction (scheme 4B).
  • Preferred conditions consist in the treatment of compounds of formulae (VIII) with sodium cyanoborohydride in a suitable solvent such as a mixture of acetic acid and water at a temperature between 0°C and RT.
  • Compounds of formulae (Vile) and (VI Id), wherein G 1 CHG 2 represents R 2 may be prepared from compounds of formulae (VIII) by reduction with hydrogen in the presence of suitable catalysts or ligands/catalysts. Appropriate choice of ligand and/or catalyst and/or protecting group can either favour the formation of (Vile) or the formation of (VI Id). The use of achiral conditions gives compounds of formulae (Vila).
  • preferred conditions consist in the treatment of compounds of formulae (VIII) with bis(cycloocat-1 ,5- dien)rhodium(l)tetrafluoroborate and one enantiomer of Josiphos ligand under a pressure of 30 bar of hydrogene in a suitable solvent such as MeOH at RT.
  • Preferred conditions for the alkylation are the treatment of compounds of formulae (lc) with sodium hydride in a suitable solvent such as THF followed by the addition of an alkyl halide at a temperature ranging from 0°C to 50°C.
  • Preferred conditions for the intramolecular cyclisation are the treatment of compounds of formulae (Xb) with a palladium source such as palladium acetate, a ligand such as triphenylphosphine and a base such as Cs 2 C0 3 in a suitable solvent such as toluene at a temperature ranging from 80°C to 1 10°C.
  • Compounds of formulae (lc) may either be prepared from derivatives of formulae (Xa) following palladium cataysed cyclisation reaction described above or by dealkylation of compounds of formulae (A) when R 4 is an alkyl ether protecting group such as a MOM group.
  • Preferred conditions for the cleavage of a MOM protecting group are the treatment of compounds of formulae (A) with a suitable acid such as HCI in a suitable solvent such as dioxane at a temperature of 100°C.
  • Compounds of formulae (Xb) may be prepared from derivatives of formulae (Xa) by treatment of compounds of formulae (Xa) with alkyl derivatives R 4 -X wherein X is a halogen or a sulfonate group and where R 4 is as above defined.
  • Preferred conditions for the alkylation are the treatment of compounds of formulae (lc) with sodium hydride in a suitable solvent such as THF followed by the addition of an alkyl halide at a temperature ranging from 0°C to 50°C
  • Compounds of formulae (Xa), where T is S0 2 may be prepared by reaction of compounds of formulae (XI) with sulfonylchloride derivatives. Preferred conditions are the treatment of compounds of formulae (XI) with sulfonyl chloride derivatives in a suitable solvent such as DCM in the presence of a base such as pyridine or TEA at RT.
  • Compounds of formulae (XI) may be prepared from compounds of formulae (XII) by a reduction reaction. Preferred conditions are the treatment of nitro derivatives (XII) with Pd/C 10% in a suitable solvent such as AcOEt under one atmosphere of hydrogen at RT.
  • Compounds (XII) may be prepared from compounds of formulae (XIII) by a coupling reaction with compounds of formulae R 2 -Y * wherein Y * is a boronic acid or boronic ester group.
  • Preferred conditions consist in the treatment of compounds of formulae (XIII) with an aromatic boronic acid in the presence of a base such as TEA and copper acetate, in a suitable solvent such as DCM at a temperature between RT and 60°C.
  • Compounds of formulae (lie) may be prepared from derivatives of formulae (XV) by a intramolecular cyclisation reaction.
  • Preferred conditions for the intramolecular cyclisation are the treatment of compounds of formulae (XV) with Cul in the presence or not of a ligand such as ⁇ /,/V-dimethylglycine in a suitable solvent such as DMSO at a temperature ranging from 100°C to 180°C.
  • Compounds of formulae (XV) may be prepared by nucleophilic substitution on derivatives of formulae (XVIc) with compounds of formulae E wherein T is a thiol group and U 2 , U 3 represents CR 1 .
  • Preferred conditions are the treatment of compounds of formulae (XVIc) wherein X are bromine atoms, R 2 represents an aryl or an heteroaryl and V respresents an ethyl group with a thiol derivative E in the presence of a base such as K 2 C0 3 in a suitable solvent such as ACN at a temperature ranging from RT to 90°C.
  • Compounds of formulae (XVIc) may be prepared from derivatives of formulae (XVIb) by an halogenation reaction.
  • Preferred conditions conditions are the treatment of compounds of formulae (XVIb) with a brominating agent such as phosphorus tribromide in a suitable solvent such as Et 2 0 at a temperature ranging from 0°C to RT.
  • Compounds of formulae (XVIb) may be prepared from derivatives of formulae (XVIa) by a reduction reaction. Preferred conditions are the treatment of compounds of formulae (XVIa) with a reductive agent such as sodium borohydride in a suitable solvent such as a mixture of THF and EtOH at a temperature between 0°C to RT.
  • a reductive agent such as sodium borohydride
  • a suitable solvent such as a mixture of THF and EtOH
  • Compounds of formulae (XVIa) may be prepared from derivatives of formulae (XVII) by a Vilsmeier-Haack reaction. Preferred conditions are the treatment of compounds of formulae (XVII) with phosphorus oxy bromide and DMF in a suitable solvent such as DCM at a temperature ranging from 50°C to 100°C.
  • Compounds (lid) may be prepared from compounds of formulae (lie) by reaction with R 2 -X wherein X is a halogen or a sulfonate group.
  • Preferred conditions consist in the treatment of compounds of formulae (lie) with an alkyl halide in the presence of Cul and PdOAc in a suitable solvent such as DMF at a temperature ranging from 100°C to 150°C.
  • Compounds of formulae (lie) may be obtained from compounds of formulae (XVIII) by cyclisation reaction with compounds F where V is as above defined. Preferred conditions are the treatment of compounds of formulae (XVIII) with a base such as potassium ie f-butoxide and diethyl chloro phosphonate followed by the addition of ethyl isocyano acetate in a suitable solvent such as DMF at a temperature ranging from 0°C to RT.
  • a base such as potassium ie f-butoxide and diethyl chloro phosphonate
  • the present invention provides a process wherein compounds of Formula (I) or ( ) wherein T is S are oxydised to compounds of Formula (I) or ( ) wherein T is S0 2 .
  • This oxidation step is performed using usual oxydizing agents, including mCPBA,
  • Preferred conditions consist in the treatment of compounds of formulae (I), (la), (lb), (Ic), (lla), (lib), (lie), (lid), (lie), (A), (B) and (C) by hydrogen peroxide 30% in water in a suitable solvent such as acetic acid at a temperature of 100°C or treatment of compounds of formulae (I), (la), (lb), (Ic), (lla), (lib), (lie), (lid), (lie), (A), (B) and (C) by meta-chloroperbenzoic acid in a suitable solvent such as DCM at a temperature between RT and 50°C.
  • a suitable solvent such as acetic acid
  • Compounds of this invention can be isolated in association with solvent molecules by crystallization from an appropriate solvent or by evaporation of an appropriate solvent.
  • the pharmaceutically acceptable anionic salts of the compounds of Formula (I), ( ) and related Formulae, which contain a basic center may be prepared in a conventional manner. For example, a solution of the free base may be treated with a suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent.
  • Compounds of the formula (I), (I * ) and related formulae can furthermore be obtained by liberating compounds of the formula (I), ( ) and related Formulae from one of their functional derivatives by treatment with a solvolysing or hydrogenolysing agent.
  • Preferred starting materials for the solvolysis or hydrogenolysis are those which conform to the formula (I), ( ) and related formulae, but contain corresponding protected amino and/or hydroxyl groups instead of one or more free amino and/or hydroxyl groups, preferably those which carry an amino-protecting group instead of an H atom bonded to an N atom, in particular those which carry an R * -N group, in which R * denotes an amino-protecting group, instead of an HN group, and/or those which carry a hydroxyl-protecting group instead of the H atom of a hydroxyl group, for example those which conform to the formula (I), (I * ) and related Formulae, but carry a -COOR ** group, in which R ** denotes a hydroxyl-protecting group, instead of a -COOH group.
  • amino-protecting group is known in general terms and relates to groups which are suitable for protecting (blocking) an amino group against chemical reactions, but which are easy to remove after the desired chemical reaction has been carried out elsewhere in the molecule. Typical of such groups are, in particular, unsubstituted or substituted acyl, aryl, aralkoxymethyl or aralkyl groups. Since the amino-protecting groups are removed after the desired reaction (or reaction sequence), their type and size are furthermore not crucial; however, preference is given to those having 1 -20, in particular 1 -8, carbon atoms.
  • acyl group is to be understood in the broadest sense in connection with the present process. It includes acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids, and, in particular, alkoxycarbonyl,
  • aryloxycarbonyl and especially aralkoxycarbonyl groups are alkanoyl, such as acetyl, propionyl and butyryl; aralkanoyl, such as phenylacetyl; aroyl, such as benzoyl and tolyl; aryloxyalkanoyl, such as POA; alkoxycarbonyl, such as methoxy- carbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC (tert-butoxycarbonyl) and 2- iodoethoxycarbonyl; aralkoxycarbonyl, such as CBZ ("carbobenzoxy”), 4- methoxybenzyloxycarbonyl and FMOC; and arylsulfonyl, such as Mtr.
  • Preferred amino- protecting groups are BOC and Mtr, furthermore CBZ, Fmoc, benzyl and acetyl.
  • hydroxyl-protecting group is likewise known in general terms and relates to groups which are suitable for protecting a hydroxyl group against chemical reactions, but are easy to remove after the desired chemical reaction has been carried out elsewhere in the molecule. Typical of such groups are the above-mentioned unsubstituted or substituted aryl, aralkyl or acyl groups, furthermore also alkyl groups.
  • the nature and size of the hydroxyl- protecting groups are not crucial since they are removed again after the desired chemical reaction or reaction sequence; preference is given to groups having 1 -20, in particular 1 -10, carbon atoms.
  • hydroxyl-protecting groups are, inter alia, benzyl, 4- methoxybenzyl, p-nitrobenzoyl, p-toluenesulfonyl, tert-butyl and acetyl, where benzyl and tert-butyl are particularly preferred.
  • the compounds of the formula (I), ( ) and related formulae are liberated from their functional derivatives - depending on the protecting group used - for example strong inorganic acids, such as hydrochloric acid, perchloric acid or sulfuric acid, strong organic carboxylic acids, such as trichloroacetic acid, TFA or sulfonic acids, such as benzene- or p-toluenesulfonic acid.
  • Suitable inert solvents are preferably organic, for example carboxylic acids, such as acetic acid, ethers, such as tetrahydrofuran or dioxane, amides, such as DMF, halogenated hydrocarbons, such as dichloromethane, furthermore also alcohols, such as methanol, ethanol or isopropanol, and water. Mixtures of the above-mentioned solvents are furthermore suitable. TFA is preferably used in excess without addition of a further solvent, and perchloric acid is preferably used in the form of a mixture of acetic acid and 70% perchloric acid in the ratio 9:1 .
  • the reaction temperatures for the cleavage are advantageously between about 0 and about 50°C, preferably between 15 and 30°C (room temperature).
  • the BOC, OtBut and Mtr groups can, for example, preferably be cleaved off using TFA in dichloromethane or using approximately 3 to 5N HCI in dioxane at 15-30°C, and the FMOC group can be cleaved off using an approximately 5 to 50% solution of dimethylamine, diethylamine or piperidine in DMF at 15-30°C.
  • Protecting groups which can be removed hydrogenolytically can be cleaved off, for example, by treatment with hydrogen in the presence of a catalyst (for example a noble- metal catalyst, such as palladium, advantageously on a support, such as carbon).
  • a catalyst for example a noble- metal catalyst, such as palladium, advantageously on a support, such as carbon.
  • Suitable solvents are those indicated above, in particular, for example, alcohols, such as methanol or ethanol, or amides, such as DMF.
  • the hydrogenolysis is generally carried out at temperatures between about 0 and 100°C and pressures between about 1 and 200 bar, preferably at 20-30°C and 1 -10 bar. Hydrogenolysis of the CBZ group succeeds well, for example, on 5 to 10% Pd/C in methanol or using ammonium formate (instead of hydrogen) on Pd/C in methanol/DMF at 20-30°C.
  • Esters can be hydrolysed, for example, using HCI, H 2 S0 4 , or using LiOH, NaOH or KOH in water, water/THF, water/THF/ethanol or water/dioxane, at temperatures between 0 and 100°C.
  • Free amino groups can furthermore be acylated in a conventional manner using an acyl chloride or anhydride or alkylated using an unsubstituted or substituted alkyl halide, advantageously in an inert solvent, such as dichloromethane or THF and/or in the presence of a base, such as triethylamine or pyridine, at temperatures between -60°C and +30°C.
  • the formula (I) and related formulae also encompasses the optically active forms (stereoisomers), the enantiomers, the racemates, the diastereomers and the hydrates and solvates of these compounds.
  • solvates of the compounds is taken to mean adductions of inert solvent molecules onto the compounds which form owing to their mutual attractive force. Solvates are, for example, mono- or dihydrates or alcoholates.
  • hydrates of the compounds refers to compounds of formula (I) associated with 1 , 2, 3 or 4 molecules of water. Preferably, hydrates are mono- or dihydrates.
  • the starting materials can also be formed in situ so that they are not isolated from the reaction mixture, but instead are immediately converted further into the compounds of the formula (I).
  • the reactions are preferably carried out in an inert solvent.
  • suitable inert solvents are hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1 ,2- dichloroethane, tetrachloromethane, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether or ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethyl- formamide (DMF); nitriles, such as
  • the invention relates to a mixture of several compounds of formula (I), ( ) and related Formulae preferably a mixture of 2 to 10 compounds, more preferably, a mixture of 2 or 3 compounds of Formula (I).
  • the invention may also encompass isomers, stereoisomers, diasteroisomers, enentiomers, as well as geometric isomers of compounds of Formula (I) or (I * ).
  • the invention also encompasses mixtures of isomers, e.g. stereoisomers, diasteroisomers, enentiomers and geometric isomers, of compounds of Formula (I), ( ) and related Formulae.
  • the invention provides pharmaceutically acceptable derivatives, solvates, hydrates, tautomers, salts and stereoisomers of Formula (I), ( ) and related Formulae.
  • the invention relates, in particular, to the use of compounds of formula (I), (I * ) and related formulae as defined above, as a medicament.
  • the invention relates, in particular, to the use of compounds of the formula(l), ( ) and related formulae as defined above, for the preparation of pharmaceutical formulations for the prevention and/or the treatment of inflammatory or autoimmune diseases, multiple sclerosis, cancers and related disorders.
  • the present invention also encompasses the metabolites of compounds of formula (I).
  • the said compounds of the formula (I), ( ) and related formulae can be used in their final non-salt form.
  • the present invention also relates to the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases by procedures known in the art.
  • compositions of the formula (I), (I * ) and related Formulae are for the most part prepared by conventional methods. If the compound of the formula (I), ( ) and related formulae contains an acidic center, such as a carboxyl group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base-addition salt.
  • an acidic center such as a carboxyl group
  • Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; alkaline earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, for example sodium- or potassium methoxide and sodium or potassiumpropoxide, alkalihydrides, such as sodium- or potassiumhydride; and various organic bases, such as piperidine, diethanolamine and N-methyl-glutamine, benzathine, choline, diethanolamine, ethylenediamine, meglumine, benethamine, diethylamine, piperazine and tromethamine.
  • the aluminium salts of the compounds of the formula (I), (I * ) and related formulae are likewise included.
  • acid-addition salts can be formed by treating these compounds with pharmaceutically acceptable organic and inorganic acids, for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoaryl-sulfonates, such as ethanesulfonate, toluenesulfonate and benzene-sulfonate, and other organic acids and corresponding salts thereof, such as acetate, trifluoro-acetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like.
  • organic and inorganic acids for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoary
  • pharmaceutically acceptable acid-addition salts of the compounds of the formula (I), ( ) and related formulae include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzene-sulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphor-sulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclo-pentane-propionate, digluconate, dihydrogen-phosphate, dinitrobenzoate, dodecyl-sulfate, ethanesulfonate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptanoate, gluco-nate, glutamate, glycerophosphate, hemi-succinate, hemisulfate, heptanoate, hexanoate, hippurate, hydro
  • the base salts of the compounds of the formula (I), ( ) and related formulae include aluminium, ammonium, calcium, copper, iron(lll), iron(ll), lithium, magne-sium, manganese(lll), manganese(ll), potassium, sodium and zink salts, but this is not intended to represent a restriction.
  • organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, also including naturally occurring substituted amines, cyclic amines, and basic ion exchanger resins, for example arginine, betaine, caffeine, chloroprocaine, choline, ⁇ , ⁇ '-dibenzyl-ethylen-ediamine (benzathine), dicyclohexylamine, diethanol-amine, diethyl-amine, 2-diethyl-amino-ethanol, 2-dimethyl-amino-ethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethyl-piperidine, glucamine, glucosamine, histidine, hydrabamine, isopropyl-amine, lido-caine, lysine, meglumine (N- methyl-D-glucamine), morpholine, piperazine, piperidine, polyamine resins, pro
  • Compounds of the formula (I), ( ) and related formulae of the present invention which contain basic nitrogen-containing groups can be quaternised using agents such as (C C 4 )-alkyl halides, for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; di(Ci-C 4 )alkyl sulfates, for example dimethyl, diethyl and diamyl sulfate; (Ci 0 -Ci 8 )alkyl halides, for example decyl, do-decyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and aryl-(Ci-C 4 )alkyl halides, for example benzyl chloride and phenethyl bromide. Both water- and oil-soluble compounds of the formula I can be prepared using such salts.
  • hydrochloride hydrobromide, isethionate, mandelate, me-glumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stea-rate, sulfate, subsalicylate, tartrate, thiomalate, tosylate and tro-meth-amine, but this is not intended to represent a restriction.
  • the pharmaceutically acceptable base-addition salts of the compounds of the formula (I), ( ) and related Formulae are formed with metals or amines, such as alkali metals and alkaline earth metals or organic amines.
  • metals are sodium, potassium, magnesium and calcium.
  • Preferred organic amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanol-amine, ethylenediamine, N-methyl-D-glucamine and procaine.
  • a compound of the formula (I), ( ) and related formulae contains more than one group which is capable of forming pharmaceutically acceptable salts of this type
  • the formula (I), ( ) and related Formulae also encompass multiple salts.
  • Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, di-phosphate, disodium and trihydrochloride, but this is not intended to represent a restriction.
  • the term "pharmaceutically acceptable salt” in the present connection is taken to mean an active ingredient which comprises a compound of the formula (I), ( ) and related formulae in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared with the free form of the active ingredient or any other salt form of the active ingredient used earlier.
  • the pharmaceutically acceptable salt form of the active ingredient can also provide this active ingredient for the first time with a desired
  • leaving group denotes an atom or a group of atoms easily cleaved, hydrolysed or substituted with a reagent.
  • Preferred leaving groups are halogens, alkylsulfonates, arylsulfonates, alcoholates or activated esters.
  • reducing agent denotes a reagent able to donate electrons.
  • Preferred reducing agents are Boranes, Catecholborane, Copper hydride, Copper (low valent), Chromium (low valent), Decaborane, DIBAL-H, Diborane, Diethyl 1 ,4-dihydro-2,6-dimethyl-3,5- pyridinedicarboxylate, Diisobutylaluminium hydride, Dimethylsulfide borane, DMSB, Fe,
  • Formaldehyde Formic acid, Hantzsch Ester, Hydrazine, Hydrogen, Indium (low valent), Iron, Isopropanol, LAH, Lithium, Lithium aluminum hydride, Lithium tetrahydridoaluminate, LiBH4, Magnesium, Manganese, 3-Mercaptopropionic acid, 3-MPA, Neodymium (low valent), Nickel, Nickel borohydride, Niobium (low valent), Phenylsilane, PMHS, Polymethylhydrosiloxane, Potassium, 2-Propanol, Red-AI, Rongalite, Samarium (low valent), Silanes, Sodium,
  • cyanoborohydride Sodium dithionite, Sodium hydrosulfite, Sodium hydroxymethanesulfinate, Sodium tetrahydroborate, Sodium triacetoxyborohydride, Strontium, Tetramethyldisiloxane, Tin hydrides, Titanium (low valent), TMDSO, Tributylstannane, Tributyltin hydride,
  • Tris(trimethylsilyl)silane TTMSS, Zinc.
  • prodrug derivatives or “prodrug” is taken to mean compounds of the formula (I) or ( ) which have been modified with, for example, alkyl or acyl groups, sugars or oligopeptides and which are rapidly cleaved in the organism to form the active compounds.
  • prodrug derivatives also include biodegradable polymer derivatives of the compounds according to the invention, as described, for example, in Int. J. Pharm. 1 15, 61 -67 (1995).
  • metabolite designates compounds of formula (I) or (I * ) which have been modified within the organism, through the reactions naturally occuring in the body.
  • the compounds of the formula (I), ( ) and related formulae can be chiral and can accordingly occur in various enantiomeric forms. They can therefore exist in racemic or in optically active form.
  • the pharmaceutical activity of the racemates or stereoisomers of the compounds according to the invention may differ, it may be desirable to use the enantiomers.
  • the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art or even employed as such in the synthesis.
  • diastereomers are formed from the mixture by reaction with an optically active resolving agent.
  • optically active acids such as the R and S forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitable N-protected amino acids (for example N- benzoylproline or N-benzenesulfonylproline), or the various optically active camphorsulfonic acids.
  • chromatographic enantiomer resolution with the aid of an optically active resolving agent (for example dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of carbohydrates or chirally derivatised methacrylate polymers immobilised on silica gel).
  • optically active resolving agent for example dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of carbohydrates or chirally derivatised methacrylate polymers immobilised on silica gel.
  • Suitable eluents for this purpose are aqueous or alcoholic solvent mixtures, such as, for example, hexane/isopropanol/ acetonitrile, for example in the ratio 82:15:3.
  • the invention furthermore relates to the use of compounds of Formula (I) or (I * ) for the manufacture of a medicament for the prevention and/or the treatment of the diseases associated to Phosphoinositide 3-kinases disorders.
  • the invention also relates to the use of compounds of Formula (I) or (I * ) for the manufacture of a medicament for the prevention and/or the treatment of inflammatory diseases, autoimmune disorder, multiple sclerosis, cancers, and related disorders.
  • the present invention relates to the use of compounds of Formula (I) or (I * ) for the manufacture of a medicament for the prevention and/or treatment of Rheumatoid arthritis, Asthma and other autoimmune diseases selected from Acute disseminated
  • ADAM encephalomyelitis
  • Addison's disease Alopecia areata, Ankylosing spondylitis
  • Antiphospholipid antibody syndrome APS
  • Autoimmune hemolytic anemia Autoimmune hepatitis
  • Autoimmune inner ear disease Bullous pemphigoid
  • Behget's disease Coeliac disease
  • Anti-transglutaminase Chagas disease
  • Chronic obstructive pulmonary disease Crohns Disease
  • Dermatomyositis Diabetes mellitus type 1
  • Endometriosis Goodpasture's syndrome
  • Graves' disease Guillain-Barre syndrome (GBS)
  • Hashimoto's disease
  • Hidradenitis suppurativa Kawasaki disease, IgA nephropathy, Idiopathic thrombocytopenic purpura, Interstitial cystitis, Lupus erythematosus, Mixed Connective Tissue Disease, Morphea, Multiple sclerosis (MS), Myasthenia gravis, Narcolepsy, Neuromyotonia,
  • Pemphigus vulgaris Pernicious anaemia, Psoriasis, Psoriatic Arthritis, Polymyositis, Primary biliary cirrhosis, Schizophrenia, Scleroderma, Sjogren's syndrome, Stiff person syndrome, Temporal arteritis, Ulcerative Colitis, Vasculitis, Vitiligo, Wegener's granulomatosis.
  • the invention also relates to the use of compounds of Formula (I) or (I * ) for the manufacture of a medicament for the prevention and/or the treatment of the disease selected from the group consisting of amyotrophic lateral sclerosis (ALS), systemic lupus erythematosus, chronic rheumatoid arthritis, lupus, dermatomyositis, autoimmune neuropathies, immune thrombocytopenic purpura, haemolytic anaemia, inflammatory bowel disease, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, bone marrow or organ transplant rejection or graft-versus-host disease, Hashimoto's thyroiditis, myasthenia gravis, uveitis, posterior uveitis, rheumatic fever inflammatory and hyperproliferative skin diseases, atopic dermatitis, contact dermatitis, areata, keratoconjun
  • the invention furthermore relates to the use of compounds of formula (I), ( ) and related formulae in combination with at least one further medicament active ingredient, preferably medicaments used in the treatment of inflammatory diseases or immune disorders such as methotrexate, leflunomide, rituxan, or anti-TNF like enbrel (etanercept), remicade
  • immunomodulating agents such as Fingolimod, cyclosporins, rapamycins or ascomycins, or their immunosuppressive analogs, e.g.
  • cyclosporin A cyclosporin G, FK-506, ABT-281 , ASM981 , rapamycin, 40-O-(2-hydroxy)ethyl- rapamycin etc.
  • corticosteroids cyclophosphamide
  • azathioprene mizoribine
  • mycophenolic add mycophenolate mofetil
  • 15-deoxyspergualine diflucortolone valerate
  • difluprednate Alclometasone dipropionate
  • amcinonide amsacrine
  • asparaginase azathioprine
  • basiliximab beclometasone dipropionate; betamethasone; betamethasone acetate;
  • fluclorolone acetonide fludrocortisone acetate; fludroxycortide; flumetasone pivalate;
  • flunisolide fluocinolone acetonide; fluocinonide; fluocortolone; fluocortolone hexanoate; fluocortolone pivalate; fluorometholone; fluprednidene acetate; fluticasone propionate;
  • gemcitabine chlorhydrate halcinonide
  • hydrocortisone hydrocortisone acetate
  • hydrocortisone butyrate hydrocortisone hemisuccinate; melphalan; meprednisone;
  • mercaptopurine methylprednisolone; methylprednisolone acetate; methylprednisolone hemisuccinate; misoprostol; muromonab-cd3; mycophenolate mofetil; paramethasone acetate; prednazoline, prednisolone; prednisolone acetate; prednisolone caproate;
  • prednisolone metasulfobenzoate sodique prednisolone metasulfobenzoate sodique
  • prednisolone phosphate sodique prednisone
  • prednylidene prednylidene
  • rifampicine rifampicine sodique
  • tacrolimus thalidomide
  • thiotepa tixocortol pivalate
  • triamcinolone triamcinolone acetonide hemisuccinate
  • triamcinolone benetonide triamcinolone diacetate
  • triamcinolone hexacetonide immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD40, CD45 or CD58 or their ligands; or other immunomodulatory compounds, e.g.
  • CTLA41 g or other adhesion molecule inhibitors, e.g. mAbs or low molecular weight inhibitors including Selectin antagonists and VLA-4 antagonists.
  • a preferred composition is with Cyclosporin A, FK506, rapamycin or 40-(2-hydroxy)ethyl-rapamycin and Fingolimod.
  • further medicaments such as interferon beta, may be administered concomitantly or sequentially, e.g. by subcutaneous, intramuscular or oral routes.
  • the invention furthermore relates to the use of compounds of formula (I) and related formulae in combination with at least one further medicament active ingredient, preferably medicaments used in the treatment of cancer wherein said antitumoral compounds are selected from those well known by the one skilled in the related art.
  • medicament active ingredient preferably medicaments used in the treatment of cancer wherein said antitumoral compounds are selected from those well known by the one skilled in the related art.
  • These compositions can be used as medicaments in human and veterinary medicine.
  • Embodiments 1 A compound of formula (I) and related formulae in combination with at least one further medicament active ingredient, preferably medicaments used in the treatment of cancer wherein said antitumoral compounds are selected from those well known by the one skilled in the related art.
  • Embodiments 1 A compound of formula (I) and related formulae in combination with at least one further medicament active ingredient, preferably medicaments used in the treatment of cancer wherein said antitumoral compounds are selected from those well known by the one skilled in the related art.
  • These compositions can be used as medicament
  • R 2 denotes H, Ar, Het, A, Cyc,
  • R 3 , R 4 denote independantly from one another H, Y, (CH 2 ) n Ar, (CH 2 ) n Cyc, (CH 2 ) n Het
  • R 5 denotes H, Y or Ar
  • U 1 , U 2 , U 3 , and U 4 denote CR 1 or one or two of U 1 , U 2 , U 3 and U 4 are independently
  • R 1 denotes H, A, Hal, CN, N0 2 , N(R 6 ) 2 , OR 6 , Ar, Het, Y, -NR 6 COR 6 , CON(R 6 ) 2 T denotes S, SO or S0 2 .
  • r denotes 0, 1 or 2
  • Ar denotes a monocyclic or fused bicyclic, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF 3 , N0 2 , CN, perfluoroalkyl, A, OR 6 , N(R 6 ) 2 , COR 6 , -C0 2 R 6 , CON(R 6 ) 2 , COHet, -NHCOR 6 , -NHS0 2 A, -NHS0 2 Ar, - NHS0 2 -N(R 6 ) 2 , N(H) 1-q A q COR 6 , N(H) 1-q A q S0 2 -N(H) 2-m (A) m , -N(H) 1-q A q CON(H) 2- m (A) m , -S0 2 A, -S0 2 Ar, -S
  • Het denotes a monocyclic or bicyclic saturated, unsaturated or aromatic
  • heterocyclic ring having 1 , 2, 3 or 4 N, O and/or S atoms which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF 3 , N0 2 , CN, perfluoroalkyl, A, OR 6 , N(R 6 ) 2 , COR 6 , -C0 2 R 6 , CON(R 6 ) 2 , -NHCOR 6 , -NHS0 2 A, -NHS0 2 R 6 , -NHS0 2 -N(H) 2-m (A) m , N(H) 1-q A q COR 6 , N(H) 1-q A q S0 2 - N(H) 2-m (A) m , -N(H) 1-q A q CON(H) 2-m (A) m , -S0 2 A, -S0 2 Ar, -S0 2 N(H) 2-m (A)
  • Cyc denotes a saturated carbocyclic ring having 1 to 8 carbon atoms, which is unsubstituted, mono-substituted, di-substituted or tri-substituted by Hal, OCF 3 N0 2 , CN, perfluoroalkyl, A, OR 6 , N(R 6 ) 2 , COR 6 , CON(R 6 ) 2 , -NHCOR 6 , - NHS0 2 A, -NHS0 2 R 6 , -NHS0 2 -N(H) 2-m (A) m , N(H) 1-q A q COR 6 , N(H) 1-q A q S0 2 - N(H) 2-m (A) m , -N(H) 1-q A q CON(H) 2-m (A) m , -COOR 6 , -S0 2 A, -S0 2 Ar, -S0 2 N(H) 2- m (A)
  • Y denotes a branched or linear alkyl having 1 to 8 carbon atoms.
  • R 6 is H, A or Ar.
  • Hal denotes F, CI, Br or I, q is O or l , m is 0, 1 or 2, n is 1 , 2, 3, or 4 and pharmaceutically acceptable derivatives, solvates, tautomers, salts, hydrates and stereoisomers thereof, including mixtures thereof in all ratios, for use as a
  • Embodiment 2 A compound of Formula (I) according to embodiment 1 for the prevention and/or treatment of the diseasediseases associated to Phosphoinositide 3-kinases disorders.
  • Embodiment 3 A compound according to embodiment 2 wherein the disease is inflammatory disease, autoimmune disorder, cancer or multiple sclerosis and related disorders.
  • Embodiment 4 A compound according to embodiment 3 wherein the autoimmune disease is selected from the group consisting of Asthma, Rheumatoid arthritis, Acute disseminated encephalomyelitis (ADEM), Addison's disease, Alopecia areata, Ankylosing spondylitis, Antiphospholipid antibody syndrome (APS), Autoimmune hemolytic anemia, Autoimmune hepatitis, Autoimmune inner ear disease, Bullous pemphigoid, Behget's disease, Coeliac disease, Anti-transglutaminase, Chagas disease, Chronic obstructive pulmonary disease, Crohns Disease, Dermatomyositis, Diabetes mellitus type 1 , Endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome (GBS), Hashimoto's disease, Hidradenitis suppurativa, Kawasaki disease, IgA nephropathy, Idiopathic
  • erythematosus Mixed Connective Tissue Disease, Morphea, Multiple sclerosis (MS), Myasthenia gravis, Narcolepsy, Neuromyotonia, Pemphigus vulgaris, Pernicious anaemia, Psoriasis, Psoriatic Arthritis, Polymyositis, Primary biliary cirrhosis, Rheumatoid arthritis, Schizophrenia, Scleroderma, Sjogren's syndrome, Stiff person syndrome, Temporal arteritis, Ulcerative Colitis, Vasculitis, Vitiligo, Wegener's granulomatosis
  • Embodiment 5 A kit consisting of separate packs of :
  • Embodiment 6 A Pharmaceutical compositions containing at least one of the compounds of Formula (I) according to any one of embodiment 1 to 5.
  • Embodiment 7 A pharmaceutical composition according to embodiment 6 wherein compounds of formula (I) are combined with at least one further medicament used in the treatment of inflammatory diseases or immune disorders.
  • Embodiment 8 A pharmaceutical composition according to embodiment 7 wherein compounds of Formula (I) are combined with at least one further immunomodulating agents.
  • Embodiment 9 A process for producing compounds of Formula (I) according to embodiment 1 to 5, wherein R 3 and R 4 are both H, comprising the step of reacting compounds of Formula (lib)
  • V is H or Y
  • R 2 , T, Y and Ui, U 2 , U 3 and U 4 are as defined in embodiment 1 ,
  • R 5 and r are as defined in embodiment 1 ,
  • R 5 , r, T and Ui, U 2 , U 3 and U 4 are as defined in embodiment 1 wwiitthh ccoommppoouunnddss ooff ffcormula R 2 -X, wherein R 2 is as defined in embodiment 1 and X is a leaving group.
  • Embodiment 10 A process according to embodiment 9 further comprising the step of reaction a compound of Formula
  • R 5 , R 2 , r, T and Ui, U 2 , U 3 and U 4 are as defined in embodiment 1 , with R 3 -X and R 4 -X,
  • compositions can be administered in the form of dosage units, which comprise a predetermined amount of active ingredient per dosage unit.
  • a unit can comprise, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a compound according to the invention, depending on the disease condition treated, the method of administration and the age, weight and condition of the patient, or pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit.
  • Preferred dosage unit formulations are those which comprise a daily dose or part-dose, as indicated above, or a corresponding fraction thereof of an active ingredient.
  • pharmaceutical formulations of this type can be prepared using a process, which is generally known in the pharmaceutical art.
  • compositions can be adapted for administration via any desired suitable method, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) methods.
  • oral including buccal or sublingual
  • rectal nasal
  • topical including buccal, sublingual or transdermal
  • vaginal or parenteral including subcutaneous, intramuscular, intravenous or intradermal
  • parenteral including subcutaneous, intramuscular, intravenous or intradermal
  • compositions adapted for oral administration can be administered as separate units, such as, for example, capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
  • the active-ingredient component in the case of oral administration in the form of a tablet or capsule, can be combined with an oral, non-toxic and pharmaceutically acceptable inert excipient, such as, for example, ethanol, glycerol, water and the like.
  • an oral, non-toxic and pharmaceutically acceptable inert excipient such as, for example, ethanol, glycerol, water and the like.
  • Powders are prepared by comminuting the compound to a suitable fine size and mixing it with a pharmaceutical excipient comminuted in a similar manner, such as, for example, an edible carbohydrate, such as, for example, starch or mannitol.
  • a pharmaceutical excipient comminuted in a similar manner, such as, for example, an edible carbohydrate, such as, for example, starch or mannitol.
  • a flavour, preservative, dispersant and dye may likewise be present.
  • Capsules are produced by preparing a powder mixture as described above and filling shaped gelatine shells therewith.
  • Glidants and lubricants such as, for example, highly disperse silicic acid, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form, can be added to the powder mixture before the filling operation.
  • a disintegrant or solubiliser such as, for example, agar-agar, calcium carbonate or sodium carbonate, may likewise be added in order to improve the availability of the medica-ment after the capsule has been taken.
  • suitable binders include starch, gelatine, natural sugars, such as, for example, glucose or beta-lactose, sweeteners made from maize, natural and synthetic rubber, such as, for example, acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like.
  • the lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • the disintegrants include, without being restricted thereto, starch, methylcellulose, agar, bentonite, xanthan gum and the like.
  • the tablets are formulated by, for example, preparing a powder mixture, granulating or dry- pressing the mixture, adding a lubricant and a disintegrant and pressing the entire mixture to give tablets.
  • a powder mixture is prepared by mixing the compound comminuted in a suitable manner with a diluent or a base, as described above, and optionally with a binder, such as, for example, carboxymethylcellulose, an alginate, gelatine or polyvinyl-pyrrolidone, a dissolution retardant, such as, for example, paraffin, an absorption accelerator, such as, for example, a quaternary salt, and/or an absorbant, such as, for example, bentonite, kaolin or dicalcium phosphate.
  • a binder such as, for example, carboxymethylcellulose, an alginate, gelatine or polyvinyl-pyrrolidone
  • a dissolution retardant such as, for example, paraffin
  • an absorption accelerator such as, for example, a quaternary salt
  • an absorbant such as, for example, bentonite, kaolin or dicalcium phosphate.
  • the powder mixture can be granulated by wetting it with a binder, such as, for example, syrup, starch paste, acadia mucilage or solutions of cellulose or polymer materials and pressing it through a sieve.
  • a binder such as, for example, syrup, starch paste, acadia mucilage or solutions of cellulose or polymer materials
  • the powder mixture can be run through a tableting machine, giving lumps of non-uniform shape which are broken up to form granules.
  • the granules can be lubricated by addition of stearic acid, a stearate salt, talc or mineral oil in order to prevent sticking to the tablet casting moulds. The lubricated mixture is then pressed to give tablets.
  • the active ingredients can also be combined with a free-flowing inert excipient and then pressed directly to give tablets without carrying out the granulation or dry-pressing steps.
  • a transparent or opaque protective layer consisting of a shellac sealing layer, a layer of sugar or polymer material and a gloss layer of wax may be present. Dyes can be added to these coatings in order to be able to differentiate between different dosage units.
  • Oral liquids such as, for example, solution, syrups and elixirs, can be prepared in the form of dosage units so that a given quantity comprises a pre-specified amount of the compounds.
  • Syrups can be prepared by dissolving the compounds in an aqueous solution with a suitable flavour, while elixirs are prepared using a non-toxic alcoholic vehicle.
  • Suspensions can be for-mulated by dispersion of the compounds in a non-toxic vehicle.
  • Solubilisers and emulsifiers such as, for example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavour additives, such as, for example, peppermint oil or natural sweeteners or saccharin, or other artificial sweeteners and the like, can likewise be added.
  • the dosage unit formulations for oral administration can, if desired, be encapsulated in microcapsules.
  • the formulation can also be prepared in such a way that the release is extended or retarded, such as, for example, by coating or embedding of particulate material in polymers, wax and the like.
  • the compounds of the formula (I), ( ) and related formulae and salts, solvates and physiologically functional derivatives thereof and the other active ingredients can also be administered in the form of liposome delivery systems, such as, for exam-pie, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed from various phospholipids, such as, for example, cholesterol, stearylamine or phosphatidylcholines.
  • the compounds of the formula (I), ( ) and related formulae and the salts, solvates and physiologically functional derivatives thereof and the other active ingredients can also be delivered using monoclonal antibodies as individual carriers to which the compound molecules are coupled.
  • the compounds can also be coupled to soluble polymers as targeted medicament carriers.
  • soluble polymers may encompass polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl-methacrylamidophenol, polyhydroxyethylaspartamido-phenol or polyethylene oxide polylysine, substituted by palmitoyl radicals.
  • the compounds may furthermore be coupled to a class of biodegradable polymers which are suitable for achieving controlled release of a medicament, for example polylactic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, poly-orthoesters, polyacetals, polydihydroxypyrans,
  • compositions adapted for transdermal administration can be administered as independent plasters for extended, close contact with the epidermis of the recipient.
  • the active ingredient can be delivered from the plaster by iontophoresis, as described in general terms in Pharmaceutical Research, 3(6), 318 (1986).
  • Pharmaceutical compounds adapted for topical administration can be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
  • the formulations are preferably applied as topical ointment or cream.
  • the active ingredient can be employed either with a paraffinic or a water- miscible cream base.
  • the active ingredient can be formulated to give a cream with an oil-in-water cream base or a water-in-oil base.
  • compositions adapted for topical application to the eye include eye drops, in which the active ingredient is dissolved or sus-pended in a suitable carrier, in particular an aqueous solvent.
  • compositions adapted for topical application in the mouth encompass lozenges, pastilles and mouthwashes.
  • Pharmaceutical formulations adapted for rectal administration can be administered in the form of suppositories or enemas.
  • compositions adapted for nasal administration in which the carrier substance is a solid comprise a coarse powder having a particle size, for example, in the range 20-500 microns, which is administered in the manner in which snuff is taken, i.e. by rapid inhalation via the nasal passages from a container containing the powder held close to the nose.
  • Suitable formulations for administration as nasal spray or nose drops with a liquid as carrier substance encompass active-ingredient solutions in water or oil.
  • compositions adapted for administration by inhalation encompass finely particulate dusts or mists, which can be generated by various types of pressurised dispensers with aerosols, nebulisers or insuf-flators.
  • Pharmaceutical formulations adapted for vaginal administration can be administered as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
  • compositions adapted for parenteral administration include aqueous and nonaqueous sterile injection solutions comprising antioxidants, buffers, bacteriostatics and solutes, by means of which the formulation is rendered isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions, which may comprise suspension media and thickeners.
  • the formulations can be administered in single-dose or multidose containers, for example sealed ampoules and vials, and stored in freeze-dried (lyophilised) state, so that only the addition of the sterile carrier liquid, for example water for injection purposes, immediately before use is necessary.
  • Injection solutions and suspensions prepared in accordance with the recipe can be prepared from sterile powders, granules and tablets.
  • the formulations may also comprise other agents usual in the art with respect to the particular type of formulation; thus, for example, formulations which are suitable for oral administration may comprise flavours.
  • a therapeutically effective amount of a compound of the formula (I), ( ) and related formulae and of the other active ingredient depends on a number of factors, including, for example, the age and weight of the animal, the precise disease condition which requires treatment, and its severity, the nature of the formulation and the method of administration, and is ultimately determined by the treating doctor or vet.
  • an effective amount of a compound is generally in the range from 0.1 to 100 mg/kg of body weight of the recipient (mammal) per day and particularly typically in the range from 1 to 10 mg/kg of body weight per day.
  • the actual amount per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can be administered as an individual dose per day or usually in a series of part-doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same.
  • An effective amount of a salt or solvate or of a physiologically functional derivative thereof can be determined as the fraction of the effective amount of the compound per se.
  • the present invention furthermore relates to a method for treating a subject suffering from a PI3K related disorder, comprising administering to said subject an effective amount of a compound of formula I and related formulae.
  • the present invention preferably relates to a method, wherein the PI3K associated disorder is an autoimmune disorder or condition associated with an overactive immune response or cancer.
  • the present invention preferably relates to a method wherein the
  • immunoregulatory abnormality is an autoimmune or chronic inflammatory disease selected from the group consisting of: allergic diseases, amyotrophic lateral sclerosis (ALS), systemic lupus erythematosus, chronic rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's
  • ALS amyotrophic lateral sclerosis
  • systemic lupus erythematosus chronic rheumatoid arthritis
  • type I diabetes mellitus inflammatory bowel disease
  • biliary cirrhosis uveitis
  • multiple sclerosis Crohn's disease
  • ulcerative colitis bullous pemphigoid
  • sarcoidosis psorias
  • the present invention furthermore relates to a method wherein the immunoregulatory abnormality is bone marrow or organ transplant rejection or graft-versus-host disease.
  • the present invention furthermore relates to a method wherein the immunoregulatory abnormality is selected from the group consisting of: transplantation of organs or tissue, graft-versus-host diseases brought about by transplantation, autoimmune syndromes including rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, posterior uveitis, allergic encephalomyelitis, glomerulonephritis, post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis, inflammatory and hyperproliferative skin diseases, psoriasis, atopic dermatitis, contact dermatitis, eczematous dermatitis, seborrhoeic dermatitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa,
  • pseudomembranous colitis colitis caused by drug or radiation
  • ischemic acute renal insufficiency chronic renal insufficiency
  • toxinosis caused by lung-oxygen or drugs
  • lung cancer pulmonary emphysema
  • cataracta siderosis
  • retinitis pigmentosa senile macular degeneration
  • vitreal scarring corneal alkali burn
  • linear IgA ballous dermatitis and cement dermatitis gingivitis, periodontitis, sepsis, pancreatitis
  • diseases caused by environmental pollution aging, carcinogenesis, metastasis of carcinoma and hypobaropathy, disease caused by histamine or leukotriene-C 4 release
  • Behcet's disease autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, partial liver resection, acute liver necrosis, necrosis caused by toxin, viral
  • compositions of this invention can be isolated in association with solvent molecules by crystallization from evaporation of an appropriate solvent.
  • the pharmaceutically acceptable acid addition salts of the compounds of formula (I), ( ) and related formulae which contain a basic center may be prepared in a conventional manner.
  • a solution of the free base may be treated with a suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent.
  • Pharmaceutically acceptable base addition salts may be obtained in an analogous manner by treating a solution of compound of formula (I), ( ) and related formulae, which contain an acid center, with a suitable base. Both types of salts may be formed or interconverted using ion-exchange resin techniques.
  • HPLC Waters Alliance 2695, column Waters XBridge C8 3.5 ⁇ 4.6x50 mm, conditions: solvent A (H 2 0 with 0.1 % TFA), solvent B (ACN with 0.05% TFA), gradient 5% B to 100% B over 8 min, UV detection with PDA Water 996 (230-400 nm).
  • UPLC/MS Waters Acquity, column Waters Acquity UPLC BEH C18 1 .7 ⁇ 2.1 x50 mm, conditions: solvent A (10mM ammonium acetate in water + 5% ACN), solvent B (ACN), gradient 5% B to 100% B over 3 min, UV detection (PDA, 230-400 nm) and MS detection (SQ detector, positive and negative ESI modes, cone voltage 30V).
  • Chiral analytical HPLC Waters Alliance 2695, column Waters chiralcel OJ-H, OB-H, OD-H, OZ-H or a Chirapak AD-H, AS, IA-3, IB, IC-3, AY-H or (SS) Whelk 01 , (RR) Whelk 01 Chiralcel OJ-H, OB-H, OD-H, OZ-H or a Chiralpak AD-H, AS, IA-3, IB, IC-3, AY-H from Chiral Technologies or (SS) Whelk -01 from Regis Technologies on a Alliance system (Waters ) with a flow rate of 1 ml min UV detection with PDA Water 996 (230-400 nm).
  • Alpha D were determined on a Polarimeter Jasco P-2000 at 25°C using Spectra Manager as software
  • 4-Chloropyridine hydrochloride 25 g is neutralized with aq. Na 2 C0 3 (10%) and extracted with DCM. The organic layer is separated, dried over Na 2 S0 4 and concentrated under reduced pressure to afford 4-chloropyridine (19 g).
  • diisopropylamine 31 ml_, 217.6 mmol
  • n-butyllithium 1 15 ml_, 184.1 mmol
  • a solution of 4-chloropyridine (19 g, 167.4 mmol) in dry THF is slowly added under nitrogen.
  • reaction mixture is futher stirred for 1 h at -78°C before addition of solid C0 2 , let warmed to RT and stirred at RT for 12 h under nitrogen. After this time, reaction mixture is concentrated under reduced pressure and acidified with aq. HCI solution (1 .5 N) under ice-cooled condition. Precipitate is filtered under reduced pressure and dried overnight under vacuum to afford 15 g (57%) of the title compound.
  • Methyl -3-( ⁇ 2-[ie f-butoxycarbonyl)amino]-1 ,3-thiazol-5-yl ⁇ thio)propanoate (9.5 g, 29.8 mmol, 1 eq.) is taken in THF/ H 2 0 (3:1 ) and LiOH (1 .87 g, 44.75 mmol, 1 .5 eq.) and the reaction mixture is stirred at RT overnight after which it is evaporated under vacuum then diluted with water and acidified with citric acid to pH (5-6) and the formed solid is filtered, washed with water and dried to give 8 g (92%) of the title compound.
  • a solution of diethyloxalate (30.9 mL; 228.34 mmol; 1 .5 eq.) in toluene (250 mL) is added dropwise at 0°C to a solution of sodium ethoxide 21 %w/w in EtOH (9.87 g; 182.67 mmol; 2 eq.).
  • a solution of thiochroman-4-one (25 g; 152.23 mmol; 1 eq.) in toluene (250 mL) is added dropwise at 0°C and the reaction mixture is allowed to warm up to rt. After overnight stirring, the solvent is removed and DCM (200 mL) and water (200 ml) are added.
  • ethyl 1 -pyridin-2-yl-1 ,4- dihydrothiochromeno[4,3-c] pyrazole-3-carboxylate is obtained from 2,3-dihydro-4/-/- thiochroman-4-one, diethyl oxalate and 4-methoxy phenyl hydrazine to afford the title compound.
  • ethyl 1 -cyclohexyl-1 ,4- dihydrothiochromeno[4,3-c] pyrazole-3-carboxylate is obtained from 2,3-dihydro-4/-/- thiochroman-4-one, diethyl oxalate and cyclohexyl hydrazine to afford the title compound.
  • ethyl 1 -(2,3-dihydro-1 ,4-benzodioxin-6-yl)- 1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4H- thiochroman-4-one, diethyl oxalate and 2,3-dihydro-1 ,4-benzodioxin-6-ylhydrazine to afford the title compound.
  • Reaction mixture is heated at 75°C for 5h after which it is concentrated under vacuum, partitioned between NaHC0 3 sat (pH 7-8) and EtOAc. Organic layer is washed NaHC0 3 sat and brine, dried over MgS04 to give 3.1 g (88%) of the title compound as a brown solid.
  • Ethyl 6-bromo-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 200 mg, 0.483 mmol
  • DMF/water (10:1 , 4.4 mL) is taken in a sealed tube and purged with nitrogen for 10 min.
  • Zinc cyanide 64 mg, 0.545 mmol
  • Pd 2 (dba) 3 (18 mg, 0.019 mmol
  • s-phos (20 mg, 0.483 mmol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)

Abstract

This invention relates to compounds of Formula (I*) as Pi3k inhibitors for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other diseases like cancers.

Description

Tricyclic Pyrazol Amine Derivatives
The invention relates to compounds of formula (I) and related formulae, their use as medicament and their use for treating autoimmune diseases, inflammatory disorders, multiple sclerosis and other diseases like cancers.
Background of the invention
Phosphoinositide 3-kinases (PI3Ks) have a critical signalling role in cell proliferation, cell survival, vascularization, membrane trafficking, glucose transport, neurite outgrowth, membrane ruffling, superoxide production, actin reorganization and chemotaxis (Cantley, 2000, Science, 296, 1655-1657).
The term PI3K is given to a family of lipid kinases which, in mammals, consists in eight identified PI3Ks that are divided into three sub-families according to their structure and their substrate specificity.
Class I group of PI3Ks consists in two sub-groups, Class IA and Class IB.
Class IA are a family of heterodimeric lipid kinases consisting in a 85 kDa regulatory unit (responsible for protein -protein interactions via the interaction of Src homology 2 (SH2) domain with phosphotyrosine residues of other proteins) and a catalytic sub-unit of 1 10kDa that generate second messenger signals downstream of tyrosine kinases, thereby controlling cell metabolism, growth, proliferation, differentiation, motility and survival. Three catalytic forms (p1 10a, p1 10β and p1 10δ) and five regulatory isoforms (ρ85α, ρ85β, ρ55γ, p55a and p50a) exist for this class.
Class IB are stimulated by G protein βγ sub-units of heterodimeric G proteins. The only characterized member of Class IB is ΡΙ3Κγ (ρ1 10γ catalytic sub-unit complex with a 101 -kDa regulatory protein, p101 ).
Class 1A PI3Ks comprises α, β and δ isoforms, which are approximately of 1 10 kDa and characterized by the presence of a C-terminal C2 domain.
Class III PI3Ks includes the phosphatidylinositol specific 3-kinases.
The evolutionary conserved isoforms p1 10a and β are ubiquitously expressed, while δ and γ are more specifically expressed in the haematopoetic cell system, smooth muscle cells, myocytes and endothelial cells (Vanhaesebroeck et al., 2001 , Annu. Rev. Biochem., 70, 535- 602). Their expression might also be regulated in an inducible manner depending on the cellular-, tissue type and stimuli as well as disease context. PI3Ks are enzymes involved in phospholipid signalling and are activated in response to a variety of extra-cellular signals such as growth factors, mitogens, integrins (cell-cell interactions) hormones, cytokines, viruses and neurotransmitters and also by intra-cellular cross regulation by other signalling molecules (cross-talk, where the original signal can activate some parallel pathways that in a second step transmit signals to PI3Ks by intracellular signalling events), such as small GTPases, kinases or phosphatases for example. Phosphatidylinositol (Ptdlns) is the basic building block for the intracellular inositol lipids in eukaryotic cells, consisting of D-myo-inositol-1 -phosphate (InsI P) linked via its phosphate group to diacylglycerol. The inositol head group of Ptdlns has five free hydroxy groups and three of these are found to be phosphorylated in cells in different combinations. Ptdlns and its phosphorylated derivatives are collectively referred as inositol phospholipids or phosphoinositides (Pis). Eight PI species have been documented in eukaryotic cells
(Vanhaesebroeck et al., 2001 , above). Pis all reside in membranes and are substrates for kinases, phosphatases and lipases.
In vitro, PI3Ks phosphorylate the 3-hydroxyl group of the inositol ring in three different substrates: phosphatidylinositol (Ptdlns), phosphatidylinositol-4-phosphate (PI(4)P) and phosphatidylinositol-4,5-biphosphate (PI(4,5)P2), respectively generating three lipid products, namely phosphatidylinositol 3-monophosphate (PI(3)P), phosphatidylinositol 3,4- bisphosphate (PI(3,4)P2) and phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3.
The preferred substrate for Class I PI3Ks is PI(4,5)P2. Class II PIKs have a strong prefererence for Ptdlns as substrate over PI(4)P and PI(4,5)P2. Class III PI3Ks can only use Ptdlns as substrate in vivo and are likely to be responsible for the generation of most PI(3)P in cells (Vanhaesebroeck et al., 2001 , above).
The phosphoinositides intracellular signalling pathway begins with the binding of a signalling molecule (extracellular ligands, stimuli, receptor dimidiation, transactivation by heterologous receptor (e.g. receptor tyrosine kinase) to a G-protein linked transmembrane receptor integrated into the plasma membrane resulting in the activation of PI3Ks.
Once activated, PI3Ks convert the membrane phospholipid PI(4,5)P2 into PI(3,4,5)P3 which in turn can be further converted into another 3' phosphorylated form of phosphoinositides by 5'-specific phosphoinositide phosphatases, thus PI3K enzymatic activity results either directly or indirectly in the generation of two 3'-phosphoinositide sub-types that function as second messengers in intra-cellular signal transduction (Toker et al., 2002, Cell Mol. Life Sci. 59(5) 761 -79).
The second messengers of phosphorylated products of Ptdlns is involved in a variety of signal transduction pathways, including those essential to cell proliferation, cell differentiation, cell growth, cell size, cell survival, apoptosis, adhesion, cell motility, cell migration, chemotaxis, invasion, cytoskeletal rearrangement, cell shape changes, vesicle trafficking and metabolic pathway (Stein, 2000, Mol. Med. Today 6(9) 347-57). Chemotaxis - the directed movement of cells toward a concentration gradient of chemical attractants, also called chemokines is involved in many important diseases such as inflammation/auto- immunity, neurodegeneration, angiogenesis, invasion/metastasis and wound healing
(Wyman et al., 2000, Immunol Today 21 (6) 260-4 and Gerard et al., 2001 , Nat Immunol. 2(2) 108-15).
PI3-kinase activation is therefore believed to be involved in a range of cellular responses including cell growth, differentiation, migration and apoptosis (Parker et al., 1995, Current Biology, 5, 577-99; Yao et al., 1995, Science, 267, 2003-05).
Recent biochemical studies revealed that, Class I PI3Ks (e.g. Class IB isoform ΡΙ3Κγ) are dual-specific kinase enzymes, i.e. they display both lipid kinase activity (phosphorylation of phospho-inositides) as well as protein kinase activity, as they are able to induce the phosphorylation of other protein as substrates, including auto-phosphorylation as intramolecular regulatory mechanism.
PI3Ks appear to be involved in a number of aspects of leukocyte activation. A p85- associated PI3-kinase activity has been shown to physically associate with the cytoplasmic domain of CD28, which is an important co-stimulatory molecule for the activation of T-cells in response to antigen. These effects are linked to increases in the transcription of a number of genes including interleukin-2 (IL-2), an important T cell growth factor (Fraser et al., 1991 , Science, 251 , 313-16). Mutation of CD28 such that it can no longer interact with PI3-kinase leads to a failure to initiate IL-2 production, suggesting a critical role for PI3-kinase in T cell activation.
Cellular processes in which PI3Ks play an essential role include suppression of apoptosis, reorganization of the actin skeleton, cardiac myocyte growth, glycogen synthase stimulation by insulin, TNFa-mediated neutrophil priming and superoxide generation, and leukocyte migration and adhesion to endothelial cells.
Recently, it has been described that ΡΙ3Κγ relays inflammatory signals through various G(i)- coupled receptors (Laffargue et al., 2002, Immunity 16(3) 441 -51 ) and its central to mast cell function, stimuli in context of leukocytes, immunology includes cytokines, chemokines, adenosines, antibodies, integrins, aggregation factors, growth factors, viruses or hormones for example (Lawlor et al., 2001 , J. Cell. Sci., 1 14 (Pt 16) 2903-10). Two compounds, LY294002 and Wortmannin (cf.hereinafter), have been widely used as PI3- kinase inhibitors. These compounds are non-specific PI3K inhibitors, as they do not distinguish among the four members of Class I PI3-kinases.
IC50 values of Wortmannin against each of the various Class I PI3-kinases are in the range of 1 -10 nM and IC50 values for LY294002 against each of these PI3-kinases are about 15-20 μΜ (Fruman et al., 1998, Ann. Rev. Biochem., 67, 481 -507), also 5-10 μΜ on CK2 protein kinase and some inhibitory activity on phospholipases.
Wortmannin is a fungal metabolite which irreversibly inhibits PI3K activity by binding covalently to the catalytic domain of this enzyme. Inhibition of PI3K activity by wortmannin eliminates the subsequent cellular response to the extracellular factor (Thelen et al., 1994, Proc. Natl. Acad. Sci. USA, 91 , 4960-64). Experiments with wortmannin, show that PI3K activity in cells of hematopoietic lineage, particularly neutrophils, monocytes, and other types of leukocytes, is involved in many of the non-memory immune response associated with acute and chronic inflammation.
Based on studies using Wortmannin, there is evidence that PI3-kinase function is also required for some aspects of leukocyte signalling through G-protein coupled receptors (Thelen et al., 1994, above). Moreover, it has been shown that Wortmannin and LY294002 block neutrophil migration and superoxide release.
Some results have indicated that PI3K inhibitors, for example, LY294002, can increase the in vivo antitumor activity of certain cytotoxic agents (e.g. paclitaxel) (Grant, 2003, Current Drugs, 6(10), 946-948).
However, these compounds are not selective for a particular isoforms of PI3K, it remains unclear which particular PI3K isoform or isoforms are involved in these phenomena. Specific inhibitors against individual members of a family of enzymes provide valuable tools for deciphering functions of each enzyme as depending on the disease application, varying the degree of selectivity for PI3K isoforms can be of interest.
p1 10 δ is expressed predominantly in cells of hemopoeitic origin such as leukocytes.
To assess the role of the delta isoform of the p1 10 catalytic subunit of PI3Ks, PI3K8-null mice have been developed (Jou et al., 2002, Molecular and Cellular biology, 22(4), 8580-8591 ) and their specific immunological phenotype has been well characterized (Vanhaesebroeck et al., 2005, Trends in Biochemical Sciences, 30(4), 194-204). These experiments show that the PI3K8-null animals are viable and that a deficiency in ΡΙ3Κδ results in a very specific loss of the function of the B-cell antigen specific receptor complex, while signalling through the cytokine receptor complexes is unaffected (Jou et al., 2002, above). It has been also shown that the inactivation of the p1 10δ isoform of PI3K in mast cells leads to defective stem cell factor-mediated in vitro proliferation, adhesion and migration and to impaired allergen-lgE-induced degranualtion and cytokine release. Inactivation of ρ1 10δ protects mice against anaphylactic allergic responses, suggesting p1 10δ as a target for therapeutic intervention in allergy and mast-cell-related pathologies (AN. et al., 2004, Nature, 431 , 1007-1010).
Mast cells have emerged as a unique immune cell that could participate in a variety of inflammatory diseases in the nervous system (e.g. multiple sclerosis), skin, joints as well as cardiopulmonary, intestinal and urinary systems (Theoharides et al., 2004, J. of
Neuroimmunology, 146, 1 -12).
The high relevance of the PI3K pathway in some widely spread diseases stresses the need to develop inhibitors, including selective inhibitors, of PI3K isozymes, in order that the functions of each isozyme can be better characterized.
PI3K inhibitors have been developed: thiazole derivatives (WO 2005/021519; and WO 04/078754), thiazolidine derivatives (WO 2004/007491 and WO 2004/056820) and
Quinazolinones derivatives (WO 03 /035075).
Dihydrochromenopyrazole derivatives have been disclosed (WO2009/010824,
WO2007/075772, and WO2008/035356). The present invention provides new tricyclic pyrazol derivatives and their used as Pi3K modulators.
Summary of the invention
According to one aspect of the invention, are provided compounds of Formula (I).
According to another aspect of the invention, are provided compounds of Formula (I) which are suitable for the treatment and/or prevention of disorders related to phosphoinositide-3- kinases, PI3Ks, such as PI3K alpha or PI3K gamma or PI3K delta or PI3K beta.
According to another aspect of the invention, are provided thichromane compounds, which are able to modulate, especially inhibit the activity or function of phosphoinositide-3-kinases, PI3Ks in disease states in mammals, especially in humans.
According to another aspect of the invention, are provided methods for the treatment and/or prevention of disorders selected from auto-immune, inflammatory disorders, cardiovascular diseases, neurodegenerative disorders, bacterial and viral infections, allergy, asthma, pancreatitis, multi-organ failure, kidney diseases, platelet aggregation, cancer,
transplantation, sperm motility, erythrocyte deficiency, graft rejection, lung injuries, respiratory diseases and ischemic conditions. According to another aspect, the present invention provides compounds of Formula (I) which are selective of the delta isoform of PI3K over the other isoforms.
According to another aspect of the invention is provided a kit or a set comprising at least one compound of Formula (I), preferably in combination with immunomodulating agents.
Preferrably, the kit consists of separate packs of:
(a) an effective amount of a compound of the formula (I) and/or pharmaceutically usable derivatives, solvates, salts, hydrates and stereoisomers thereof, including mixtures thereof in all ratios, and
(b) an effective amount of a further medicament active ingredient.
According to another aspect of the invention, is provided a process for the synthesis of compounds of Formulae (I) and ( ). Detailed description of the invention:
The present invention provides compounds of Formula ( )
(I*) wherein
denotes a nitrogen atom or CR3,
X2, X5 are independently from one another nitrogen or carbon atoms,
U denotes an aromatic 6-membered ring having optionally 1 , 2 or 3 nitrogen atoms, including X5, or an unsaturated or aromatic 5-membered ring having 1 to 3 heteroatoms selected from N, S or O, including the meaning of X5,
Z denotes an unsaturated or aromatic 5-membered heterocyclic ring having 2 nitrogen atoms, including the meaning of X2.
T denotes S, SO or SO ':2, R1 denotes H, A, Hal, CN, N02, N(R6)2, OR6, Ar, Het, Y, -NR6COR6, CON(R6)2,
NR6COAr, NR6COHet, COHet, -NR6S02R6, C02R6, including C02Y,
R2 denotes H, Ar, Het, A, Cyc,
R3 denotes H, Y,
R4 denotes H, Y, (CH2)nAr, (CH2)nCyc, (CH2)nHet, (CH2)nOY, (CH2)nNHY,
(CH2)nNH2, or if X, is CR3, also Hal,
R5 denotes H, Y or Ar, when R5 is Y and r is 2, two R5 groups may be linked
together to provide with the morpholine group to which they are linked, a bridged system.
R6 is H, A, Cyc or Ar.
u is 0, 1 , 2, 3, or 4, preferably 0 or 1 ,
r is 0, 1 or 2,
g is 1 or 2, Ar denotes a monocyclic or fused bicyclic, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF3, N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, -C02R6, CON(R6)2, COHet, -NHCOR6, -NHS02A, -NHS02Ar, - NHS02-N(R6)2, N(H)1-qAqCOR6, N(H)1-qAqS02-N(H)2-m(A)m, -N(H)1-qAqCON(H)2. m(A)m, -S02A, -S02Ar, -S02N(H)2-m(A)m, -S02Het, -(CH2)n-N(R6)2, -(CH2)n-
OR6, -(CH2)n-N(R6)S02A, -(CH2)n-N(R6)S02R6, Het2, -(CH2)n-Het2, -(CHY)n- Het2; denotes a monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 , 2, 3 or 4 N, O and/or S atoms and eventually comprising a S02 or a CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF3, N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, -C02R6, CON(R6)2, -NHCOR6, -NHS02A, -NHS02R6, -NHS02- N(H)2-m(A)m, N(H)1-qAqCOR6, N(H)1-qAqS02-N(H)2-m(A)m, -N(H)1-qAqCON(H)2- m(A)m, -S02A, -S02Ar, -S02N(H)2-m(A)m, COHet, -S02Het, -(CH2)n-N(H)2-m(A)m -(CH2)n-OR6, -(CH2)n-N(R6)S02A, -(CH2)n-N(R6)S02R6, Het2, -(CH2)n-Het2; - (CHY)n-Het2;
Cyc denotes a saturated or unsaturated carbocyclic ring having 3 to 8 carbon atoms, which is unsubstituted, mono-substituted, di-substituted or tri- substituted by Hal, OCF3, N02, CN, perfluoroalkyi, A, OR6, N(R6)2, COR6, CON(R6)2, -NHCOR6, -NHS02A, -NHS02R6, -NHS02-N(H)2-m(A)m, N(H)1- qAqCOR6, N(H)1-qAqS02-N(H)2-m(A)m, -N(H)1-qAqCON(H)2-m(A)m, -COOR6, - S02A, -S02Ar, -S02N(H)2-m(A)m, -S02Het, -(CH2)p-N(H)2-m(A)m, -(CH2)n-OR6, - (CH2)n-N(R6)S02A, -(CH2)n-N(R6)S02R6, Het2, -(CH2)n-Het2; -(CHY)n-Het2;
A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by Hal, Ar, Het, Cyc, OR6, -CN, - C02Y, C02H or N(R6)2 and wherein one or more, preferably 1 to 7 non- adjacent CH2-groups may be replaced by O, NR6, CO, CONR6, NR6CO, OCO, - and/or by -CH=CH- or -C≡C- groups, or denotes cycloalkyl or cycloalkylalkylen having 3-7 ring C atoms;
Y denotes a branched or linear alkyl having 1 to 8 carbon atoms.
Hal denotes F, CI, Br or I, q is O or l , m is 0, 1 or 2, n is 1 , 2, 3, or 4 and pharmaceutically acceptable derivatives, solvates, tautomers, salts, hydrates and stereoisomers thereof, including mixtures thereof in all ratios.
In a specific embodiment, U is an aromatic 6-membered ring having optionally 1 or 2 nitrogen atoms, including the meaning of X5,
In another specific embodiment, X5 is a carbon atom,
In another secific embodiment, X2 is a carbon atom,
In another specific embodiment, X2 and X5 are carbon atoms, U is an aromatic 6-membered ring having optionally 1 or 2 nitrogen atoms, Z is an unsaturated or aromatic 5-membered heterocyclic ring having 2 nitrogen atoms. In another embodiment, X-i is CR3 wherein R3 is as defined above.
In another embodiment, T is S02.
In another embodiment, X2 and X5 are carbon atoms, U is an aromatic 6-membered ring having optionally 1 nitrogen atoms, Z is an unsaturated or aromatic 5-membered heterocyclic ring having 2 nitrogen atoms, T is S02, and Xi is CR3 wherein R3 is as defined above.
In a more specific embodiment, the moiety:
Wherein R1, R2, R3, R4, T, are as defined above.
And wherein
U1, U2, U3, and U4 denote CR1 or one or two of U1, U2, U3 and U4 are independently N, and the remaining are CR1, or one of U1 and U4 is S, U2-U3 form together a group CR1 and the remaining is CR1, or one of U1 and U4 is S, U2-U3 form together a group CR1 and the remaining is N, or denotes the following group
wherein U1 denotes N, U2-U3 form together a group CR1, U4 is CR1, X5 is N, and Z, X1, X2, R2, T, are as above defined.
In a specific embodiment R2 is Ar.
In another specific embodiment, R2 is Het or Cyc.
In another specific embodiment, R2 contains 1 or 2 chiral centers. In a preferred embodiment, the present invention provides compounds of Formula (la*)
(la*)
Wherein, X^ X2, X5, R4, T, R1, Z, U, r and u are as defined above and
wherein
M denotes a saturated or unsaturated 4-, 5-, 6-, 7- or 8-membered ring optinally containing 1 to 3 heteroatoms selected from N, S and O,
The sign * denotes a chiral center,
,M
R' denotes Hal, OCF3, N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, -C02R6,
CON(R6)2, -NHCOR6, -NHS02A, -NHS02R6, -NHS02-N(H)2-m(A)m, N(H)L qAqCOR6, N(H)1-qAqS02-N(H)2-m(A)m, -N(H)1-qAqCON(H)2-m(A)m, -S02A, -S02Ar, -S02N(H)2-m(A)m, COHet, -S02Het, -(CH2)n-N(H)2-m(A)m, -(CH2)n-OR6, -(CH2)n- N(R6)S02A, -(CH2)n-N(R6)S02R6, Het2, -(CH2)n-Het2; or -(CHY)n-Het2;
is 0, 1 , 2, 3 or 4, preferably 0 or 1 . In a more specific embodiment, the invention provides compounds of Formula (I):
(I)
Wherein U1, U2, U3, and U4 are a above defined R2 denotes H, Ar, Het, A, Cyc,
R4 denotes H, Hal, Y, (CH2)nAr, (CH2)nCyc, (CH2)nHet, (CH2)nOY, (CH2)nNHY, (CH2)nNH2,
R3 denotes H, Y,
R5 denotes H, Y or Ar, when R5 is Y and r is 2, two R5 groups may be linked together to provide with the morpholine group a bridged system.
R1 denotes H, A, Hal, CN, N02, N(R6)2, OR6, Ar, Het, Y, -NR6COR6, CON(R6)2, - NR6COAr, NR6COHet, COHet, -NR6S02R6, C02R6, including C02Y,
T denotes S, SO or S02.
r denotes 0, 1 or 2,
Ar denotes a monocyclic or fused bicyclic, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF3, N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, -C02R6, CON(R6)2, COHet, -NHCOR6, -NHS02A, -NHS02Ar, - NHS02-N(R6)2, N(H)1-qAqCOR6, N(H)1-qAqS02-N(H)2-m(A)m, -N(H)1-qAqCON(H) m(A)m, -S02A, -S02Ar, -S02N(H)2-m(A)m, -S02Het, -(CH2)n-N(R6)2, -(CH2)n- OR6, -(CH2)n-N(R6)S02A, -(CH2)n-N(R6)S02R6, Het2, -(CH2)n-Het2; or -(CHY)n- Het2;
Het denotes a monocyclic or bicyclic saturated, unsaturated or aromatic
heterocyclic ring having 1 , 2, 3 or 4 N, O and/or S atoms which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, -C02R6, CON(R6)2, -NHCOR1 -NHS02A, -NHS02R6, -NHS02-N(H)2-m(A)m, N(H)1-qAqCOR6, N(H)1-qAqS02- N(H)2-m(A)m, -N(H)1-qAqCON(H)2-m(A)m, -S02A, -S02Ar, -S02N(H)2-m(A)m, COHet, -S02Het, -(CH2)n-N(H)2-m(A)m, -(CH2)n-OR6, -(CH2)n-N(R6)S02A, - (CH2)n-N(R6)S02R6, Het2, -(CH2)n-Het2; or -(CHY)n-Het2; Cyc denotes a saturated or unsaturated carbocyclic ring having 3 to 8 carbon atoms, which is unsubstituted, mono-substituted, di-substituted or tri- substituted by Hal, OCF3, N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, CON(R6)2, -NHCOR6, -NHS02A, -NHS02R6, -NHS02-N(H)2-m(A)m, N(H)1- qAqCOR6, N(H)1-qAqS02-N(H)2-m(A)m, -N(H)1-qAqCON(H)2-m(A)m, -COOR6, - S02A, -S02Ar, -S02N(H)2-m(A)m, -S02Het, -(CH2)p-N(H)2-m(A)m, -(CH2)n-OR6, -
(CH2)n-N(R6)S02A, -(CH2)n-N(R6)S02R6, Het2, -(CH2)n-Het2; or -(CHY)n-Het2; is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by Hal, Ar, Het, Cyc, OR6, -CN, - C02Y or N(R6)2 and wherein one or more, preferably 1 to 7 non-adjacent CH2 groups may be replaced by O, NR6, CONR6- and/or by -CH=CH- or -C≡C- groups, or denotes cycloalkyi or cycloalkylalkylen having 3-7 ring C atoms; denotes a branched or linear alkyl having 1 to 8 carbon atoms. is H, A, Cyc or Ar.
Hal denotes F, CI, Br or I, is 0 or 1 . m is 0, 1 or 2, n is 1 , 2, 3, or 4
In another embodinnent, the present invention provides compounds of Formula (I) wherein U1, U2, U3, and U4 denote CR1 wherein 2 or 3 of the R1 groups are H, preferably 3 R1 goups are H. In another embodiment, the present invention provides compounds of Formula (I) wherein U1, U2, U3, and U4 denote CH.
In another embodiment, the present invention provides compounds of Formula (I) wherein one of U1 and U4 is S, U2-U3 form together a group CR1 and the remaining is CR1.
In another ambodiment, the present invention provides compounds of Formula
( ) or (I) wherein
R2 denotes H, Ar, Het, A, Cyc,
R3, R4 denote independantly from one another H, Y, (CH2)nAr, (CH2)nCyc, (CH2)nHet R5 denotes H, Y or Ar,
U1, U2, U3, and U4 denote CR1 or one or two of U1, U2, U3 and U4 are independently
N, and the remaining are CR1
R1 denotes H, A, Hal, CN, N02, N(R6)2, OR6, Ar, Het, Y, -NR6COR6, CON(R6)2 T denotes S, - SO or -S02.
r denotes 0, 1 or 2,
Ar denotes a monocyclic or fused bicyclic, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF3, N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, -C02R6, CON(R6)2, COHet, -NHCOR6, -NHS02A, -NHS02Ar, - NHS02-N(R6)2, N(H)1-qAqCOR6, N(H)1-qAqS02-N(H)2-m(A)m, -N(H)1-qAqCON(H)2- m(A)m, -S02A, -S02Ar, -S02N(H)2-m(A)m, -S02Het, -(CH2)n-N(R6)2, -(CH2)n- OR6, -(CH2)n-N(R6)S02A, -(CH2)n-N(R6)S02R6, Het2, -(CH2)n-Het2; or -(CHY)n- Het2;
Het denotes a monocyclic or bicyclic saturated, unsaturated or aromatic
heterocyclic ring having 1 , 2, 3 or 4 N, O and/or S atoms which is
unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF3, N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, -C02R6, CON(R6)2, -NHCOR6, -NHS02A, -NHS02R6, -NHS02-N(H)2-m(A)m, N(H)1-qAqCOR6, N(H)1-qAqS02- N(H)2-m(A)m, -N(H)1-qAqCON(H)2-m(A)m, -S02A, -S02Ar, -S02N(H)2-m(A)m, COHet, -S02Het, -(CH2)n-N(H)2-m(A)m, -(CH2)n-OR6, -(CH2)n-N(R6)S02A, - (CH2)n-N(R6)S02R6, Het2, -(CH2)n-Het2; or -(CHY)n-Het2;
Cyc denotes a saturated carbocyclic ring having 1 to 8 carbon atoms, which is unsubstituted, mono-substituted, di-substituted or tri-substituted by Hal, OCF3 N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, CON(R6)2, -NHCOR6, - NHS02A, -NHS02R6, -NHS02-N(H)2-m(A)m, N(H)1-qAqCOR6, N(H)1-qAqS02- N(H)2-m(A)m, -N(H)1-qAqCON(H)2-m(A)m, -COOR6, -S02A, -S02Ar, -S02N(H)2- m(A)m, -S02Het, -(CH2)p-N(H)2-m(A)m, -(CH2)n-OR6, -(CH2)n-N(R6)S02A, -(CH2)n N(R6)S02R6, Het2, -(CH2)n-Het2; or -(CHY)n-Het2;
A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by Hal, Ar, Het, Cyc, OR6, -CN, - C02Y or N(R6)2 and wherein one or more, preferably 1 to 7 non-adjacent CH2- groups may be replaced by O, NR6, CONR6- and/or by -CH=CH- or -C≡C- groups, or denotes cycloalkyl or cycloalkylalkylen having 3-7 ring C atoms;
Y denotes a branched or linear alkyl having 1 to 8 carbon atoms.
R6 is H, A, Cyc or Ar.
Hal denotes F, CI, Br or I, q is O or l , m is 0, 1 or 2, n is 1 , 2, 3, or 4 and pharmaceutically acceptable derivatives, solvates, tautomers, salts, hydrates and stereo isomers thereof, including mixtures thereof in all ratios.
In the compounds of Formulae (I) and related Formulae, wherein a substituent occurs more than once, such as R5, each of them has the meaning hereby defined, independently from one another. In another embodiment, the invention relates to compounds of formula (A1 )
(A1 )
Wherein R1, R2, R5, r and T are as above defined, and pharmaceutically acceptable derivatives, solvates, tautomers, salts, hydrates and stereoisomers thereof, including mixtures thereof in all ratios.
In a second embodiment, the invention relates to compounds of formula (A2)
(A2)
Wherein R1, R2, R5 and r are as above defined, and pharmaceutically acceptable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.
In another embodiment, the invention relates to the compounds of formula (A3),
(A3)
wherein Q is Ar, Cyc, alkyl having 1 to 8 carbon atoms, or Het, and wherein R1, R3, R4, are as above defined,
and pharmaceutically acceptable derivatives, solvates, tautomers, salts, hydrates and stereoisomers thereof, including mixtures thereof in all ratios.
In another embodiment, the invention relates to the compounds of formula (A4),
wherein R1, R3, R4, R5, T and r are as above defined, and wherein R7a and R7b are independently from one another selected from H, Y, A, Hal, N02, CN, OR6, N(R6)2, COR6, - C02R6, CON(R6)2, COHet, -NHCOA, -NHS02A, -NHS02-N(R6)2, N(H)1-qAqCOA, N(H)1- qAqS02-N(H)2-m(A)m, -N(H)1-qAqCON(H)2-m(A)m, -S02A, -S02N(H)2-m(A)m, -S02Het, -(CH2)n- N(R6)2, -(CH2)n-OR6, -(CH2)n-N(R6)S02A, and pharmaceutically acceptable derivatives, solvates, tautomers, salts, hydrates and stereoisomers thereof, including mixtures thereof in all ratios.
In another embodiment, the invention relates to compounds of Formula (A5):
(A5)
wherein R1 , R2, R3, R4, R5, T and r are as above defined and wherein W is H, Y, Q, - (CH2)PQ, -(CH2)pN(R6)2j -(CH2)POR6,
whereby p is 1 , 2 or 3 and Q is Ar, Cyc, or Het;
In another preferred embodiment, the present invention provides compounds of Formula (A6) or (A7):
(A6) (A7)
As well as a mixture of (A6) and (A7) in all ratios, wherein R1, R3, R4, R5, T, g, and r are as above defined and wherein
R10 denotes perfluoroalkyl, A, COR6, -C02R6, CON(R6)2, COHet, -S02A, -S02Ar, - S02N(H)2-m(A)m, -S02Het, -(CH2)n-N(R6)2, -(CH2)n-OR6, -(CH2)n-N(R6)S02A, -(CH2)n-
N(R6)S02R6, Het2, -(CH2)n-Het2, -(CHY)n-Het2;
Wherein R6, Y, A, m, n, Het and Het2 are as above defined.
Preferably R10 denotes A, Het2, -(CH2)n-Het2, or -(CHY)n-Het2.
More preferably, R10 denotes a branched or linear alkyl having 1 to 6 C-atoms, wherein one or more, preferably 1 to 3 H-atoms may be replaced by Hal, Ar, Het, Cyc, OR6, -CN, wherein R6 is a linear or branched alkyl having 1 to 6 carbon atoms. and pharmaceutically acceptable derivatives, solvates, tautomers, salts, hydrates and stereoisomers thereof, including mixtures thereof in all ratios.
The following compound B1 , referenced under the Registry Number 931355-99-6, is commercially available from ChemDiv Company. This compound was not used for any pharmaceutical or medical indication.
B1
In a preferred embodiment, the compound B1 is excluded from the compounds of the invention.
Above and below, Me refers to a methyl group, Et refers to an ethyl group.
The formula (I), (I*) and related formulae also encompasses mixtures of the compounds of the formula (I), ( ) and related Formulae, for example mixtures of two diastereomers or enantiomers, for example in the ratio 1 :1 , 1 :2, 1 :3, 1 :4, 1 :5, 1 :10, 1 :100 or 1 :1000.
"AlkyI" denotes a carbon chain having 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , or 12 carbon atoms. AlkyI preferably denotes methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1 -, 2- or 3-methylbutyl, 1 ,1 -, 1 ,2- or 2,2-dimethylpropyl, 1 -ethylpropyl, hexyl, 1 -, 2-, 3- or 4-methylpentyl, 1 ,1 -, 1 ,2-, 1 ,3-, 2,2-, 2,3- or 3,3- dimethylbutyl, 1 - or 2-ethylbutyl, 1 -ethyl-1 -methylpropyl, 1 -ethyl-2-methylpropyl, 1 ,1 ,2- or 1 ,2,2-trimethylpropyl, furthermore preferably, for example, trifluoromethyl, pentafluoroethyl or 1 ,1 ,1 -trifluoroethyl.
"Cycloalkylalkylene" or "cycloalkylalylen group" denotes a carbon chain having 1 to 6 carbon atoms wherein 1 H atom is substituted by a cycloalkyl group. Cycloalkylalkylene preferably denotes cyclopropylmethylene, cyclobutylmethylene, cyclopentylmethylene, cyclo- hexylmethylene or cycloheptylmethylene. "Perfluoroalkyl" denotes an alkyl chain having 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms, and wherein all the hydrogen atoms are replaced by F atoms. Perfluoroalkyl more preferably denotes CF3. Hal preferably denotes F, CI or Br.
"Amino" or "amino group" denotes the group -NR'R" where each R', R" is independently hydrogen, Y, Ar, Het, Cyc or A. R and R , together with the nitrogen atom to which they are attached, can optionally form a Het group. R' and R", together with the nitrogen atom to which they are attached, preferrably form a 5-membered unsaturated or aromatic
heterocyclic ring having 1 , 2, 3, or 4, heteroatoms selected in the group of N, O, and S.
Ar preferably denotes a monocyclic or bicyclic, aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by F, CI, Br, CF3, OCF3, N02, CN, A, OR6, N(H)2-m(A)m, -CON(R6)2, COHet, -NHCOA, C02A, - S02A, -S02N(H)2-m(A)m, -S02Het, -(CH2)n-N(R6)S02A,
More particulary, Ar is
where Ra and Rb denote independently from one another H, Hal, N02, A, CN, N(R6)2, - NR6COA , -NR6C02A , -OR6, -C02A, -CON(R6)2, -COHet, -S02N(H)2-m(A)m, -NHS02A, (CH2)n-N(R6)S02A, -S02A, -S02Het, Het, Ar, or Cyc,
wherein R6, A, Ar, Het, Cyc and m are as above defined.
Examples of the preferred Ar groups are selected from the following groups:
Het preferably denotes monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 or 2 heteroatoms selected from N, O and S, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by alkyl having 1 to 8 carbon atoms, Hal, CF3, OCF3, N02, CN, OR6, N(R6)2, CON(R6)2, -C02A, -S02A, -S02N(H)2-m(A)m, COHet, -S02Het, - (CH2)n-OR6, -(CH2)n-N(R6)2.
In one embodiment, Het is preferably the group wherein h is 0, 1 or 2, preferably
1 , and which is optionally substituted by Hal, OCF3, N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, -C02R6, CON(R6)2, -NHCOR6, -NHS02A, -NHS02R6, -NHS02-N(H)2-m(A)m, N(H)1- qAqCOR6, N(H)1-qAqS02-N(H)2-m(A)m, -N(H)1-qAqCON(H)2-m(A)m, -S02A, -S02Ar, -S02N(H)2- m(A)m, COHet, -S02Het, -(CH2)n-N(H)2-m(A)m, -(CH2)n-OR6, -(CH2)n-N(R6)S02A, -(CH2)n- N(R6)S02R6, Het2, -(CH2)n-Het2; -(CHY)n-Het2;
Het more preferably denotes one of the following groups
wherein Ra and Rb are as above defined.
Preferably, Ra and Rb denote independently from one another one of the following groups: Y, H, Hal, N02, CN, -(CH2)n-NH-S02Y, -0(CH2)n-N(H)2-m(Y)m, -NH(CH2)n-N(H)2-m(Y)m, - NH(CH2)n-OH, -NH(CH2)n-OY, -0-(CH2)n-OH, -0-(CH2)n-OY, OH, OY, -(CH2)n-OY, -(CH2)n- OH, -(CH2)n-N(H)2-m(Y)m, -NHCOY, -NHC02Y, -CF3, Het2, -(CH2)n-Het2; -(CHY)n-Het2;
whereby Y, m, and n are as above defined.
The group -(CH2)n-Het2 preferably denotes , wherein n is as above defined. Preferrably n is 2.
Y preferably denotes a branched or linear alkyl having 1 to 6 carbon atoms.
T preferably denotes SO or S02. Cyc preferably denotes a saturated carbocyclic ring having 1 to 8 carbon atoms, which is unsubstituted, mono-substituted, or di-substituted by alkyl having 1 to 8 carbon atoms, alkoxy having 1 to 8 carbon atoms, Hal, CF3, OCF3, N02, CN, perfluoroalkyl, OH, NH2, COH, C02H, CONH2, -(CH2)n-OR6, whereby R6 and n are as above defined.
Most preferably, Cyc denotes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and
cycloheptyl. R3 and R4 preferably denote H or Y.
Most preferably, both R3 and R4 denote H.
Alternatively, R3 also denotes (CH2)nAr, (CH2)nCyc, (CH2)nHet, (CH2)nOY, (CH2)nNHY, (CH2)nNH2.
In case Xi is a nitrogen atom, R4 is preferably Y, (CH2)nAr, (CH2)nCyc, (CH2)nHet, (CH2)nOY, (CH2)nNHY, (CH2)nNH2, R1 preferably denotes H, OR6, Hal, CN, N02, -(CH2)n-N(R6)2, -0(CH2)n-N(R6)2, -NR6-(CH2)n- N(R6)2, -NR6-(CH2)n-OR6, -NR6-C02R6, -NR6-COR6.
More preferably, R1 is H or Hal.
R2 is preferably selected from H, a linear or branched CrC6-alkyl or one of the following groups:



31
32
33
More preferrably, R6 denotes H or A.
More preferably, the group A denotes a branched or linear alkyl having 1 to 8 C-atoms, wherein one or more, preferably 1 to 3 H-atoms may be replaced by Hal, Ar, Het, Cyc, OR6, - CN, -C02Y or N(R6)2 and wherein one or more, preferably 1 to 3 non-adjacent CH2-groups may be replaced by O, NR6, CONR6- and/or by -CH=CH- or -C≡C- groups, or denotes cycloalkyl or cycloalkylalkylen having 3-7 ring C atoms; In a preferred embodiment, the invention provides compounds of Formula (I) wherein R5 is H.
In another preferred embodiment, the invention provides compounds of formula (I) wherein one of U1, U2, U3 and U4 is N and the remaining are CR1 whereby R1 is as above defined. In another preferred embodiment, the invention provides compounds of formula (I) wherein R2 denotes H, Y, Ar, Het or Cyc, R3 and R4 are both H.
In another preferred embodiment, the present invention provides compounds of Formula (I) wherein R2 denotes H, Y, Ar, Het or Cyc, R3 and R4 are both H, T is S02.
In another preferred embodiment, the present invention provides compounds of Formula (I) wherein R2 denotes H, Y, Ar, Het or Cyc, R3 and R4 are both H, T is S02, and Ui, U2, U3 and U4 are CR1.
Most preferably, the invention relates to compounds of Formula (I), (I*) and related Formulae, selected from the following group. In the table below, in case the structures contain one or more stereogenic centers, the respective structure is depicted in an arbitrary absolute configuration. These structures also include the respective structure having the opposite stereochemistry and the corresponding racemate:
50
Synthesis of compounds of the invention The following abbreviations refer respectively to the definitions below:
aq (aqueous), h (hour), g (gram), L (liter), mg (milligram), MHz (Megahertz), μΜ
(micormolar), min. (minute), mm (millimeter), mmol (millimole), mM (millimolar), m.p. (melting point), eq (equivalent), mL (milliliter), μΙ_ (microliter), ACN (acetonitrile), BOC (tert- butoxy-carbonyl), CBZ (carbobenzoxy), CDCI3 (deuterated chloroform), CD3OD (deuterated methanol), CH3CN (acetonitrile), c-hex (cyclohexane), DCC (dicyclohexyl carbodiimide),
DCM (dichloromethane), DIC (diisopropyl carbodiimide), DIEA (diisopropylethyl-amine), DMA (dimethylacetamide), DMF (dimethylformamide), DMSO (dimethylsulfoxide), DMSO-d6 (deuterated dimethylsulfoxide), EDC (1 -(3-dimethyl-amino-propyl)-3-ethylcarbodiimide), ESI (Electro-spray ionization), EtOAc (ethyl acetate), Et20 (diethyl ether), EtOH (ethanol), FMOC (fluorenylmethyloxycarbonyl), HATU (dimethylamino-([1 ,2,3]triazolo[4,5-b]pyridin-3-yloxy)- methylene]-dimethyl-ammonium hexafluorophosphate), HPLC (High Performance Liquid Chromatography), i-PrOH (2-propanol), K2C03 (potassium carbonate), LC (Liquid
Chromatography), MeCN (Acetonitrile), MeOH (methanol), MgS04 (magnesium sulfate), MS (mass spectrometry), MTBE (Methyl tert-butyl ether), Mtr. (4-Methoxy-2, 3, 6- trimethylbenzensulfonyl), MW(microwave), NaHC03 (sodium bicarbonate), NaBH4 (sodium borohydride), NMM (N-methyl morpholine), NMR (Nuclear Magnetic Resonance), POA (phenoxyacetate), PyBOP (benzotriazole-1 -yl-oxy-tris-pyrrolidino-phosphonium
hexafluorophosphate), RT (room temperature), Rt (retention time), SPE (solid phase extraction), T3P (propane phosphonic acid anhydride), tBu (tert-butyl), TEA (triethylamine), TFA (trifluoroacetic acid), THF (tetrahydrofuran), TLC (Thin Layer Chromatography), UV (Ultraviolet).
The following general methods and procedures described hereinafter in the examples may be used to prepare compounds of formula (I) and related formulae. The compounds according to Formula (I) may be prepared from readily available starting materials using the following general methods and procedures. If such starting materials are not commercially available they may be prepared by standard synthetic techniques. It will be appreciated that where typical or preferred experimental conditions (i.e. reaction
temperatures, time, stoechiometry of reagents, solvents, etc.) are given, other experimental conditions can also be used unless otherwise stated. Generally, the compounds according to the general Formula (I) may be obtained by several processes using both solution-phase and/or solid-phase chemistry protocols. Examples of synthetic pathways for the preparation of compounds according to the general Formula (I) are described herebelow. Optimum reaction conditions may vary with particular reactants or solvents used, but such conditions can be determined by the person skilled in the art, using routine optimization procedures.
Below, all substituents, such as Q,R1, R2, R3, R4, R5, R6, T, Ui, U2, U3, U4, A, Het, Ar, m, n, r and p have the meaning indicated under the formulae (I) and ( ), unless expressly stated otherwise. Depending on the nature of R1,R2, R3, R4, R5, Ui, U2, U3, and U4, different synthetic strategies may be selected for the synthesis of compounds of Formula (I). In general, the synthesis pathways for any individual compound of Formula (I) or (I*) will depend on the specific substitutents of each molecule and upon the availability of intermediates; again such factors being appreciated by those skilled in the art. For all the protection and deprotection methods, see Philip J. Kocienski, in "Protecting Groups", Georg Thieme Verlag Stuttgart, New York, 1994 and, Theodora W. Greene and Peter G. M. Wuts in "Protective Groups in Organic Synthesis", Wiley Interscience, 3rd Edition 1999. The compounds according to Formula ( ) may be prepared following the synthetic pathway described in the general scheme A:
Scheme A:
(I*)
Wherein R5, g, R4, R2, R1, T, U, Z, X-i , X2, X5, u and r are as above defined and wherein V denotes H or Y.
As a representative example, the compounds according to Formula (I) may be prepared following the synthetic pathways described in the general scheme 1. According to a preferred synthetic pathway, compounds of Formula (I), may be prepared from the corresponding derivatives of Formula (lb), by one or two alkylation reaction with R3-X (and possibly R4-X) where X is a leaving group such as a halogen or a sulfonate group and wherein R3 and R4 are as defined above. Preferred conditions consist in the treatment of compounds of Formula (lb) with a base such as NaH followed by addition of alkyl or benzyl halide in a suitable solvent such as THF at room temperature.
Scheme 1
Compounds of Formula (lb) may be prepared from the corresponding derivatives of Formula (lib), wherein R2 is as above defined and V denotes H or Y which is as defined above, either directly by reaction of compounds of Formula (lib) where V is Y with an amine, or via the hydrolysis of the ester (lib) into an acid wherein V is H and subsequent coupling with an amine. Starting from the acid (lib) wherein V is H, compounds of formula (lb) can be obtained using usual conditions for the formation of an amide starting from a carboxylic acid and an amine by using coupling agents such as DCC, DIC, EDC, HATU or via the formation of an acid chloride or an activated ester. Preferred conditions consist in the treatment of compounds of Formula (lib) with a solution of propane phosphonic acid anhydride 50% in EtOAc followed with the addition of morpholine derivatives (D), wherein R5 and r are as defined above, in the presence of a base such as triethylamine in a suitable solvent such as THF at room temperature. Another preferred condition is the pre-treatment of amine derivative D with AICI3 or AIMe3 followed by the addition of compounds of formulae (lib) where V is an alkyl group in a suitable solvent such as DCM or THF at a temperature between 0°C to 50°C. The corresponding carboxylic acid can be obtained by hydrolysis of the corresponding esters using reagents such as, but not limited to, LiOH, NaOH or KOH in solvents such water, alcohol, THF, dioxane, or mixture thereof.
Compounds (lib) may be prepared from compounds of Formula (I la) by alkylation reaction with R2-X wherein X is a halogen or a sulfonate group. Preferred conditions consist in the treatment of compounds of formula (I la) with an alkyl halide in the presence of a base such as potassium carbonate, in a suitable solvent such as acetonitrile at a temperature between room temperature and 60°C.
An alternative pathway for the synthesis of compounds of Formula (lb) consists in alkylating compounds of Formula (la) with R2-X wherein X is a halogen or a sulfonate group. Preferred conditions consist in the treatment of compounds of formula (la) with an alkyl halide in the presence of a base such as potassium carbonate in a suitable solvent such as acetonitrile at a temperature between room temperature and 60°C.
Compounds of Formula (la) may be prepared from the corresponding derivatives of Formula (I la), wherein R2 and V are as defined above, either directly by reaction with a morpholine derivative D, or via the hydrolysis of the ester (lib) into an acid wherein V is H and
subsequent coupling with a morpholine derivative D. Starting from the acid (lib) wherein V is H, compounds of formula (la) can be obtained using usual conditions for the formation of an amide starting from a carboxylic acid and an amine by using coupling agent such as DCC, DIC, EDC, HATU or via the formation of an acid chloride or an activated ester. Preferred conditions consist in the treatment of compounds of Formula (lib) with 50% propane phosphonic acid anhydride in EtOAc followed with the addition of morpholine derivative D, wherein R5 and r are as defined above, in a suitable solvent such as THF, at room
temperature. Another preferred condition is the pre-treatment of amine derivative D with AICI3 or AIMe3 followed by the addition of compounds of formulae (lib) where V is an alkyl group in a suitable solvent such as DCM or THF at a temperature between 0°C to 50°C.
The corresponding carboxylic acid can be obtained by hydrolysis of esters using reagents such as, but not limited to, LiOH, NaOH or KOH in solvents such water, alcohol, THF, dioxane, or mixture thereof. Compounds of Formula (lla) and Formula (lib) may be prepared from compounds of Formula (III) by cyclization with hydrazine, substituted hydrazines, and protected hydrazines, e.g. hydrazine having a PG group,wherein R2 is as defined above, respectively (scheme 2).
Hydrazine derivatives VII may or may not be protected by a protecting group such as a Boc group. Preferred conditions consist in the treatment of compounds (III) with hydrazine derivatives in a presence of an acid such as acetic acid in a suitable solvent such as methanol or ethanol at reflux. Another preferred condition is the treatment of compounds (III) with Boc-hydrazine derivatives in a presence of an acid such as HCI in a suitable solvent such as ethanol at reflux.
Compounds of Formula (III) may be prepared from compounds of Formula (IV) by reaction with V-OCOCO-X, wherein V and X are as defined above, in the presence of a base.
Preferraby, the base is a metal alkoxide. Preferred conditions consist in the treatment of compounds (IV) with butyl lithium and then V-OCOCO-X in a suitable solvent such as THF, MTBE or Toluene at a temperature between -78°C and room temperature. Preferably, V- OCOCO-X is the diethyl oxalate. Other preferred conditions consists in the treatment of compounds (IV) with sodium ethoxide and then diethyloxalate in a suitable solvent such as toluene or MTBE at a temperature between 0°C and room temperature. Compounds of Formulae (I), (la), (lb), (lla) and (lib) may be converted to alternative compounds of Formulae (I), (la), (lb), (lla) and (lib) respectively, using suitable
interconversion procedures such as those described hereinafter in the examples, or conventional interconversion procedures, well known by one skilled in the art. Compounds of Formulae (I), (la), (lb), (lla) and (lib), wherein T is S may be converted to the corresponding compounds of Formulae (I), (la), (lb), (lla) and (lib), wherein T is SO or S02, by oxidation. Preferred conditions consist in the treatment of compounds of Formulae (I), (la), (lb), (lla) and (lib) by hydrogen peroxide 30% in water in a suitable solvent such as acetic acid at a temperature of 100°C.
Scheme 2
Mb
Compounds of Formula (IV) wherein Ui, U2, U3 and U4 are as defined above, (e.g. Ui, U2, U3 and U4 denote CR1) may be obtained either from commercial sources or they may be prepared from compounds of Formula (V) by Friedel-Craft type reaction (scheme 3).
Preferred conditions consist in the treatment of compounds (V) by oxalyl chloride and by tin (IV) chloride in a suitable solvent such as dichloromethane at a temperature between 0°C and room temperature. Other preferred conditions consist in the treatment of compounds (V) with polyphosphoric acid at a temperature ranging from 80°C to 120°C. Compounds of formulae (IV) wherein Ui, denote N and U2, U3 and U4 denote CR1 may be obtained either from commercial sources or following procedure described in Journal of Heterocyclic Chemistry, 37(2), 379-382; 2000.
Compounds of formulae (IV) wherein U3, denotes N and Ui, U2 and U4 denote CR1 may be obtained following procedure described in Journal of Heterocyclic Chemistry, 37(2), 379-382; 2000 starting from 4-chloronicotinic acid.
Compounds of formulae (IV) wherein Ui denotes S and U2-U3 and U4 denote CR1 to form a 5 member ring may be obtained either from commercial sources or following procedure described in Tetrahedron, 54(21 ), 5599-5606; 1998.
Compounds of formulae (IV) wherein U4 denotes S and U2-U3 and Ui denote CR1 to form a 5 member ring may be obtained either from commercial sources or following procedure described in Tetrahedron, 54(21 ), 5599-5606; 1998 starting from 3-bromothiophene. Compounds of formulae (IV) wherein U4 denotes N, Ui denotes S and U2-U3 denotes CR1 to form a 5 member ring may be obtained either from commercial sources or following procedure described in Tetrahedron, 54(21 ), 5599-5606; 1998 starting from ie f-butyl (5- bromo-1 ,3-thiazol-2-yl)carbamate.
Scheme 3
Compounds of Formula (V), wherein Ui, U2, U3 and U4 are as defined as above, may be prepared from compounds of Formula (VI) by alkylation. Preferred conditions consist in the treatment of compounds of formula (VI) by G4-CH2CH2CO-G3, wherein G4 is halogen and G3 is OH or OY, whereby Y is as above defined, in the presence of a base such as potassium carbonate in a suitable solvent such as dimethylformamide at a temperature of 60°C.
Preparation of compounds of general formulae (VII) is described in general scheme 4.
Compounds of formulae (Vila) or (VI lb), wherein R2 is Ar or Het and PG represents a protecting group, including by way of non limiting examples, carabamate groups or alkyl groups, may be prepared from compounds of formulae (IX) and R2-X when R2 is an aryl or heteroaryl group. X is then either an halogen or a sulfonate group and coupling is catalysed by a metal as described in Journal of Organic Chemistry, 74(12), 4542-4546; 2009. Preferred conditions consist in the treatment of compounds of formulae (IX) with aryl halide, preferably iodine derivatives, in the presence of copper iodide and Cs2C03 in a suitable solvent such as DMSO at a temperature between 50°C and 100°C.
Compounds of formulae (Vila), wherein G1CHG2 represents R2 may be prepared from compounds of formulae (VIII) by a reduction reaction (scheme 4B). Preferred conditions consist in the treatment of compounds of formulae (VIII) with sodium cyanoborohydride in a suitable solvent such as a mixture of acetic acid and water at a temperature between 0°C and RT.
Compounds of formulae (Vile) and (VI Id), wherein G1CHG2 represents R2 may be prepared from compounds of formulae (VIII) by reduction with hydrogen in the presence of suitable catalysts or ligands/catalysts. Appropriate choice of ligand and/or catalyst and/or protecting group can either favour the formation of (Vile) or the formation of (VI Id). The use of achiral conditions gives compounds of formulae (Vila). For chiral reduction, preferred conditions consist in the treatment of compounds of formulae (VIII) with bis(cycloocat-1 ,5- dien)rhodium(l)tetrafluoroborate and one enantiomer of Josiphos ligand under a pressure of 30 bar of hydrogene in a suitable solvent such as MeOH at RT.
Compounds of formulae (VIII), wherein G1 and G2 are independently from one another H or A or G1 and G2 together represent Cyc, may be prepared from compounds of formulae G1COG2 by reaction with hydrazine derivatives (IX) (scheme 4B). Preferred conditions consist in the treatment of derivatives G1COG2 with Boc-hydrazine, in a suitable solvent such as toluene at a temperature of 60°C. Enantiomers Vile and VI Id result from an asymmetric reduction of compound VIII. This reaction can be perform using a known asymmetric reduction or one of the procedures detailed below in the experimental part.
Scheme 4
IX
Vila Vllb
Scheme 4B
Vlld
Preparation of compounds of general formulae (A) wherein R5, R2, R4, T and U1, U2, U3 U4 are as above defined is described in general scheme 5. Compounds of formulae (A) wherein R4 is as above defined may be prepared either by reaction of derivatives of formulae (lc) with compounds of formulae R4-X wherein X is a halogen or a sulfonate group or by
intramolecular cyclisation of compounds of formulae (Xb). Preferred conditions for the alkylation are the treatment of compounds of formulae (lc) with sodium hydride in a suitable solvent such as THF followed by the addition of an alkyl halide at a temperature ranging from 0°C to 50°C. Preferred conditions for the intramolecular cyclisation are the treatment of compounds of formulae (Xb) with a palladium source such as palladium acetate, a ligand such as triphenylphosphine and a base such as Cs2C03 in a suitable solvent such as toluene at a temperature ranging from 80°C to 1 10°C. Compounds of formulae (lc) may either be prepared from derivatives of formulae (Xa) following palladium cataysed cyclisation reaction described above or by dealkylation of compounds of formulae (A) when R4 is an alkyl ether protecting group such as a MOM group. Preferred conditions for the cleavage of a MOM protecting group are the treatment of compounds of formulae (A) with a suitable acid such as HCI in a suitable solvent such as dioxane at a temperature of 100°C. Compounds of formulae (Xb) may be prepared from derivatives of formulae (Xa) by treatment of compounds of formulae (Xa) with alkyl derivatives R4-X wherein X is a halogen or a sulfonate group and where R4 is as above defined. Preferred conditions for the alkylation are the treatment of compounds of formulae (lc) with sodium hydride in a suitable solvent such as THF followed by the addition of an alkyl halide at a temperature ranging from 0°C to 50°C
Compounds of formulae (Xa), where T is S02, may be prepared by reaction of compounds of formulae (XI) with sulfonylchloride derivatives. Preferred conditions are the treatment of compounds of formulae (XI) with sulfonyl chloride derivatives in a suitable solvent such as DCM in the presence of a base such as pyridine or TEA at RT.
Compounds of formulae (XI) may be prepared from compounds of formulae (XII) by a reduction reaction. Preferred conditions are the treatment of nitro derivatives (XII) with Pd/C 10% in a suitable solvent such as AcOEt under one atmosphere of hydrogen at RT.
Compounds (XII) may be prepared from compounds of formulae (XIII) by a coupling reaction with compounds of formulae R2-Y* wherein Y* is a boronic acid or boronic ester group.
Preferred conditions consist in the treatment of compounds of formulae (XIII) with an aromatic boronic acid in the presence of a base such as TEA and copper acetate, in a suitable solvent such as DCM at a temperature between RT and 60°C.
Compounds of formulae (XIII) may be prepared from the corresponding derivatives of formulae (XIV), wherein V is as defined above, following conditions described for general scheme 1.
Scheme 5
dealkylation
Preparation of compounds of general formulae (B) wherein R5, R2, T and U2, U3 are as above defined is described in general scheme 6. Compounds of formulae (B) may be prepared from the corresponding derivatives of formulae (lie), wherein V is as defined above, following conditions described for general scheme 1 .
Compounds of formulae (lie) may be prepared from derivatives of formulae (XV) by a intramolecular cyclisation reaction. Preferred conditions for the intramolecular cyclisation are the treatment of compounds of formulae (XV) with Cul in the presence or not of a ligand such as Λ/,/V-dimethylglycine in a suitable solvent such as DMSO at a temperature ranging from 100°C to 180°C.
Compounds of formulae (XV) may be prepared by nucleophilic substitution on derivatives of formulae (XVIc) with compounds of formulae E wherein T is a thiol group and U2, U3 represents CR1. Preferred conditions are the treatment of compounds of formulae (XVIc) wherein X are bromine atoms, R2 represents an aryl or an heteroaryl and V respresents an ethyl group with a thiol derivative E in the presence of a base such as K2C03 in a suitable solvent such as ACN at a temperature ranging from RT to 90°C.
Compounds of formulae (XVIc) may be prepared from derivatives of formulae (XVIb) by an halogenation reaction. Preferred conditions conditions are the treatment of compounds of formulae (XVIb) with a brominating agent such as phosphorus tribromide in a suitable solvent such as Et20 at a temperature ranging from 0°C to RT.
Compounds of formulae (XVIb) may be prepared from derivatives of formulae (XVIa) by a reduction reaction. Preferred conditions are the treatment of compounds of formulae (XVIa) with a reductive agent such as sodium borohydride in a suitable solvent such as a mixture of THF and EtOH at a temperature between 0°C to RT.
Compounds of formulae (XVIa) may be prepared from derivatives of formulae (XVII) by a Vilsmeier-Haack reaction. Preferred conditions are the treatment of compounds of formulae (XVII) with phosphorus oxy bromide and DMF in a suitable solvent such as DCM at a temperature ranging from 50°C to 100°C.
Compounds of formulae (XVII) may be obtained either from commercial sources or following the procedure described in Synthesis (2003), (15), 2353-2357.
Scheme 6
XV Preparation of compounds of general formulae (C) wherein R5, R2, T and U1, U2, U3 U4 are as above defined is described in general scheme 7. Compounds of formulae (C) may be prepared from the corresponding derivatives of formulae (lid), wherein V is as defined above, following conditions described for general scheme 1 .
Compounds (lid) may be prepared from compounds of formulae (lie) by reaction with R2-X wherein X is a halogen or a sulfonate group. Preferred conditions consist in the treatment of compounds of formulae (lie) with an alkyl halide in the presence of Cul and PdOAc in a suitable solvent such as DMF at a temperature ranging from 100°C to 150°C.
Compounds of formulae (lie) may be obtained from compounds of formulae (XVIII) by cyclisation reaction with compounds F where V is as above defined. Preferred conditions are the treatment of compounds of formulae (XVIII) with a base such as potassium ie f-butoxide and diethyl chloro phosphonate followed by the addition of ethyl isocyano acetate in a suitable solvent such as DMF at a temperature ranging from 0°C to RT.
Compounds of formulae (XVIII) wherein T, U1 U2, U3 and U4 are as above defined may be obtained either from commercial sources or following procedure described in Journal of Medicinal Chemistry (2010), 53(17), 6386-6397
Scheme 7
Compounds of Formula (I*) can be obtained following the procedures outlined in schemes 1 to 8 wherein compound D is replaced by compounds D*:
Wherein g is as above defined. In a specific embodiment, the present invention provides a process wherein compounds of Formula (I) or ( ) wherein T is S are oxydised to compounds of Formula (I) or ( ) wherein T is S02. This oxidation step is performed using usual oxydizing agents, including mCPBA,
Compounds of formulae (I), (I*), (la), (lb), (Ic), (lla), (lib), (lie), (lid), (lie), (A), (B) and (C) may be converted to alternative compounds of formulae (I), (la), (lb), (Ic), (lla), (lib), (lie), (lid), (lie), (A), (B) and (C) respectively, using suitable interconversion procedures such as those described hereinafter in the examples, or conventional interconversion procedures, well known by one skilled in the art. Compounds of formulae (I), (I*), (la), (lb), (lla), (lib), (lie), (lid), (lie), (B) and (C) wherein T is S may be converted to the corresponding compounds of formulae (I), (la), (lb), (Ic), (lla), (lib), (lid), (lie), (B) and (C), wherein T is SO or S02, by oxidation. Preferred conditions consist in the treatment of compounds of formulae (I), (la), (lb), (Ic), (lla), (lib), (lie), (lid), (lie), (A), (B) and (C) by hydrogen peroxide 30% in water in a suitable solvent such as acetic acid at a temperature of 100°C or treatment of compounds of formulae (I), (la), (lb), (Ic), (lla), (lib), (lie), (lid), (lie), (A), (B) and (C) by meta-chloroperbenzoic acid in a suitable solvent such as DCM at a temperature between RT and 50°C. Compounds of Formula (VI), E, F, (IX), XIV), (XVII), (XVIII) and reagents of Formulae G3- CH2CH2CO-G4, V-OCOCO-X, H2N-NH-R2, R2-X, morpholine derivatives D, D*, R3-X and R4-X may be obtained either from commercial sources or they may be prepared from known compounds using procedures such as those described hereinafter in the examples, or conventional procedures, well known by one skilled in the art.
If the above set of general synthetic methods is not applicable to obtain compounds according to Formula (I) and/or necessary intermediates for the synthesis of compounds of Formula (I), suitable methods of preparation known by a person skilled in the art should be used.
Compounds of this invention can be isolated in association with solvent molecules by crystallization from an appropriate solvent or by evaporation of an appropriate solvent. The pharmaceutically acceptable anionic salts of the compounds of Formula (I), ( ) and related Formulae, which contain a basic center, may be prepared in a conventional manner. For example, a solution of the free base may be treated with a suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent.
Compounds of the formula (I), (I*) and related formulae can furthermore be obtained by liberating compounds of the formula (I), ( ) and related Formulae from one of their functional derivatives by treatment with a solvolysing or hydrogenolysing agent. Preferred starting materials for the solvolysis or hydrogenolysis are those which conform to the formula (I), ( ) and related formulae, but contain corresponding protected amino and/or hydroxyl groups instead of one or more free amino and/or hydroxyl groups, preferably those which carry an amino-protecting group instead of an H atom bonded to an N atom, in particular those which carry an R*-N group, in which R* denotes an amino-protecting group, instead of an HN group, and/or those which carry a hydroxyl-protecting group instead of the H atom of a hydroxyl group, for example those which conform to the formula (I), (I*) and related Formulae, but carry a -COOR** group, in which R** denotes a hydroxyl-protecting group, instead of a -COOH group. It is also possible for a plurality of - identical or different - protected amino and/or hydroxyl groups to be present in the molecule of the starting material. If the protecting groups present are different from one another, they can in many cases be cleaved off selectively. The term "amino-protecting group" is known in general terms and relates to groups which are suitable for protecting (blocking) an amino group against chemical reactions, but which are easy to remove after the desired chemical reaction has been carried out elsewhere in the molecule. Typical of such groups are, in particular, unsubstituted or substituted acyl, aryl, aralkoxymethyl or aralkyl groups. Since the amino-protecting groups are removed after the desired reaction (or reaction sequence), their type and size are furthermore not crucial; however, preference is given to those having 1 -20, in particular 1 -8, carbon atoms.
The term "acyl group" is to be understood in the broadest sense in connection with the present process. It includes acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids, and, in particular, alkoxycarbonyl,
aryloxycarbonyl and especially aralkoxycarbonyl groups. Examples of such acyl groups are alkanoyl, such as acetyl, propionyl and butyryl; aralkanoyl, such as phenylacetyl; aroyl, such as benzoyl and tolyl; aryloxyalkanoyl, such as POA; alkoxycarbonyl, such as methoxy- carbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC (tert-butoxycarbonyl) and 2- iodoethoxycarbonyl; aralkoxycarbonyl, such as CBZ ("carbobenzoxy"), 4- methoxybenzyloxycarbonyl and FMOC; and arylsulfonyl, such as Mtr. Preferred amino- protecting groups are BOC and Mtr, furthermore CBZ, Fmoc, benzyl and acetyl.
The term "hydroxyl-protecting group" is likewise known in general terms and relates to groups which are suitable for protecting a hydroxyl group against chemical reactions, but are easy to remove after the desired chemical reaction has been carried out elsewhere in the molecule. Typical of such groups are the above-mentioned unsubstituted or substituted aryl, aralkyl or acyl groups, furthermore also alkyl groups. The nature and size of the hydroxyl- protecting groups are not crucial since they are removed again after the desired chemical reaction or reaction sequence; preference is given to groups having 1 -20, in particular 1 -10, carbon atoms. Examples of hydroxyl-protecting groups are, inter alia, benzyl, 4- methoxybenzyl, p-nitrobenzoyl, p-toluenesulfonyl, tert-butyl and acetyl, where benzyl and tert-butyl are particularly preferred. The compounds of the formula (I), ( ) and related formulae are liberated from their functional derivatives - depending on the protecting group used - for example strong inorganic acids, such as hydrochloric acid, perchloric acid or sulfuric acid, strong organic carboxylic acids, such as trichloroacetic acid, TFA or sulfonic acids, such as benzene- or p-toluenesulfonic acid. The presence of an additional inert solvent is possible, but is not always necessary. Suitable inert solvents are preferably organic, for example carboxylic acids, such as acetic acid, ethers, such as tetrahydrofuran or dioxane, amides, such as DMF, halogenated hydrocarbons, such as dichloromethane, furthermore also alcohols, such as methanol, ethanol or isopropanol, and water. Mixtures of the above-mentioned solvents are furthermore suitable. TFA is preferably used in excess without addition of a further solvent, and perchloric acid is preferably used in the form of a mixture of acetic acid and 70% perchloric acid in the ratio 9:1 . The reaction temperatures for the cleavage are advantageously between about 0 and about 50°C, preferably between 15 and 30°C (room temperature). The BOC, OtBut and Mtr groups can, for example, preferably be cleaved off using TFA in dichloromethane or using approximately 3 to 5N HCI in dioxane at 15-30°C, and the FMOC group can be cleaved off using an approximately 5 to 50% solution of dimethylamine, diethylamine or piperidine in DMF at 15-30°C. Protecting groups which can be removed hydrogenolytically (for example CBZ, benzyl or the liberation of the amidino group from the oxadiazole derivative thereof) can be cleaved off, for example, by treatment with hydrogen in the presence of a catalyst (for example a noble- metal catalyst, such as palladium, advantageously on a support, such as carbon). Suitable solvents here are those indicated above, in particular, for example, alcohols, such as methanol or ethanol, or amides, such as DMF. The hydrogenolysis is generally carried out at temperatures between about 0 and 100°C and pressures between about 1 and 200 bar, preferably at 20-30°C and 1 -10 bar. Hydrogenolysis of the CBZ group succeeds well, for example, on 5 to 10% Pd/C in methanol or using ammonium formate (instead of hydrogen) on Pd/C in methanol/DMF at 20-30°C.
Esters can be hydrolysed, for example, using HCI, H2S04, or using LiOH, NaOH or KOH in water, water/THF, water/THF/ethanol or water/dioxane, at temperatures between 0 and 100°C. Free amino groups can furthermore be acylated in a conventional manner using an acyl chloride or anhydride or alkylated using an unsubstituted or substituted alkyl halide, advantageously in an inert solvent, such as dichloromethane or THF and/or in the presence of a base, such as triethylamine or pyridine, at temperatures between -60°C and +30°C.
The formula (I) and related formulae also encompasses the optically active forms (stereoisomers), the enantiomers, the racemates, the diastereomers and the hydrates and solvates of these compounds. The term "solvates of the compounds" is taken to mean adductions of inert solvent molecules onto the compounds which form owing to their mutual attractive force. Solvates are, for example, mono- or dihydrates or alcoholates.
The term "hydrates of the compounds" refers to compounds of formula (I) associated with 1 , 2, 3 or 4 molecules of water. Preferably, hydrates are mono- or dihydrates.
Use can also be made here of variants which are known per se, but are not mentioned here in greater detail.
If desired, the starting materials can also be formed in situ so that they are not isolated from the reaction mixture, but instead are immediately converted further into the compounds of the formula (I).
The starting compounds for the preparation of compounds of formula (I) and related formulae are generally known. If they are novel, they can, however, be prepared by methods known per se.
The reactions are preferably carried out in an inert solvent.
Examples of suitable inert solvents are hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1 ,2- dichloroethane, tetrachloromethane, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether or ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethyl- formamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as formic acid or acetic acid; esters, such as ethyl acetate, or mixtures of the said solvents.
In another aspect, the invention relates to a mixture of several compounds of formula (I), ( ) and related Formulae preferably a mixture of 2 to 10 compounds, more preferably, a mixture of 2 or 3 compounds of Formula (I). In another aspect, the invention may also encompass isomers, stereoisomers, diasteroisomers, enentiomers, as well as geometric isomers of compounds of Formula (I) or (I*). The invention also encompasses mixtures of isomers, e.g. stereoisomers, diasteroisomers, enentiomers and geometric isomers, of compounds of Formula (I), ( ) and related Formulae.
In a further aspect, the invention provides pharmaceutically acceptable derivatives, solvates, hydrates, tautomers, salts and stereoisomers of Formula (I), ( ) and related Formulae.
Accordingly, the invention relates, in particular, to the use of compounds of formula (I), (I*) and related formulae as defined above, as a medicament.
Accordingly, the invention relates, in particular, to the use of compounds of the formula(l), ( ) and related formulae as defined above, for the preparation of pharmaceutical formulations for the prevention and/or the treatment of inflammatory or autoimmune diseases, multiple sclerosis, cancers and related disorders.
The present invention also encompasses the metabolites of compounds of formula (I).
The said compounds of the formula (I), ( ) and related formulae can be used in their final non-salt form. On the other hand, the present invention also relates to the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases by procedures known in the art.
Pharmaceutically acceptable salt forms of the compounds of the formula (I), (I*) and related Formulae are for the most part prepared by conventional methods. If the compound of the formula (I), ( ) and related formulae contains an acidic center, such as a carboxyl group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base-addition salt. Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; alkaline earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, for example sodium- or potassium methoxide and sodium or potassiumpropoxide, alkalihydrides, such as sodium- or potassiumhydride; and various organic bases, such as piperidine, diethanolamine and N-methyl-glutamine, benzathine, choline, diethanolamine, ethylenediamine, meglumine, benethamine, diethylamine, piperazine and tromethamine. The aluminium salts of the compounds of the formula (I), (I*) and related formulae are likewise included. In the case of certain compounds of the formula I and related formulae, which contain a basic center, acid-addition salts can be formed by treating these compounds with pharmaceutically acceptable organic and inorganic acids, for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoaryl-sulfonates, such as ethanesulfonate, toluenesulfonate and benzene-sulfonate, and other organic acids and corresponding salts thereof, such as acetate, trifluoro-acetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like. Accordingly, pharmaceutically acceptable acid-addition salts of the compounds of the formula (I), ( ) and related formulae include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzene-sulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphor-sulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclo-pentane-propionate, digluconate, dihydrogen-phosphate, dinitrobenzoate, dodecyl-sulfate, ethanesulfonate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptanoate, gluco-nate, glutamate, glycerophosphate, hemi-succinate, hemisulfate, heptanoate, hexanoate, hippurate, hydro-chloride, hydrobromide, hydroiodide, 2-hydroxy-ethane-sulfonate, iodide, isethionate, isobutyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, mono-hydrogen-phosphate, 2- naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, palmo-ate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate, phthalate, but this does not represent a restriction. Both types of salts may be formed or interconverted preferably using ion-exchange resin techniques.
Furthermore, the base salts of the compounds of the formula (I), ( ) and related formulae include aluminium, ammonium, calcium, copper, iron(lll), iron(ll), lithium, magne-sium, manganese(lll), manganese(ll), potassium, sodium and zink salts, but this is not intended to represent a restriction. Of the above-mentioned salts, preference is given to ammonium; the alkali metal salts sodium and potassium, and the alkaline earth metal salts calcium and magnesium. Salts of the compounds of the formula I which are derived from
pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, also including naturally occurring substituted amines, cyclic amines, and basic ion exchanger resins, for example arginine, betaine, caffeine, chloroprocaine, choline, Ν,Ν'-dibenzyl-ethylen-ediamine (benzathine), dicyclohexylamine, diethanol-amine, diethyl-amine, 2-diethyl-amino-ethanol, 2-dimethyl-amino-ethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethyl-piperidine, glucamine, glucosamine, histidine, hydrabamine, isopropyl-amine, lido-caine, lysine, meglumine (N- methyl-D-glucamine), morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanol-amine, triethylamine, trimethylamine, tripropyl-amine and tris(hydroxy-methyl)-methylamine (tromethamine), but this is not intended to represent a restriction.
Compounds of the formula (I), ( ) and related formulae of the present invention which contain basic nitrogen-containing groups can be quaternised using agents such as (C C4)-alkyl halides, for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; di(Ci-C4)alkyl sulfates, for example dimethyl, diethyl and diamyl sulfate; (Ci0-Ci8)alkyl halides, for example decyl, do-decyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and aryl-(Ci-C4)alkyl halides, for example benzyl chloride and phenethyl bromide. Both water- and oil-soluble compounds of the formula I can be prepared using such salts.
The above-mentioned pharmaceutical salts which are preferred include acetate,
trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate,
hydrochloride, hydrobromide, isethionate, mandelate, me-glumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stea-rate, sulfate, subsalicylate, tartrate, thiomalate, tosylate and tro-meth-amine, but this is not intended to represent a restriction.
As mentioned, the pharmaceutically acceptable base-addition salts of the compounds of the formula (I), ( ) and related Formulae are formed with metals or amines, such as alkali metals and alkaline earth metals or organic amines. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanol-amine, ethylenediamine, N-methyl-D-glucamine and procaine.
If a compound of the formula (I), ( ) and related formulae contains more than one group which is capable of forming pharmaceutically acceptable salts of this type, the formula (I), ( ) and related Formulae also encompass multiple salts. Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, di-phosphate, disodium and trihydrochloride, but this is not intended to represent a restriction. With regard to that stated above, it can be seen that the term "pharmaceutically acceptable salt" in the present connection is taken to mean an active ingredient which comprises a compound of the formula (I), ( ) and related formulae in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared with the free form of the active ingredient or any other salt form of the active ingredient used earlier. The pharmaceutically acceptable salt form of the active ingredient can also provide this active ingredient for the first time with a desired
pharmacokinetic property which it did not have earlier and can even have a positive influence on the pharmacodynamics of this active ingredient with respect to its therapeutic efficacy in the body.
The term "leaving group" or "leaving groups" denotes an atom or a group of atoms easily cleaved, hydrolysed or substituted with a reagent. Preferred leaving groups are halogens, alkylsulfonates, arylsulfonates, alcoholates or activated esters.
The term "reducing agent" denotes a reagent able to donate electrons. Preferred reducing agents are Boranes, Catecholborane, Copper hydride, Copper (low valent), Chromium (low valent), Decaborane, DIBAL-H, Diborane, Diethyl 1 ,4-dihydro-2,6-dimethyl-3,5- pyridinedicarboxylate, Diisobutylaluminium hydride, Dimethylsulfide borane, DMSB, Fe,
Formaldehyde, Formic acid, Hantzsch Ester, Hydrazine, Hydrogen, Indium (low valent), Iron, Isopropanol, LAH, Lithium, Lithium aluminum hydride, Lithium tetrahydridoaluminate, LiBH4, Magnesium, Manganese, 3-Mercaptopropionic acid, 3-MPA, Neodymium (low valent), Nickel, Nickel borohydride, Niobium (low valent), Phenylsilane, PMHS, Polymethylhydrosiloxane, Potassium, 2-Propanol, Red-AI, Rongalite, Samarium (low valent), Silanes, Sodium,
Sodium bis(2-methoxyethoxy)aluminumhydride, Sodium borohydride, Sodium
cyanoborohydride, Sodium dithionite, Sodium hydrosulfite, Sodium hydroxymethanesulfinate, Sodium tetrahydroborate, Sodium triacetoxyborohydride, Strontium, Tetramethyldisiloxane, Tin hydrides, Titanium (low valent), TMDSO, Tributylstannane, Tributyltin hydride,
Trichlorosilane, Triphenylphosphine, Triphenylphosphite, Triethylsilane,
Tris(trimethylsilyl)silane, TTMSS, Zinc.
The term "prodrug derivatives" or "prodrug" is taken to mean compounds of the formula (I) or ( ) which have been modified with, for example, alkyl or acyl groups, sugars or oligopeptides and which are rapidly cleaved in the organism to form the active compounds. These also include biodegradable polymer derivatives of the compounds according to the invention, as described, for example, in Int. J. Pharm. 1 15, 61 -67 (1995).
The term "metabolite" designates compounds of formula (I) or (I*) which have been modified within the organism, through the reactions naturally occuring in the body.
Owing to their molecular structure, the compounds of the formula (I), ( ) and related formulae can be chiral and can accordingly occur in various enantiomeric forms. They can therefore exist in racemic or in optically active form.
Since the pharmaceutical activity of the racemates or stereoisomers of the compounds according to the invention may differ, it may be desirable to use the enantiomers. In these cases, the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art or even employed as such in the synthesis.
In the case of racemic amines, diastereomers are formed from the mixture by reaction with an optically active resolving agent. Examples of suitable resolving agents are optically active acids, such as the R and S forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitable N-protected amino acids (for example N- benzoylproline or N-benzenesulfonylproline), or the various optically active camphorsulfonic acids. Also advantageous is chromatographic enantiomer resolution with the aid of an optically active resolving agent (for example dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of carbohydrates or chirally derivatised methacrylate polymers immobilised on silica gel). Suitable eluents for this purpose are aqueous or alcoholic solvent mixtures, such as, for example, hexane/isopropanol/ acetonitrile, for example in the ratio 82:15:3.
The invention furthermore relates to the use of compounds of Formula (I) or (I*) for the manufacture of a medicament for the prevention and/or the treatment of the diseases associated to Phosphoinositide 3-kinases disorders.
The invention also relates to the use of compounds of Formula (I) or (I*) for the manufacture of a medicament for the prevention and/or the treatment of inflammatory diseases, autoimmune disorder, multiple sclerosis, cancers, and related disorders. In particular, the present invention relates to the use of compounds of Formula (I) or (I*) for the manufacture of a medicament for the prevention and/or treatment of Rheumatoid arthritis, Asthma and other autoimmune diseases selected from Acute disseminated
encephalomyelitis (ADEM), Addison's disease, Alopecia areata, Ankylosing spondylitis, Antiphospholipid antibody syndrome (APS), Autoimmune hemolytic anemia, Autoimmune hepatitis, Autoimmune inner ear disease, Bullous pemphigoid, Behget's disease, Coeliac disease, Anti-transglutaminase, Chagas disease, Chronic obstructive pulmonary disease, Crohns Disease, Dermatomyositis, Diabetes mellitus type 1 , Endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome (GBS), Hashimoto's disease,
Hidradenitis suppurativa, Kawasaki disease, IgA nephropathy, Idiopathic thrombocytopenic purpura, Interstitial cystitis, Lupus erythematosus, Mixed Connective Tissue Disease, Morphea, Multiple sclerosis (MS), Myasthenia gravis, Narcolepsy, Neuromyotonia,
Pemphigus vulgaris, Pernicious anaemia, Psoriasis, Psoriatic Arthritis, Polymyositis, Primary biliary cirrhosis, Schizophrenia, Scleroderma, Sjogren's syndrome, Stiff person syndrome, Temporal arteritis, Ulcerative Colitis, Vasculitis, Vitiligo, Wegener's granulomatosis.
The invention also relates to the use of compounds of Formula (I) or (I*) for the manufacture of a medicament for the prevention and/or the treatment of the disease selected from the group consisting of amyotrophic lateral sclerosis (ALS), systemic lupus erythematosus, chronic rheumatoid arthritis, lupus, dermatomyositis, autoimmune neuropathies, immune thrombocytopenic purpura, haemolytic anaemia, inflammatory bowel disease, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, bone marrow or organ transplant rejection or graft-versus-host disease, Hashimoto's thyroiditis, myasthenia gravis, uveitis, posterior uveitis, rheumatic fever inflammatory and hyperproliferative skin diseases, atopic dermatitis, contact dermatitis, areata, keratoconjunctivitis, autoimmune hemolytic anemia, agranulocytosis, cutaneous T cell lymphoma, chronic lymphocytic leukemia, arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa, lung cancer, carcinogenesis, metastasis of carcinoma and hypobaropathy, disease caused by histamine or leukotriene-C4 release, autoimmune hepatitis, primary biliary cirrhosis, parkison diseases.
The invention furthermore relates to the use of compounds of formula (I), ( ) and related formulae in combination with at least one further medicament active ingredient, preferably medicaments used in the treatment of inflammatory diseases or immune disorders such as methotrexate, leflunomide, rituxan, or anti-TNF like enbrel (etanercept), remicade
(infliximab), humira (adalimumab), or with immunomodulating agents such as Fingolimod, cyclosporins, rapamycins or ascomycins, or their immunosuppressive analogs, e.g.
cyclosporin A, cyclosporin G, FK-506, ABT-281 , ASM981 , rapamycin, 40-O-(2-hydroxy)ethyl- rapamycin etc.; corticosteroids; cyclophosphamide; azathioprene; mizoribine; mycophenolic add; mycophenolate mofetil; 15-deoxyspergualine; diflucortolone valerate; difluprednate; Alclometasone dipropionate; amcinonide; amsacrine; asparaginase; azathioprine;
basiliximab; beclometasone dipropionate; betamethasone; betamethasone acetate;
betamethasone dipropionate; betamethasone phosphate sodique; betamethasone valerate; budesonide; captopril; chlormethine chlorhydrate; cladribine; clobetasol propionate; cortisone acetate; cortivazol; cyclophosphamide; cytarabine; daclizumab; dactinomycine; desonide; desoximetasone; dexamethasone; dexamethasone acetate; dexamethasone isonicotinate; dexamethasone metasulfobenzoate sodique; dexamethasone phosphate;dexamethasone tebutate;dichlorisone acetate; doxorubicine chlorhydrate; epirubicine chlorhydrate;
fluclorolone acetonide; fludrocortisone acetate; fludroxycortide; flumetasone pivalate;
flunisolide; fluocinolone acetonide; fluocinonide; fluocortolone; fluocortolone hexanoate; fluocortolone pivalate; fluorometholone; fluprednidene acetate; fluticasone propionate;
gemcitabine chlorhydrate; halcinonide; hydrocortisone, hydrocortisone acetate,
hydrocortisone butyrate, hydrocortisone hemisuccinate; melphalan; meprednisone;
mercaptopurine; methylprednisolone; methylprednisolone acetate; methylprednisolone hemisuccinate; misoprostol; muromonab-cd3; mycophenolate mofetil; paramethasone acetate; prednazoline, prednisolone; prednisolone acetate; prednisolone caproate;
prednisolone metasulfobenzoate sodique; prednisolone phosphate sodique; prednisone; prednylidene; rifampicine; rifampicine sodique; tacrolimus; thalidomide; thiotepa; tixocortol pivalate; triamcinolone; triamcinolone acetonide hemisuccinate; triamcinolone benetonide; triamcinolone diacetate; triamcinolone hexacetonide; immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD40, CD45 or CD58 or their ligands; or other immunomodulatory compounds, e.g. CTLA41 g, or other adhesion molecule inhibitors, e.g. mAbs or low molecular weight inhibitors including Selectin antagonists and VLA-4 antagonists. A preferred composition is with Cyclosporin A, FK506, rapamycin or 40-(2-hydroxy)ethyl-rapamycin and Fingolimod. These further medicaments, such as interferon beta, may be administered concomitantly or sequentially, e.g. by subcutaneous, intramuscular or oral routes.
The invention furthermore relates to the use of compounds of formula (I) and related formulae in combination with at least one further medicament active ingredient, preferably medicaments used in the treatment of cancer wherein said antitumoral compounds are selected from those well known by the one skilled in the related art. These compositions can be used as medicaments in human and veterinary medicine. Other embodiments: Embodiments 1 : A compound of
(I)
wherein
R2 denotes H, Ar, Het, A, Cyc,
R3, R4 denote independantly from one another H, Y, (CH2)nAr, (CH2)nCyc, (CH2)nHet R5 denotes H, Y or Ar,
U1, U2, U3, and U4 denote CR1 or one or two of U1, U2, U3 and U4 are independently
N, and the remaining are CR1
R1 denotes H, A, Hal, CN, N02, N(R6)2, OR6, Ar, Het, Y, -NR6COR6, CON(R6)2 T denotes S, SO or S02.
r denotes 0, 1 or 2,
Ar denotes a monocyclic or fused bicyclic, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF3, N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, -C02R6, CON(R6)2, COHet, -NHCOR6, -NHS02A, -NHS02Ar, - NHS02-N(R6)2, N(H)1-qAqCOR6, N(H)1-qAqS02-N(H)2-m(A)m, -N(H)1-qAqCON(H)2- m(A)m, -S02A, -S02Ar, -S02N(H)2-m(A)m, -S02Het, -(CH2)n-N(R6)2, -(CH2)n- OR6, -(CH2)n-N(R6)S02A, -(CH2)n-N(R6)S02R6;
Het denotes a monocyclic or bicyclic saturated, unsaturated or aromatic
heterocyclic ring having 1 , 2, 3 or 4 N, O and/or S atoms which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF3, N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, -C02R6, CON(R6)2, -NHCOR6, -NHS02A, -NHS02R6, -NHS02-N(H)2-m(A)m, N(H)1-qAqCOR6, N(H)1-qAqS02- N(H)2-m(A)m, -N(H)1-qAqCON(H)2-m(A)m, -S02A, -S02Ar, -S02N(H)2-m(A)m, COHet, -S02Het, -(CH2)n-N(H)2-m(A)m, -(CH2)n-OR6, -(CH2)n-N(R6)S02A, - (CH2)n-N(R6)S02R6;
Cyc denotes a saturated carbocyclic ring having 1 to 8 carbon atoms, which is unsubstituted, mono-substituted, di-substituted or tri-substituted by Hal, OCF3 N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, CON(R6)2, -NHCOR6, - NHS02A, -NHS02R6, -NHS02-N(H)2-m(A)m, N(H)1-qAqCOR6, N(H)1-qAqS02- N(H)2-m(A)m, -N(H)1-qAqCON(H)2-m(A)m, -COOR6, -S02A, -S02Ar, -S02N(H)2- m(A)m, -S02Het, -(CH2)p-N(H)2-m(A)m, -(CH2)n-OR6, -(CH2)n-N(R6)S02A, -(CH2)n N(R6)S02R6;
A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by Hal, Ar, Het, Cyc, OR6, -CN, - C02Y or N(R6)2 and wherein one or more, preferably 1 to 7 non-adjacent CH2 groups may be replaced by O, NR6, CONR6- and/or by -CH=CH- or -C≡C- groups, or denotes cycloalkyi or cycloalkylalkylen having 3-7 ring C atoms;
Y denotes a branched or linear alkyl having 1 to 8 carbon atoms.
R6 is H, A or Ar.
Hal denotes F, CI, Br or I, q is O or l , m is 0, 1 or 2, n is 1 , 2, 3, or 4 and pharmaceutically acceptable derivatives, solvates, tautomers, salts, hydrates and stereoisomers thereof, including mixtures thereof in all ratios, for use as a
medicament. Embodiment 2: A compound of Formula (I) according to embodiment 1 for the prevention and/or treatment of the diseasediseases associated to Phosphoinositide 3-kinases disorders.
Embodiment 3: A compound according to embodiment 2 wherein the disease is inflammatory disease, autoimmune disorder, cancer or multiple sclerosis and related disorders.
Embodiment 4: A compound according to embodiment 3 wherein the autoimmune disease is selected from the group consisting of Asthma, Rheumatoid arthritis, Acute disseminated encephalomyelitis (ADEM), Addison's disease, Alopecia areata, Ankylosing spondylitis, Antiphospholipid antibody syndrome (APS), Autoimmune hemolytic anemia, Autoimmune hepatitis, Autoimmune inner ear disease, Bullous pemphigoid, Behget's disease, Coeliac disease, Anti-transglutaminase, Chagas disease, Chronic obstructive pulmonary disease, Crohns Disease, Dermatomyositis, Diabetes mellitus type 1 , Endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome (GBS), Hashimoto's disease, Hidradenitis suppurativa, Kawasaki disease, IgA nephropathy, Idiopathic thrombocytopenic purpura, Interstitial cystitis, Lupus
erythematosus, Mixed Connective Tissue Disease, Morphea, Multiple sclerosis (MS), Myasthenia gravis, Narcolepsy, Neuromyotonia, Pemphigus vulgaris, Pernicious anaemia, Psoriasis, Psoriatic Arthritis, Polymyositis, Primary biliary cirrhosis, Rheumatoid arthritis, Schizophrenia, Scleroderma, Sjogren's syndrome, Stiff person syndrome, Temporal arteritis, Ulcerative Colitis, Vasculitis, Vitiligo, Wegener's granulomatosis
Embodiment 5: A kit consisting of separate packs of :
(a) an effective amount of a compound of the formula (I) and/or pharmaceutically usable derivatives, solvates, salts, hydrates and stereoisomers thereof, including mixtures thereof in all ratios, and
(b) an effective amount of a further medicament active ingredient. Embodiment 6: A Pharmaceutical compositions containing at least one of the compounds of Formula (I) according to any one of embodiment 1 to 5.
Embodiment 7: A pharmaceutical composition according to embodiment 6 wherein compounds of formula (I) are combined with at least one further medicament used in the treatment of inflammatory diseases or immune disorders.
Embodiment 8: A pharmaceutical composition according to embodiment 7 wherein compounds of Formula (I) are combined with at least one further immunomodulating agents.
Embodiment 9: A process for producing compounds of Formula (I) according to embodiment 1 to 5, wherein R3 and R4 are both H, comprising the step of reacting compounds of Formula (lib)
Mb
wherein V is H or Y, and wherein R2, T, Y and Ui, U2, U3 and U4 are as defined in embodiment 1 ,
with a morpholine derivative D:
D
wherein R5 and r are as defined in embodiment 1 ,
or reacting compounds of Formula (la)
wherein R5, r, T and Ui, U2, U3 and U4 are as defined in embodiment 1 wwiitthh ccoommppoouunnddss ooff ffcormula R2-X, wherein R2 is as defined in embodiment 1 and X is a leaving group.
Embodiment 10: A process according to embodiment 9 further comprising the step of reaction a compound of Formula
wherein R5, R2, r, T and Ui, U2, U3 and U4 are as defined in embodiment 1 , with R3-X and R4-X,
wherein X is a leaving group and R3 and R4 are as defined in embodiment 1.
Pharmaceutical formulations can be administered in the form of dosage units, which comprise a predetermined amount of active ingredient per dosage unit. Such a unit can comprise, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a compound according to the invention, depending on the disease condition treated, the method of administration and the age, weight and condition of the patient, or pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit. Preferred dosage unit formulations are those which comprise a daily dose or part-dose, as indicated above, or a corresponding fraction thereof of an active ingredient. Furthermore, pharmaceutical formulations of this type can be prepared using a process, which is generally known in the pharmaceutical art.
Pharmaceutical formulations can be adapted for administration via any desired suitable method, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) methods. Such formulations can be prepared using all processes known in the pharmaceutical art by, for example, combining the active ingredient with the excipient(s) or adjuvant(s). Pharmaceutical formulations adapted for oral administration can be administered as separate units, such as, for example, capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
Thus, for example, in the case of oral administration in the form of a tablet or capsule, the active-ingredient component can be combined with an oral, non-toxic and pharmaceutically acceptable inert excipient, such as, for example, ethanol, glycerol, water and the like.
Powders are prepared by comminuting the compound to a suitable fine size and mixing it with a pharmaceutical excipient comminuted in a similar manner, such as, for example, an edible carbohydrate, such as, for example, starch or mannitol. A flavour, preservative, dispersant and dye may likewise be present.
Capsules are produced by preparing a powder mixture as described above and filling shaped gelatine shells therewith. Glidants and lubricants, such as, for example, highly disperse silicic acid, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form, can be added to the powder mixture before the filling operation. A disintegrant or solubiliser, such as, for example, agar-agar, calcium carbonate or sodium carbonate, may likewise be added in order to improve the availability of the medica-ment after the capsule has been taken.
In addition, if desired or necessary, suitable binders, lubricants and disintegrants as well as dyes can likewise be incorporated into the mixture. Suitable binders include starch, gelatine, natural sugars, such as, for example, glucose or beta-lactose, sweeteners made from maize, natural and synthetic rubber, such as, for example, acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. The lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. The disintegrants include, without being restricted thereto, starch, methylcellulose, agar, bentonite, xanthan gum and the like. The tablets are formulated by, for example, preparing a powder mixture, granulating or dry- pressing the mixture, adding a lubricant and a disintegrant and pressing the entire mixture to give tablets. A powder mixture is prepared by mixing the compound comminuted in a suitable manner with a diluent or a base, as described above, and optionally with a binder, such as, for example, carboxymethylcellulose, an alginate, gelatine or polyvinyl-pyrrolidone, a dissolution retardant, such as, for example, paraffin, an absorption accelerator, such as, for example, a quaternary salt, and/or an absorbant, such as, for example, bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting it with a binder, such as, for example, syrup, starch paste, acadia mucilage or solutions of cellulose or polymer materials and pressing it through a sieve. As an alternative to granulation, the powder mixture can be run through a tableting machine, giving lumps of non-uniform shape which are broken up to form granules. The granules can be lubricated by addition of stearic acid, a stearate salt, talc or mineral oil in order to prevent sticking to the tablet casting moulds. The lubricated mixture is then pressed to give tablets. The active ingredients can also be combined with a free-flowing inert excipient and then pressed directly to give tablets without carrying out the granulation or dry-pressing steps. A transparent or opaque protective layer consisting of a shellac sealing layer, a layer of sugar or polymer material and a gloss layer of wax may be present. Dyes can be added to these coatings in order to be able to differentiate between different dosage units.
Oral liquids, such as, for example, solution, syrups and elixirs, can be prepared in the form of dosage units so that a given quantity comprises a pre-specified amount of the compounds. Syrups can be prepared by dissolving the compounds in an aqueous solution with a suitable flavour, while elixirs are prepared using a non-toxic alcoholic vehicle. Suspensions can be for-mulated by dispersion of the compounds in a non-toxic vehicle. Solubilisers and emulsifiers, such as, for example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavour additives, such as, for example, peppermint oil or natural sweeteners or saccharin, or other artificial sweeteners and the like, can likewise be added.
The dosage unit formulations for oral administration can, if desired, be encapsulated in microcapsules. The formulation can also be prepared in such a way that the release is extended or retarded, such as, for example, by coating or embedding of particulate material in polymers, wax and the like.
The compounds of the formula (I), ( ) and related formulae and salts, solvates and physiologically functional derivatives thereof and the other active ingredients can also be administered in the form of liposome delivery systems, such as, for exam-pie, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from various phospholipids, such as, for example, cholesterol, stearylamine or phosphatidylcholines. The compounds of the formula (I), ( ) and related formulae and the salts, solvates and physiologically functional derivatives thereof and the other active ingredients can also be delivered using monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds can also be coupled to soluble polymers as targeted medicament carriers. Such polymers may encompass polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl-methacrylamidophenol, polyhydroxyethylaspartamido-phenol or polyethylene oxide polylysine, substituted by palmitoyl radicals. The compounds may furthermore be coupled to a class of biodegradable polymers which are suitable for achieving controlled release of a medicament, for example polylactic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, poly-orthoesters, polyacetals, polydihydroxypyrans,
polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
Pharmaceutical formulations adapted for transdermal administration can be administered as independent plasters for extended, close contact with the epidermis of the recipient. Thus, for example, the active ingredient can be delivered from the plaster by iontophoresis, as described in general terms in Pharmaceutical Research, 3(6), 318 (1986).
Pharmaceutical compounds adapted for topical administration can be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
For the treatment of the eye or other external tissue, for example mouth and skin, the formulations are preferably applied as topical ointment or cream. In the case of formulation to give an ointment, the active ingredient can be employed either with a paraffinic or a water- miscible cream base. Alternatively, the active ingredient can be formulated to give a cream with an oil-in-water cream base or a water-in-oil base.
Pharmaceutical formulations adapted for topical application to the eye include eye drops, in which the active ingredient is dissolved or sus-pended in a suitable carrier, in particular an aqueous solvent.
Pharmaceutical formulations adapted for topical application in the mouth encompass lozenges, pastilles and mouthwashes. Pharmaceutical formulations adapted for rectal administration can be administered in the form of suppositories or enemas.
Pharmaceutical formulations adapted for nasal administration in which the carrier substance is a solid comprise a coarse powder having a particle size, for example, in the range 20-500 microns, which is administered in the manner in which snuff is taken, i.e. by rapid inhalation via the nasal passages from a container containing the powder held close to the nose.
Suitable formulations for administration as nasal spray or nose drops with a liquid as carrier substance encompass active-ingredient solutions in water or oil.
Pharmaceutical formulations adapted for administration by inhalation encompass finely particulate dusts or mists, which can be generated by various types of pressurised dispensers with aerosols, nebulisers or insuf-flators. Pharmaceutical formulations adapted for vaginal administration can be administered as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
Pharmaceutical formulations adapted for parenteral administration include aqueous and nonaqueous sterile injection solutions comprising antioxidants, buffers, bacteriostatics and solutes, by means of which the formulation is rendered isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions, which may comprise suspension media and thickeners. The formulations can be administered in single-dose or multidose containers, for example sealed ampoules and vials, and stored in freeze-dried (lyophilised) state, so that only the addition of the sterile carrier liquid, for example water for injection purposes, immediately before use is necessary.
Injection solutions and suspensions prepared in accordance with the recipe can be prepared from sterile powders, granules and tablets. It goes without saying that, in addition to the above particularly mentioned constituents, the formulations may also comprise other agents usual in the art with respect to the particular type of formulation; thus, for example, formulations which are suitable for oral administration may comprise flavours. A therapeutically effective amount of a compound of the formula (I), ( ) and related formulae and of the other active ingredient depends on a number of factors, including, for example, the age and weight of the animal, the precise disease condition which requires treatment, and its severity, the nature of the formulation and the method of administration, and is ultimately determined by the treating doctor or vet. However, an effective amount of a compound is generally in the range from 0.1 to 100 mg/kg of body weight of the recipient (mammal) per day and particularly typically in the range from 1 to 10 mg/kg of body weight per day. Thus, the actual amount per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can be administered as an individual dose per day or usually in a series of part-doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same. An effective amount of a salt or solvate or of a physiologically functional derivative thereof can be determined as the fraction of the effective amount of the compound per se. The present invention furthermore relates to a method for treating a subject suffering from a PI3K related disorder, comprising administering to said subject an effective amount of a compound of formula I and related formulae. The present invention preferably relates to a method, wherein the PI3K associated disorder is an autoimmune disorder or condition associated with an overactive immune response or cancer. The present invention
furthermore relates to a method of treating a subject suffering from an immunoregulatory abnomality, comprising administering to said subject a compound of formula (I), ( ) and related formulae in an amount that is effective for treating said immunoregulatory
abnormality. The present invention preferably relates to a method wherein the
immunoregulatory abnormality is an autoimmune or chronic inflammatory disease selected from the group consisting of: allergic diseases, amyotrophic lateral sclerosis (ALS), systemic lupus erythematosus, chronic rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's
granulomatosis, ichthyosis, Graves ophthalmopathy and asthma. The present invention furthermore relates to a method wherein the immunoregulatory abnormality is bone marrow or organ transplant rejection or graft-versus-host disease. The present invention furthermore relates to a method wherein the immunoregulatory abnormality is selected from the group consisting of: transplantation of organs or tissue, graft-versus-host diseases brought about by transplantation, autoimmune syndromes including rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, posterior uveitis, allergic encephalomyelitis, glomerulonephritis, post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis, inflammatory and hyperproliferative skin diseases, psoriasis, atopic dermatitis, contact dermatitis, eczematous dermatitis, seborrhoeic dermatitis, lichen planus, pemphigus, bullous pemphigoid, epidermolysis bullosa, urticaria, angioedemas, vasculitis, erythema, cutaneous eosinophilia, lupus erythematosus, acne, alopecia areata, keratoconjunctivitis, vernal conjunctivitis, uveitis associated with Behcet's disease, keratitis, herpetic keratitis, conical cornea, dystrophia epithelialis corneae, corneal leukoma, ocular pemphigus, Mooren's ulcer, scleritis, Graves' opthalmopathy, Vogt-Koyanagi-Harada syndrome, sarcoidosis, pollen allergies, reversible obstructive airway disease, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust asthma, chronic or inveterate asthma, late asthma and airway hyper-responsiveness, bronchitis, gastric ulcers, vascular damage caused by ischemic diseases and thrombosis, ischemic bowel diseases, inflammatory bowel diseases, necrotizing enterocolitis, intestinal lesions associated with thermal burns, coeliac diseases, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease, ulcerative colitis, migraine, rhinitis, eczema, interstitial nephritis, Goodpasture's syndrome, hemolytic-uremic syndrome, diabetic nephropathy, multiple myositis, Guillain-Barre syndrome, Meniere's disease, polyneuritis, multiple neuritis, mononeuritis, radiculopathy, hyperthyroidism, Basedow's disease, pure red cell aplasia, aplastic anemia, hypoplastic anemia, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, agranulocytosis, pernicious anemia, megaloblastic anemia, anerythroplasia, osteoporosis, sarcoidosis, fibroid lung, idiopathic interstitial pneumonia, dermatomyositis, leukoderma vulgaris, ichthyosis vulgaris, photoallergic sensitivity, cutaneous T cell lymphoma, chronic lymphocytic leukemia, arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritis nodosa, myocardosis, scleroderma, Wegener's granuloma, Sjogren's syndrome, adiposis, eosinophilic fascitis, lesions of gingiva, periodontium, alveolar bone, substantia ossea dentis, glomerulonephritis, male pattern alopecia or alopecia senilis by preventing epilation or providing hair germination and/or promoting hair generation and hair growth, muscular dystrophy, pyoderma and Sezary's syndrome, Addison's disease, ischemia-reperfusion injury of organs which occurs upon preservation, transplantation or ischemic disease, endotoxin-shock,
pseudomembranous colitis, colitis caused by drug or radiation, ischemic acute renal insufficiency, chronic renal insufficiency, toxinosis caused by lung-oxygen or drugs, lung cancer, pulmonary emphysema, cataracta, siderosis, retinitis pigmentosa, senile macular degeneration, vitreal scarring, corneal alkali burn, dermatitis erythema multiforme, linear IgA ballous dermatitis and cement dermatitis, gingivitis, periodontitis, sepsis, pancreatitis, diseases caused by environmental pollution, aging, carcinogenesis, metastasis of carcinoma and hypobaropathy, disease caused by histamine or leukotriene-C4 release, Behcet's disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, partial liver resection, acute liver necrosis, necrosis caused by toxin, viral hepatitis, shock, or anoxia, B- virus hepatitis, non-A/non-B hepatitis, cirrhosis, alcoholic cirrhosis, hepatic failure, fulminant hepatic failure, late-onset hepatic failure, "acute-on-chronic" liver failure, augmentation of chemotherapeutic effect, cytomegalovirus infection, HCMV infection, AIDS, cancer, senile dementia, parkison diseases,trauma, and chronic bacterial infection. Preferred compounds of formula (I), ( ) and related formulae exhibit a IC50 for the binding to PI3K of less than about 5 μΜ, preferably less than about 1 μΜ and even more preferably less than about 0.100 μΜ.
Compounds according to formula formula (I), ( ) and related formulae may be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions (i.e. reaction temperatures, time, moles of reagents, solvents etc.) are given, other experimental conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by the person skilled in the art, using routine optimisation procedures.
In general, the synthesis pathways for any individual compound of formula (I), ( ) and related formulae will depend on the specific substitutents of each molecule and upon the ready availability of intermediates necessary; again such factors being appreciated by those of ordinary skill in the art.
Compounds of this invention can be isolated in association with solvent molecules by crystallization from evaporation of an appropriate solvent. The pharmaceutically acceptable acid addition salts of the compounds of formula (I), ( ) and related formulae which contain a basic center may be prepared in a conventional manner. For example, a solution of the free base may be treated with a suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent. Pharmaceutically acceptable base addition salts may be obtained in an analogous manner by treating a solution of compound of formula (I), ( ) and related formulae, which contain an acid center, with a suitable base. Both types of salts may be formed or interconverted using ion-exchange resin techniques.
In the following the present invention shall be illustrated by means of some examples, which are not construed to be viewed as limiting the scope of the invention.
EXPERIMENTAL PART
1H NMR was recorded on 400 MHz spectrometers. Chemical shifts (δ) are reported in ppm relative to the residual solvent signal (δ = 2.49 ppm for 1H NMR in DMSO-c/6). 1H NMR data are reported as follows: chemical shift (multiplicity, coupling constants, and number of hydrogens). Multiplicity is abbreviated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad). NMR, HPLC and MS data provided in the examples described below are registered on: NMR: Bruker DPX-300, using residual signal of deuterated solvent as internal reference. HPLC: Waters Alliance 2695, column Waters XBridge C8 3.5 μηι 4.6x50 mm, conditions: solvent A (H20 with 0.1 % TFA), solvent B (ACN with 0.05% TFA), gradient 5% B to 100% B over 8 min, UV detection with PDA Water 996 (230-400 nm).
LCMS method : 0.1 % TFA in H20, B : 0.1 % TFA in ACN Flow Rate : 2.0 mL/min Column : Xbridge C8 (50*4.6 mm, 3.5 μ).
UPLC/MS: Waters Acquity, column Waters Acquity UPLC BEH C18 1 .7 μηι 2.1 x50 mm, conditions: solvent A (10mM ammonium acetate in water + 5% ACN), solvent B (ACN), gradient 5% B to 100% B over 3 min, UV detection (PDA, 230-400 nm) and MS detection (SQ detector, positive and negative ESI modes, cone voltage 30V).
Autoprep purification: preparative HPLC purifications are performed with a mass directed autopurification Fractionlynx from Waters equipped with a Sunfire Prep C18 OBD column 19x100 mm 5 μηη, unless otherwise reported. All HPLC purifications were performed with a gradient of ACN/H20 or ACN/H20/HCOOH (0.1 %).
Chiral analytical HPLC: Waters Alliance 2695, column Waters chiralcel OJ-H, OB-H, OD-H, OZ-H or a Chirapak AD-H, AS, IA-3, IB, IC-3, AY-H or (SS) Whelk 01 , (RR) Whelk 01 Chiralcel OJ-H, OB-H, OD-H, OZ-H or a Chiralpak AD-H, AS, IA-3, IB, IC-3, AY-H from Chiral Technologies or (SS) Whelk -01 from Regis Technologies on a Alliance system (Waters ) with a flow rate of 1 ml min UV detection with PDA Water 996 (230-400 nm).
Chiral chromatography separations have been performed with stationary phase chosen from either chiralcel OJ-H, OD-H or a Chirapak AD-H, IC-3, AY-H or Welk 01 on either a 2777C Sample Manager PAL, Prep LC 4000 using a Waters 2487 Dual Detector and Waters Fraction collector III that operates with Fraction lynx software or on a Hipersep 80
(supplier.NOVASEP), Detection wavelength between 305 and 320nm.
Alpha D were determined on a Polarimeter Jasco P-2000 at 25°C using Spectra Manager as software
Chiral centers of enantiomerically enriched material have been drawn arbitrarily. Isolated enantiomers have been named "enantiomer (A) " and "enantiomer (B) " arbitrarily.
Intermediates
Intermediate A.0: 4-Chloronicotinic acid
4-Chloropyridine hydrochloride (25 g) is neutralized with aq. Na2C03 (10%) and extracted with DCM. The organic layer is separated, dried over Na2S04 and concentrated under reduced pressure to afford 4-chloropyridine (19 g). To a solution of diisopropylamine (31 ml_, 217.6 mmol) in dry THF is added n-butyllithium (1 15 ml_, 184.1 mmol) dropwise at -78°C under nitrogen. After 30 min, a solution of 4-chloropyridine (19 g, 167.4 mmol) in dry THF is slowly added under nitrogen. The reaction mixture is futher stirred for 1 h at -78°C before addition of solid C02, let warmed to RT and stirred at RT for 12 h under nitrogen. After this time, reaction mixture is concentrated under reduced pressure and acidified with aq. HCI solution (1 .5 N) under ice-cooled condition. Precipitate is filtered under reduced pressure and dried overnight under vacuum to afford 15 g (57%) of the title compound. 1H NMR (DMSO-c/6, 400 MHz): δ 13.83 (bs, 1 H), 8.92 (s, 1 H), 8.64-8.63 (d, J = 5.4 Hz, 1 H), 7.66-7.65 (d, J = 5.4 Hz, 1 H).
Procedure A
Intermediate A.1 : 3-r(2-methoxyphenyl)thio1propanoic acid
To a solution of 2-methoxythiophenol (5.0 g, 3.56 mmol) in DMF (125 mL) is added potassium carbonate (14.76 g, 10.69 mmol, 3 Eq) at 60 °C under nitrogen. The reaction mixture is stirred for 30 minutes then bromopropionic acid (6.0 g, 3.92 mmol, 1.1 Eq) is added and the resulting mixture is stirred for 90 minutes at 60 °C under nitrogen. The solvent is removed under reduced pressure and the residue is taken up in water then washed with EtOAc. The aqueous layer is acidified with aq. solution of HCI and the product is extracted with EtOAc. The organic layer is dried over MgS04 and concentrated in under reduced pressure to afford 5.7 g (75%) of the title compound as a yellow oil.
1H NMR (DMSO-d6, 400 MHz): δ 7.23-7.16 (m, 2H), 6.98-6.91 (m, 2H), 3.79 (s, 3H), 3.03 (t, J = 7.0 Hz, 2H), 2.51 -2.48 (m, 2H).MS (ESI+): 213.0. HPLC (max plot) 99.5%; Rt 3.59 min.
Intermediates described below are obtained following procedure A
Procedure B
Intermediate B.1 : 8-methoxy-2,3-dihydro-4H-thiochromen-4-one
To a solution of 3-[(2-methoxyphenyl)thio]propanoic acid (5.0 g, 23.6 mmol) in dry DCM (50 mL) at 0 °C is added oxalyl chloride (6.01 g, 4.09 mL, 47.2 mmol, 2 Eq) followed by few drops of DMF. The reaction mixture is stirred at 0 °C for 30 minutes. After 30 minutes, the solvent is removed under reduced pressure. To a solution of the acid chloride in DCM (150 mL) at 0 °C is added a solution of tin (IV) chloride in DCM (26 mL, 1 M, 26.0 mmol, 1 .1 Eq) and the reaction mixture is stirred for 2 h. The reaction is quenched by addition of water and the product is extracted with DCM. The organic layer is dried over MgS04, concentrated under reduced pressure. The crude residue is purified by flash chromatography (eluent: ethyl acetate/hexane 4/6) to afford 3.2 g of the title compound as a white solid.1H NMR (DMSO-c/6, 400 MHz): δ 7.59-7.57 (m, 1 H), 7.18 (m, 2H), 3.84 (s, 3H), 3.24-3.21 (m, 2H), 2.84-2.81 (m, 2H). MS (ESI+): 196.0. HPLC (max plot) 89.4%; Rt 3.36 min.
Intermediates described below are obtained following procedure B
4 g of the title compound as a pale brown solid. 1H NMR (DMSO-c/6, 400 MHz): δ 8.12-8.10 (d, J = 8.2 Hz, 1 H), 7.78 (s, 1 H), 7.54-7.52 (dd, J = 1 .2,
0 8.2 Hz, 1 H), 3.40-3.39 (t, J = 6.3 Hz, 2H), 2.97-2.95 (t, J = 6.5 Hz, 2H).
Intermediate B.4: 6-Methoxv-2,3-dihvdro-4H-thiochromen-4-one
4.5 g (82%) yield of the title compound as a brown liquid. 1H NMR (DMSO- d6, 400 MHz): δ 7.45 (d, J = 3.0 Hz, 1 H), 7.29-7.26 (d, J = 8.7 Hz, 1 H), o 1 7.12-7.09 (dd, J = 3.0, 8.6 Hz, 1 H), 3.75 (s, 3H), 3.27-3.24 (m, 2H), 2.88- 2.85 (m, 2H).
Intermediate B.5: 8-Chloro-2,3-dihvdro-4H-thiochromen-4-one
8 g of the title compound as a pale orange solid. 1 H NMR (DMSO-d6) δ 7.92-7.96 (m, 1 H), 7.67-7.70 (m, 1 H), 7.21 -7.29 (t, J = 6 Hz, 1 H), 3.32-3.37 o (m, 2H), 2.87-2.91 (m, 2H). HPLC (max plot) 94.8%; Rt 3.02 min.
Procedure C
Intermediate C.1 : 2,3-Dihvdro-4H-thiopyranor3,2-c1pyridin-4-one
Following the Procedure C (thiochromanone, 2,3-dihydro-4H-thiopyrano[3,2-c]pyridin-4-one is obtained from 4-[(2-Carboxyethyl)thio]nicotinic acid to afford 1.4 g of the title compound as a brown solid. 1H NMR (DMSO-d6, 400 MHz): δ 8.89 (s, 1 H), 8.41 -8.40 (d, J = 5.4 Hz, 1 H), 7.41 -7.39 (d, J = 5.5 Hz, 1 H), 3.42-3.39 (m, 2H), 2.93-2.90 (m, 2H). Procedure D
Intermediate D.1 : 6-nitro-2,3-dihydro- -thiochromen-4-one
To 4-nitrothiophenol (5.0 g, 3.22 mmol) in 40 mL DMF was added potassium carbonate (13.4 g, 9.69 mmol, 3 Eq) at 60 °C under nitrogen and stirred for 30 minutes. To this was added bromopropionic acid (5.43 g, 3.54 mmol, 1 .1 Eq) and stirring continued for further 90 minutes at 60 °C under nitrogen, At the end, the solvent was removed under vacuo. The residue was extracted with ethyl acetate to remove non-polar impurities. Then the aqueous layer was acidified with concentrated HCI and again extracted with ethyl acetate. The organic layer dried with MgS04 and concentrated in vacuo to yield yellowish oil (7.3 g). To this yellowish oil (1 .0 g, 4.44 mmol) was added polyphosphonic acid (15.0 g). The reaction mixture was stirred at 100 °C for 30 minutes. After 30 minutes the solvent was removed under high vacuum the compound was purified by column chromatography (1 :7 ethyl acetate/hexane) to afford the title compound as a white solid.1H NMR (DMSO-d6, 400MHz) δ 8.94 (d, J = 2.6 Hz, 1 H), 8.20 (dd, J = 8.7 Hz, J = 2.6 Hz, 1 H), 7.45 (d, J = 8.7 Hz, 1 H), 3.36-3.33 (m, 2H), 3.07-3.04 (m, 2H). MS (ESI+): 210.0. HPLC (max plot) 99.7%; Rt 5.44 min.
Intermediate D.2: terf-Butyl 1 ,3-thiazol- -ylcarbamate
To a suspension of 2-aminothiazole (50 g, 499 mmol, 1 eq.) and 4-dimethylaminopyridine (0.1 g) in acetonitrile (125 mL) is added boc anhydride (130.6 g, 599 mmol, 1.2 eq.) over a period of 30 min at RT. The reaction mixture is then stirred at RT overnight. The reaction mass is then concentrated and partitioned between EtOAc and water by which time solid precipitated and is filtered to get 40 g of the product. The organic layer is washed with brine, separated and dried over sodium sulfate and concentrated to get the product (50 g) which is mixed with the initially obtained product to give 90 g (90%) of the title compound. 1H NMR (DMSO-c/6, 400 MHz): δ 1 1 .41 (bs, 1 H), 7.34-7.33 (d, J = 3.56 Hz, 1 H), 7.13-7.12 (d, J = 3.56 Hz, 1 H), 1 .46 (s, 9H).
Intermediate D.3: terf-Butyl (5-brom -1 ,3-thiazol-2-yl)carbamate
Terf-butyl 1 ,3-thiazol-2-ylcarbamate (90 g, 449.8 mmol, 1 eq.) is taken in THF (1 .4 L) to which is added /V-bromosuccinimide (88.06 g, 494.8 mmol, 1 .1 eq.) portion wise. The reaction mixture is then stirred at RT overnight. The reaction mass is concentrated to remove THF. The crude is purified by column chromatography to get the titled product.1H NMR
(DMSO-d6, 400 MHz): δ 1 1 .73 (bs, 1 H), 7.42 (s, 1 H), 1.46 (s, 9H).
Intermediate D.4: Methyl -3-({2-rterf-butoxycarbonyl)amino1-1 ,3-thiazol-5- yl)thio)propanoate
fe/f-Butyl-(5-bromo-1 ,3-thiazol-2-yl)carbamate (12 g, 43.17 mmol, 1 eq.), 3-mercapto propionic acid methylester (5.7 g, 47.4 mmol, 1.1 eq.), tris(dibenzylidene acetone)di Pd(0) (1 g, 1 .07 mmol, 0.025 eq.), 9,9'-dimethyl-4,5-bis(diphenyl phosphino) xanthene (1 .24 g, 2.15 mmol, 0.05 eq.) and Λ/,/V-diisopropyl ethyl amine (1 1 .15 g, 86.34 mmol, 2 eq.) are taken in degassed 1 ,4-dioxane (200 mL) in a pressure tube and heated under sealed condition at 125°C overnight. Reaction mixture is filtered through celite, concentrated under vacuum and purified by flash chromatography to afford 9.5 g (69%) of the product. 1H NMR (DMSO-c/6, 400 MHz): δ 1 1 .64 (bs, 1 H), 7.38 (s, 1 H), 3.58 (s, 3H), 2.90-2.87 (t, J = 6.8 Hz, 2H), 2.59- 2.55 (t, J = 6.9 Hz, 2H), 1 .46 (s, 9H).
Intermediate D.5: 3-({2-rterf-Butoxycarbonyl)amino1-1 ,3-thizol-5-yl)thio)propanoic acid
Methyl -3-({2-[ie f-butoxycarbonyl)amino]-1 ,3-thiazol-5-yl}thio)propanoate (9.5 g, 29.8 mmol, 1 eq.) is taken in THF/ H20 (3:1 ) and LiOH (1 .87 g, 44.75 mmol, 1 .5 eq.) and the reaction mixture is stirred at RT overnight after which it is evaporated under vacuum then diluted with water and acidified with citric acid to pH (5-6) and the formed solid is filtered, washed with water and dried to give 8 g (92%) of the title compound. 1H NMR (DMSO-c/6, 400 MHz): δ 1 1 .82 (bs, 2H), 7.38 (s, 1 H), 2.86-2.83 (t, J = 6.8 Hz, 2H), 2.48-2.45 (t, J = 7.0 Hz, 2H), 1 .46 (s, 9H).
Intermediate D.6: 2-Amino-5,6-dihvdr -7H-thiopyranof3,2-d1f1 ,31thiazol-7-one
3-({2-[ie f-butoxycarbonyl)amino]-1 ,3-thizol-5-yl}thio)propanoic acid (8 g, 26.31 mmol, 1 eq) is taken in polyphosphoric acid (80 g) and heated at 60°C for 1 h. The reaction mixture is diluted with ice-cold water and neutralized with NaHC03 and the solid formed is filtered. The solid is dissolved in EtOAc and washed with water, dried over Na2S04 and concentrated to afford the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 7.21 (bs, 2H), 3.39-3.35 (m, 3H), 2.72-2.69 (m, 3H).
Intermediate D.7: terf-Butyl-i7-oxo-6,7-dihvdro-5H-thiopyrano r3,2-d1H ,31thiazol-2- vDcarbamate
To a solution of 2-amino-5,6-dihydro-7/-/-thiopyrano[3,2-d][1 ,3]thiazol-7-one (3 g, 16.1 mmol, 1 eq) in DMF (60 mL) is added dimethylamino pyridine (0.075 g). The reaction mixture is cooled with ice and boc anhydride (7.02 g, 32.2 mmol, 2 eq) is added and stirred at RT for 48 hours. The solvent is removed under reduced pressure and the residue taken in EtOAc, washed with water, dried over Na2S04 and concentrated. The crude is purified by column chromatography to afford the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 1 1.80 (bs, 1 H), 3.46-3.42 (m, 2H), 2.81 -2.77 (t, J = 6.3 Hz, 2H), 1.45 (s, 9H). MS (ESI+): 287.0. HPLC (max plot): 96.63%; Rt 3.95 min.
Procedure E
Intermediate E.1 : Ethyl oxo(4-oxo-3 -dihydro-2H-thiochromen-3-yl)acetate
A solution of diethyloxalate (30.9 mL; 228.34 mmol; 1 .5 eq.) in toluene (250 mL) is added dropwise at 0°C to a solution of sodium ethoxide 21 %w/w in EtOH (9.87 g; 182.67 mmol; 2 eq.). A solution of thiochroman-4-one (25 g; 152.23 mmol; 1 eq.) in toluene (250 mL) is added dropwise at 0°C and the reaction mixture is allowed to warm up to rt. After overnight stirring, the solvent is removed and DCM (200 mL) and water (200 ml) are added. The aqueous phase is washed with DCM then acidified to pH = 1 -2 with 5N HCI (-50 mL). The product is extracted with EtOAc (2 x 200 mL). The organic phases are combined, dried over MgS04 and the solvent evaporated to afford 39.4 g (98%) of the title compound as an orange oil. MS (ESI+): 265.9.
Intermediates described below are obtained following Procedure E
Intermediate E.2: Ethyl (8-fluoro-4-oxo-3,4-dihydro-2H-thiochromen-3-yl)(oxo)acetate
vl)(oxo)acetate 30 g of the title compound as a pale brown solid. 1 H NMR (DMSO-d6,
400 MHz): δ 7.39-7.38 (d, J = 4.0 Hz, 1 H), 7.34-7.31 (d, J = 12.0 Hz, 1 H ), 7.10-7.07 (m, 1 H), 4.28-4.23 (m, 2H), 3.82-3.81 (d, J = 4.0 Hz,
2H), 3.77 (s, 3H), 1.31 -1 .25 (m, 3H). MS (ESI+): 293.0. HPLC (max plot): 93.73%; Rt 3.72 min.
Intermediate E.10: El hyl-4-oxo-3,4-dihydro-2H-thiopyrano[2,3-fe]pyridine-3-carboxylate
4.0 g as yellow solid. 1H NMR (CDCI3, 400 MHz): δ 8.27-8.61 (1 H, t, J = 2.72 Hz ), 8.05-8.03 (1 H, q), 7.12-7.095 (1 H, m), 3.9-3.8 (2H, m), o o
3.9-3.7 ( 2H, t, J = 7.12 Hz): 1 .14-1 .10 (m, 3H). MS (ESI+): 266.0.
Intermediate E.11 : El hvl oxo(4-oxo-5,6-dihvdro-4H-thienor2,3-blthiopvran-5-vl)acetate
1 .1 g of the title compound as a dark yellow oil. MS (ESI+): 270.6. o o procedure F
Intermediate F.1 : terf-Butyl (3E)-3-r(terf-butoxycarbonyl)hydrazono1piperidine-1 - carboxylate
1 -Boc-3-piperidone (25 g; 125.47 mmol; 1 .00 eq.) is dissolved in toluene (250 mL) to which ie f-butyl-carbazate (16.58 g; 125.47 mmol; 1 .00 eq.) is added and reaction mixture is heated to 60°C for 4 hours. After this time reaction mixture is evaporated to dryness, taken up in ethyl acetate (100 mL) and heptane (100 mL), and the supension is heated, then cooled down to rt and the suspension is filtered and dried to give 15 g (95%) of the title compound as a beige solid. MS (ESI-): 31 1 .9.
Intermediates described below are obtained following procedure F
procedure G
Intermediate G.1 : terf-Butyl 4-r2-(terf-butoxycarbonyl)hydrazino1piperidine-1 - carboxylate
To ie f-butyl 4-[(ie f-butoxycarbonyl)hydrazono]piperidine-1 -carboxylate (15.7 g; 50.1 mmol; 1 eq.) in water (78.5 mL) and glacial acetic acid (78.5 mL) is added sodium
cyanoborohydride (3.15 g; 50.1 mmol; 1 eq.) and the reaction mixture is stirred at rt overnight. The solvents are removed to near dryness and the product is extracted with AcOEt. The combined organic phase is washed with NaOH (1 M), dried over MgS04, filtered and concentrated to afford: 14.1 g (89%) of the title compound. 1H NMR (300 MHz, DMSO): δ 8.22 (s, 1 H), 4.61 -4.14 (m, 1 H), 3.81 -3.55 (m, 2H), 3.08-2.67 (m, 2H), 1 .73-1 .50 (m, 2H), 1 .38 (s, 18H), 1 .22-0.98 (m, 2H).
Intermediates described below are obtained following procedure G
Intermediate G.2: terf-Butyl 3-[2-(ferf-butoxycarbonyl)hydrazino]azetidine-1 - carboxylate 18 g (90%) of the title compound as a colorless liquid. 1H
NMR (DMSO-d6, 400 MHz): δ 8.35 (bs, 1 H), 4.94-4.92 (m, 1 H), 3.79-3.69 (m, 2H), 3.67-3.64 (m, 1 H), 3.63-3.58 (m, 2H), 1 .37 (s, 9H), 1.35 (s, 9H). HPLC (max plot): 99.88%;
Rt 3.93 min.
Intermediate G.3: ferf-Butvl 3-r2-(ferf-butoxvcarbonvl)hvdrazinolpvrrolidine-1 - carboxvlate
14 mg of the title compound as a brown solid. 1H NMR (CDCIs, 400 MHz): δ 8.17-8.15 (m, 1 H), 7.80-7.78 (m, 1 H), 7.65-7.61 (m, 2H), 5.07 (m, 1 H), 4.65 (s, 2H), 4.14 (bs, 2H),
H 0
3.75 (m, 6H), 3.48-3.46 (m, 2H), 3.34 (s, 3H), 3.03-2.82 (m, 6H), 2.42 (m, 2H), 2.30 (m, 2H), 2.02 (m, 2H), 1.92 (m, 2H). MS (ESI+): 503.3. HPLC (max plot) 99.02%; Rt 2.57 min.
Intermediate G.4: ferf-Butvl 3-r2-(ferf-butoxvcarbonvl)hvdrazinolpiperidine-1 - carboxvlate
15 g (99%) of the title compound as a yellow oil. 1 H NMR (DMSO-d6, 400 MHz): 5 8.17 (bs, 1 H), 4.38 (bs, 1 H), 3.88- 3.85 (m, 1 H), 3.70-3.67 (m, 2H), 2.66-2.5 (m, 2H), 2.50- 2.48 (m, 1 H), 1 .74-1 .71 (d, J = 12.3 Hz, 1 H), 1 .62-1 .59 (m, 1 H), 1 .37 (s, 9H), 1 .36 (s, 9H). MS (ESI+): 216.2. HPLC (max plot): 90.75%; Rt 5.33 min.
Intermediate G.5: ferf-Butvl 4-r2-(ferf-butoxvcarbonvl)hvdrazinolazepane-1 - carboxvlate
1 g (99%) of the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 8.32 (bs, 1 H), 4.53 (m, 1 H), 3.52 (m, 1 H), 3.32- 3.20 (m, 2H), 3.15-3.13 (m, 2H), 1 .74-1 .69 (m, 2H), 1.37 (s, 18H).
Intermediate G.6: 2-(4-lodophenyl)-2-methylpropanal
To a solution of 2-(4-lodophenyl)-2-methylpropanenitrile (19 g, 0.066 mol) in toluene (150 mL) is added Diisobutyl aluminum hydride (1.0 M in THF, 200 mL, 0.199 mol) in a dropwise fashion at -78 °C. The reaction mixture is stirred at same temperature for 30 min and then at Rt for 12 h. After completion of the reaction, the reaction mixture is quenched with saturated sodium sulphate (100 mL) and extracted with EtOAc (200 mL). The organic layer is washed with water (100 mL), brine (50 mL), dried over sodium sulphate and concentrated under reduced pressure to afford the title compound as pale brown liquid. 1H NMR (DMSO-d6, 400 MHz): δ 9.48 (s, 1 H), 7.74-7.72 (t, J = 4 Hz, 2H), 7.1 1 -7.09 (t, J = 1.4 Hz, 2H), 1 .35 (s, 6H). MS (ESI+): 276.0.
Intermediate G.7: 2-(4-lodophenyl)propa
To a solution of methyl magnesium bromide (59 mL, 3 M in THF, 17 mmol) in THF (100 mL) is added methyl-4-iodobenzoate (20 g, 76.2 mmol) in THF (100 mL) in drops at -78°C. The reaction mixture was stirred at the same temperature for 30 min and then added a second portion of methyl magnesium bromide (59 mL, 3 M in THF, 17 mmol) in drops at -78 °C. The resulting mixture is stirred for another 2 h and quenched with saturated ammonium chloride solution (100 mL) and extracted with EtOAc (200 mL). The combined organic layer is washed with water (100 mL), brine (50 mL), dried over sodium sulphate and concentrated under reduced pressure to afford 18 g (90%) the title compound as pale yellow liquid. 1H NMR (DMSO-de, 400 MHz): δ 7.63-7.617 (dd, J= 2.0, 6.8 Hz, 2H), 7.27-7.24 (d, J = 6.8 Hz, 2H), 5.071 (s, 1 H), 1 .37 (s, 6H).
Intermediate G.8: 1 -(1 -Chloro-1 -methylet -iodobenzene
To a stirred solution of 2-(4-lodophenyl)propan-2-ol (15 g, 0.057 mol) in dry DCM (150 mL) is added thionyl chloride (8.4 mL, 7 mmol) in drops at 0°C under nitrogen atmosphere. The mixture is heated to 40°C for 12h. After the completion the reaction, the reaction mixture is diluted with DCM (100 mL), washed with 10% sodium bicarbonate, brine, dried over sodium sulphate and concentrated under vacuum. The crude product is further purified by column chromatography (10% EtOAc in pet ether) to afford 15 g (95%) of title compound as light brown solid. 1H NMR (DMSO-d6, 400 MHz) δ 7.73-7.71 (d, J = 8.8 Hz, 2H), 7.41 -7.38 (d, J = 8.8 Hz, 2H), 1.92 (s, 6H). Intermediate G.9: 4-f2-(4-lodophenyl)-2-methylpropynmorpholine
To a solution of 2-(4-lodophenyl)-2-methylpropanal (7 g, 0.025 mol) in 1 ,2-Dichloro ethane (100 mL) is added morpholine (4.4 mL, 0.051 mol) in drops at 0 °C. After 10 min, NaBH3CN (2 g, 30 mmol) is added in a portion wise fashion at 0 °C followed by acetic acid (500 μί). The reaction mixture is stirred for another 1 h at same temperature and then at Rt for 10 h. After this time, the reaction mixture is quenched with 10% sodium bicarbonate (50 mL) and extracted with EtOAc. The combined organic layer is washed with water, brine, dried over sodium sulphate and evaporated. The crude product is purified by column chromatography (pet ether and EtOAc) to afford the title compound as a pale yellow liquid. 1H NMR (DMSO- d6, 400 MHz): δ 7.61 -7.59 (q, J= 1 .8, 6.6 Hz, 2H), 7.19-7.17 (q, J= 1.9, 6.6 Hz, 2H), 3.42- 3.40 (m, 4H), 2.38-2.36 (d, 2H), 2.17-2.15 (m, 4H), 1 .21 (s, 6H). MS (ESI+): 346.0.
Intermediate G.10: 4-Γ1 -(4-lodophenyl)-1 -methylethyl]morpholine To a solution of 1 -(1 -Chloro-1 -methylethyl)-4-iodobenzene (2 g, 7 mmol) in morpholine (10 mL) is added Kl (0.5 g). The mixture is irradiated under microwave irradiation for 20 min at 160°C (x10). The combined reaction mixtures are dissolved in EtOAc, washed with water, brine and dried over sodium sulphate. The solvent is concentrated under vacuum and purified by column chromatography (50% EtOAc in pet ether) to afford title compound as a light brown liquid. 1H NMR (DMSO-d6, 400 MHz): δ 7.65-7.63 (dd, J= 2, 6.8 Hz, 2H), 7.30- 7.28 (dd, J = 2, 6.8 Hz, 2H), 3.53-3.65 (t, 4H), 2.33-2.31 (t, 4H), 1 .22 (s, 6H). Intermediate G.11 : ferf-Butyl 1 -[4-(1 -methyl-1 -morpholin-4- ylethyl)phenyl]hydrazinecarboxylate
A solution of 4-[1 -(4-lodophenyl)-1 -methylethyl]morpholine (3.4 g, 10 mmol) in DMSO (35 mL) is added cesium carbonate (5.1 g, 15 mmol) and ie f-butyl carbazate (1 .5 g, 1 1 mmol) at RT under argon. The reaction mixture is stirred for 10 min at RT after which copper (I) iodide (0.1 g, 0.5 mol) is added. The reaction mixture is stirred at 50°C for 6 h under nitrogen. After this time, reaction mixture is cooled to RT, diluted with water and extracted with MTBE. The combined organic layer is concentrated under vacuum and purified by acid-base work up using 10% citric acid, sodium bicarbonate and MTBE to afford the title compound as pale a brown liquid. 1H NMR (DMSO-d6, 400 MHz): δ 737 (s, 4H), 5.00 (bs, 2H), 3.54-3.521 (m, 4H), 2.35-2.33 (m, 4H), 1 .43 (s, 9H), 1 .26 (s, 6H). MS (ESI+): 249.0. HPLC (max plot): 96.0%; Rt 2.57 min. Intermediate G.12: tert-Butyl 1 -r4-(1 ,1 -dimethyl-2-morpholin-4- ylethvDphenyllhvdrazinecarboxylate
To a solution of 4-[2-(4-lodophenyl)-2-methylpropyl] morpholine (3.2 g, 0.092 mol) in DMSO (30 mL) is added cesium carbonate (4.6 g, 0.013 mol) and ferf-Butyl carbazate (1 .35 g, 0.010 mol) at RT under argon. The reaction mixture is stirred for 10 min at RT after which is added copper (I) iodide (0.09 g, 0.4 mmol). The reaction mixture is stirred at 50°C for 2 h under nitrogen then cooled to RT, diluted with water and extracted with EtOAc. The combined organic layer is washed with water, brine, dried over sodium sulphate and purified by column chromatography (Neutral alumina, pet ether and EtOAc) to afford the titled compound as pale brown liquid. 1H NMR (DMSO-d6, 400 MHz): δ 7.34-7.32 (d, J = 8 Hz, 2H), 7.28-7.25 (t, J = 4 Hz, 2H), 4.98 (bs, 2H), 3.42-3.40 (m, 4H), 2.36 (s, 2H), 2.17-2.15 (m, 4H), 1.41 (s, 9H), 1 .24 (s, 6H). MS (ESI+): 350.0. HPLC (max plot): 91 %, Rt 6.38 min ntermediate G.13: f2-(4-lodophenyl)-2-methylpropyndimethylamine
To a solution of 2-(4-lodophenyl)-2-methylpropanal (7 g, 0.025 mol) in 1 ,2-Dichloro ethane (100 mL) is added dimethylamine (2 M in THF, 46 mL, 92 mmol) in drops at 0 °C. After 10 min, NaBH3CN (1 .8 g, 27 mmol) is added in a portion wise fashion at 0 °C followed by acetic acid (500 μΙ_). The reaction mixture is stirred for another 1 h at same temperature and then at Rt for 10 h. After this time, the reaction mixture is quenched with 10% sodium bicarbonate and extracted with EtOAc. The combined organic layer is washed with water, brine, dried over sodium sulphate and evaporated. The crude product is purified by column
chromatography (pet ether and EtOAc) to afford the title compound as brown liquid. 1H NMR (DMSO-de, 400 MHz) δ 7.62-7.60 (q, Hz, J2=8 Hz, 2H), 7.17-7.15 (d, J =8 Hz, 2H), 2.35 (s, 2H), 1 .96 (s, 6H), 1 .20 (s, 6H). Intermediate G.14: tert-Butyl 1 -{4-r2-(dimethylamino)-1 ,1 - dimethylethyllphenvDhydrazinecarboxylate
To a solution of [2-(4-lodophenyl)-2-methylpropyl]dimethylamine (5 g, 0.01 mol) in DMSO (50 mL) is added cesium carbonate (3.6 g, 0.01 mol) and ie f-butyl carbazate (2.4 g, 0.018 mol) at RT under argon. The reaction mixture is stirred for 10 min at RT after which is added copper (I) iodide (0.16 g, 0.8 mmol). The reaction mixture is stirred at 50°C for 2 h under nitrogen then cooled to RT, diluted with water and extracted with EtOAc. The combined organic layer is washed with water, brine, dried over sodium sulphate and purified by column chromatography (Neutral alumina, pet ether and EtOAc) to afford the title compound as pale brown liquid. 1H NMR (DMSO-d6, 400 MHz): δ 7.34-7.32 (d, J = 8 Hz, 2H), 7.25-7.23 (d, J = 8 Hz, 2H), 4.99 (bs, 2H), 2.37 (s, 2H), 1 .97 (s, 6H), 1 .41 (s, 9H), 1 .23 (s, 6H). MS (ESI+):
350.0. HPLC (max plot): 89%; 2.66 min. Intermediate G.15:1 -(4-iodophenyl)cvclopropanecarbaldehyde
To a solution of 2-(4-lodophenyl)-2-methylpropanenitrile (9 g, 0.033 mol) in toluene (250 mL) is added diisobutyl aluminum hydride (1 .0 M in THF, 66 mL, 66 mmol) in a dropwise fashion at -78 °C. The reaction mixture is stirred at same temperature for 2 h after which it is quenched with saturated sodium sulphate (100 mL) and extracted with EtOAc (200 mL). The organic layer is washed with water (100 mL), brine (50 mL), dried over sodium sulphate and concentrated under reduced pressure to afford. Purification by column chromatography (7% EtOAc in pet ether) gives the title compound as pale yellow solid. 1H NMR (DMSO-d6, 400 MHz): δ 8.85 (s,1 H) 7.69-7.67 (m, 2), 7.09-7.07 (m, 2H), 1 .57-1.54 (m, 2H), 1 .40-1 .37 (m, 2H).
Intermediate G.16: 4-{ri -(4-lodophenyl)cvclopropynmethyl)morpholine
To a solution of 1 -(4-iodophenyl)cyclopropanecarbaldehyde (7 g, 0.025 mol) in 1 ,2-
Dichloroethane (100 mL) is added morpholine (4.5 mL, 0.051 mol) in drops at 0 °C . After 10 min, NaBH3CN (3.2 g, 30 mmol) is added in a portion wise fashion at 0 °C followed by acetic acid (500 μί). The reaction mixture is stirred for another 1 h at same temperature and then at Rt for 10 h. After this time, the reaction mixture is quenched with 10% sodium bicarbonate and extracted with EtOAc. The combined organic layer is washed with water, brine, dried over sodium sulphate and evaporated. The crude product is purified by column
chromatography (pet ether and EtOAc) to afford the title compound as colourless liquid. 1H NMR (DMSO-de, 400 MHz) δ 7.60-7.56 (m, 2H), 7.13-7.08 (m, 2H), 3.47-3.43 (m, 4H), 2.50- 2.46 (m, 2H), 2.34 (bs, 4H) .0.80-0.77 (m, 2H),0.72-.0.69 (m, 2H ).
Intermediate G.17: terf-Butyl 1 -f4-f1 -(morpholin-4- ylmethvDcvclopropyllphenvDhvdrazinecarboxylate bo
To a solution of 4-{[1 -(4-lodophenyl)cyclopropyl]methyl}morpholine (4 g, 1 1 mmol) in DMSO (40 mL) is added cesium carbonate (5.3 g, 16 mmol) and ie f-Butyl carbazate (1.59 g, 0.012 mol) at RT under argon. The reaction mixture is stirred for 10 min at RT after which is added copper (I) iodide (0.1 g, 0.5 mmol). The reaction mixture is stirred at 50°C for 2 h under nitrogen then cooled to RT, diluted with water and extracted with EtOAc. The combined organic layer is washed with water, brine, dried over sodium sulphate and purified by column chromatography (Neutral alumina, 30% pet ether and EtOAc) to afford the title compound as a colourless liquid . 1H NMR (DMSO-d6, 400 MHz): δ 7.30-7.28 (d, J = 8.7 Hz, 2H), 7.21 -7.18 (d, J = 8.7 Hz, 2H), 5.00 (bs, 2H), 3.47-3.44 (m, 4H), 2.46 (s, 2H), 2.36 (m, 4H), 1 .42 (s, 9H), 0.76-0.75 (t, J = 5.2 Hz, 2H), 0.68-0.67 (t, J = 5.2 Hz, 2H). MS (ESI+): 348.0. HPLC (max plot): 90.3%; Rt 5.72 min.
Procedure H
Intermediate H.1 : ethyl 6-methoxy-1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
To a solution of diisopropylamine (0.67 g, 0.9 mL, 6.7 mmol, 1 .3 Eq) in THF (8 mL) at -78 °C under nitrogen is added a solution of n-butyl lithium (3.8 mL, 1 .6M in hexane) and the reaction mixture is stirred at -20 °C for 30 minutes. The reaction mixture is again cooled to - 78 °C and a solution of 8-methoxy-2,3-dihydro-4H-thiochromen-4-one (1 .0 g, 5.1 mmol) in THF (15 mL) is added slowly over 40 minutes followed by the addition of a solution of diethyl oxalate (1 .05 g, 7.21 mmol, 1.4 Eq) in THF (10 mL). The resulting mixture is stirred at -78 °C for 2 h then allowed to reach 0 °C. The solvent is removed under reduced pressure at 25 °C. The yellow solid (1 .3 g, 4.4 mmol) obtained is dissolved in a 1 :1 mixture of acetic
acid/methanol (40 mL) and phenyl hydrazine (0.7 mL, 6.6 mmol, 1.5 Eq) is added. The resulting mixture is stirred under nitrogen at 90 °C for 5 h. The solvent is removed under reduced pressure. An aq. solution of NaHC03 10% is added to the residue and after 15 minutes stirring, the solid obtained is filtered off then recrystallized from diethyl ether to afford 1 .2 g (74%) of the title compound as a pale yellow solid. 1H NMR (DMSO-c/6, 400 MHz): δ 7.58-7.53 (m, 3H), 7.43-7.41 (m, 2H), 6.93 (t, J = 4.6 Hz, 2H), 6.30 (t, J = 9.00 Hz, 1 H), 4.32 (q, J = 7.0 Hz, 2H), 4.15 (s, 2H), 3.85 (s, 3H), 1 .31 (t, J = 7.12 Hz, 3H). MS (ESI+): 367.0. HPLC (max plot) 96.7%; Rt 5.29 min.
Intermediate H.2: ethyl 6-methoxy-1 -methyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure H, ethyl 6-methoxy-1 -methyl-1 ,4- dihydrothiochromeno [4,3-c]pyrazole-3-carboxylate is obtained from 8-methoxy-2,3-dihydro- 4/-/-thiochromen-4-one, diethyl oxalate and methyl hydrazine to afford the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 7.48-7.46 (m, 1 H), 7.30 (t, J = 8.1 Hz, 1 H), 7.06 (d, J = 7.6 Hz, 1 H), 4.28 (q, J = 7.12 Hz, 2H), 4.12 (s, 3H), 4.06 (s, 2H), 3.85 (s, 3H), 1 .30 (t, J = 7.12 Hz, 3H). MS (ESI+): 305.0. HPLC (max plot) 97.0%; Rt 4.28 min.
Intermediate H.3: ethyl 7-methoxy-1 -methyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure H, ethyl 7-methoxy-1 -methyl-1 ,4- dihydrothiochromeno [4,3-c]pyrazole-3-carboxylate is obtained from 7-methoxy-2,3-dihydro- 4/-/-thiochromen-4-one, diethyl oxalate and methyl hydrazine to afford the title compound. 1H NMR (DMSO-de, 400MHz,) δ = 7.78 (d, J = 8.7 Hz, 1 H), 7.09 (d, J = 2.6 Hz, 1 H), 6.90 (dd, J = 8.6 Hz, J = 2.5 Hz, 1 H), 4.28 (q, J = 7.1 Hz, 2H), 4.12 (s, 2H), 4.1 1 (s, 3H), 3.79 (s, 3H), 1 .29 (t, J = 7.0 Hz, 3H). MS (ESI+): 305.0. HPLC (max plot) 99.4%; Rt 4.51 min. Intermediate H.4: ethyl 1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c] pyrazole-3-carboxylate is obtained from 2,3-dihydro-4/-/- thiochroman-4-one, diethyl oxalate and phenyl hydrazine to afford the title compound. 1H NMR (DMSO-d6! 400 MHz): δ 7.59-7.57 (m, 3H), 7.49-7.45 (m, 3H), 7.20 (t, J = 7.6 Hz, 1 H), 6.96 (d, J = 6.36 Hz, 1 H), 6.66 (d, J = 7.92 Hz, 1 H), 4.33 (q, J = 7.04 Hz, 2H) 4.24 (s, 2H), 1 .31 (d, J = 7.08 Hz, 3H). MS (ESI+): 337.0. HPLC (max plot) 98.7%; Rt 6.64 min.
Intermediate H.5: ethyl 1 -methyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -methyl-1 ,4- dihydrothiochromeno[4,3-c] pyrazole-3-carboxylate is obtained from 2,3-dihydro-4/-/- thiochroman-4-one, diethyl oxalate and methyl hydrazine to afford the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 7.85 (dd, J = 7.1 Hz, J = 1 .6 Hz, 1 H), 7.52 (dd, J = 7.2 Hz, J 1 .3 Hz, 1 H), 7.37-7.29 (m, 2H), 4.30 (q, J = 7.1 Hz, 2H), 4.15 (d, J = 4.8 Hz, 2H), 1.31 (t, J 7.1 Hz, 3H). MS (ESI+): 275.0. HPLC (max plot) 98.9%; Rt 4.50 min.
Intermediate H.6: ethyl 1 ,4-dihvdrothiochromenor4,3-c1pyrazole-3-carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 ,4-dihydrothiochromeno[4,3- c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4/-/-thiochroman-4-one, diethyl oxalate and methyl hydrazine to afford 0.87 g (80%) of the title compound as a white solid. 1H NMR (DMSO-d6, 400 MHz): δ 14.0 (s, 1 H), 7.83-7.72 (m, 1 H), 7.36-7.33 (m, 1 H), 7.23 (brs, 2H), 4.35-4.21 (m, 4H), 1 .34-1.29 (m, 3H). MS (ESI+): 261 .0. HPLC (max plot) 98.2%; Rt 4.34 min. Intermediate H.7: ethyl 7-methoxy-1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 7-methoxy-1 -methyl-1 ,4- dihydrothiochromeno [4,3-c]pyrazole-3-carboxylate is obtained from 7-methoxy-2,3-dihydro- 4/-/-thiochromen-4-one, diethyl oxalate and phenyl hydrazine to afford 1.32 g (81 %) of the title compound. 1H NMR (400MHz, DMSO-d6) δ 7.59 - 7.56 (m, 3H), 7.46 - 7.43 (m, 2H), 7.05 (s, 1 H), 6.58 (m, 2H), 4.31 (q, J = 8.8 Hz, 2H), 4.21 (s, 2H), 3.71 (s, 3H), 1.31 (t, J = 7.0 Hz, 3H). MS (ESI+): 367.0. HPLC (max plot) 98.9%; Rt 5.46 min.
Intermediate H.8: ethyl 1 -(3-methylphenyl)-1 ,4-dihvdrothiochromenor4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -(3-methylphenyl)-1 ,4- dihydrothiochromeno [4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4/-/- thiochroman-4-one, diethyl oxalate and 3-methyl phenyl hydrazine to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.49 - 7.39 (m, 3H), 7.31 (s, 1 H), 7.21 - 7.18 (m, 2H), 7.01 - 6.97 (m, 1 H), 6.70 (dd, J = 7.9 Hz, J = 1 .0 Hz, 1 H), 4.32 (q, J = 7.1 Hz, 2H), 4.23 (s, 2H), 2.37 (m, 3H), 1.31 (t, J = 7.1 Hz, 3H). MS (ESI+): 351 .0. HPLC (max plot) 99.2%; Rt 5.84 min.
Intermediate H.9: ethyl 1 -(4-methylphenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -(4-methylphenyl)-1 ,4- dihydrothiochromeno [4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4/-/- thiochroman-4-one, diethyl oxalate and 4-methyl phenyl hydrazine to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.47 (d, J = 7.8 Hz, 1 H), 7.38-7.31 (m, 4H), 7.19 (t, J = 7.6 Hz, 1 H), 6.99 (t, J = 7.8 Hz, 1 H), 6.70 (d, J = 7.8 Hz, 1 H), 4.32 (q, J = 7.1 Hz, 2H), 4.22 (s, 2H), 2.41 (m, 3H), 1 .31 (t, J = 7.1 Hz, 3H). MS (ESI+): 351 .0. HPLC (max plot) 99.7%; Rt 5.79 min. Intermediate H.10: ethyl 1 -(5-fluoro-2-methylphenyl)-1 ,4-dihydrothiochromenof4,3- cl p yrazo I e -3 -ca r boxy I ate
Following the protocol outlined in Procedure AA, ethyl 1 -(5-fluoro-2-methylphenyl)-1 ,4- dihydrothio chromeno[4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4/-/- thiochroman-4-one, diethyl oxalate and (5-fluoro-2-methylphenyl)-hydrazine to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.52-7.42 (m, 4H), 7.22-7.18 (m, 1 H), 7.00-6.96 (m, 1 H), 6.58 (d, J = 7.0 Hz, 1 H), 4.35-4.22 (m, 4H), 1 .78 (s, 3H), 1 .31 (t, J = 7.1 Hz, 3H). MS (ESI+): 369.0. HPLC (max plot) 99.2%; Rt 5.76 min. Intermediate H.11 : ethyl 1 -(3-methoxyphenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole- 3-carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -(3-methoxyphenyl)-1 ,4-dihydrothio chromeno[4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4/-/-thiochroman-4-one, diethyl oxalate and 3-methoxy phenyl hydrazine hydrochloride to afford the title compound. 1H NMR (DMSO-de, 400MHz) δ 7.48-7.44 (m, 2H), 7.22-7.15 (m, 2H), 7.06-6.95 (m, 2H), 6.73 (d, J = 7.9 Hz, 2H), 4.32 (q, J = 7.0 Hz, 2H), 4.23 (s, 2H), 3.78 (s, 3H), 1 .31 (t, J = 7.1 Hz, 3H). MS (ESI+): 367.0. HPLC (max plot) 97.5%; Rt 5.55 min. Intermediate H.12: ethyl 1 -(4-methoxyphenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole- 3-carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -(4-methoxyphenyl)-1 ,4- dihydrothiochromeno [4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4/-/- thiochroman-4-one, diethyl oxalate and 4-methoxy phenyl hydrazine to afford 1 .38 g (71 %) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.47 (d, J = 7.8 Hz, 1 H), 7.38 (d, J = 8.6 Hz, 1 H), 7.19 (t, J = 7.4 Hz, 1 H), 7.10 (d, J = 8.7 Hz, 2H), 7.00 (t, J = 7.7 Hz, 1 H), 6.71 (d, J = 7.9 Hz, 2H), 4.32 (q, J = 7.1 Hz, 2H), 4.22 (s, 2H), 3.84 (s, 3H), 1 .31 (t, J = 7.1 Hz, 3H). MS (ESI+): 367.0. HPLC (max plot) 98.6%; Rt 5.51 min.
Intermediate H.13: ethyl 1 -pyridin-2-yl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -pyridin-2-yl-1 ,4- dihydrothiochromeno[4,3-c] pyrazole-3-carboxylate is obtained from 2,3-dihydro-4/-/- thiochroman-4-one, diethyl oxalate and 4-methoxy phenyl hydrazine to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.51 (dd, J = 4.8 Hz, J = 0.8 Hz, 1 H), 8.18-8.13 (m, 1 H), 7.79 (d, J = 7.9 Hz, 1 H), 7.65 - 7.62 (m, 1 H), 7.48 (d, J = 7.8 Hz, 1 H), 7.23-7.19 (m, 1 H), 7.02-6.98 (m, 1 H), 6.64-6.62 (m, 1 H), .4.34 (q, J = 7.1 Hz, 2H), 4.22 (s, 2H), 1.32 (t, J = 7.1 Hz, 3H). MS (ESI+): 338.0. HPLC (max plot) 98.5%; Rt 4.81 min.
Intermediate H.14: ethyl 1 -cvclohexyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -cyclohexyl-1 ,4- dihydrothiochromeno[4,3-c] pyrazole-3-carboxylate is obtained from 2,3-dihydro-4/-/- thiochroman-4-one, diethyl oxalate and cyclohexyl hydrazine to afford the title compound. 1H NMR (DMSO-de, 400MHz) δ 7.61 (d, J = 7.8 Hz, 1 H), 7.55 (d, J = 7.6 Hz, 1 H), 7.39 (t, J = 7.5 Hz, 1 H), 7.32 (t, J = 7.5 Hz, 1 H), 4.57-4.52 (m, 1 H), 4.30 (q, J = 7.1 Hz, 2H), 4.09 (s, 2H), 2.00-1 .81 (m, 4H), 1 .69-1.66 (m, 2H), 1.49-1 .42 (m, 3H), 1 .38 (t, J = 7.1 Hz, 3H). MS (ESI+): 343.0. HPLC (max plot) 99.5%; Rt 5.98 min. Intermediate H.15: ethyl 6-bromo-1 -methyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 6-bromo-1 -methyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 8-bromo-2,3-dihydro-4H- thiochromen-4-one, diethyl oxalate and methyl hydrazine to afford the title compound. 1H NMR (DMSO-de, 400MHz) δ 7.86 (dd, J = 7.8 Hz, J = 1.0 Hz, 1 H), 7.62 (dd, J = 8.0 Hz, J = 1 .0 Hz, 1 H), 7.27 (t, J = 8.0 Hz, 1 H), 4.29 (q, J = 7.1 Hz, 2H), 4.21 (s, 2H), 4.13 (s, 3H), 1 .30 (t, J = 7.0 Hz, 3H). MS (ESI+): 354.0. HPLC: RT 5.03 min (HPLC purity 98.6 %, 97.6 %). Intermediate H.16: ethyl 1 -methyl-8-nitro-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -methyl-8-nitro-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 6-nitro-2,3-dihydro-4H- thiochromen-4-one, diethyl oxalate and methyl hydrazine to afford of the title compound. 1H NMR (DMSO-de, 400MHz) δ 8.56 (d, J = 2.3 Hz, 1 H), 8.1 1 (dd, J = 8.7 Hz, J = 2.4 Hz, 1 H), 7.77 (d, J = 8.7 Hz, 1 H), 4.31 -4.21 (m, 4H), 4.24 (s, 3H), 1 .31 (t, J = 7.12 Hz, 3H). MS (ESI+) 320.0. HPLC (max plot) 98.3%; Rt 4.53 min.
Intermediate H.17: ethyl 6-fluoro-1 -methyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 6-fluoro-1 -methyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 8-fluoro-2,3-dihydro-4H- thiochromen-4-one, diethyl oxalate and methyl hydrazine to afford the title compound. 1H NMR (DMSO-d6, 400MHz) 8 7.72 (d, J = 7.8 Hz, 1 H), 7.41 -7.35 (m, 1 H), 7.29-7.26 (m, 1 H), 4.29 (q, J = 7.1 Hz, 2H), 4.19 (s, 2H), 4.16 (s, 3H), 1 .30 (t, J = 7.1 Hz, 3H). MS (ESI+): 293.0. HPLC (max plot) 98.2%; Rt 4.61 min.
Intermediate H.18: ethyl 6-fluoro-1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 6-fluoro-1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 8-fluoro-2,3-dihydro-4H- thiochromen-4-one, diethyl oxalate and phenyl hydrazine to afford the title compound. 1H NMR (DMSO-de, 400MHz) δ 7.60-7.55 (m, 3H), 7.48-7.46 (m, 2H), 7.18 (t, J = 8.6 Hz, 1 H), 7.06-7.01 (m, 1 H), 6.51 (d, J = 7.8 Hz, 1 H), 4.33 (q, J = 7.1 Hz, 2H), 4.28 (s, 2H), 1.31 (t, J = 7.1 Hz, 3H). MS (ESI+): 355.0.
Intermediate H.19: ethyl 8-fluoro-1 -methyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate Following the protocol outlined in Procedure AA, ethyl 8-fluoro-1 -methyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 6-fluoro-2,3-dihydro-4H- thiochromen-4-one, diethyl oxalate and methyl hydrazine to afford the title compound. 1H NMR (DMSO-d6, 400MHz) 8 7.72 (dd, J = 10.1 Hz, J = 2.4 Hz, 1 H), 7.57-7.53 (m, 1 H), 7.22- 7.17 (m, 1 H), 4.29 (q, J = 7.1 Hz, 2H), 4.17 (s, 2H), 4.13 (s, 3H), 1 .30 (t, J = 7.1 Hz, 3 H). MS (ESI+): 293.0. HPLC (max plot) 98.8%; Rt 3.79 min.
Intermediate H.20: ethyl 8-fluoro-1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 8-fluoro-1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 6-fluoro-2,3-dihydro-4H- thiochromen-4-one, diethyl oxalate and phenyl hydrazine to afford the title compound. 1H NMR (DMSO-de, 400MHz) δ 7.63-7.59 (m, 2H), 7.55-7.48 (m, 3H), 7.13-7.08 (m, 2H), 6.33 (dd, J = 10.3 Hz, J = 2.7 Hz, 1 H), 4.33 (q, J = 7.1 Hz, 2H), 4.24 (s, 2H), 1 .30 (t, J = 7.1 Hz, 3H). MS (ESI+): 355.0. HPLC (max plot) 98.7%; Rt 5.67 min.
Intermediate H.21 : ethyl 6-bromo-1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 6-bromo-1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 8-bromo-2,3-dihydro-4H- thiochromen-4-one, diethyl oxalate and phenyl hydrazine to afford the title compound. 1H NMR (DMSO-de, 400MHz) δ 7.58-7.51 (m, 3H), 7.45 (d, J = 8.0 Hz, 2H), 6.92 (t, J = 8.0 Hz, 2H), 6.68 (d, J = 7.9 Hz, 1 H), 4.36-4.30 (m, 4H), 1 .31 (t, J = 7.0 Hz, 3H). MS (ESI+): 416.0. HPLC (max plot) 98.4%; Rt 5.96 min. Intermediate H.22: ethyl 8-nitro-1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 8-nitro-1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 6-nitro-2,3-dihydro-4H- thiochromen-4-one, diethyl oxalate and phenyl hydrazine to afford the title compound. 1H NMR (DMSO-de, 400MHz) δ 8.01 (dd, J = 8.8 Hz, J = 2.4 Hz, 1 H), 7.50 (d, J = 8.8 Hz, 1 H), 7.66-7.60 (m, 3H), 7.53 (dd, J = 8.0 Hz, J = 1 .2 Hz, 1 H), 7.42 (s, 1 H), 4.41 (s, 2H), 4.34 (q, J = 7.1 Hz, 2H), 1 .32 (t, J = 7.1 Hz, 3H). MS (ESI+): 382.0. HPLC (max plot) 90.6%; Rt 7.10 min.
Intermediate H.23: ethyl 1 -(2-methylphenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -(2-methylphenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4/-/- thiochroman-4-one, diethyl oxalate and 2-methyl phenyl hydrazine to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.56-7.42 (m, 5H), 7.20-7.16 (m, 1 H), 6.95-6.90 (m, 1 H), 6.53-6.51 (m, 1 H), 4.32 (q, J = 7.0 Hz, 2H), 4.28 (d, J = 3.5 Hz, 2H), 1.85 (s, 3H), 1 .31 (t, J = 7.0 Hz, 3H). MS (ESI+): 351 .0. HPLC (max plot) 98.0%; Rt 7.27 min
Intermediate H.24: ethyl 1 -(2-bromophenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -(2-bromophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4/-/- thiochroman-4-one, diethyl oxalate and 2-bromophenyl hydrazine to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.90 (dd, J = 7.6 Hz, J = 1.2 Hz, 1 H), 7.73-7.58 (m, 1 H), 7.46 (d, J = 8.0 Hz, 1 H), 7.19 (t, J = 7.6 Hz, 1 H), 6.96 (t, J = 7.8 Hz, 1 H), 6.52 (d, J = 8.0 Hz, 1 H), 4.35-4.24 (m, 4H), 1 .32 (t, J = 7.0 Hz, 3H). MS (ESI+): 416.0.
Intermediate H.25: ethyl 1 -(2-fluorophenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -(2-fluorophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4/-/- thiochroman-4-one, diethyl oxalate and 2-fluorophenyl hydrazine to afford 0.77 g (73%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.74 - 7.67 (m, 2H), 7.53-7.45 (m, 3H), 7.23-7.19 (m, 1 H), 7.02-6.98 (m, 1 H), 6.68 (d, J = 7.8 Hz, 1 H), 4.36-4.25 (m, 4H), 1 .31 (d, J = 7.1 Hz, 3H). MS (ESI+): 355.0. HPLC (max plot) 97.7%, Rt 6.99 min.
Intermediate H.26: ethyl 1 -(2-chlorophenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -(2-chlorophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4/-/- thiochroman-4-one, diethyl oxalate and 2-chlorophenyl hydrazine to afford 0.8 g (73%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.76-7.67 (m, 2H), 7.64-7.60 (m, 1 H), 7.47 (d, J = 7.8 Hz, 1 H), 7.21 -7.17 (m, 2H), 6.98-6.94 (m, 1 H), 6.54 (d, J = 7.8 Hz, 1 H) 4.35-4.30 (m, 2H), 4.28-4.23 (s, 2H), 1 .31 (t, J = 7.1 Hz, 3H). MS (ESI+): 370.0. HPLC (max plot) 99.2%; Rt 7.12 min. Intermediate H.27: ethyl 1 -f2-(methylthio)phenvn-1 ,4-dihydrothiochromenof4,3- clpyrazole-3-carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -[2-(methylthio)phenyl]-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4/-/- thiochroman-4-one, diethyl oxalate and [2-(methylthio)phenyl]hydrazine to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.63-7.61 (m, 1 H), 7.51 (d, J = 7.2 Hz, 1 H), 7.45 (d, J = 2.4 Hz, 1 H), 7.38-7.36 (m, 1 H), 7.17-7.16 (m, 1 H), 6.94-6.93 (m, 1 H), 6.58 (dd, J = 8.0 Hz, J = 1 .2 Hz, 1 H), 4.30 (q, J = 7.0 Hz, 2H), 4.26 (s, 2H), 2.34 (s, 3H), 1 .31 (t, J = 7.1 Hz, 3H). MS (ESI+): 415.0. HPLC (max plot) 97.6%; Rt 5.55 min.
Intermediate H.28: ethyl 1 -(2,3-dihydro-1 ,4-benzodioxin-6-yl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole-3-carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -(2,3-dihydro-1 ,4-benzodioxin-6-yl)- 1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4H- thiochroman-4-one, diethyl oxalate and 2,3-dihydro-1 ,4-benzodioxin-6-ylhydrazine to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.47 (d, J = 7.8 Hz, 1 H), 7.22-7.18 (m, 1 H), 7.05-7.00 (m, 3H), 6.87-6.84 (m, 1 H), 6.79-6.77 (m, 1 H), 4.34-4.30 (m, 6H), 4.21 (s, 2H), 1 .30 (t, J = 7.1 Hz, 3H). MS (ESI+): 427.0. HPLC (max plot) 99.2%; Rt 5.39 min.
Intermediate H.29: ethyl 1 -(2-methyl-1 ,3-benzothiazol-6-yl)-1 ,4- dihvdrothiochromenor4,3-c1pyrazole-3-carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -(2-methyl-1 ,3-benzothiazol-6-yl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4H- thiochroman-4-one, diethyl oxalate and 6-hydrazino-2-methyl-1 ,3-benzothiazole to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.28 (d, J = 2.0 Hz, 1 H), 8.05 (d, J = 8.2 Hz, 1 H), 7.53-7.48 (m, 2H), 7.19 (t, J = 7.5 Hz, 1 H), 6.95 (t, J = 7.8 Hz, 1 H), 6.64 (d, J = 8.0 Hz, 1 H), 4.33 (q, J = 7.0 Hz, 2H), 4.26 (s, 2H), 2.85 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H). MS (ESI+): 408.0. HPLC (max plot) 97.1 %; Rt 7.30 min.
Intermediate H.30: ethyl 1 -(3-bromophenyl)-1 ,4-dihvdrothiochromenor4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -(3-bromophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4H- thiochroman-4-one, diethyl oxalate and (3-bromophenyl)hydrazine to afford 0.55 g (70%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.81 -7.78 (m, 2H), 7.54-7.45 (m, 3H), 7.25-7.20 (m, 1 H), 7.06-7.02 (m, 1 H), 6.74-6.72 (m, 1 H), 4.33 (q, J = 7.0 Hz, 2H), 4.23 (s, 2H), 1 .31 (t, J = 7.0 Hz, 3H). MS (ESI+): 416.0. HPLC (max plot) 98.4%; Rt 7.56 min.
Intermediate H.31 : ethyl 1 -(3-chlorophenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -(3-chlorophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4H- thiochroman-4-one, diethyl oxalate and (3-chlorophenyl)hydrazine to afford 0.56 g (79%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.68-7.66 (m, 1 H), 7.59 (t, J = 7.8 Hz, 1 H), 7.50 (t, J = 7.8 Hz, 1 H), 7.44-7.41 (m, 1 H), 7.24-7.20 (m, 1 H), 7.06-7.02 (m, 1 H), 6.74- 6.72 (m, 1 H), 4.33 (q, J = 7.2 Hz, 2H), 4.23 (s, 2H), 1 .31 (t, J = 7.2 Hz, 3H). MS (ESI+):
370.0. HPLC (max plot) 98.7%; Rt 7.51 min.
Intermediate H.32: ethyl 1 -(4-bromophenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -(4-bromophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4H- thiochroman-4-one, diethyl oxalate and (4-bromophenyl)hydrazine to afford 1.1 g (70%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.77 (dd, J = 6.7 Hz, J = 2.0 Hz, 1 H), 7.50 (d, J = 7.8 Hz, 2H), 7.45-7.43 (m, 2H), 7.24-7.20 (m, 1 H), 7.07-7.03 (m, 1 H), 6.75-6.73 (m, 1 H), 4.32 (q, J = 7.1 Hz, 2H), 1 .31 (t, J = 7.1 Hz, 3H). MS (ESI+): 416.0. HPLC (max plot) 99.6%; Rt 5.94 min. Intermediate H.33: ethyl 1 -(4-fluorophenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -(4-fluorophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4H- thiochroman-4-one, diethyl oxalate and (4-fluorophenyl)hydrazine to afford 0.35 g (82%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.53-7.40 (m, 5H), 7.23-7.18 (m, 1 H), 7.04-7.00 (m, 1 H), 6.70-6.68 (m, 1 H), 4.32 (q, J = 7.1 Hz, 2H), 4.23 (s, 2H), 1.31 (t, J = 7.1 Hz, 3H). MS (ESI+): 355.0. HPLC (max plot) 99.5%; Rt 7.26 min.
Intermediate H.34 : ethyl 1 -(4-chlorophenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -(4-chlorophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4H- thiochroman-4-one, diethyl oxalate and (4-chlorophenyl)hydrazine to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.64 (dd, J = 6.6 Hz, J = 1.6 Hz, 1 H), 7.52-7.48 (m, 3H), 7.24-7.20 (m, 1 H), 7.07-7.03 (m, 1 H), 6.74-6.72 (m, 1 H), 4.33 (q, J = 7.1 Hz, 2H), 4.22 (s, 2H), 1 .31 (t, J = 7.1 Hz, 3H). MS (ESI+): 371 .0. HPLC (max plot) 99.4%; Rt 7.48 min.
Intermediate H.35: ethyl 1 -(4-isopropylphenyl)-1 ,4-dihydrothiochromenor4,3- clpyrazole-3-carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -(4-isopropylphenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4H- thiochroman-4-one, diethyl oxalate and (4-isopropylphenyl)hydrazine to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.49-7.42 (m, 3H), 7.37-7.34 (m, 2H), 7.19 (t, J = 7.5 Hz, 1 H), 6.98 (t, J = 7.7 Hz, 1 H), 6.70 (d, J = 8.1 Hz, 1 H), 4.32 (q, J = 7.1 Hz, 2H), 3.05- 2.98 (m, 1 H), 1.30 (t, J = 7.1 Hz, 3H), 1 .25 (d, J = 6.8 Hz, 6H). MS (ESI+): 379.0. HPLC (max plot) 98.5%; Rt 7.80 min. Intermediate H.36: ethyl 1 -(4-methylpyridin-3-yl)-1 ,4-dihydrothiochromenof4,3- cl p yrazo I e -3 -ca r boxy I ate
Following the protocol outlined in Procedure AA, ethyl 1 -(4-methylpyridin-3-yl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4H- thiochroman-4-one, diethyl oxalate and 3-hydrazino-4-methylpyridine to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.35 (d, J = 2.1 Hz, 1 H), 7.96 (dd, J = 8.1 Hz, J = 1 .8 Hz, 1 H), 7.67 (d, J = 8.1 Hz, 1 H), 7.48-7.46 (m, 1 H), 7.22-7.18 (m, 1 H), 7.02-6.98 (m, 1 H), 6.63 (dd, J = 7.9 Hz, J = 1.0 Hz, 1 H), 4.33 (q, J = 7.0 Hz, 2H), 4.22 (s, 2H), 2.41 (s, 3H), 1 .32 (t, J = 7.0 Hz, 3H). MS (ESI+): 352.0. HPLC (max plot) 98.6%; Rt 5.1 1 min.
Intermediate H.37: ethyl 1 -(tetrahvdro-2H-pyran-4-yl)-1 ,4-dihydrothiochromenof4,3- clpyrazole-3-carboxylate
Following the protocol outlined in Procedure AA, ethyl 1 -(tetrahydro-2H-pyran-4-yl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 2,3-dihydro-4H- thiochroman-4-one, diethyl oxalate and tetrahydro-2H-pyran-4-ylhydrazine to afford of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.70 (d, J = 7.3 Hz, 1 H), 7.55 (dd, J = 7.6 Hz, J = 1.2 Hz, 1 H), 7.40-7.30 (m, 2H), 4.88-4.84 (m, 1 H), 4.30 (q, J = 7.0 Hz, 1 H), 4.10 (s, 2H), 3.98-3.94 (m, 2H), 3.51 (t, J = 1 1 .1 Hz, 3H), 2.16-2.10 (m, 2H), 1.97-1 .94 (m, 2H), 1 .31 (t, J = 7.0 Hz, 3H). MS (ESI+): 345.0. HPLC (max plot) 98.0%; Rt 4.79 min.
Intermediates described below are obtained following procedure AA described below
Intermediate H.38: Ethyl 1 -f4-(methylthio)phenvn-1 ,4-dihydrothiochromenof4,3- clpyrazole-3-carboxylate
300 mg of the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 7.49-7.48 (d, J = 7.8 Hz ,1 H), 7.43-7.37 (m, 4H), 7.23-7.19 (t, J 7.6 Hz , 1 H), 7.05-7.01 (t, J = 7.7 Hz , 1 H), 6.77-6.75 (d, J = 7.9 Hz ,1 H), 4.35-4.30 (m, 2H), 4.22 (s, 2H), 2.54 (s, 3H), 1 .33-1.29 (t, J = 5.6 Hz, 3H). MS (ESI+): 383.0. HPLC (max plot) 93.72%;
Rt 5.85 min.
Intermediate H.39: Ethyl 1 -(3-fluorophenyl)-1 ,4-dihydrothiochromenof4,3- clpyrazole-3-carboxylate 150 mg of the title compound.1H NMR (DMSO-d6, 400 MHz): δ
7.64-7.58 (m, 1H), 7.50-7.45 (m, 3H), 7.30 (d, J= 7.5 Hz, 1H), 7.24-7.20 (m, 1H), 7.05-7.01 (m, 1H), 6.75-6.71 (m, 1H), 4.35- 4.30 (m, 2H), 4.23 (s, 2H), 1.33-1.29 (t, J= 7.1 Hz, 3H). MS
(ESI+): 355.0.
Intermediate H.40: Ethyl 1-(3-cvanophenvl)-1,4-dihvdrothiochromenor4,3- clpvrazole-3-carboxvlate
0.50 g (81 %) of the title compound.1 H NMR (DMSO-d6, 400 MHz) δ 8.12 (s, 1 H), 8.07 (d, J = 6.0 Hz, 1 H), 7.80-7.77 (m, 2H), 7.51 (d, J = 7.8 Hz, 1 H), 7.23 (t, J = 7.5 Hz, 1 H), 7.03 (t, J = 7.8
> Hz, 1 H), 6.69 (d, J = 7.8 Hz, 1 H), 4.34 (d, J = 7.8 Hz, 2H), 4.24 (s, 2H), 1.31 (t, J = 7.0 Hz, 3H). MS (ESI+): 362.0. HPLC (max plot) 98.0%; Rt 5.22 min
Intermediate H.41: Ethvl 1-(pvridin-3-vD-1,4-dihvdrothiochromenor4,3-clpvrazole-3- carboxvlate
320 mg of the title compound.1H NMR (400 MHz, DMSO-d6) δ = 8.78-8.77 (dd, J= 1.4, 4.7 Hz, 1 H),8.70-8.69 (m,1H), 8.00-7.97 (m,1H), 7.65-7.62 (m, 1H), 7.52-7.50 (m, 1H), 7.23-7.20 (m,1H), 7.04-7.00 (m,1H), 6.69-6.67 (m,1H), 4.36-4.31 (q,2H), 4.24 (s, 2H), 1.33-1.29 (t, J = 7.12 Hz, 3H). MS (ESI+): 338.0; HPLC (max plot) 97.09%; Rt 4.33 min
Intermediate H.42: Ethvl 1-(6-methvlpvridin-3-vD-1,4-dihvdrothiochromenor4,3- clpvrazole-3-carboxvlate
1H NMR(DMSO-d6,400 MHz): δ 8.54-8.53 (m, 1H), 7.86-7.83 (dd, J = 2.6, 8.2 Hz, 1 H), 7.51-7.47 (m, 2H), 7.24-7.20 (m, 1 H), 7.05-7.01 (m, 1 H), 6.73-6.71 (d, J = 7.8 Hz, 1 H), 4.36-4.30 (q, 2H), 4.23 (s, 2H), 2.59 (s, 3H), 1.33-1.29 (t, J = 11.1 Hz, 3H). MS (ESI+): 352.2
Intermediate H.43: Ethvl 1-(6-methoxvPVridin-3-vD-1,4-dihvdrothiochromenor4,3- clpvrazole-3-carboxvlate
Intermediate H.48: Ethvl 1-(2-isopropvlphenvl)-1,4-dihvdrothiochromenor4,3- δ:
J =
δ: H), Hz, (t, Rt
Rt
1 .33-
clpyrazole-3-carboxylate 1 .6 g of the title compound. 1H NMR (DMSO-d6, 400 MHz): δ
7.61 -7.60 (m, 3H), 7.51 -7.47 (m, 2H), 7.39 (d, J = 8.6 Hz, 1 H), 6.82 (dd, J = 2.7, 8.6 Hz, 1 H), 6.21 -6.20 (d, J = 2.7 Hz, 1 H), 4.35-4.30 (m, 2H), 4.18 (s, 2H), 3.13 (s, 3H), 1 .33-1 .29 (t, J = 7.1 Hz, 3H). MS (ESI+): 367.0. HPLC (max plot) 98.48%; Rt
5.1 1 min.
Intermediate H.53: Ethyl 8-bromo-1 -phenvl-1 ,4-dihvdrothiochromenor4,3- clpvrazole-3-carboxvlate
0.50 g of the title compound. 1 H NMR (400 mHz, DMSO-d6) δ = 7.64-7.59 (m, 3H), 7.52-7.39 (m, 3H), 7.39-7.36 (m, 1 H), 6.68 (d, J = 2.0 Hz, 1 H), 4.35-4.30 (m, 2H), 4.26 (s,2H), 1 .33- 1 .29 (t, J = 7.1 Hz, 3H).MS (ESI+): 416.0. HPLC (max plot) 89.65%; Rt 5.96 min
Intermediate H.54: Ethvl 1 -cvclopentvl-1 ,4-dihvdrothiochromenor4,3-clpvrazole-3- carboxvlate
600 mg (96%) of the title compound. 1H NMR (400 MHz, DMSO-de): δ = 7.75-7.72 (d, J = 8.2 Hz, 1 H), 7.55-7.53 (d, J = 7.5 Hz, 1 H), 7.39-7.30 (m, 1 H), 5.14-5.1 1 (t, J = 7.16 Hz 1 H), 4.32-4.27 (q, J = 7.1 14.2 Hz, 2H), 4.09 (s, 2H), 2.31 (m, 2H), 2.16-2.15 (m, 2H), 2.06-2.03 (t, J = 6.6 Hz, 2H), 1.88 (m, 2H), 1 .32 (m, 3H). MS (ESI+): 329. HPLC (max plot) 98.12%; Rt 5.76 min.
Intermediate H.55: Ethvl 1 -(4-methvlcvclohexvD-1 ,4-dihvdrothiochromenor4,3- clpvrazole-3-carboxvlate
400 mg (59%) of the title compound. MS (ESI+): 357.0.
Intermediate H.56: Ethvl 1 -(4-ieri-butvlcvclohexvD-1 ,4-dihvdrothiochromenor4,3- clpvrazole-3-carboxvlate 220 mg of the title compound. MS (ESI+): 399.3.
Intermediate H.57: Ethvl 1 -(4,4-difluorocvclohexvD-1 ,4-dihvdrothiochromenor4,3- clpvrazole-3-carboxvlate
230 mg of the title compound. 1H NMR (DMSO-d6, 400 MHz) δ 7.70-7.68 (d, J = 7.6 Hz, 1 H), 7.56-7.54 (d, J = 7.5 Hz, 1 H), 7.40-7.31 (m, 2H), 4.87 (m, 1 H), 4.33-4.28 (m, 2H), 4.09 (s, 2H), 2.18-2.08 (m, 8H), 1 .32-1 .29 (t, J = 7.6 Hz , 3H). MS
F
(ESI+): 379.2. HPLC (max plot) 98.69%; Rt 5.74 min
Intermediate H.58: Ethvl 1 -(3,3-dimethvlcvclohexvD-1 ,4-dihvdrothiochromenor4,3- clpvrazole-3-carboxvlate
300 mg (81 %) of the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 7.62-7.60 (d, J = 7.7 Hz, 1 H),7.56-7.54 (d, J = 7.7 Hz, 1 H), 7.54-7.30 (m, 2H), 4.74 (m, 1 H), 4.32-4.24 (m, 2H), 4.09 (s, 2H), 1 .97-1 .95 (m, 2H), 1 .79-1 .61 (m, 4H), 1.39-1 .22 (m, 4H), 1 .01 (s, 3H), 0.96 (s, 3H). MS (ESI+): 371.2. HPLC (max plot) 93.91 %; Rt 6.54 min
Intermediate H.59: 3-r3-(Ethoxvcarbonvl)thiochromenor4,3-clpvrazol-1 (4H)- vHcvclohexanecarboxvlic acid
200 mg of the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 12.23 (bs, 1 H), 7.65-7.63 (d, J = 7.7 Hz , 1 H), 7.55-7.54 (d, J
OH = 7.6 Hz, 1 H), 7.38-7.32 (m, 2H), 4.71 (m, 1 H), 4.33-4.28 (m,
2H), 4.10 (s, 2H), 2.49-2.48 (m, 2H), 2.04 (m, 1 H), 2.00-1.84 (m, 5H), 1 .33-1 .29 (m, 4H). MS (ESI+): 387.0.
Intermediate H.60: 4-r3-(Ethoxvcarbonvl)thiochromenor4,3-clpvrazol-1 (4H)- vHcvclohexanecarboxvlic acid
500 mg of the title compound. MS (ESI+): 387.0.
0
Intermediate H.61 : Ethvl 1 -(4-hvdroxvcvclohexvD-1 ,4-dihvdrothiochromenor4,3-
blpvridine-3-carboxvlate 400 mg of the title compound. ΊΗ NMR (DMSO-d6, 400 MHz):
δ 8.27-8.26 (dd, J = 1 .6, 4.5 Hz, 1 H), 7.61 -7.56 (m, 3H), 7.49- 7.47 (m, 2H), 6.99-6.96 (dd, J = 4.7, 7.9 Hz, 1 H), 6.88-6.86 (dd, J = 1 .1 , 6.8 Hz ,1 H), 4.41 (s, 2H), 4.36-4.30 (m, 2H), 1 .33- 1 .30 (t, J = 7.2 Hz, 3H). MS (ESI+): 338.0. HPLC (max plot)
97.34%; Rt 4.18 min.
Intermediate H.67: Ethvl 1 -cvclohexvl-1 ,4-dihvdropvrazolor3',4':4,5lthiopvranor2,3- blpvridine-3-carboxvlate
230 mg yield of the title compound. 1H NMR (400 MHz, DMSO-de) δ = 8.37-8.36 (dd, J 1 = 1 .32 Hz, J 2= 4.72 Hz , 1 H), 7.95-7.93 (m, 1 H), 7.36-7.33 (dd, J1 = 4.76 Hz, J2= 7.96 Hz,
N-N 1 H), 4.49-4.44 (m, 1 H), 4.33-4.28 (q, 2H), 4.26 (s, 2H), 1 .99- 1 .96 (m, 2H), 1.92-1 .86 (m, 4H), 1 .83-1.79 (m, 1 H), 1 .68-1.64 (m, 2H), 1.46-1 .40 (t, J = 13 Hz, 3H), 1 .32 (m, 1 H). MS (ESI+): 344.0. HPLC (max plot) 95.77%; Rt 4.67 min.
Intermediate H.68: 4-r3-(Ethoxvcarbonvl)pvrazolor3',4':4,51thiopvranor2,3- blpvridin-1 (4H)-vllbenzoic acid
960 mg of the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 8.28-8.26 (m, 1 H), 8.05-8.03 (m, 2H), 7.49-7.47 (d, J = 8.0 Hz, 2H), 7.02-76.99 (m, 1 H), 6.95-6.93 (d, J = 7.9 Hz, 1 H), 4.40 (s, 2H), 4.35-4.30 (m, 2H), 1 .33-1 .29 (t, J = 7.1 Hz, 3H). MS
0 (ESI+): 382.0.
Intermediate H.69: Ethvl 1 -phenvl-1 ,4-dihvdropvrazolor3',4':4,5lthiopvranor3,2- clpvridine-3-carboxvlate
450 mg of the title compound. ΊΗ NMR (DMSO-d6, 400 MHz): δ 8.22-8.21 (d, J = 5.2 Hz, 1 H), 7.69 (s, 1 H), 7.62-7.61 (d, J = 7.0 Hz, 3H), 7.52-7.49 (m, 3H), 4.37 (s, 2H), 4.35-4.30 (m, 2H), 1 .33-1 .30 (t, J = 7.1 Hz, 3H). MS (ESI+): 338.2. HPLC (max plot) 94.29%; Rt 3.02 min.
Intermediate H.70: Ethvl 1 -phenvl-1 ,4-dihvdrothienor3',2':5,6lthiopvranor4,3- clpvrazole-3-carboxvlate
vl)-1 ,4-dihvdropvrazolor3',4':4,5lthiopvranor3,2-diri,3lthiazole-3-carboxvlate 630 mg of the title compound. It is used in the next step without further purification. HPLC (max plot) 76.8%; Rt 5.06 min. MS (ESI+): 466.7.
Procedure I:
Intermediate 1.1 : 4-f3-(Ethoxycarbonyl)thiochromenof4,3-c1pyrazol-1 (4H)-yl1benzoic acid
To a solution of ethyl oxo(4-oxo-3,4-dihydro-2H-thiochromen-3-yl)acetate (10.1 g; 38.21 mmol; 1 eq.) in EtOH (100 mL) and acetic acid (6.56 mL) is added 4-hydrazinobenzoic acid 97% (8.39 g; 53.5 mmol; 1 .4 eq.). The reaction mixture is heated up to reflux for 2h. The precipitate is filtrated off and washed with water. The filtrate is evaporated to dryness. Water is added and the mixture is sonicated then filtered off, washed with water (x3) and dried under reduced pressure to afford an orange solid. The 2 solid residues are combined and taken up in MTBE (250 ml) then heated to reflux for 30 min. The precipitate is filtered off, washed with MTBE (X2) and dried under reduced pressure to afford 19.05 g of the title compound. 1H NMR (DMSO-d6) δ 13.30 (br s, 1 H), 8.1 1 (d, J = 8.6 Hz, 2H), 7.60 (d, J = 8.6 Hz, 2H), 7.53-7.51 (m, 1 H), 7.27-7.19 (m, 1 H), 7.07-7.01 (m, 1 H), 6.77-6.73 (m, 1 H), 4.35 (q, J = 7.1 Hz, 2H), 4.24 (s, 2H), 1.33 (t, J = 7.1 Hz, 3H). HPLC (max plot) 61 .0%; Rt 4.15 min. MS (ESI+): 380.9
Intermediates described below are obtained following procedure I
chromenor4,3-clpvrazole-3-carboxvlate 5,5-dioxide °¾'·° 200 mg (86%) of the title compound as a yellow solid. 1 H NMR
(DMSO-d6) δ 8.1 1 (dd, J = 5.6, 8.7 Hz, 1 H), 7.66-7.44 (m, 5H), 6.40 (dd, J = 2.47, 10.1 Hz, 1 H), 5.03 (s, 2H), 4.38 (q, J = 7.09 Hz, 2H), 3.69-3.54 (m, 6H), 2.46-2.36 (m, 4H), 1 .35 (tr, 3H). HPLC (max plot) 99.3%; Rt 2.59 min. MS (ESI+): 486.3.
Intermediate 1.8: Ethyl 1 -azetidin-3-vl-1 ,4-dihvdrothiochromenor4,3-clpvrazole-3- carboxvlate
5.75 g (86%) of the title compound as a beige powder. HPLC (max plot) 61 .3%; Rt 2.91 min. MS (ESI+): 315.8.
L-NH
Intermediate 1.9: Ethvl 1 -pvrrolidin-3-vl-1 ,4-dihvdrothiochromenor4,3-clpvrazole-3- carboxvlate
7 g (93.2%) of the title compound as a brown solid. It is used in the next step without further purification. MS (ESI+): 330.0.
Intermediate 1.10: Ethvl 1 -(tetra h vd rof u ra n -3 -vl ) -1 , 4-d i h vd roth i oc h ro me n o Γ4, 3 -cl pvrazole-3-carboxvlate
945 mg of the title compound as a brown oil. 1H NMR (DMSO-d6) δ 7.75-7.72 (m, 1 H), 7.58-7.55 (m, 1 H), 7.41 -7.31 (m, 2H), 5.52- 5.45 (m, 1 H), 4.35-4.28 (quad, J = 7.10 Hz, 2H), 4.18-3.98 (m,
Co 5H), 3.90-3.83 (m, 1 H), 2.47-2.31 (m, 2H), 1 .34-1 .30 (t, J = 7.10
Hz, 3H). HPLC (max plot) 95.7%; Rt 4.47 min. MS (ESI+): 331.1.
Intermediate 1.11 : Ethvl 1 -piperidin-4-vl-1 ,4-dihvdrothiochromenor4,3-clpvrazole-3- carboxvlate
2.95 g (97%) of the title compound as a yellow foam. HPLC (max plot) 77.3%; Rt 3.09 min.
Intermediate 1.12: Ethvl 1 -piperidin-3-vl-1 ,4-dihvdrothiochromenor4,3-clpvrazole-3- carboxvlate
Procedure J
Intermediate J.1 : Ethyl 1 -piperidin-3-yl-7-(trifluoromethoxy)-1 ,4-
To a solution of ethyl oxo[4-oxo-7-(trifluoromethoxy)-3,4-dihydro-2/-/-thiochromen-3-yl]acetate (3.00 g; 8.61 mmol; 1 eq.) and ie f-butyl 3-[2-(tert-butoxycarbonyl)hydrazino]piperidine-1 - carboxylate (4.08 g; 12.92 mmol; 1.50 eq.) in EtOH (80 ml) is added HCI (4M in dioxane, 42.38 mL) were added in a dropwise fashion. Reaction mixture is heated at 75°C for 5h after which it is concentrated under vacuum, partitioned between NaHC03 sat (pH 7-8) and EtOAc. Organic layer is washed NaHC03 sat and brine, dried over MgS04 to give 3.1 g (88%) of the title compound as a brown solid.1H NMR (DMSO, 300 MHz): δ 7.77 (d, J = 9.43 Hz, 1H), 7.62 (s, 1H), 7.39 (d, J= 7.7 Hz, 1H), 4.61-4.46 (m, 1H), 4.40-4.26 (m, 2H), 4.17 (s, 1H), 4.09-3.98 (m, 1H), 3.19-3.06 (m, 1H), 2.97-2.82 (m, 2H), 2.17-2.05 (m, 2H), 1.99 (s, 1H), 1.80-1.67 (m, 1H), 1.67-1.45 (m, 1H), 1.32 (t, J = 7.0 Hz, 3H), 1.18 (t, J = 6.9 Hz, 1H). Intermediates described below are obtained following protocole outlined in procedure J
°¾"° 700 mg (88%) of the title compound as a orange solid. 1H NMR
(DMSO-d6, 300 MHz): δ 8.10-7.96 (m, 1 H), 7.72-7.56 (m, 3H), 7.56-7.36 (m, 3H), 6.82-6.71 (m, 1 H), 4.99 (s, 2H), 4.37 (q, J = 7.09 Hz, 2H), 2.53-2.45 (m, 2H), 2.03 (s, 6H), 1 .40-1 .28 (m, 9H).
Ν- MS (ESI+): 468.3.
/
Intermediate J.5: Ethyl 1 -{4-ri -(morpholin-4-vlmethvl)cvclopropvHphenvl}-1 ,4- dihvdrothiochromenor4,3-clpvrazole-3-carboxvlate 5,5-dioxide
°s*° 189 mg of the title compound as a orange solid. 1H NMR (DMSO- d6, 300 MHz): δ 8.09-7.97 (m, 1 H), 7.72-7.61 (m, 1 H), 7.61 -7.48 (m, 3H), 7.48-7.34 (m, 2H), 6.87-6.74 (m, 1 H), 4.99 (s, 2H), 4.37 (q, J = 7.1 Hz, 2H), 3.58-3.39 (m, 4H), 2.61 (s, 2H), 2.48-2.29 (m, 4H), 1 .34 (t, J = 7.1 Hz, 3H), 1.01 -0.92 (m, 2H), 0.88-0.76 (m,
N-\
2H). MS (ESI+): 508.44. .
Intermediate J.6: Ethvl 6-methoxv-1 -piperidin-3-vl-1 ,4-dihvdrothiochromenor4,3- clpvrazole-3-carboxvlate
13.8 g (90%) of the title compound as an orange solid. MS (ESI+): 374.24. .
Intermediate J.7; Ethvl 6-methvl-1 -piperidin-3-vl-1 ,4-dihvdrothiochromenor4,3- c] py razo I e -3 -ca r boxy I ate
12 g (80%) of the title compound. HPLC (max plot) 61 .4%; Rt 3.18 min. MS (ESI+): 358.21
Intermediate J.8; Ethvl 7-fluoro-1 -piperidin-3-vl-1 ,4-dihvdrothiochromenor4,3- c] py razo I e -3 -ca r boxy I ate
fsTPTF 5.4 g of the title compound a white powder. MS (ESI+): 362.19.
HPLC (max plot) 79.6%; Rt 3.70 min
Intermediate J.9: Ethvl 7-methoxv-1 -piperidin-3-vl-1 ,4-dihvdrothiochromenor4,3- cl p vrazo 1 e -3 -ca r boxvl ate
6 mg of the title compound as a brown solid. 1H NMR (DMSO-c/6, 300 MHz): δ 7.59 (d, J = 8.8, 1 H), 7.14 (d, J = 2.7, 1 H), 6.96 (dd, J = 8.7, 2.7, 1 H), 4.61 -4.44 (m, 1 H), 4.30 (q, J = 7.1 , 2H), 4.09 (s, 2H), 3.81 (s, 3H), 3.12 (dd, J = 12.3, 3.5, 1 H), 3.00-2.82 (m, 3H), 2.63-2.40 (m, 1 H), 2.19-2.01 (m, 2H), 1.81 -1 .66 (m, 1 H), 1 .64- 1 .47 (m, 1 H), 1.31 (t, J = 7.1 , 3H). MS (ESI+): 372.22. HPLC (max plot) 92.1 %; Rt 3.67 min.
Intermediate J.10; Ethvl 8-methoxv-1 -piperidin-3-vl-1 ,4-dihvdrothiochromenor4,3- clpvrazole-3-carboxvlate
3.5 g of the title compound a brown oil. 1H NMR (300 MHz, DMSO) 5 7.49 (d, J = 8.6, 1 H), 7.14 (d, J = 2.6, 1 H), 6.97 (dd, J = 8.6, 2.6, 1 H), 4.68-4.51 (m, 1 H), 4.31 (q, J = 7.1 , 2H), 3.84 (s,
CNH 3H), 3.33 (s, 7H), 3.13 (d, J = 9.9, 1 H), 3.01 -2.83 (m, 2H), 2.12 (s,
2H), 1 .82-1 .46 (m, 2H), 1 .17 (dd, J = 8.6, 5.6, 3H).
Procedure K
Intermediate K.1 : Ethvl 1 -ri -(ieri-butoxvcarbonvl)piperidin-4-vll-1 ,4-dihvdrothio
chromenor4,3-c1pyrazole-3-carboxylate
Ethyl 1 -piperidin-4-yl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate (2.95 g; 8.59 mmol; 1 eq.), di-ie f-butyl dicarbonate (2.25 g; 10.31 mmol; 1.2 eq.) and trietylamine (1 .2 ml; 8.59 mmol; 1 eq.) are dissolved in DCM (29.5 ml) and the reaction mixture is stirred for 3 days at room temperature. DCM is added and the organic phase is washed with water, dried over MgS04, filtered and concentrated. The residue is purified on silica eluting from 5 to 15% EtOAc in cyclohexane to afford, after concentration of the desired fractions, 3.05 g (80%) of the title compound as a beige foam. 1H NMR (DMSO-d6) δ 7.69 (d, 1 H, J = 7.6 Hz): 7.56 (dd, 1 H, J = 7.5 Hz): 7.43-7.30 (m, 2H), 4.84 (m, 1 H), 4.1 (q, 2H, J = 7.7 Hz): 4.10 (s, 2H), 3.10- 2.85 (m, 2H), 2.06-1 .86 (m, 4H), 1 .49 (s, 9H), 1 .31 (t, 3H, J = 7.7 Hz). HPLC (max plot) 85.2%; Rt 5.79 min. Intermediates described below are obtained following Procedure K.
min
General protocole L.
Intermediate L.1: Ethyl 1-r3-(3-methyl-1,2,4-oxadiazol-5-yl)phenvn-1,4- dihydrothiochromenor4,3-c1pyrazole-3-carboxylate 5,5-dioxide
To a solution of 3-[3-(ethoxycarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4/-/)- yl]benzoic acid (100 mg, 0.24 mmol) in EtOAc is added methylamidoxime (17 mg, 0.24 mmol) under nitrogen followed by TEA (0.1 ml_, 0.73 mmol) and propane phosphonic acid cyclic anhydride (0.4 ml_, 0.60 mmol) at 0°C under nitrogen. The reaction mixture is refluxed at 80°C for 12 h under nitrogen after which time, EtOAc is added. Organic layer is washed with 10% aq. solution Na2C03 solution dried over Na2S04 and concentrated under reduced pressure. The crude material obtained is purified by silica gel column chromatography (1 .5% MeOH in DCM) to afford the title compound.
Intermediate L.2: Ethyl 1 -(3-f3-f(dimethylamino)methvn-1 ,2,4-oxadiazol-5-yl)phenyl)-
Following the protocol outlined in procedure L, ethyl 1 -(3-{3-[(dimethylamino)methyl]-1 ,2,4- oxadiazol-5-yl}phenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from 3-[3-(ethoxycarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4/-/)-yl]benzoic acid and (1 Z)-2-(dimethylamino)-/V'-hydroxyethanimidamide to afford the title compound. MS (ESI+): 494.0. Intermediate L.3: Ethyl 1 -f3-r3-imethoxymethyl)-1 ,2,4-oxadiazol-5-vnphenyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole-3-carboxylate 5,5-dioxide
Following the protocol outlined in procedure L, ethyl 1 -{3-[3-(methoxymethyl)-1 ,2,4- oxadiazol-5-yl]phenyl}-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from 3-[3-(ethoxycarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4/-/)-yl]benzoic acid and (1 Z)-/V'-hydroxy-2-methoxyethanimidamide to afford the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 8.38-8.36 (d, J = 6.8 Hz,1 H), 8.24 (s, 1 H), 8.06-8.04 (d, J = 7.7 Hz , 1 H), 7.90-7.86 (m, 2H), 7.68-7.56 (m, 2H), 6.98-6.96 (d, J = 7.8 Hz, 1 H), 5.01 -4.97 (s, 2H), 4.62 (s, 2H), 4.40-4.35 (m, 2H), 3.35 (s, 3H), 1 .36-1 .32 (t, J = 7.1 Hz, 3H). MS (ESI+): 481 .2 Intermediate L.4: A/'-hvdroxy-3-f3-(morpholin-4-ylcarbonyl)-5,5- dioxidothiochromenof4,3-c1pyrazol- -vnbenzenecarboximidamide
To a solution of 3-[3-(morpholin-4-ylcarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4/-/)- yl]benzonitrile (0.3 g, 0.69 mmol) in EtOH (20 mL) is added 50% aq. hydroxylamine solution (0.14 mL, 2.07 mmol). The reaction mass is heated to 85°C for 12 h. The solvent is removed completely under reduced pressure to afford 150 mg (89%) of the title compound as a white solid. MS (ESI+): 468.0.
Intermediate L.5: Ethyl 1 -r3-(5-methyl-1 ,3,4-oxadiazol-2-yl)phenvn-1 ,4- dihydrothiochromenor4,3-c1pyrazole-3-carboxylate 5,5-dioxide
To a solution of 3-[3-(ethoxycarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4/-/)- yl]benzoic acid (200 mg, 0.485 mmol) in EtOAc is added acetic hydrazide (35 mg, 0.485 mmol) under nitrogen. Then TEA (0.2 ml_, 1 .45 mmol) and propane phosphonic acid cyclic anhydride (0.7 ml_, 1 .2 mmol) is added to the reaction mixture at 0°C under nitrogen. The reaction mixture is refluxed at 80°C for 12 h after which it is diluted with EtOAC and washed with 10% aq. Na2C03 solution. The organic layer is separated, dried over Na2S04 and concentrated under reduced pressure. The solid residue is purified by silica gel column chromatography over (1.5% MeOH in DCM to afford the title compound. MS (ESI+): 451 .2.
Intermediate L.6: Ethyl 1 -r3-i5-methyl-1 ,3,4-thiadiazol-2-yl)phenvn-1 ,4- dihydrothiochromenor4,3-c1pyrazole-3-carboxylate 5,5-dioxide
To a solution of 3-[3-(ethoxycarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4/-/)- yl]benzoic acid (0.4 g, 0.97 mmol) in EtOAc is added acetic hydrazide (72 mg, 0.97 mmol) under nitrogen. Then TEA (0.4 ml_, 2.93 mmol) , Lawssen's reagent (0.6 g, 1 .46 mmol) and propane phosphonic acid cyclic anhydride (2 ml_, 2.93 mmol) is added to the reaction mass at 0°C under nitrogen. The reaction mixture is refluxed at 80°C for 12 h under nitrogen after which time, EtOAc is added. Organic layer is washed with 10% aq. solution Na2C03 solution dried over Na2S04 and concentrated under reduced pressure. The crude material obtained is purified by silica gel column chromatography (1.5% MeOH in DCM) to afford the title compound. MS (ESI+):467.0.
Procedure M. Intermediate M.1 : Ethyl 1 -(6-oxo-1 ,6-dihvdropyridin-3-yl)-1 ,4- dihvdrothienor3',2':5,61thiopyranor -c1pyrazole-3-carboxylate
To a suspension of ethyl 1 -(6-methoxypyridin-3-yl)-1 ,4-dihydrothieno[3',2':5,6]thiopyrano[4,3- c]pyrazole-3-carboxylate (200 mg, 0.535 mmol) and sodium iodide (80 mg, 0.535 mmol) in dry ACN is added trimethylsilylchloride (350 mg, 3.22 mmol) at RT under nitrogen. The reaction mass is heated to 80°C for 48 h under nitrogen after which it is cooled to 0°C.
Reaction mixture is diluted with sat. aq. solution of Na2C03 and sat. sodiumthiosulphate solution and stirred for 0.5 h. The solid precipitated is filtered through vacuum, washed with water and dried overnight to afford 190 mg (98%) of the title compound. MS (ESI+): 360.0.
Intermediate M.2: Ethyl 1 -(6-oxo-1 ,6-dihvdropyridin-3-yl)-1 ,4-dihydrothiochromenof4,3- clpyrazole-3-carboxylate
Following the protocol outlined in procedure AN, ethyl 1 -(6-oxo-1 ,6-dihyd ropyridin-3-yl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from ethyl 1 -(6- methoxypyridin-3-yl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate to afford 230 mg (69%) of the title compound. MS (ESI+): 354.2.
Procedure N.
Intermediate N.1 : Ethyl 1 -(1 -methyl-6-oxo-1 ,6-dihvdropyridin-3-yl)-1 ,4- dihvdrothienor3',2':5,61thiopyranor -c1pyrazole-3-carboxylate
To a solution of ethyl 1 -(6-oxo-1 ,6-dihydropyridin-3-yl)-1 ,4- dihydrothieno[3',2':5,6]thiopyrano[4,3-c]pyrazole-3-carboxylate (75 mg, 0.208 mmol) in water/DCM (1 :2) is added tetrabutylammonium bromide (0.135 g, 0.417 mmol), sodium hydroxide (17 mg, 0.417 mmol) and methyl iodide (0.13 mL, 2.08 mmol). The reaction mass is stirred at RT for 12 h after which reaction mixture is diluted with DCM and washed with water. The organic layer is separated, dried over Na2S04, concentrated under reduced pressure and purified by silica gel column chromatography over (5% MeOH in DCM) to afford the title compound. MS (ESI+): 374.0. Intermediate N.2: Ethyl 1 -(1 -methyl-6-oxo-1 ,6-dihvdropyridin-3-yl)-1 ,4- d i h yd roth i oc h ro me n o Γ4, 3 -cl p yrazo I e -3 -ca rboxyl ate
Following the protocol outlined in Procedure N, ethyl 1 -(1 -methyl-6-oxo-1 ,6-dihydropyridin-3- yl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate is obtained from 1 -(6-oxo-1 ,6- dihydropyridin-3-yl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate to afford the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 8.25 (m, 1 H), 7.49-7.46 (m, 2H), 7.26-7.22 (m, 1 H), 7.18-7.15 (m, 2H), 6.50-6.47 (d, J = 9.6 Hz, 1 H), 4.35-4.29 (m, 2H), 4.22 (s, 2H), 3.46 (s, 3H), 1 .32-1 .29 (t, J = 7.1 Hz, 3H). MS (ESI+): 368.2. Intermediate 0.1 : Ethyl 1 -{3-r(terf-butoxycarbonyl)amino1phenyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole-3-carboxylate 5,5-dioxide
To a solution of 3-[3-(ethoxycarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4H)- yl]benzoic acid (500 mg, 1 .21 mmol) in ferf-butanol:DMF (8: 2) is added TEA (0.68 mL, 4.85 mmol) under nitrogen followed by diphenylphosphonylazide (0.4 mL, 1.82 mmol). It is then heated to 60°C for 20 min and slowly increased to 100°C at which it is heated for 2 h. After this time, solvents are evaporated under reduced pressure, diluted with water and extracted with ethylacetate. The organic layer is separated, washed with brine, dried over Na2S04, concentrated under reduced pressure and purified by silica gel column chromatography (20% EtOAc, pet. ether) to afford the title compound as white solid. MS (ESI+): 484.0.
Intermediate 0.2: Ethyl 1 -f3-f(phenoxycarbonyl)amino1phenyl)-1 ,4- dihvdrothiochromenor4,3-c1pyrazole-3-carboxylate 5,5-dioxide
To a solution of ethyl 1 -(3-aminophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3- carboxylate 5,5-dioxide hydrochloride (100 mg, 0.243 mmol) in THF (10 mL) are added 2,4,6 collidine (0.06 mL, 0.487 mmol), phenylchloroformate (0.04 mL, 0.365 mmol) then stirred at RT for 18 h. After this time, reaction mixture is concentrated under reduced pressure, diluted with water, and extracted with EtOAc. The organic laye is separated, washed with brine, dried over Na2S04 and concentrated under reduced pressure to afford 100 mg of the title compound. MS (ESI+):504.0. Intermediate 0.3: Ethyl 1 -f3-f(morpholin-4-ylcarbonyl)amino1phenyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole-3-carboxylate 5,5-dioxide
A mixture of ethyl 1 -{3-[(phenoxycarbonyl)amino]phenyl}-1 ,4-dihydrothiochromeno[4,3- c]pyrazole-3-carboxylate 5,5-dioxide (100 mg, 0.198 mmol), morpholine (0.03 mL, 0.3 mmol), triethylamine (0.03 mL, 0.3 mmol) in /V-methyl-2-pyrrolidone is heated under microwave irradiation for 15 min at 55°C. The reaction mixture is diluted with water and is stirred for another hour. The precipitate is filtered and dried under vacuum to afford 80 mg (81 %) of the title compound. MS (ESI+): 497.2. Intermediate 0.4: Ethyl 6-cvano-1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate
Ethyl 6-bromo-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate (200 mg, 0.483 mmol) in DMF/water (10:1 , 4.4 mL) is taken in a sealed tube and purged with nitrogen for 10 min. Zinc cyanide (64 mg, 0.545 mmol), Pd2 (dba)3 (18 mg, 0.019 mmol) and s-phos (20 mg, 0.483 mmol) are then added and heated to 120°C for 2 h. After this time, the reaction mixture is diluted with DCM, filtered through acelite pad, washed with water, dried over Na2S04 and concentrated under reduced pressure to afford 200 mg of the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 7.74-7.72 (m, 1 H), 7.60-7.55 (m, 3H), 7.48-7.46 (m, 2H), 7.18-7.14 (m, 1 H), 6.91 -6.89 (dd, J = 1 .1 , 8.0 Hz, 1 H), 4.40 (s, 2H), 4.36-4.31 (m, 2H), 1 .33-1 .29 (t, J = 7.1 Hz, 3H). MS (ESI+): 362.2.
Procedure P
Intermediate P.1 : ethyl 6-methoxy-1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate 5,5-dioxide
A solution of ethyl 6-methoxy-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3- carboxylate (0.30 g, 0.81 mmol) in acetic acid (5 mL) is heated at 100 °C under nitrogen. Hydrogen peroxide 30% in water (0.5 mL, 3.6 mmol, 4.5 Eq) is added and the reaction mixture is heated for 30 minutes. After 30 minutes, the solvent is removed under reduced pressure. An aq. solution of NaHC03 10% is added to the residue. After 15 minutes stirring, the solid obtained is filtered off then dried to afford 0.26 g (79%) of the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 7.63-7.58 (m, 3H), 7.46-7.42 (m, 3H), 7.26 (d, J = 8.6 Hz, 1 H), 6.34 (d, J = 7.92 Hz, 1 H), 4.90 (s, 2H), 4.36 (q, J = 7.0 Hz, 2H), 3.33 (s, 3H), 1 .32 (t, J = 7.08 Hz, 3H). MS (ESI+): 399.0. HPLC (max plot) 94.0%; Rt 4.17 min.
Intermediate P.2: ethyl 6-methoxy-1 -methyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 6-methoxy-1 -methyl-1 ,4- dihydrothiochromeno [4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 6- methoxy-1 -methyl-1 ,4-dihydrothio chromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford the title compound. 1 H NMR (DMSO-d6, 400 MHz): δ 7.78 (t, J = 8.16 Hz, 1 H), 7.53 (d, J = 7.44 Hz, 1 H), 7.38 (d, J = 8.4 Hz, 1 H), 4.79 (s, 2H), 4.32 (q, J = 7.08 Hz, 2H), 4.20 (s, 3H), 3.92 (s, 3H), 1 .31 (t, J = 7.12 Hz, 3H). MS (ESI+): 337.0. HPLC (max plot) 96.5%; Rt 4.01 min. Intermediate P.3: ethyl 1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -phenyl-1 ,4-dihydrothiochromeno[4,3- c] pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c] pyrazole-3-carboxylate and hydrogen peroxide to afford title compound. 1 H NMR (DMSO-d6, 400 MHz): δ 8.03-8.01 (m, 1 H), 7.68-7.62 (m, 4H), 7.59-7.52 (m, 3H), 6.80 (d, J = 7.7 Hz, 1 H), 4.99 (s, 2H), 4.36 (q, J = 7.0 Hz, 2H), 1 .33 (t, J = 7.1 Hz, 3H). MS (ESI+): 369.0. HPLC (max plot) 96.9%; Rt 4.42 min. Intermediate P.4: ethyl 1 -methyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -methyl-1 ,4-dihydrothiochromeno[4,3- c] pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -methyl-1 ,4- dihydrothiochromeno[4,3-c] pyrazole-3-carboxylate and hydrogen peroxide to afford the title compound. 1 H NMR (DMSO-d6, 400 MHz): δ 8.07-8.02 (m, 2H), 7.91 -7.87 (m, 1 H), 7.75-7.71 (m, 1 H), 4.88 (s, 2H), 4.32 (q, J = 7.0 Hz, 2H), 4.29 (s, 3H), 1.32 (t, J = 7.1 Hz, 3H). MS (ESI+): 307.0. HPLC (max plot) 96.6%; Rt 3.25 min.
Intermediate P.5: ethyl 1 ,4-dihvdrothiochromenor4,3-c1pyrazole-3-carboxylate 5,5- dioxide
Following the protocol outlined in Procedure P, ethyl 1 ,4-dihydrothiochromeno[4,3- c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 ,4-dihydrothiochromeno[4,3- c]pyrazole-3-carboxylate and hydrogen peroxide to afford 1.0 g (90%) of the title compound as a white solid. 1H NMR (DMSO-d6, 400 MHz): δ 14.6 (s, 1 H), 8.06-7.93 (m, 2H), 7.88-7.78 (m, 1 H), 7.70-7.63 (m, 1 H), 4.88 (s, 2H), 4.40-4.32 (m, 2H), 1 .37-1 .31 (m, 3H). MS (ESI+): 293.0 HPLC (max plot) 93.1 %; Rt 3.19 min.
Intermediate P.6: ethyl 7-methoxy-1 -methyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 7-methoxy-1 -methyl-1 ,4- dihydrothiochromeno [4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 7- methoxy-1 -methyl-1 ,4-dihydrothio chromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 0.49 g (87%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 10.20 (s, 1 H), 8.00 (d, J = 8.8 Hz, 1 H), 7.48 (s, 1 H), 7.43-7.40 (m, 1 H), 4.85 (s, 2H), 4.32 (q, J = 7.1 Hz, 2H), 4.25 (s, 3H), 3.92 (s, 3H), 1 .31 (t, J = 7.1 Hz, 3H). MS (ESI+): 337.0. HPLC (max plot) 98.7%; Rt 3.55 min. Intermediate P.7: ethyl 7-methoxy-1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 7-methoxy-1 -phenyl-1 ,4- dihydrothiochromeno [4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 7- methoxy-1 -phenyl-1 ,4-dihydrothio chromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 1 .01 g (85%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.65- 7.62 (m, 3H), 7.53-7.45 (m, 3H), 7.17 (dd, J = 8.8 Hz, J = 3.1 Hz, 1 H), 6.73 (d, J = 8.8 Hz, 1 H), 4.95 (s, 2H), 4.36 (q, J = 7.1 Hz, 2H), 3.84 (s, 3H), 1.33 (t, J = 7.1 Hz, 3H). MS (ESI+): 399.0. HPLC (max plot) 98.0%; Rt 4.63 min. Intermediate P.8: ethyl 1 -(3-methylphenyl)-1 ,4-dihvdrothiochromenor4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -(3-methylphenyl)-1 ,4- dihydrothiochromeno [4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -(3- methylphenyl)-1 ,4-dihydrothio chromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 1 .08 g (97%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.02 (dd, J = 7.7 Hz, J = 1 .3 Hz, 1 H), 7.66-7.56 (m, 3H), 7.53-7.46 (m, 2H), 7.38 (s, 1 H), 7.28 (d, J = 7.4 Hz, 1 H), 4.98 (s, 2H), 4.36 (q, J = 7.1 Hz, 2H), 2.40 (s, 3H), 1.33 (t, J = 7.1 Hz, 3H). MS (ESI+): 383.0. HPLC (max plot) 97.3%; Rt 4.85 min.
Intermediate P.9: ethyl 1 -(4-methylphenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -(4-methylphenyl)-1 ,4- dihydrothiochromeno [4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -(4- methylphenyl)-1 ,4-dihydrothio chromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 1 .1 g (92%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.01 (d, J = 7.4 Hz, 1 H), 7.63-7.57 (m, 2H), 7.45-7.39 (m, 4H), 6.84 (s, 1 H), 4.97 (s, 2H), 4.36 (q, J = 7.1 Hz, 2H), 2.44 (s, 3H), 1.33 (t, J = 7.1 Hz, 3H). MS (ESI+): 383.0. HPLC (max plot) 97.5%; Rt 4.77 min.
Intermediate P.10: ethyl 1 -(5-fluoro-2-methylphenyl)-1 ,4-dihydrothiochromenof4,3- clpyrazole-3-carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -(5-fluoro-2-methylphenyl)-1 ,4- dihydrothio chromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -(5- fluoro-2-methyl phenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 0.7 g (92%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.03 (dd, J = 7.6 Hz, J = 1 .1 Hz, 1 H), 7.65-7.60 (m, 3H), 7.54-7.50 (m, 2H), 6.74 (d, J = 7.9 Hz, 1 H), 5.01 (s, 2H), 4.39-4.34 (m, 2H), 1 .76 (s, 3H), 1 .33 (t, J = 7.1 Hz, 3H). MS (ESI+): 401 .0. HPLC (max plot) 98.4%; Rt 4.71 min. Intermediate P.11 : ethyl 1 -(3-methoxyphenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-
3-carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -(3-methoxyphenyl)-1 ,4- dihydrothiochromeno [4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -(3- methoxyphenyl)-1 ,4-dihydrothio chromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 0.625 g (88%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.03- 8.01 (m, 1 H), 7.66-7.58 (m, 1 H), 7.52 (t, J = 8.0 Hz, 1 H), 7.23 (dd, J = 8.1 Hz, J = 1.3 Hz, 1 H), 7.15-7.13 (m, 1 H), 7.13 (s, 1 H), 7.02 (d, J = 7.8 Hz, 1 H), 6.87 (d, J = 7.5 Hz, 1 H), 4.98 (s, 2H), 4.36 (q, J = 7.1 Hz, 2H), 3.81 (s, 3H), 1 .33 (t, J = 7.1 Hz, 3H). MS (ESI+): 399.0. HPLC (max plot) 92.3%; Rt 4.55 min. Intermediate P.12: ethyl 1 -(4-methoxyphenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-
3-carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -(4-methoxyphenyl)-1 ,4- dihydrothiochromeno [4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -(4- methoxyphenyl)-1 ,4-dihydrothio chromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 1 .0 g (82%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.02- 8.00 (m, 1 H), 7.65-7.58 (m, 2H), 7.47-7.43 (m, 2H), 7.17-7.13 (m, 2H), 6.86-6.84 (m, 1 H), 4.97 (s, 2H), 4.36 (q, J = 7.1 Hz, 2H), 1 .33 (t, J = 7.1 Hz, 3H). MS (ESI+): 399.0. HPLC (max plot) 95.4%; Rt 4.49 min.
Following the protocol outlined in Procedure P, ethyl 1 -pyridin-2-yl-1 ,4- dihydrothiochromeno[4,3-c] pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 - pyridin-2-yl-1 ,4-dihydrothiochromeno [4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.55-8.54 (m, 1 H), 8.24-8.20 (m, 2H), 8.01 (dd, J = 7.7 Hz, J = 1.0 Hz, 1 H), 7.90 (d, J = 8.0 Hz, 2H), 7.70-7.57 (m, 1 H), 6.87 (d, J = 7.9 Hz, 1 H), 4.98 (s, 2H), 4.36 (q, J = 7.1 Hz, 2H), 1 .34 (t, J = 7.1 Hz, 3H). MS (ESI+): 370.0. HPLC (max plot) 97.9%; Rt 3.76 min.
Following the protocol outlined in Procedure P, ethyl 1 -cyclohexyl-1 ,4- dihydrothiochromeno[4,3-c] pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 - cyclohexyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 1 .1 g (92%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.04 (d, J = 7.6 Hz, 1 H), 7.93 (t, J = 7.2 Hz, 1 H), 7.85 (d, J = 7.7 Hz, 1 H), 7.74 (t, J = 7.6 Hz, 1 H), 4.85 (s, 2H), 4.76-4.71 (m, 1 H), 4.34 (q, J = 7.1 Hz, 2H), 2.02-1.82 (m, 6H), 1 .70 - 1 .67 (m, 1 H), 1 .56-1.49 (m, 2H), 1.38 (t, J = 7.1 Hz, 3H). MS (ESI+): 375.0. HPLC (max plot) 98.5%; Rt 4.91 min.
Intermediate P.15: ethyl 6-bromo-1 -methyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 6-bromo-1 -methyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 6- bromo-1 -methyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford the title compound. 1H NMR (400MHz, DMSO-d6, 400MHz) δ 8.02 (d, J = 7.8 Hz, 1 H), 7.93 (dd, J = 8.0 Hz, J = 1.0 Hz, 1 H), 7.71 (t, J = 8.0 Hz, 1 H), 4.98 (s, 2H), 4.33 (q, J = 7.1 Hz, 2H), 4.22 (s, 3H), 1 .32 (t, J = 7.1 Hz, 3H). MS (ESI+): 386.0. HPLC (max plot) 98.7%; Rt 3.80 min.
Intermediate P.16: ethyl 6-fluoro-1 -methyl-1.4-dihvdrothiochromenof4.3-c1pyrazole-3- carboxylate 5,5-dioxide Following the protocol outlined in Procedure P, ethyl 6-fluoro-1 -methyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 6-fluoro- 1 -methyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.94-7.85 (m, 1 H), 7.59-7.54 (m, 1 H), 4.97 (s, 2H), 4.32 (q, J = 7.1 Hz, 2H), 4.26 (s, 3H), 1.32 (t, J = 7.1 Hz, 3H). MS (ESI+): 325.0. HPLC (max plot) 98.7%; Rt 3.45 min.
Intermediate P.17: ethyl 6-fluoro-1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 6-fluoro-1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 6-fluoro- 1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.65-7.57 (m, 4H), 7.52-7.45 (m, 3H), 6.63 (d, J = 7.9 Hz, 1 H), 5.08 (s, 2H), 4.36 (q, J = 7.1 Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H). MS (ESI+): 387.0. HPLC (max plot) 97.9%; Rt 4.55 min.
Intermediate P.18: ethyl 8-fluoro-1 -methyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 8-fluoro-1 -methyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 8-fluoro-
1 -methyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 10.2 (brs, 1 H), 8.1 1 -8.08 (m, 1 H), 7.91 (dd, J = 9.9 Hz, J = 2.4 Hz, 1 H), 7.60-7.55 (m, 1 H), 4.90 (m, 2H), 4.32 (q, J = 7.1 Hz,
2H), 1 .32 (t, J = 7.1 Hz, 3H). MS (ESI+): 325.0. Intermediate P.19: ethyl 8-fluoro-1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 8-fluoro-1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 8-fluoro- 1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 0.71 g (73%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.12-8.09 (m, 1 H), 7.70-7.49 (m, 1 H), 6.42 (d, J = 10.1 Hz, 2H), 5.02 (m, 2H), 4.37 (q, J = 7.1 Hz, 2H), 1 .33 (t, J = 7.1 Hz, 3H). MS (ESI+): 387.0. HPLC (max plot) 98.6%; Rt 4.71 min.
Intermediate P.20 : ethyl 6-bromo-1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 6-bromo-1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 6- bromo-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 0.4 g (79%) of the title compound.1H NMR (DMSO-d6, 400MHz) δ 7.84 (d, J = 8.0 Hz, 1 H), 7.61 (d, J = 6.8 Hz, 2H), 7.48-7.46 (m, 2H), 7.38 (t, J = 8.0 Hz, 2H), 6.83 (d, J = 8.0 Hz, 1 H), 5.08 (s, 2H), 4.37 (q, J = 7.1 Hz, 2H), 1 .33 (t, J = 7.0 Hz, 3H). MS (ESI+): 448.0. HPLC (max plot) 99.2%; Rt 4.84 min.
Intermediate P.21 : ethyl 1 -(2-methylphenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-
3-carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -(2-methylphenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -(2- methylphenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 0.62 g (88%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.01 (dd, J = 7.8 Hz, J = 1 .0 Hz, 1 H), 7.65-7.50 (m, 6H), 6.65 (d, J = 7.4 Hz, 1 H), 5.01 (s, 2H), 4.37-4.34 (m, 2H), 1 .85 (s, 3H), 1.33 (t, J = 7.1 Hz, 3H). MS (ESI+): 383.0. HPLC (max plot) 96.7%; Rt 5.85 min.
Intermediate P.22: ethyl 1 -(2-bromophenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -(2-bromophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -(2- bromophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 0.55 g (82%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.03 (dd, J = 7.8 Hz, J = 1 .2 Hz, 1 H), 7.95 (dd, J = 7.8 Hz, J = 1 .6 Hz, 1 H), 7.80 (dd, J = 7.8 Hz, J = 1 .6 Hz, 1 H), 7.73-7.58 (m, 4H), 6.76 (d, J = 6.7 Hz, 1 H), 5.08-4.97 (m, 2H), 4.37 (q, J = 7.0 Hz, 2H), 1 .34 (t, J = 7.0 Hz, 3H). MS (ESI+): 448.0. HPLC (max plot) 97.6%; Rt 4.61 min. Intermediate P.23: ethyl 1 -(2-fluorophenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -(2-fluorophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -(2- fluorophenyl)-! ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 0.65 g (78%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.04 (dd, J = 7.7 Hz, J = 1 .2 Hz, 1 H), 7.81 -7.53 (m, 6H), 6.84 (d, J = 7.6 Hz, 1 H), 5.01 (d, J = 7.0 Hz, 2H), 4.37 (q, J = 7.1 Hz, 2H), 1 .33 (t, J = 7.1 Hz, 3H). MS (ESI+): 387.0. HPLC (max plot) 97.4%; Rt 4.43 min.
Intemediate P.24: ethyl 1 -(2-chlorophenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -(2-chlorophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -(2- chlorophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 0.74 g (90%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.04-8.02 (m, 1 H), 7.85-7.73 (m, 3H), 7.70-7.56 (m, 3H), 6.69 (d, J = 7.7 Hz, 1 H), 5.03-4.97 (m, 2H), 4.37 (q, J = 7.0 Hz, 1 H), 1 .34 (t, J = 7.1 Hz, 3H). MS (ESI+): 403.0. HPLC (max plot) 99.1 %; Rt 5.94 min. Intermediate P.25: ethyl 1 -f2-(methylsulfonyl)phenvn-1 ,4-dihydrothiochromenof4,3- clpyrazole-3-carboxylate 5,5-dioxi
Following the protocol outlined in Procedure P, ethyl 1 -[2-(methylsulfonyl)phenyl]-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -(2- chlorophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 0.5 g (71 %) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.30-8.28 (m, 1 H), 8.03-7.94 (m, 3H), 7.64-7.56 (m, 3H), 6.60 (dd, J = 7.8 Hz, J = 1.0 Hz, 1 H), 5.04 (s, 2H), 4.38 (q, J = 7.0 Hz, 2H), 3.40 (s, 3H), 1 .33 (t, J = 7.1 Hz, 3H). MS (ESI+): 447.0. HPLC (max plot) 97.7%; Rt 3.98 min.
Intermediate P.26: ethyl 1 -(2,3-dihydro-1 ,4-benzodioxin-6-yl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole-3-carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -(2,3-dihydro-1 ,4-benzodioxin-6-yl)- 1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 - (2,3-dihydro-1 ,4-benzodioxin-6-yl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 0.2 g (93%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.01 (dd, J = 7.0 Hz, 1 H), 7.64-7.61 (m, 2H), 7.09-7.05 (m, 2H), 6.94-6.90 (m, 2H), 4.96 (m, 2H), 4.38-4.33 (m, 6H), 1 .33 (t, J = 7.1 Hz, 3H). MS (ESI+): 427.0. HPLC (max plot) 96.3%; Rt 4.45 min. Intermediate P.27: ethyl 1 -(2-methyl-1 ,3-benzothiazol-6-yl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole-3-carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -(2-methyl-1 ,3-benzothiazol-6-yl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -(2- methyl-1 ,3-benzothiazol-6-yl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.38 (d, J = 1 .3 Hz, 1 H), 8.1 1 (d, J = 8.2 Hz, 1 H), 8.03 (d, J = 6.6 Hz, 1 H), 7.64-7.52 (m, 3H), 6.79 (d, J = 7.8 Hz, 1 H), 5.01 (s, 2H), 4.37 (q, J = 7.2 Hz, 2H), 2.86 (s, 3H), 1 .33 (t, J = 7.1 Hz, 3H). MS (ESI+): 440.0. HPLC (max plot) 95.5%; Rt 4.31 min.
Intermediate P.28: ethyl 1 -(3-bromophenyl)-1 ,4-dihydrothiochromenor4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -(3-bromophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -(3- bromophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 0.417 g (86%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.04 (d, J = 7.0 Hz, 1 H), 7.88-7.87 (m, 2H), 7.67-7.63 (m, 2H), 7.57-7.53 (m, 2H), 6.90 (d, J = 7.0 Hz, 1 H), 4.99 (s, 2H), 4.39-4.36 (m, 2H), 1 .33 (t, J = 7.0 Hz, 3H). MS (ESI+): 448.0. HPLC (max plot) 96.9%; Rt 4.91 min.
Intermediate P.29: ethyl 1 -(3-chlorophenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -(3-chlorophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -(3- chlorophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 0.39 g (79%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.05-8.03 (m, 1 H), 7.77-7.74 (m, 2H), 7.67-7.62 (m, 3H), 7.50-7.47 (m, 1 H), 6.91 -6.88 (m, 1 H), 4.99 (s, 2H), 4.35 (q, J = 7.2 Hz, 2H), 1 .33 (t, J = 7.2 Hz, 3H). MS (ESI+): 403.0. HPLC (max plot) 97.7%; Rt 4.84 min. Intermediate P.30: ethyl 1 -(4-bromophenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -(4-bromophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -(4- bromophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 0.3 g (85%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.04-8.02 (m, 1 H), 7.84-7.82 (m, 2H), 7.66-7.62 (m, 2H), 7.52-7.50 (m, 2H), 6.92-6.90 (m, 1 H), 4.98 (s, 2H), 4.36 (q, J = 7.1 Hz, 2H), 1 .33 (t, J = 7.1 Hz, 3H). MS (ESI+): 448.0. HPLC (max plot) 99.7%; Rt 4.90 min Intermediate P.31 : ethyl 1 -(4-fluorophenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -(4-fluorophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -(4- fluorophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 0.38 g (94%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.03 (dd, J = 7.7 Hz, J = 1 .6 Hz, 1 H), 7.67-7.59 (m, 4H), 7.50-7.46 (m, 2H), 6.85-6.83 (m, 1 H), 4.98 (m, 2H), 4.36 (q, J = 7.1 Hz, 2H), 1 .33 (t, J = 7.1 Hz, 3H). MS (ESI+): 387.0. HPLC (max plot) 98.6%; Rt 4.54 min.
Intermediate P.32: ethyl 1 -(4-chlorophenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -(4-chlorophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -(4- chlorophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 0.32 g (84%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.04-8.02 (m, 2H), 7.71 -7.57 (m, 5H), 6.91 -6.89 (m, 1 H), 4.98 (s, 2H), 4.37 (q, J = 7.1 Hz, 2H), 4.22 (s, 2H), 1 .33 (t, J = 7.1 Hz, 3H). MS (ESI+): 403.0. HPLC (max plot) 97.3%; Rt 4.82 min.
Intermediate P.33: ethyl 1 -(4-isopropylphenyl)-1 ,4-dihydrothiochromenor4,3- clpyrazole-3-carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -(4-isopropylphenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -(4- isopropylphenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 0.6 g (79%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.02 (q, J = 7.6 Hz, 1 H), 7.65-7.56 (m, 2H), 7.51 -7.43 (m, 4H), 6.83 (d, J = 7.8 Hz, 1 H), 4.98 (s, 2H), 4.36 (q, J = 7.0 Hz, 2H), 3.06-3.03 (m, 1 H), 1.33 (t, J = 7.1 Hz, 3H), 1 .25 (d, J = 6.8 Hz, 6H). MS (ESI+): 41 1.0. HPLC (max plot) 98.2%; Rt 6.79 min. Intermediate P.34: ethyl 1 -(4-methylpyridin-3-yl)-1 ,4-dihvdrothiochromenof4,3- clpyrazole-3-carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -(4-methylpyridin-3-yl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 -(4- methylpyridin-3-yl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 0.3 g (83%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.38 (d, J = 1.4 Hz, 1 H), 8.04-7.99 (m, 2H), 7.78 (d, J = 8.1 Hz, 1 H), 7.66-7.57 (m, 2H), 6.86 (d, J = 7.6 Hz, 1 H), 4.97 (s 2H), 4.37 (q, J = 7.1 Hz, 2H), 2.43 (s, 3H), 1 .34 (t, J = 7.1 Hz, 3H). MS (ESI+): 384.0. HPLC (max plot) 96.1 %;Rt 4.13 min.
Intermediate P.35: ethyl 1 -(tetrahvdro-2H-pyran-4-yl)-1 ,4-dihydrothiochromenof4,3- clpyrazole-3-carboxylate 5,5-dioxide
Following the protocol outlined in Procedure P, ethyl 1 -(tetrahydro-2H-pyran-4-yl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide is obtained from ethyl 1 - (tetrahydro-2H-pyran-4-yl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate and hydrogen peroxide to afford 0.6 g (91 %) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.06-8.04 (m, 1 H), 7.96-7.89 (m, 2H), 7.77-7.73 (m, 1 H), 5.09-5.04 (m, 1 H), 4.86 (s, 2H), 4.34 (q, J = 7.0 Hz, 1 H), 4.00-3.96 (m, 2H), 3.60-3.54 (m, 3H), 2.21 -2.1 1 (m, 2H), 2.02-1 .99 (m, 2H), 1.33 (t, J = 7.1 Hz, 3H). MS (ESI+): 377.0. HPLC (max plot) 94.4%; Rt 3.61 min.
Intermediates described below are obtained following procedure P
1 10 mg of the title compound. ΊΗ NMR (DMSO-d6, 400
MHz): δ 8.04-8.02 (d, J = 7.4 Hz, 1 H), 7.69-7.52 (m, 5H), 7.36-7.34 (d, J = 8.8 Hz, 1 H), 6.89-6.87 (d, J = 6.9 Hz, 1 H), 4.99 (s, 2H), 4.39-4.34 (m, 2H), 1 .35-1 .31 (t, J = 7.1 Hz, 3H). MS (ESI+): 387.0. HPLC (max plot) 95.14%; Rt 4.58 min.
Intermediate P.40: Ethvl 1 -(3-cvanophenvl)-1 ,4-dihvdrothiochromenor4,3- clpvrazole-3-carboxvlate 5,5-dioxide
0.22 g of the title compound. 1 H NMR (DMSO-d6, 400 MHz) δ 8.24 (s, 1 H), 8.15-8.13 (d, J = 7.5 Hz, 1 H), 8.04 (d, J = 7.6 Hz, 1 H), 7.88-7.79 (m, 2H), 7.69-7.59 (m, 2H), 6.87 (d, J = 7.8 Hz, 1 H), 5.00 (s, 2H), 4.37 (q, J = 7.8 Hz, 2H), 1.33 (t, J = 7.2 Hz, 3H).MS (ESI+): 394.0. HPLC (max plot) 96.7%; Rt 4.26 min.
Intermediate P.41 : Ethvl 1 -r4-(methvlsulfonvl)phenvll-1 ,4- dihvdrothiochromenor4,3-clpvrazole-3-carboxvlate 5,5-dioxide
260 mg (80%) of the title compound. ΊΗ NMR (DMSO-d6, 400 MHz): δ 7.49-7.48 (d, J = 7.8 Hz ,1 H), 7.43-7.37 (m, 4H), 7.23-7.19 (t, J = 7.6 Hz , 1 H), 7.05-7.01 (t, J = 7.7 Hz , 1 H), 6.77-6.75 (d, J = 7.9 Hz , 1 H), 4.35-4.30 (m, 2H), 4.22 (s, 2H), 2.54 (s, 3H), 1 .33-1.29 (t, J = 5.6 Hz, 3H). MS (ESI- ): 444.8. HPLC (max plot) 95.32%; Rt 3.88 min.
Intermediate P.42: Ethvl 1 -r3-(methvlsulfonvl)phenvH-1 ,4- dihvdrothiochromenor4,3-clpvrazole-3-carboxvlate 5,5-dioxide
220 mg (94%) of the title compound. ΊΗ NMR (DMSO-d6, 400 MHz): δ 7.49-7.48 (dd, J= 2.4, 3.9 Hz, 1 H), 8.12 (s, 1 H), 8.06-8.04 (dd, J = 1 .2, 7.8 Hz, 1 H), 7.93-7.08 (m, 2H),
^° -N o. n 7.69-7.59 (m, 2H), 6.92-6.90 (d, J = 7.4 Hz, 1 H), 5.01 (s,
2H), 4.41 -4.36 (m, 2H), 1 .36-1 .32 (t, J = 7.1 Hz, 3H). MS (ESI+): 446.7. HPLC (max plot) 97.52%; Rt 3.87 min.
Intermediate P.43: Ethvl 1 -(6-methoxvPVridin-3-vD-1 ,4- dihvdrothiochromenor4,3-clpvrazole-3-carboxvlate 5,5-dioxide
dihvdrothiochromenor4,3-clpvrazole-3-carboxvlate 5,5-dioxide
3-carboxvlate 5,5-dioxide
dihvdropvrazolor3',4':4,51thiopvranor2,3-blpvridine-3-carboxvlate 5,5-dioxide
(max plot) 97.3%; Rt 3.25 min.
To a solution of ethyl 1 -(1 -oxidopyridin-3-yl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3- carboxylate 5,5-dioxide (300 mg, 0.78 mmol) in glacial acetic acid (15 mL) is added iron powder (175 mg, 3.12 mmol) . The reaction mass is heated to 85°C for 1 h under nitrogen. The reaction progress is monitored by TLC. The solvent is removed completely under reduced pressure. The crude material obtained is diluted with water and is extracted with ethylacetate. The organic layer is separated and is dried using sodium sulphate and concentrated under reduced pressure to afford the title compound. 1H NMR (400 MHz,
DMSO-de) δ = 8.85-8.84 (d, J = 4.7 Hz, 1 H), 8.79-8.78 (m, 1 H), 8.07-8.03 (m, 2H), 7.70-7.59 (m, 3H), 6.87-6.85 (d, J = 7.84 Hz , 1 H), 5.00 (s, 2H), 4.40-4.35 (q, 2H), 1 .35-1.32 (t, J = 7.12 Hz, 3H). MS (ESI+): 370.2. HPLC (max plot): 97.29%; Rt 3.24 min. Intermediate P.81 : Ethyl 1 -phenyl-1 ,4-dihvdropyrazolor3',4':4,51thiopyranor3,2- clpyridine-3-carboxylate 5,5-dioxid
To a solution of ethyl 1 -phenyl-1 ,4-dihydropyrazolo[3',4':4,5]thiopyrano[3,2-c]pyridine-3- carboxylate 5,5,8-trioxide (0.1 g, 0.259 mmol) in glacial acetic acid is added iron powder (58 mg, 1.038 mmol) under nitrogen and the reaction mass is heated to 85°C for 1 h. The reaction mass is concentrated completely under reduced pressure and is partitioned between water and ethylacetate. The organic layer is separated, dried using sodium sulphate and is concentrated under reduced pressure to afford 80 mg, 83% yield of the title compound. 1H NMR (400 MHz, DMSO-d6) δ = 8.85-8.84 (d, J = 5.2 Hz, 1 H), 8.00-7.98 (m, 2H), 7.68-7.66 (m, 3H), 7.61 (m,1 H), 5.12 (s, 2H), 4.38-4.36 (q, 2H), 1 .35-1.32 (t, J = 7.12 Hz, 3H). MS (ESI+): 370.0.
Procedure Q Intermediate Q.1 : Ethyl 1 -ri -(terf-butoxycarbonyl)piperidin-4-vn-1 ,4-dihydrothio chromenor4,3-c1pyrazole-3-carboxylate 5,5-dioxide
To a solution of ethyl 1 -[1 -(ie f-butoxycarbonyl)piperidin-4-yl]-1 ,4-dihydrothiochromeno [4,3- c]pyrazole-3-carboxylate (3.05 g; 6.88 mmol; 1 eq.) in DCM (36.6 ml) at 0°C is added 3- chloroperoxybenzoic acid (2.97 g; 17.19 mmol; 2.5 eq.) and the rection mixture is stirred at rt for 30 min. DCM is added and the organic phase is washed 3 times with a saturated aqueous solution of NaHC03, dried over MgS04 then concentrated to afford 2.8 g (86%) of the title compound. HPLC (max plot) 64.9%; Rt 4.90 min. MS (ESI-): 474.3
Intermediates described below are obtained following protocole outlined in procedure Q
chromenor4,3-clpvrazole-3-carboxvlate 5,5-dioxide
dihvdrothiochromenor4,3-clpvrazole-3-carboxvlate 5,5-dioxide
Intermediate Q.19: Ethv 1 -Γ1 -(ferf-butoxvcarbonvl)piperidin-3-vll-7-fluoro-1 ,4-
1 ,4-dihvdropvrazolor3',4':4,51thiopvranor3,2-diri ,31thiazole-3-carboxvlate 5,5-dioxide
Intermediate Q.25 : Ethyl 7-amino-1 -(tetrahvdro-2H-pyran-4-yl)-1 ,4- dihvdropyrazolor3',4':4,51thiopyranor3,2-diri,31thiazole-3-carboxylate 5,5-dioxide
To a fine suspension of ethyl 7-[(ie f-butoxycarbonyl)amino]-1 -(tetrahydro-2/-/-pyran-4-yl)-1 ,4- dihydropyrazolo[3',4':4,5]thiopyrano[3,2-d][1 ,3]thiazole-3-carboxylate 5,5-dioxide (182 mg; 0.37 mmol; 1.00 eq.) in DCM (540 μΙ) is added TFA (180 μΙ; 2.34 mmol; 6.40 eq.). The mixture is stirred at rt overnight after which water is added to the reaction mixture. The precipitate is washed with water then dried under vacuum to afford the title compound as an off-white powder. 1 H NMR (DMSO) δ 8.34 (bs, 2H), 5.61 -5.43 (m, 1 H), 4.91 (s, 2H), 4.33 (q, J = 7.1 Hz, 2H), 4.12-3.93 (m, 2H), 3.52-3.35 (m, 2H), 3.20-1 .87 (m, 4H), 1 .33 (t, J = 7.1 Hz, 3H). HPLC (max plot) 95.1 %; Rt 2.28 min. MS (ESI+): 398.7. procedure R
Intermediate R.1 : Ethyl 1 -f4-(hvdroxymethyl)phenvn-1 ,4-dihydrothiochromenof4,3- clpyrazole-3-carboxylate 5,5-dioxide
To a solution of4-[3-(ethoxycarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4/-/)- yl]benzoic acid (21. 88 g; 53.05 mmol; 1 eq.) in THF (350 ml) is added triethylamine (14.71 ml; 106.1 1 mmol; 2 eq.) followed by isobutyl chloroformate (13.83 ml; 106.1 1 mmol; 2 eq.) at 0°C under nitrogen. The reaction mixture is stirred at rt for 30 min then cooled at 0°C.
Sodium borohydride (10 g; 265.27 mmol; 5 eq.) is added portionwise. After 5h, THF (100 mL) is added and the reaction mixture is heated at 35°C for 1 day then at rt for 2 days. Sodium borohydride is added (1 eq) and after 6h stirring the reaction is quenched by dropwise addition of water at 0°C over 2h. The product is extracted with EtOAc, the organic layers washed with HCI 1 m (2X) and brine then dried over MgS04. After evaporation of the solvent, the residue is taken up in DCM and HCI 1 m. The precipitate formed is filtered off and recrystallized in DCE to afford the title compound as a white solid. 1H NMR (DMSO-d6) δ 8.05-8.02 (m, 1 H), 7.68-7.48 (m, 6H), 6.88-6.84 (m, 1 H), 5.76 (s, 2H), 4.99 (s, 2H), 4.37 (q, J = 7.1 Hz, 2H), 3.90 (s, 1 H), 1 .35 (t, J = 7.1 Hz, 3H). HPLC (max plot) 68.2%; Rt 3.02 min. MS (ESI+): 398.9
Compounds described below are obtained following protocole outlined in procedure R.
350 mg (80%) of the title compound. MS (ESI+): 406.0.
Intermediate R.4: Ethyl ' -r4-(hvdroxvmethvl)phenvll-1 ,4- dihvdropvrazolor3',4':4,51thiopvranor2,3-blpvridine-3-carboxvlate 5,5-dioxide
160 mg of the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 8.72-8.71 (d, J = 4.6 Hz, 1 H), 7.63-7.60 (m, 1 H), 7.56-7.54 (m, 2H), 7.50-7.48 (m, 2H), 7.20-7.18 (d, J = 8.1 Hz, 1 H), 5.46-5.43 (m, 1 H), 5.09 (s, 2H), 4.64-4.63 (d, J = 5.7 Hz, 2H), 4.39-4.34 (m, 2H), 1 .35-1 .31 (t, J = 7.2 Hz, 3H). MS (ESI+): 400.0.
Procedure S
Intermediate S.1 : 6-methoxy-1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
To a solution of ethyl 6-methoxy-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3- carboxylate 5,5-dioxide (0.23 g, 0.57 mmol) in THF (10 mL) is added aq. solution of NaOH (2.8 mL, 1 M, 2.85 mmol, 5 Eq) at 0 °C and the reaction mixture is stirred for 4 h. The solvent is removed under reduced pressure and aq. solution of HC1 1 M is added. The product is extracted with EtOAc (2x). The organic layer is washed with brine, dried over MgS04 and concentrated under reduced pressure to afford 0.2 g (70%) of the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 13.5 (brs, 1 H), 7.61 -7.57 (m, 3H), 7.46-7.42 (m, 3H), 7.26 (d, J = 8.6 Hz, 1 H), 6.35 (d, J = 8.0 Hz, 1 H), 4.88 (s, 2H), 3.90 (s, 3H). MS (ESI+):
371 .0. HPLC (max plot) 98.9%; Rt 3.30 min.
Intermediate S.2: 6-methoxy-1 -methyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 6-methoxy-1 -methyl-1 ,4- dihydrothiochromeno[4,3-c] pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 6- methoxy-1 -methyl-1 ,4-dihydrothio chromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford the title compound as a white solid. 1H NMR (DMSO-d6, 400 MHz): δ 13.3 (bs, 1 H), 7.78 (t, J = 8.12 Hz, 1 H), 7.52 (t, J = 7.76 Hz, 1 H), 7.37 (d, J = 8.5 Hz, 1 H), 4.77 (s, 2H), 4.15 (s, 3H), 3.92 (s, 3H). MS (ESI+): 309.0. HPLC (max plot) 96.3%; Rt 2.12 min.
Intermediate S.3: 1 -phenvH ,4-dihvdrothiochromenor4,3-c1pyrazole-3-carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -phenyl-1 ,4-dihydrothiochromeno[4,3- c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.47 g (quant.) of the title compound as a white solid. 1H NMR (DMSO-d6, 400 MHz): δ 13.5 (brs, 1 H), 8.01 (d, J = 7.72 Hz, 1 H), 7.65-7.57 (m, 5H), 7.55-7.51 (m, 2H), 6.80 (d, J = 7.64 Hz, 1 H), 4.97 (s, 2H). MS (ESI+): 341.0. HPLC (max plot) 97.0%; Rt 3.48 min.
Intermediate S.4: 1 -methyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3-carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -methyl-1 ,4-dihydrothiochromeno[4,3- c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 -methyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.69 g (94%) of the title compound as a white solid. 1H NMR (DMSO-d6, 400 MHz): δ 13.32 (s, 1 H), 8.06-8.01 (m, 2H), 7.90-7.86 (m, 1 H), 7.72 (t, J = 7.6 Hz, 1 H), 4.86 (s, 2H), 4.27 (s, 3H). MS (ESI+): 279.0. HPLC (max plot) 95.4%; Rt 2.3 min.
Intermediate S.5: 1 ,4-dihvdrothiochromenor4,3-c1pyrazole-3-carboxylic acid 5,5- dioxide
Following the protocol outlined in Procedure S, 1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3- carboxylic acid 5,5-dioxide is obtained from ethyl 1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3- carboxylate 5,5-dioxide to afford 0.32 g (71 %) of the title compound as an off-white solid. 1H NMR (DMSO-d6, 400 MHz): δ 8.01 (d, J = 7.6 Hz, 1 H), 7.94 (d, J = 7.7 Hz, 1 H), 7.81 (t, J = 7.52 Hz, 1 H), 7.64 (t, J = 7.7 Hz, 1 H), 4.85 (s, 2H). MS (ESI+): 265.0. HPLC (max plot) 93.5%; Rt 2.32 min.
Intermediate S.6: 7-methoxy-1 -methyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 7-methoxy-1 -methyl-1 ,4- dihydrothiochromeno[4,3-c] pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 7- methoxy-1 -methyl-1 ,4-dihydrothio chromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.34 g (89%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 13.26 (brs, 1 H), 7.99 (d, J = 8.7 Hz, 1 H), 7.47 (s, 1 H), 7.43-7.40 (m, 1 H), 4.83 (s, 2H), 4.23 (s, 3H), 3.91 (s, 3H). MS (ESI+): 309.0. HPLC (max plot) 99.4%; Rt 2.63 min.
Intermediate S.7: 7-methoxy-1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 7-methoxy-1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c] pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 7- methoxy-1 -phenyl-1 ,4-dihydrothio chromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.49 g (87%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 7.64-7.61 (m, 3H), 7.52-7.45 (m, 2H), 7.17-7.14 (m, 2H), 6.73 (d, J = 8.8 Hz, 1 H), 4.93 (s, 2H), 3.84 (s, 3H). MS (ESI+): 371 .0. HPLC (max plot) 97.9%; Rt 3.72 min.
Intermediate S.8: 1 -(3-methylphenyl)-1 ,4-dihydrothiochromenor4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -(3-methylphenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 -(3- methylphenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.70 g (83%) of the title compound as an off-white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.01 (dd, J = 7.7 Hz, J = 1 .3 Hz, 1 H), 7.65-7.56 (m, 2H), 7.52-7.45 (m, 2H), 7.37 (s, 1 H), 7.28 (d, J = 7.4 Hz, 1 H), 6.85-6.83 (m, 1 H), 4.96 (s, 2H), 2.39 (s, 3H). MS (ESI+): 355.0. HPLC (max plot) 97.9%; Rt 3.85 min.
Intermediate S.9: 1 -(4-methylphenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -(4-methylphenyl)-1 ,4- dihydrothiochromeno[4,3-c] pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 - (4-methylphenyl)-1 ,4-dihydrothio chromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.88 g (95%) of the title compound as an off-white solid. 1H NMR (DMSO-d6, 400MHz) δ
13.55 (brs, 1 H), 8.01 (dd, J = 7.6 Hz, J = 1 .4 Hz, 1 H), 7.64-7.56 (m, 2H), 7.44-7.38 (m, 4H), 6.84 (d, J = 7.8 Hz, 1 H), 4.95 (s, 2H), 2.43 (s, 3H). MS (ESI+): 355.0. HPLC (max plot) 98.0%; Rt 3.84 min.
Intermediate S.10: 1 -(5-fluoro-2-methylphenyl)-1 ,4-dihydrothiochromenof4,3- clpyrazole-3-carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -(5-fluoro-2-methylphenyl)-1 ,4- dihydrothiochromeno [4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 - (5-fluoro-2-methylphenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.54 g (96%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 13.62 (brs, 1 H), 8.02 (dd, J = 7.7 Hz, J = 1 .3 Hz, 1 H), 7.66-7.47 (m, 5H), 6.74-6.72 (m, 1 H), 4.99 (s, 2H), 1.77 (s, 3H). MS (ESI+): 373.0. HPLC (max plot) 97.6%; Rt 3.84 min.
Intermediate S.11 : 1 -(3-methoxyphenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -(3-methoxyphenyl)-1 ,4- dihydrothiochromeno[4,3-c] pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 - (3-methoxyphenyl)-1 ,4-dihydrothio chromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.35 g (75%) of the title compound as an off-white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.01 (dd, J = 7.7 Hz, J = 1 .3 Hz, 1 H), 7.65-7.57 (m, 2H), 7.51 (t, J = 8.1 Hz, 1 H), 7.21 (dd, J = 8.2 Hz, J = 2.2 Hz, 1 H), 7.12 (s, 1 H), 7.02-7.00 (m, 1 H), 6.88-6.86 (m, 1 H), 4.96 (s, 2H), 3.80 (s, 3H). MS (ESI+): 371 .0. HPLC (max plot) 93.5%; Rt 3.62 min. Intermediate S.12: 1 -(4-methoxyphenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -(4-methoxyphenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 -(4- methoxyphenyl)-1 ,4-dihydrothio chromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.83 g (99%) of the title compound as an off-white solid. 1H NMR (DMSO-d6, 400MHz) δ
13.54 (brs, 1 H), 8.00 (dd, J = 7.6 Hz, J = 1 .4 Hz, 2H), 7.64-7.58 (m, 2H), 7.44 (d, J = 8.8 Hz, 1 H), 7.15 (d, J = 8.8 Hz, 1 H), 6.86-6.83 (m, 2H), 4.95 (s, 2H), 2.43 (s, 3H). MS (ESI+): 371 .0. HPLC (max plot) 92.3%; Rt 3.57 min. Intermediate S.13: 1 -pyridin-2-yl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3-carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -pyridin-2-yl-1 ,4-dihydrothiochromeno[4,3-c] pyrazole-3-carboxylic acid 5,5-dioxide is obtained ethyl 1 -pyridin-2-yl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.22 g (95%) of the title compound as an off-white solid. 1H NMR (DMSO-d6, 400MHz) δ 13.68 (brs, 1 H), 8.54 (dd, J = 4.7 Hz, J = 0.8 Hz, 1 H), 8.23 - 8.19 (m, 1 H), 8.00 (dd, J = 7.5 Hz, J = 1 .0 Hz, 1 H), 7.89 (d, J = 7.9 Hz, 1 H), 7.69-7.56 (m, 3H), 6.89 (d, J = 7.6 Hz, 1 H), 4.95 (s, 2H). MS (ESI+): 342.0. HPLC (max plot) 98.0%; Rt 2.79 min.
Intermediate S.14: 1 -cvclohexyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3-carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -cyclohexyl-1 ,4-dihydrothiochromeno[4,3-c] pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 -cyclohexyl-1 ,4- dihydrothiochromeno [4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.88 g (95%) of the title compound as an off-white solid. 1H NMR (DMSO-d6, 400MHz) δ 13.34 (brs, 1 H), 8.03 (d, J = 7.8 Hz, 1 H), 7.92 (t, J = 7.8 Hz, 1 H), 7.85 (d, J = 8.0 Hz, 1 H), 7.31 (d, J = 7.6 Hz, 1 H), 4.83 (s, 2H), 4.72 (t, J = 1 1 .0 Hz, 1 H), 2.04 - 1 .82 (m, 8H), 1.70-1 .67 (m, 1 H), 1 .56-1.49 (m, 1 H). MS (ESI+): 347.0. HPLC (max plot) 98.8%; Rt 3.89 min.
Intermediate S.15: 6-bromo-1 -methyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 6-bromo-1 -methyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 6- bromo-1 -methyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford the title compound. 1H NMR (DMSO-d6, 400MHz) 513.3 (brs, 1 H), 8.01 (d, J = 8.0 Hz, 1 H), 7.92 (d, J = 8.0 Hz, 1 H), 7.70 (t, J = 8.0 Hz, 1 H), 4.96 (s, 2H), 4.20 (s, 3H). MS (ESI+): 357.0 HPLC (max plot) 99.2%; Rt 2.89 min.
Intermediate S.16: 1 -methyl-8-nitro-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylic acid
Following the protocol outlined in Procedure S, 1 -methyl-8-nitro-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid is obtained from ethyl 1 -methyl-8-nitro- 1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate to afford 0.088 g (72%) of the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz,) δ 13.1 (brs, 1 H), 8.55 (d, J = 2.3 Hz, 1 H), 8.1 1 (dd, J = 8.7 Hz, J = 2.3 Hz, 1 H), 7.76 (d, J = 8.6 Hz, 1 H), 4.29 (s, 2H), 4.22 (s, 2H). MS (ESI+): 292.0. HPLC (max plot) 96.8%; Rt 3.55 min.
Intermediate S.17: 6-fluoro-1 -methyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 6-fluoro-1 -methyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 6- fluoro-1 -methyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.24 g (77%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 13.3 (brs, 1 H), 7.93-7.84 (m, 2H), 7.56 (m, 1 H), 4.96 (s, 2H), 4.24 (s, 3H). MS (ESI+): 297.0. HPLC (max plot) 96.3%; Rt 2.46 min.
Intermediate S.18: 6-fluoro-1 -phenyH ,4-dihvdrothiochromenor4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 6-fluoro-1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 6- fluoro-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.29 g (78%) of the title compound. MS (ESI+): 359.0.
Intermediate S.19: 8-fluoro-1 -methyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 8-fluoro-1 -methyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 8- fluoro-1 -methyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.1 1 -8.07 (m, 1 H), 7.91 -7.88 (m, 1 H), 7.59-7.55 (m, 1 H), 4.27 (s, 2H), 3.72 (s, 3H). MS (ESI+): 297.0. Intermediate S.20: 8-fluoro-1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 8-fluoro-1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 8- fluoro-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.12-8.08 (m, 1 H), 7.69-7.63 (m, 2H), 7.57-7.48 (m, 2H), 7.25-7.1 1 (m, 2H), 6.43-6.40 (m, 1 H), 4.97 (s, 2H). MS (ESI+): 359.0. Intermediate S.21 : 6-bromo-1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 6-bromo-1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 6- bromo-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 13.6 (brs, 1 H), 7.83 (d, J = 8.0 Hz, 1 H), 7.61 -7.57 (m, 3H), 7.46 (d, J = 7.9 Hz, 1 H), 7.38 (t, J = 8.0 Hz, 1 H), 7.25-7.13 (m, 1 H), 6.83 (d, J = 8.0 Hz, 1 H), 5.08 (s, 2H), 4.37 (q, J = 7.1 Hz, 2H), 1 .33 (t, J = 7.9 Hz, 3H). MS (ESI+): 420.0. HPLC (max plot) 97.8%; Rt 3.96 min.
Intermediate S.22: 8-nitro-1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylic acid
Following the protocol outlined in Procedure S, 8-nitro-1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid is obtained from ethyl 8-nitro-1 -phenyl- 1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate to afford 0.7 g (71 %) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 13.3 (brs, 1 H), 8.01 -7.98 (m, 1 H), 7.50 (d, J = 8.8 Hz, 1 H), 7.74 (d, J = 8.2 Hz, 3H), 7.65-7.59 (m, 3H), 7.52 (dd, J = 8.2 Hz, J = 1 .2 Hz, 1 H), 7.42 (s, 1 H), 4.40 (s, 2H). MS (ESI+): 354.0. HPLC (max plot) 93.2%; Rt 4.33 min.
Intermediate S.23: 1 -(2-methylphenyl)-1 ,4-dihydrothiochromenor4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -(2-methylphenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 -(2- methylphenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.4 g (85%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 13.6 (brs, 1 H), 8.00 (dd, J = 7.8 Hz, J = 1 .2 Hz, 1 H), 7.63-7.48 (m, 6H), 6.65 (d, J = 7.8 Hz, 1 H), 5.00 (s, 2H), 1 .85 (s, 3H). MS (ESI+): 355.0. HPLC (max plot) 96.9%; Rt 3.74 min.
Intermediate S.24: 1 -(2-bromophenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -(2-bromophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 -(2- bromophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.3 g (71 %) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 13.6 (s, 1 H), 8.02 (dd, J = 7.8 Hz, J = 1 .2 Hz, 1 H), 7.95 (dd, J = 7.8 Hz, J = 1 .2 Hz, 1 H), 7.79 (dd, J = 7.8 Hz, J = 1 .2 Hz, 1 H), 7.73-7.58 (m, 4H), 6.66-6.64 (m, 1 H), 5.06-4.95 (m, 2H). MS (ESI+): 420.0. HPLC (max plot) 98.0%; Rt 3.70 min.
Following the protocol outlined in Procedure S, 1 -(2-fluorophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 -(2- fluorophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 13.6 (brs, 1 H), 8.02 (dd, J = 7.7 Hz, J = 1 .2 Hz, 1 H), 7.81 -7.74 (m, 2H), 7.67-7.50 (m, 4H), 6.84 (d, J = 7.6 Hz, 1 H), 4.99 (d, J = 7.0 Hz, 2H). MS (ESI+): 359.0. HPLC (max plot) 99.0%; Rt 3.48 min.
Intermediate S.26: 1 -(2-chlorophenyl)-1 ,4-dihydrothiochromenor4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -(2-chlorophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 -(2- chlorophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 13.6 (brs, 1 H), 8.02 (d, J = 7.6 Hz, 1 H), 7.83- 7.56 (m, 6H), 6.68 (d, J = 7.7 Hz, 1 H), 5.06-4.95 (m, 2H). MS (ESI+): 375.0. HPLC (max plot) 97.6%; Rt 3.65 min.
Intermediate S.27: 1 -f2-(methylsulfonyl)phenvn-1 ,4-dihydrothiochromenof4,3- clpyrazole-3-carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -[2-(methylsulfonyl)phenyl]-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 -[2- (methylsulfonyl)phenyl]-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.35 g (74%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 8.29 (dd, J = 7.8 Hz, J = 1 .2 Hz, 1 H), 8.02-7.92 (m, 3H), 7.65-7.54 (m, 3H), 6.60 (d, J = 7.2 Hz, 1 H), 5.02 (s, 2H), 3.42 (s, 3H). MS (ESI+): 419.0. HPLC (max plot) 96.6%; Rt 3.09 min.
Intermediate S.28: 1 -(2,3-dihydro-1 ,4-benzodioxin-6-yl)-1 ,4-dihydrothiochromenof4,3- clpyrazole-3-carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -(2,3-dihydro-1 ,4-benzodioxin-6-yl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 - (2,3-dihydro-1 ,4-benzodioxin-6-yl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.15 g (97%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 13.5 (brs, 1 H), 8.00 (dd, J = 7.2 Hz, J = 4.2 Hz, 1 H), 7.65-7.60 (m, 2H), 7.07-7.04 (m, 2H), 6.93- 6.89 (m, 2H), 4.94 (s, 2H), 4.35-4.34 (m, 4H). MS (ESI+): 399.0. HPLC (max plot) 96.4%; Rt 3.35 min.
Intermediate S.29: 1 -(2-methyH ,3-benzothiazol-6-yl)-1 ,4-dihydrothiochromenof4,3- clpyrazole-3-carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -(2-methyl-1 ,3-benzothiazol-6-yl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 -(2- methyl-1 ,3-benzothiazol-6-yl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5- dioxide to afford 0.090 g (79%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 13.6 (brs, 1 H), 8.36 (d, J = 2.0 Hz, 1 H), 8.1 1 (d, J = 8.3 Hz, 1 H), 8.02 (dd, J = 7.8 Hz, J = 1 .1 Hz, 1 H), 7.64-7.53 (m, 3H), 6.79 (d, J = 7.8 Hz, 1 H), 4.99 (s, 2H), 2.86 (s, 3H). MS (ESI+): 412.0. HPLC (max plot) 95.9%; Rt 3.24 min.
Intermediate S.30: 1 -(3-bromophenyl)-1 ,4-dihydrothiochromenor4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -(3-bromophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 -(3- bromophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.29 g (88%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 13.6 (brs, 1 H), 8.04-8.02 (m, 1 H), 7.87-7.85 (m, 2H), 7.67-7.50 (m, 4H), 6.91 -6.89 (m, 1 H), 4.97 (s, 2H). MS (ESI+): 420.0. HPLC (max plot) 98.7%; Rt 3.95 min.
Intermediate S.31 : 1 -(3-chlorophenyl)-1 ,4-dihvdrothiochromenor4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -(3-chlorophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 -(3- chlorophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.28 g (97%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 13.6 (brs, 1 H), 8.04-8.02 (m, 1 H), 7.75-7.73 (m, 2H), 7.67-7.60 (m, 1 H), 7.48-7.46 (m, 1 H), 6.91 -6.89 (m, 1 H), 4.97 (s, 2H). MS (ESI+): 375.0. HPLC (max plot) 98.0%; Rt 5.87 min. Intermediate S.32: 1 -(4-bromophenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -(4-bromophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 -(4- bromophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 13.6 (brs, 1 H), 8.03-8.01 (m, 1 H), 7.83 (d, J = 8.6 Hz, 2H), 7.67-7.62 (m, 2H), 7.52-7.49 (m, 2H), 6.93-6.90 (m, 1 H), 4.96 (s, 2H). MS (ESI+): 420.0. HPLC (max plot) 96.4%;Rt 4.03 min.
Intermediate S.33 : 1 -(4-fluorophenyl)-1 ,4-dihvdrothiochromenor4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -(4-fluorophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 -(4- fluorophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 13.6 (brs, 1 H), 8.02 (d, J = 7.7 Hz, 1 H), 7.66- 7.59 (m, 4H), 7.50-7.45 (m, 2H), 6.85-6.83 (m, 1 H), 4.96 (m, 2H). MS (ESI+): 359.0. HPLC (max plot) 99.0%; Rt 3.57 min.
Intermediate S.34: 1 -(4-chlorophenyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -(4-chlorophenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 -(4- chlorophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford the title compound. 1H NMR (DMSO-d6, 400MHz) δ 13.63 (m, 1 H), 8.04-8.02 (m, 1 H), 7.71 -7.56 (m, 6H), 6.92-6.89 (m, 1 H), 4.96 (s, 2H). MS (ESI+): 343.0. HPLC (max plot) 98.5%, Rt 3.93 min.
Intermediate S.35: 1 -(4-isopropylphenyl)-1 ,4-dihydrothiochromenor4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -(4-isopropylphenyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 -(4- isopropylphenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.45 g (88%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 13.5 (brs, 1 H), 8.01 (d, J = 7.6 Hz, 1 H), 7.64-7.56 (m, 2H), 7.50-7.42 (m, 4H), 6.83 (d, J = 7.7 Hz, 1 H), 4.95 (s, 2H), 3.07-3.00 (m, 1 H), 1 .27 (d, J = 6.9 Hz, 6H). MS (ESI+): 383.0. HPLC (max plot) 95.2%; Rt 4.56 min.
Intermediate S.36: 1 -(4-methylpyridin-3-yl)-1 ,4-dihydrothiochromenor4,3-c1pyrazole-3- carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -(4-methylpyridin-3-yl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 -(4- methylpyridin-3-yl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford the title compound. 1H NMR ((DMSO-d6, 400MHz) δ 13.65 (brs, 1 H), 8.37 (d, J = 1 .6 Hz, 1 H), 8.03-7.98 (m, 2H), 7.77 (d, J = 8.0 Hz, 1 H), 7.65-7.56 (m, 2H), 6.88-6.86 (m, 1 H), 4.95 (s 2H), 2.43 (s, 3H). MS (ESI+): 356.0. HPLC (max plot) 97.4%; Rt 3.22 min. Intermediate S.37: 1 -(tetrahydro-2H-pyran-4-yl)-1 ,4-dihydrothiochromenof4,3- clpyrazole-3-carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure S, 1 -(tetrahydro-2H-pyran-4-yl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from ethyl 1 - (tetrahydro-2H-pyran-4-yl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5-dioxide to afford 0.35 g (75%) of the title compound. 1H NMR (DMSO-d6, 400MHz) δ 13.3 (brs, 1 H), 8.04 (q, J = 7.9 Hz, 1 H), 7.95-7.89 (m, 2H), 7.74 (t, J = 6.7 Hz, 1 H), 5.07-5.02 (m, 1 H), 4.84 (s, 2H), 4.00-3.96 (m, 2H), 4.00-3.96 (m, 2H), 3.60-3.54 (m, 1 H), 2.21 -2.18 (m, 1 H), 2.17- 2.12 (m, 2H). MS (ESI+): 349.0. HPLC (max plot) 94.6%; Rt 2.69 min.
Compounds described below are obtained following procedure S.
dihvdrothiochromenor4,3-clpvrazole-3-carboxvlic acid 5,5-dioxide
dihvdrothiochromenor4,3-clpvrazole-3-carboxvlic acid 5,5-dioxide
dihvdrothiochromenor4,3-clpvrazole-3-carboxvlic acid 5,5-dioxide
carboxvlic acid 5,5-dioxide
dihvdrothiochromenor4,3-clpvrazole-3-carboxvlic acid 5,5-dioxide
dihvdrothiochromenor4,3-clpvrazole-3-carboxvlic acid 5,5-dioxide hydrochloride
clpvrazole-3-carboxvlic acid 5,5-dioxide
Intermediate S.83: 7-Fluoro-1 -r4-(morpholin-4-vlmethvl)phenvH-1 ,4-dihvdrothio
Intermediate S.88: 1-Π-ί feri-Butoxvcarbonvl)piperidin-4-vH-1,4-
3-carboxvlic acid 5,5-dioxide
carboxvlic acid 5,5-dioxide
clpvrazole-3-carboxvlic acid 5,5-dioxide
dihvdropvrazolor3',4':4,51thiopvranor2,3-blpvridine-3-carboxvlic acid 5,5-dioxide
r4,3-clpvrazole-3-carboxvlic acid 5,5-dioxide
Intermediate S.118: 6-(Aminocarbonyl)-1 -phenyl-1 ,4-dihydrothiochromenof4,3- clpyrazole-3-carboxylic acid 5,5-dioxide
To a solution of Ethyl 6-cyano-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3- carboxylate 5,5-dioxide (100 mg, 0.254 mmol) in EtOH (10 mL) is added an aq. solution of NaOH (10%, 1 mL) and 30% hydrogen peroxide (2 mL) at 100°C and the heating is continued for another 2 h. The reaction mixture is evaporated under vacuum, acidified with HCI (1 .5 N) and extracted with EtOAc. The organic layer is separated, dried over Na2S04 and concentrated under reduced pressure to afford the title compound. MS (ESI+): 384.0.
Procedure T
Intermediate T.1 : 1 -methyl-3-(morpholin-4-ylcarbonyl)-8-nitro-1 ,4- dihydrothiochromenor4,3-c1pyrazole
To 1 -methyl-8-nitro-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid
(0.088 g, 0.30 mmol) in THF is added triethylamine (0.13 mL, 0.9 mmol, 3 Eq) followed by 50 % T3P (propane phosphonic acid anhydride) in EtOAc (0.50 mL, 0.81 mmol, 2.7 Eq). The reaction mixture is cooled to 0 °C and then morpholine (0.38 mL, 0.60 mmol, 2Eq) is added and the reaction is stirred overnight at rt. Then the solvent is removed under vacuo and the residue is diluted with EtOAc. The organic layer is washed with 10% NaHC03 followed by brine. The organic layer is dried over MgS04 and concentrated in vacuo to afford 0.084 g (77%) of the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.55 (d, J = 2.4 Hz, 1 H), 8.10 (dd, J = 8.5 Hz, J = 2.4 Hz, 1 H), 7.76 (d, J = 8.7 Hz, 1 H), 4.20 (s, 3H), 4.19 (s, 2H), 3.95 (brs, 2H), 3.63 (brs, 6H). MS (ESI+): 359.0. HPLC (max plot) 96.9%; Rt 3.78 min.
Intermediate T.2: 3-(morpholin-4-ylcarbonyl)-8-nitro-1 -phenyl-1 ,4- dihydrothiochromenor4,3-c1pyrazole
Following the protocol outlined in Procedure G, 3-(morpholin-4-ylcarbonyl)-8-nitro-1 -phenyl- 1 ,4-dihydrothiochromeno[4,3-c]pyrazole is obtained from 8-nitro-1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid and morpholine to afford 0.628 g (79%) of the title compound. MS (ESI+): 423.0.
Intermediates described below are obtained following procedure T.
dihydrothiochromenor4,3-c1pyrazole-3-carboxylate 5,5-dioxide
dihvdrothiochromenor4,3-clpvrazole-3-carboxvlate 5,5-dioxide
Intermediates described below are obtained following procedure AA, described below. Intermediate U.1 : 6-Bromo-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4- dihydrothiochromenor4,3-c1pyrazole
dioxidothiochromenor4,3-clpvrazol-1(4H)-vllazepane-1-carboxvlate 140 mg of the title compound as a white solid. 1H NMR (DMSO- d6, 400 MHz): δ 8.04-8.02 (m, 1 H), 7.85 (m, 2H), 7.74-7.72 (m, 1 H), 4.85 (m, 1 H), 4.76 (s, 2H), 3.89 (bs, 2H), 3.64 (m, 8H), 3.41 (m, 2H), 2.21 (bs, 2H), 2.04 (bs, 2H), 1.95 (m, 2H), 1 .40 (s, 9H). MS (ESI-BOC): 431 .3. HPLC (max plot) 99.0%; Rt 4.53 min.
Intermediate U.7: 8-Bromo-3-(morpholin-4-vlcarbonvl)-1 -methyl-5,5- dioxidothiochromeno r4,3-clpvrazole
o 60 mg of the title compound. 1H NMR (400 MHz, DMSO-d6) δ =
8.18 (s, 1 H), 7.94 (m, 2H), 4.84 (s, 2H), 4.28 (s, 3H), 3.94 (m, rfH 2H), 3.64 (m, 6H). MS (ESI+): 426.0. HPLC (max plot) 97.85%; Rt
3.37 min.
Intermediates described below are synthesised folloing procedure AC, described below,
chromenor4,3-c1pyrazol-1 (4H)-vnpyrrolidine-1 -carboxylate
chromenor4,3-clpvrazol-1 (4H)-vllpiperidine-1 -carboxvlate Procedure W
Intermediate W.1 : 4-r3-(Morpholin-4-ylcarbonyl)-5,5- ■<dioxidothiochromenof4,3- clpyrazol-1 (4H)-yllbenzyl methanesulfonate
To a solution of {4-[3-(morpholin-4-ylcarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4H)- yl]phenyl}methanol (300 mg; 0.68 mmol; 1 eq.) in DCM (15 mL) is added trietylamine (190.28 μΙ; 1.37 mmol; 2 eq.) and methanesulfonyl chloride (105.67 μΙ; 1.37 mmol; 2 eq.) at 0°C under nitrogen. The reaction mixture is stirred at rt for 1 h. The reaction is stopped by addition of water and the product is extracted with DCM. The organic layers are dried over MgS04 and the solvent evaporated to afford 400 mg (quant) of the title compound as a beige oil. It is used in the next steps without further purification. MS (ESI+): 518.0.
Intermediate W.2: 3-r3-(Morpholin-4-ylcarbonyl)-5,5-dioxidothiochromenor4,3- clpyrazol-1 (4H)-yllbenzyl methanesulfonate
Following the protocol outlined in procedure W (New: mesylate formation), 3-[3-(morpholin-4- ylcarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4H)-yl]benzyl methanesulfonate is obtained from {4-[3-(morpholin-4-ylcarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4H)- yl]phenyl}methanol to afford 1 .85 g (quant) of the title compound. HPLC (max plot) 62.6%; Rt 3.69 min. HPLC (max plot) 78.4%; Rt 3.66 min. MS (ESI+): 517.9.
Compounds described below are obtained following protocole outlined in procedure AM, described below,
Intermediate X.3: 1 -Azetidin-3-yl-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno r4,3-c1pyrazole 5,5-dioxide (hydrochloride)
chromenor4,3-clpvrazole 5,5-dioxide (hydrochloride)
Procedure Y
Intermediate Y.1 : 4-Hydrazinopiperidine (hydrochloride)
To ie f-butyl 4-[2-(ie f-butoxycarbonyl)hydrazino]piperidine-1 -carboxylate (15 g; 47.56 mmol; 1 eq.) in DCM (100 ml) is added a solution of hydrogen chloride in 1 ,4-dioxane (30 ml; 4 M; 120 mmol; 2.52 eq.). The reaction mixture is stirred 2h at rt then concentrated under reduced pressure. The solid obtained is dried under vaccuum to afford 9.1 g (100%) of the title compound as a white powder. 1 H NMR (300 MHz, DMSO) δ 9.26-9.06 (m, 2H), 7.95 (bs, 5H), 3.39-3.05 (m, 3H), 3.02-2.69 (m, 2H), 2.21 -1 .95 (m, 2H), 1 .84-1 .61 (m, 2H).
Compounds described below are obtained following protocole outlined in procedure Y
Obtained from Enantiomer A of fe/f-butyl 3-[3-(morpholin-4- ylcarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4/-/)-
<¾ ,ρ yl]pyrrolidine-1 -carboxylate to give 760 mg (100%) of the title compound as a white powder. 1H NMR (DMSO-c/6, 300 MHz): δ 9.62 (s, 4H), 8.14-8.02 (m, 2H), 8.00-7.85 (m, 4H), 7.83-7.70 (m, 2H), 5.78 (dd, J = 6.8, 3.5, 2H), 4.80 (s, 4H), 3.97-3.74 (m, 6H), 3.68 (d, J = 9.5, 13H), 3.53-3.38 (m, 4H), 2.57 (dd, J = 13.9, 7.2, 2H), 2.41 (m, 2H). HPLC (max plot) 73.7%; Rt 1 .82 min.
Intermediate Y.8: Enantiomer B of 3-(morpholin-4-vlcarbonvl)-1 -rpvrrolidin-3-vH-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from Enantiomer B of ie f-butyl 3-[3-(morpholin-4- ylcarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4/-/)-
<¾ .p yl]pyrrolidine-1 -carboxylate to give 500 mg (85%) of the title
compound as a pink powder. 1H NMR (DMSO-c/6, 300 MHz): δ 9.56 (s, 4H), 8.12-8.02 (m, 2H), 7.93 (qd, J = 8.0, 4.0, 4H), 7.84- 7.69 (m, 2H), 5.87-5.67 (m, 2H), 4.79 (s, 4H), 3.95-3.74 (m, 6H), 3.74-3.59 (m, 13H), 3.53-3.41 (m, 4H), 2.68-2.52 (m, 2H), 2.41 (m, 2H). HPLC (max plot) 50.3%; Rt 1 .68 min.
Intermediate Y.9: Enantiomer A of 1 -azepan-4-vl-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from Enantiomer A of ie f-butyl 4-[3-(morpholin-4- ylcarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4/-/)- yl]azepane-1 -carboxylate to give 245 mg (92%) of the title compound as a white solid. MS (ESI+): 431 .3. HPLC (max plot) 77.5%; Rt 2.23 min
Intermediate Y.10: Enan iomer B of 1 -azepan-4-vl-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from Enantiomer B of ie/f-butyl 4-[3-(morpholin-4- ylcarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4/-/)- yl]azepane-1 -carboxylate to give 498 mg (94%) of the title compound as a white solid. MS (ESI+): 431 .3. HPLC (max plot) 96.3%; Rt 2.22 min
Intermediate Y.11 : Enan iomer A of 6-fluoro-3-(morpholin-4-vlcarbonvl)-1 -rpvrrolidin-3- vH-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide hydrochloride
dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide (example 481 ) 1 g (quant) of the title compound as a white solid. 1H NMR
Q. .p (DMSO-d6, 300 MHz): δ 8.05 (d, J = 8.94 Hz, 1 H), 8.00-7.90 (m,
2H), 4.89 (brs, 2H), 4.79-4.61 (m, 1 H), 3.98-3.84 (m, 2H), 3.78-
N-N 3.55 (m, 6H), 3.25-3.12 (m, 1 H), 3.01-2.62 (m, 3H), 2.30-2.00 (m,
O- Γ NH
2H), 1.86-1.49 (m, 3H). MS (ESI+): 501.1. HPLC (max plot) 97.1%; Rt 2.70 min
Intermediate Y.17: Enan iomer B of 6-chloro-3-(morpholin-4-vlcarbonvl)-1 -rpiperidin-3- vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from Enantiomer B of ie f-butyl 3-[6-chloro-3- (morpholin-4-ylcarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol- 1 (4/-/)-yl]piperidine-1-carboxylate to give 208 mg (97%) of the title
Q~ Γ NH compound as a beige solid. 1H NMR (DMSO-c/6, 300 MHz): δ . MS
(ESI+): 451.3. no.
Procedure Z
Intermediate Z.1 : 1 -Π -(2-Chloroethyl)piperidin-4-vn-3-(morpholin-4-ylcarbonyl)-1 ,4- dihvdrothiochromenor4,3-clpyrazole 5,5-dioxide
A suspension of 3-(morpholin-4-ylcarbonyl)-1-piperidin-4-yl-1 ,4-dihydrothiochromeno[4,3- c]pyrazole 5,5-dioxide hydrochloride (100 mg; 0.23 mmol; 1 eq.), chloroacetaldehyde (31.13 mg; 0.24 mmol; 1.1 eq.) in DCE (4.2 ml) is added sodium triacetoxyborohydride (229.27 mg; 1.08 mmol; 1.4 eq) and the reaction mixture is stirred at 65°C overnight. The reaction mixture is diluted with DCM and the organic phase is washed with a saturated aqueous solution of NaHC03 then dried on MgS04 and concentrated. The residue is purified by flash chromatography eluting from 100% to 30% AcOEt and MeOH to afford after concentration of the desired fractions of the title compound as a brown oil. HPLC (max plot) 89.6%; Rt 2.33 min.
Intermediates described below are obtained following protocole outlined in procedure Z
(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide Obtained from enantiomer B of 3-[6-chloro-3-(morpholin-4- ylcarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4/-/)- yl]piperidine-1 -carboxylate to give 78 mg (75%) of the title compound as a white foam. 1H NMR (DMSO-c/6, 300 MHz): δ 7.92-7.81 (m, 1 H), 7.81 -7.69 (m, 2H), 4.91 (s, 2H), 4.74- 4.54 (m, 1 H), 3.99-3.84 (m, 2H), 3.79-3.55 (m, 8H), 3.24-
ON"^CI 3.13 (m, 1 H), 2.98-2.84 (m, 1 H), 2.82-2.65 (m, 2H), 2.59- 2.45 (m, 1 H), 2.23-2.02 (m, 2H), 2.02-2.1 .83 (m, 1 H), 1 .83- 1 .57 (m, 2H). MS (ESI+): 513.37. HPLC (max plot) 95.9%; Rt 7.88 min
Intermediate Z.13: Enantiomer B of 1 -ri -(2-chloroethvl)piperidin-3-vH-6-methvl-3-
(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 6-methyl-3-(morpholin-4- ylcarbonyl)-1 -[piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3- c]pyrazole 5,5-dioxide to give 780 mg (97%) of the title compound as a colourless foam. 1H NMR (DMSO-c/6, 300 MHz): δ . HPLC (max plot) 94.5%; Rt 2.06 min
Intermediate Z.14: Enantiomer B 1 -ri -(2-chloroethvl)piperidin-3-vH-7-fluoro-3-
(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 7-fluoro-3-(morpholin-4-
Γ3ϊΎΡ ylcarbonyl)-1 -[piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3- c]pyrazole 5,5-dioxide to give 25 mg (72%) of the title compound as an oil. δ. MS (ESI+): 497.21.
Intermediate Z.15: Enantiomer B of 1 -ri -(2-chloroethvl)piperidin-3-vH-7-methoxv-3-
(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 7-methoxy-3-(morpholin-4- ylcarbonyl)-1 -[piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3- c]pyrazole 5,5-dioxide to give 600 mg (70%) of the title compound as a white foam. 1H NMR (DMSO-c/6, 300 MHz): δ 7.78 (d, J = 8.7 Hz, 1 H), 7.51 -7.44 (m, 2H), 4.78-4.64 (m, 4H), 3.96-3.88 (m, 4H), 3.75-3.60 (m, 7H), 3.22 (d, J = 10.0
Hz, 1 H), 2.93 (d, J = 10.6 Hz, 1 H), 2.75 (td, J = 6.7, 2.4 Hz, 2H), 2.56-2.46 (m, 2H), 2.20-2.06 (m, 2H), 1 .96-1 .85 (m, 1 H), 1 .84-1 .62 (m, 2H).. MS (ESI+): 509.4. HPLC (max plot)
Intermediate Z.19: 3-[3-(Morpholin-4-ylcarbonyl)-5,5-dioxidothiochromeno[4,3- c]pyrazol-1 (4H)-yl]phenol
To a solution 1 -[3-(benzyloxy)phenyl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide (8 g, 155 mmol) in MeOH (500 mL) is added 10% Pd /C (0.5 g) and the reaction mixture is hydrogenated at 12 Kg/cm2 pressure of hydrogen at RT for 20 h in Autoclave. The catalyst is filtered through celite and filtrate is concentrated to afford 4.9 g (89%) of the title compound as a brown solid. 1H NMR (DMSO- d6, 400 MHz): δ 10.08 (s, 1 H), 8.02-8.00 (dd, J= 2.4, 3.2 Hz, 1 H), 7.65-7.59 (m, 2H), 7.42- 7.38 (t, J = 8.0 Hz, 1 H), 7.01 -6.99 (t, J = 8.4 Hz, 1 H), 6.93-6.88 (m, 3H), 4.88 (s, 2H), 3.95 (m, 2H), 3.66-3.61 (m, 4H),3.56 (s, 2H). MS (ESI+): 426.0. HPLC (max plot): 96%; Rt 3.25 min.
Intermediate Z.20: Ethyl 1 -{6-r(acetyloxy)methyl1pyridin-3-yl)-1 ,4- dihvdrothiochromenor4,3-c1pyrazol -3-carboxylate 5,5-dioxide.
A solution of ethyl 1 -(1 -oxidopyridin-3-yl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3- carboxylate 5,5-dioxide (637 mg) in acetic anhydride (30 mL) is heated to 130°C for 2 h under nitrogen. After completion of the reaction, the reaction mass is concentrated under reduced pressure and triturated in water, filtered and dried to afford 700 mg (99%) of the title compound. MS (ESI+): 442.0. Intermediate Z.21 : 3-f3-(Morpholin-4-ylcarbonyl)-5,5-dioxidothiochromenof4,3- c1pyrazol-1(4H)-vnaniline:
1 -(3-Bromophenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5- dioxide (0.15 g, 0.308 mmol), copper acetate (6 mg, 0.03 mmol), cesium carbonate (200 mg, 0.616 mmol) and acetyl acetone (13 μί, 0.123 mmol) are taken DMF purged with NH3 gas. The reaction mixture is heated to 90°C for 24 h. After this time, reaction mixture is concentrated under reduced pressure and purified by column chromatography (100% EtOAc) to afford the title compound as a pale brown solid. 1H NMR (400 MHz, DMSO-d6) δ = 7.99- 7.97 (m, 1 H), 7.62-7.60 (m, 1 H), 7.24-7.20 (t, J = 7.84 Hz, 1 H), 6.98-6.95 (m, 1 H), 6.75-6.73 (d, J = 9.32 Hz, 1 H), 6.58-6.56 (m, 2H), 5.57 (s, 2H), 4.87 (s, 2H), 3.95 (m, 2H), 3.66 (m, 6H), MS (ESI+): 425.0. HPLC (max plot): 94.69%; Rt 2.65 min.
Intermediate Z.22: Ethyl 7-(acetylamino)-1 -(tetrahvdro-2H-pyran-4-yl)-1 ,4- dihvdropyrazolor3',4':4,51thiopyranor3,2-diri,31thiazole-3-carboxylate 5,5-dioxide
To suspension of ethyl 7-amino-1 -(tetrahydro-2/-/-pyran-4-yl)-1 ,4-dihydropyrazolo[3',4':4,5] thiopyrano[3,2-d][1 ,3]thiazole-3-carboxylate 5,5-dioxide (71 mg; 0.18 mmol; 1 eq.) and triethylamine (98.8 μΙ_; 0.71 mmol; 4 eq.) in DCM (710 μΙ_) at 0°C is added acetylchloride (30 μΙ_; 0.46 mmol; 2.5 eq.). The suspension is stirred at rt overnight then heated up to 100°C for 1 day. Water is added to reacture mixture and the product is extracted with DCM (X2). The combined organic layers are washed with brine, dried over Na2S04 then concentrated under vacuum affording a beige solid residue. The residue is triturated then sonicated in Et20 and the solid is filtered-off to afford the title compound. HPLC (max plot) 98.8%; Rt 3.28 min. MS (ESI+): 441 .1 . Intermediate Z.23: 4-f(4-Nitro-1 H-pyrazol-3-yl)carbonyl1morpholine
Following protocole outlined in procedure AD (described below), 4-[(4-nitro-1 /-/-pyrazol-3- yl)carbonyl]morpholine is obtained from 4-nitro-1 /-/-pyrazole-3-carboxylic acid and
morpholine to give 3.0 g (41 %) of the title compound as a white solid. 1 H NMR 14.22 (brs, 1 H), 8.92 (brs, 1 H), 3.66 (s, 4H), 3.52-3.45 (m, 2H), 3.25-3.18 (m, 2H), MS (ESI+): 226.9.
Intermediate Z.24: 4-f(4-Nitro-1 -phenyl-1 H-pyrazol-3-yl)carbonyl1morpholine
A solution of 4-[(4-nitro-1 /-/-pyrazol-3-yl)carbonyl]morpholine (1 .50 g; 6.63 mmol; 1 .00 eq.) and copper acetate (1 204.49 mg; 6.63 mmol; 1 .00 eq.) in DCM (5 mL) is stirred at rt for 18h after which phenylboronic acid (808.58 mg; 6.63 mmol; 1 .00 eq.) and TEA (1 .83 mL) are added and the mixture is stirred at room temperature for 18h. After this time, reaction mixture is diluted with DCM, ished with sat. aq. NaHC03 then brine, dried over MgS04, filtered through a short plug of silica and concentrated in vacuo to give as a pale yellow oil.
Purification by column chromatography (DCM to 15% ethyl acetate in DCM) followed by crystallization from MTBE afford 60 mg of the title compound as a white solid. 1H NMR (DMSO) 9.76 (s, 1 H), 8.00-7.91 (m, 2H), 7.65-7.54 (m, 2H), 7.53-7.43 (m, 1 H), 3.70 (s, 4H), 3.60-3.48 (m, 2H), 3.41 -3.32 (m, 2H). MS (ESI+): 303.0.
Intermediate Z.25 : 3-(Morpholin-4-ylcarbonyl)-1 -phenyl-1 H-pyrazol-4-amine
To a solution of 4-[(4-nitro-1 -phenyl-1 /-/-pyrazol-3-yl)carbonyl]morpholine (376 mg; 1 .24 mmol; 1 .00 eq.) in AcOEt (10 mL) is added Pd/C 10% (-50% H20) (13.24 mg; 0.12 mmol; 0.10 eq.) and under H2 Atm. (1 atm.). After 18h, reaction mixture is filtered over a celite bed, ished with AcOEt to give 310 mg (92%) of the title compound as a purple solid. 1 H NMR (DMSO): δ 7.85 (s, 1 H), 7.77-7.72 (m, 2H), 7.53-7.44 (m, 2H), 7.30 (t, J = 7.4 Hz, 1 H), 5.14- 4.90 (m, 2H), 4.31 -4.14 (m, 2H), 3.73-3.58 (m, 4H), 3.43-3.23 (m, 2H). HPLC (max plot) 95.6%; Rt 2.01 min. MS (ESI+): 272.9.
Intermediate Z.26 : 2-Bromo-A/-f3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 H-pyrazol-4- yllbenzenesulfonamide
To a solution of 3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 /-/-pyrazol-4-amine (260 mg; 0.95 mmol; 1 eq.) in DCM (10 mL) is added pyridine (151 μΙ_; 1.91 mmol; 2.00 eq.) and 2- bromobenzene-1 -sulfonyl chloride (317 mg; 1 .24 mmol; 1 .30 eq.). The reaction is stirred for 48h at room temperature. After this time, DCM is added to the reaction mixture which is ished with NH4CI sat, dried over MgS04 and purified by flash chromatography (AcOEt / heptane 4 : 1 ) to give 440 mg (94%) of the title compound as a white solid. 1H NMR (DMSO) δ . 9.93 (s, 1 H), 8.43 (s, 1 H), 8.1 1 -8.02 (m, 1 H), 7.91 -7.84 (m, 1 H), 7.84-7.76 (m, 2H), 7.59- 7.45 (m, 4H), 7.40-7.31 (m, 1 H), 3.81 -3.69 (m, 2H), 3.67-3.49 (m, 6H) HPLC (max plot) 94.6%; Rt 4.83 min. MS (ESI+): 493.2.
Intermediate Z.27 : 2-Bromo-A/-(methoxymethyl)-A/-f3-(morpholin-4-ylcarbonyl)-1 - phenyl-1 H-pyrazol-4-yllbenzenesulfonamide
To a solution of 2-bromo-/V-[3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 /-/-pyrazol-4- yl]benzenesulfonamide (200 mg; 0.41 mmol; 1 .00 eq.) in THF (30 mL) is added NaH (24 mg; 0.61 mmol; 1 .50 eq.) in a portionwise manner and the resulting mixture is stirred at room temperature for 15 minutes whereupon Chloromethyl methyl ether (82 μΙ; 0.81 mmol; 2.00 eq.) is added dropwise. The reaction mixture is stirred at room temperature for 2 hours then quenched with sat. aq. NaHC03. Extraction with ethyl acetate (2x), ishing with brine, drying over magnesium sulfate and concentration in vacuo gives 240 mg (quant) of the title compound as a colourless oil. 1H NMR (DMSO) δ 8.82 (s, 1 H), 7.93-7.8 (m, 4H), 7.64-7.46 (m, 4H), 7.39 (t, J = 7.4 Hz, 1 H), 5.32 (s, 2H), 3.59-3.51 (m, 2H), 3.42 (s, 3H), 3.46-3.37 (m, 4H), 3.15-3.06 (m, 2H). MS (ESI+): 505.2. Intermediate Z.28 : 2-Bromo-A/-methyl-A/-f3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 H- pyrazol-4-yllbenzenesulfonamide
To a solution of 2-bromo-/V-[3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 /-/-pyrazol-4- yl]benzenesulfonamide (30 mg; 0.06 mmol; 1 .00 eq.) in THF (6 mL) is added sodium hydride (3 mg; 0.07 mmol; 1 .20 eq.) and the reaction is stirred for 10 min before the addition of iodomethane (4 μΙ_; 0.07 mmol; 1.10 eq.). After 12h, DCM is added to the reaction mixture, ished with water (x2) and dried the organic phase over MgS04 give 30 mg (97%) of the title compound as a white solid. 1 H NMR (DMSO) δ 8.64 (s, 1 H), 7.93-7.86 (m, 2H), 7.80-7.73 (m, 2H), 7.62-7.47 (m, 4H), 7.41 -7.32 (m, 1 H), 3.65-3.51 (m, 6H), 3.48-3.42 (m, 2H), 3.35 (s, 3H). HPLC (max plot) 89.7%; Rt 3.98 min. MS (ESI+): 507.2.
Intermediate Z.29: Ethyl 5-hydroxy-1 -phenyl-1 H-pyrazole-3-carboxylate
To a solution of phenyl hydrazine (10 g, 92.6 mmol) in absolute ethanol (100 mL) is added dry K2C03 (15.3 g, 1 1 1 mmol) and followed by slow addition of diethylacetylene
dicarboxylate (10.6 g, 62.03 mmol) and the reaction mixture is heated at 85°C for 12h. The reaction mixture is then cooled to rt and 38 mL of 6N HCI is added dropwise. The reaction mixture is diluted with 150 mL water, extracted with ethylacetate. The organic layer is washed with water twice, dried over Na2S04 and concentrated under vacuum. The residue is triturated with MTBE and the solid formed is filtered, washed with MTBE and dried to afford the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 12.12 (bs, 1 H), 7.72-7.70 (m, 2H), 7.51 -7.47 (m, 2H), 7.37-7.34 (m, 1 H), 5.93 (s, 1 H), 4.26 (q, J = 4.1 Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H). MS (ESI+): 233.2.
Intermediate Z.30: Ethyl 5-bromo-4-formyl-1 -phenyl-1 H-pyrazole-3-carboxylate:
To a solution of ethyl 5-hydroxy-1 -phenyl-1 /-/-pyrazole-3-carboxylate (6.47 g, 27.52 mmol) in DCE (70 mL) is added phosphorus oxy bromide (13.86 g, 48.16 mmol) and DMF (4 ml_, 51 .46 mmol). The reaction mixture is refluxed at 90°C for 3h. Phosphorus oxy bromide (34.8 g, 121 .38 mmol) is added again and the reaction mixture is refluxed at 90°C for 20h. The reaction mixture is poured over ice and extracted with DCM twice. The organic layer is dried over Na2S04 and concentrated. The crude is purified by column chromatography to afford the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 10.30 (s, 1 H), 7.63-7.61 (m, 5H), 4.38 (q, J = 3.6 Hz, 2H), 1 .32 (t, J = 7.1 Hz, 3H). MS (ESI+): 325.0, HPLC (max plot) 97.37%, Rt 4.42 min.
Intermediate Z.31 : Ethyl 5-bromo-4-(hvdroxymethyl)-1 -phenyl-1 H-pyrazole-3- carboxylate
To an ice cooled solution of ethyl 5-bromo-4-formyl-1 -phenyl-1 /-/-pyrazole-3-carboxylate
(3.82 g, 1 1 .86 mmol, 1 eq) in a 1 :1 mixture of THF: EtOH is added sodium borohydride (0.5 g, 13.04 mmol, 1 .1 eq) portion wise. The reaction mixture is stirred at RT for 2h. The reaction mixture is quenched with sat. NH4CI solution and extracted with EtOAc. The organic layer is dried over Na2S04 and concentrated. The crude is purified by column chromatography to afford 2.91 g (75%) of the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 7.60-7.56 (m, 5H), 4.95 (t, J = 5.4 Hz, 1 H), 4.60-4.58 (d, J = 5.4 Hz, 2H), 4.32 (q, J = 7.01 Hz, 2H), 1 .30 (t, J = 7.7 Hz, 3H). HPLC (max plot) 96.75%; Rt 3.69 min
Intermediate Z.32: Ethyl 5-bromo-4-(bromomethyl)-1 -phenyl-1 H-pyrazole-3-carboxylate
To a solution of ethyl-5-bromo-4-(hydroxymethyl)-1 -phenyl-1 /-/-pyrazole-3-carboxylate (2.91 g, 8.98 mmol, 1 eq) in Et20 cooled at -10°C is added phosphorus tribromide (1 .02 mL, 10.77 mmol, 1 .2 eq) and the reaction mixture is stirred at Rt for 1 h. The reaction mixture is poured over ice and extracted with MTBE. The organic layer is washed with brine, dried over Na2S04 and concentrated to afford 2.1 g (60%) of the title compound. 1H NMR (DMSO-c/6, 400 MHz): δ 7.65-7.57 (m, 5H), 4.77 (s, 2H), 4.35 (q, J = 6.0 Hz, 2H), 1.32 (t, J = 6.6 Hz, 3H). HPLC (max plot) 83.30%; Rt 5.33 min.
Intermediate Z.33: Ethyl-5-bromo-4-r(1 H-imidazol-2ylthio) methyl1-1 -phenyl-1 H- pyrazole-3-carboxylate
To a solution of ethyl-5-bromo-4-(bromomethyl)-1 -phenyl-1 /-/-pyrazole-3-carboxylate (2.1 g, 5.44 mmol, 1 eq) and 2-mercaptoimidazole (0.6 g, 5.98 mmol, 1.1 eq) in ACN (30 mL) is added dry K2C03 (2.25 g, 16.32 mmol, 3 eq) and the reaction mixture is heated at 85°C for 1 h. The reaction mixture is diluted with DCM and filtered. The filtrate is concentrated and the residue is partitioned between DCM/water. The organic layer is dried over Na2S04 and concentrated to afford the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 12.29 (bs, 1 H), 7.59-7.53 (m, 5H), 7.16 (d, J = 1 .4 Hz, 1 H), 6.94 (d, J = 1.4 Hz, 1 H), 4.28-4.26 (m, 2H), 4.19 (s, 2H), 1 .29 (t, J = 7.7 Hz, 3H).
Intermediate Z.34: Ethyl 1 -phenyl-1 ,4-dihvdroimidazof2,1 -b1pyrazolof3,4- dlH ,31thiazine-3-carboxylate
Ethyl-5-bromo-4-[(1 H-imidazol-2ylthio) methyl]-1 -phenyl-1 /-/-pyrazole-3-carboxylate (0.3 g, 0.74 mmol, 1 eq), Cul (14 mg, 0.074 mmol, 0.1 eq), Λ/,/V-dimethylglycine (15 mg, 0.147 mmol, 0.2 eq), K2C03 (0.2 g, 1 .47 mmol, 2 eq) are taken in DMSO (6 mL) heated at 180°C for 0.5 h under microwave irradiation. The reaction mixture is diluted with DCM and filtered through a pad of celite. The filtrate is partitioned between DCM and water. The organic layer is washed with brine, dried over Na2S04 and concentrated. The crude is purified by flash chromatography to afford the title compound. 1H NMR (DMSO-c/6, 400 MHz): δ 7.67-7.59 (m, 5H), 6.93 (d, J = 1 .5 Hz, 1 H), 6.48 (d, J = 1.4 Hz, 1 H), 4.40 (s, 2H), 4.34 (q, J = 7.7 Hz, 2H), 1 .31 (t, J = 7.7 Hz, 3H). MS (ESI+): 313.2. HPLC (max plot) 97.73%; Rt 2.73 min.
Intermediate Z.35: 2H-1 , 4-Benzothiazi -3(4H)-one:
Sodium methoxide is prepared by dissolving 920 mg of sodium metal in 40 mL of ethanol and 5 g of ortho-aminothiophenol is added to it and the reaction mixture is stirred at RT for 10 min. Then the reaction mixture is cooled with ice and 4.8 mL of ethylbromoacetate is added dropwise and the reaction mixture is stirred at RT for 3h. The precipitated solid is filtered off and the filtrate is concentrated and triturated with ether and the solid formed is filtered, washed with water, hexane and dried. The solid is then azeotroped with toluene and taken for next step. 1H NMR (DMSO-d6, 400 MHz): δ 10.55 (bs, 1 H), 7.31 -7.29 (d, J = 8.2 Hz, 1 H), 7.17-7.13 (m, 1 H), 6.97-6.93 (m, 2H), 3.49 (s, 2H). MS (ESI+): 166.0.
Intermediate Z.36: Ethyl 4H-imidazo -cl Π , 41 benzothiazine-3-carboxylate
To a solution of 2/-/-1 ,4-benzothiazin-3(4/-/)-one (0.7 g, 4.24 mmol, 1 eq) in DMF (20 mL) is added potassium tert- butoxide (0.50 g, 4.49 mmol, 1 .06 eq) and the reaction mixture is stirred at RT for 10 min. The reaction mixture is cooled with ice and diethyl chloro
phosphonate (1.1 mL, 7.63 mmol, 1 .8 eq) is added and the reaction mixture is stirred at RT for 5 minutes. The reaction mixture is then cooled with ice and a solution of ethyl isocyano acetate (0.65 mL, 5.94 mmol, 1 .4 eq) in DMF and potassium ie f-butoxide (0.66 g, 5.93 mmol, 1 .4 eq) are sequentially added and the reaction mixture is stirred at RT overnight. The reaction mixture is acidified with 10 mL of acetic acid, diluted with water and poured into ice and extracted with ethylacetate. The organic layer is dried over Na2S04 and concentrated. The crude is purified by column chromatography to afford the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 8.50 (s, 1 H), 7.90-7.88 (d, J = 7.3 Hz, 1 H), 7.56-7.54 (m, 1 H), 7.39- 7.36 (m, 1 H), 7.32-7.30 (m, 1 H), 4.42 (s, 2H), 4.27 (q, J = 7.7 Hz, 2H), 1 .29 (t, J = 6.6 Hz, 3H). MS (ESI+): 261 .2. HPLC (max plot) 95.13%; Rt 3.62 min. Intermediate Z.37: Ethyl 1 -phenyl-4H- imidazo Γ5, 1 -d Π , 41 benzothiazine-3- carboxylate
lodo benzene (0.15 mL, 1 .15 mmol, 2 eq), palladium (II) acetate (6.4 mg, 0.03 mmol, 0.05 eq), and Cul (0.22 g, 1 .15 mmol, 2 eq) are taken in pressure tube to which is added ethyl 4H- imidazo [5, 1 -c] [1 , 4] benzothiazine-3-carboxylate (0.15 g, 0.576 mmol, 1 eq) taken in degassed DMF (6 mL) and the contents are heated at 140°C for 12 h. The reaction mixture is diluted with DCM and filtered through celite. The filtrate is concentrated, passed through a plug of silica gel and concentrated to get the crude product 60 mg which is taken as such to next step. MS (ESI+): 337.2.
Examples
Procedure AA
Example 1 : 6-methoxy-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4- dihvdrothiochromenor4,3-c1pyrazol -dioxide
To a solution of 6-methoxy-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide (0.20 g, 0.54 mmol) in THF (20 mL) is added triethylamine (0.20 mL, 1.63 mmol) followed by 50 % propane phosphonic acid anhydride in EtOAc (0.70 mL, 0.347 g, 1 .09 mmol). The reaction mixture is cooled to 0 °C and then morpholine (0.049 g, 0.59 mmol) is added and the reaction mixture is stirred overnight at room temperature. The solvent is removed under reduced pressure and the residue is diluted with EtOAc. The organic layer is washed with 10% NaHC03 then brine, dried over MgS04 and concentrated under reduced pressure. The residue is purified by column chromatography (eluent 1 to 2 % MeOH in DCM) to afford the title compound as an off-white solid. 1H NMR (DMSO-c/6, 400 MHz): δ 7.59-7.58 (m, 3H) 7.46-7.42 (m, 3H) 7.25 (d, J = 8.60 Hz, 1 H), 6.35 (d, J = 7.92 Hz, 1 H), 4.82 (s, 2H), 3.95 (br, 2H), 3.90 (s, 3H), 3.65 (br, 4H), 3.59 (br, 2H). MS (ESI+): 440.0. HPLC (max plot) 96.0%; Rt 4.81 min. Example 2: 6-methoxy-1 -methyl-3-(morpholin-4-ylcarbonyl)-1 ,4- dihvdrothiochromenor4,3-clpyrazol 5,5-dioxide
Following the protocol outlined in Procedure AA, 6-methoxy-1 -methyl-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 6-methoxy- 1 -methyl-1 ,4-dihydro thiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford 0.15 g (98%) of the title compound as a white solid. 1H NMR (DMSO-c/6, 400 MHz): δ 7.77 (t, J = 8.08 Hz, 1 H), 7.51 (d, J = 7.84 Hz, 1 H), 7.36 (d, J = 8.44 Hz, 1 H), 4.72 (m, 2H), 4.15 (s, 3H), 3.95 (br, 2H), 3.91 (s, 3H), 3.64-3.62 (m, 6H). MS (ESI+): 378.0. HPLC (max plot) 97.0%; Rt 2.51 min.
Example 3: 3-(morpholin-4-ylcarbonyl)-2,4-dihvdrothiochromenof4,3-c1pyrazole 5,5- dioxide
Following the protocol outlined in Procedure AA, 3-(morpholin-4-ylcarbonyl)-2,4- dihydrothiochromeno [4,3-c]pyrazole 5,5-dioxide is obtained from 2,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford the title compound as a white solid. 1H NMR (DMSO-d6, 400 MHz): δ 7.99-7.94 (m, 2H), 7.83 (t, J = 7.28 Hz, 1 H), 7.65 (t, J = 7.6 Hz, 1 H), 4.81 (s, 2H), 4.57 (q, J = 7.12 Hz, 2H), 3.82-3.54 (m, 8H). MS (ESI+): 334.0. HPLC (max plot) 97.5%; Rt 2.32 min.
Example 4: 7-methoxy-1 -methyl-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
Following the protocol outlined in Procedure AA, 7-methoxy-1 -methyl-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 7-methoxy- 1 -methyl-1 ,4-dihydro thiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 7.98 (d, J = 8.7 Hz, 1 H), 7.47 (d, J = 2.6 Hz, 1 H), 7.42-7.40 (m, 1 H), 4.77 (s, 2H), 4.20 (s, 3H), 3.95 (brs, 2H), 3.91 (s, 3H), 3.65-3.62 (m, 6H). MS (ESI+): 378.0. HPLC (max plot) 99.0%; Rt 2.94 min. Example 5: 7-methoxy-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4- dihydrothiochromenor4,3-c1pyra -dioxide
Following the protocol outlined in Procedure AA, 7-methoxy-3-(morpholin-4-ylcarbonyl)-1 - phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 7-methoxy-1 - phenyl-1 ,4-dihydro thiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and
morpholine to afford 0.13 g (74%) of the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 7.63-7.61 (m, 3H), 7.54 - 7.44 (m, 3H), 7.17-7.14 (m, 1 H), 6.75 (d, J = 8.8 Hz, 1 H), 4.86 (s, 2H), 3.96-3.94 (m, 2H), 3.84 (s, 3H), 3.66-3.59 (m, 6H). MS (ESI+): 440.0. HPLC (max plot) 98.8%; Rt 4.04 min.
Example 6: 1 -(3-methylphenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyraz -dioxide
Following the protocol outlined in Procedure AA, 1-(3-methylphenyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -(3- methylphenyl)-1 ,4-dihydrothio chromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford 0.14 g (78%) of the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.00 (dd, J = 7.7 Hz, J = 1 .3 Hz, 1 H), 7.64-7.55 (m, 3H), 7.52-7.43 (m, 2H), 7.37 (s, 1 H), 6.84 (dd, J = 7.9 Hz, J = 1 .2 Hz, 1 H), 4.89 (s, 2H), 3.94-3.92 (m, 2H), 3.66-3.32 (m, 6H), 2.38 (s, 3H). MS (ESI+): 424.0. HPLC (max plot) 98.8%; Rt 4.18 min.
Example 7: 1 -(4-methylphenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazo -dioxide
Following the protocol outlined in Procedure AA, 1-(4-methylphenyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -(4- methylphenyl)-1 ,4-dihydrothio chromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.00 (dd, J = 8.0 Hz, J = 1 .5 Hz, 1 H), 7.62-7.58 (m, 2H), 7.41 (m, 4H), 6.85 (dd, J = 6.5 Hz, J = 1 .4 Hz, 1 H), 4.88 (s, 2H), 3.94 (m, 2H), 3.66-3.60 (m, 6H), 2.43 (s, 3H). MS (ESI+): 424.0. HPLC (max plot) 98.3%; Rt 4.18 min. Example 8: 1 -(5-fluoro-2-methylphenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno r4,3-c1pyraz -dioxide
Following the protocol outlined in Procedure AA, 1-(5-fluoro-2-methylphenyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -(5-fluoro- 2-methylphenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford 0.15 g (89%) of the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.01 (d, J = 7.6 Hz, 1 H), 7.65-7.45 (m, 5H), 6.73 (d, J = 7.6 Hz, 1 H), 4.97-4.86 (m, 2H), 3.92 - 3.90(m, 2H), 3.70-3.60 (m, 6H), 1 .79 (s, 3H). MS (ESI+): 442.0. HPLC (max plot) 99.3%; Rt 4.13 min.
Example 9: 1 -(3-methoxyphenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyraz -dioxide
Following the protocol outlined in Procedure AA, 1-(3-methoxyphenyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -(3- methoxyphenyl)-1 ,4-dihydro thiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford 0.13 g (73%) of the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.00 (dd, J = 7.8 Hz, J = 1 .5 Hz, 1 H), 7.65-7.57 (m, 2H), 7.53-7.48 (m, 2H), 7.20 (dd, J = 8.1 Hz, J = 2.2 Hz, 1 H), 7.13 (s, 1 H), 7.02 (d, J = 8.1 Hz, J = 1.3 Hz, 1 H), 4.89 (s, 2H), 3.93-3.92 (m, 2H), 3.80 (s, 3H), 3.66-3.59 (m, 6H). MS (ESI+): 440.0. HPLC (max plot) 98.7%; Rt 3.94 min.
Example 10: 1 -(4-methoxyphenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyraz -dioxide
Following the protocol outlined in Procedure AA, 1-(4-methoxyphenyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -(4- methoxyphenyl)-1 ,4-dihydro thiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.01 -7.99 (m, 1 H), 7.64-7.57 (m, 2H), 7.47-7.43 (m, 2H), 7.16-7.12 (m, 2H), 6.87-6.85 (m, 1 H), 4.88 (s, 2H), 3.95-3.93 (m, 2H), 3.85 (s, 3H), 3.66-3.59 (m, 6H). MS (ESI+): 440.0. HPLC (max plot) 97.1 %; Rt 3.90 min. Example 11 : 3-(morpholin-4-ylcarbonyl)-1 -pyridin-2-yl-1 ,4-dihydrothiochromenof4,3- clpyrazole 5,5-dioxide
Following the protocol outlined in Procedure AA, 3-(morpholin-4-ylcarbonyl)-1 -pyridin-2-yl- 1 ,4-dihydro thiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -pyridin-2-yl-1 ,4- dihydrothiochromeno [4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.53 (dd, J = 7.6 Hz, J = 1 .6 Hz, 1 H), 8.19 (dd, J = 7.8 Hz, J = 1.8 Hz, 1 H), 7.99 (dd, J = 8.0 Hz, J = 1 .6 Hz, 1 H), 7.89 (d, J = 8.0 Hz, 1 H), 7.66-7.56 (m, 3H), 6.92 (d, J = 7.6 Hz, 1 H), 4.88 (s, 2H), 3.92 - 3.91 (m, 2H), 3.67 - 3.60 (m, 6H). MS (ESI+): 41 1 .0. HPLC (max plot) 98.4%; Rt 3.1 1 min. Example 12: 1 -cyclohexyl-3-(morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromenof4,3- clpyrazole 5,5-dioxide
Following the protocol outlined in Procedure AA, 1-cyclohexyl-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydro thiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -cyclohexyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford the title compound as a white solid.1H NMR (DMSO-d6, 400MHz) δ 8.03 (d, J = 7.6 Hz, 1 H), 7.91 (t, J = 7.2 Hz, 1 H), 7.84 (d, J = 7.7 Hz, 1 H), 7.72 (t, J = 7.5 Hz, 1 H), 4.76 (s, 2H), 4.73- 4.68 (m, 1 H), 3.93 (m, 2H), 3.64 (m, 6H), 2.03-1 .81 (m, 6H), 1 .70-1 .67 (m, 1 H), 1 .56-1 .53 (m, 2H), 1 .49-1 .47 (m, 1 H). MS (ESI+): 416.0. HPLC (max plot) 99.0%; Rt 4.31 min.
Example 13: 6-bromo-1 -methyl-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
Following the protocol outlined in Procedure AA, 6-bromo-1 -methyl-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 6-bromo-1 - methyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford 0.13 g (73%) of the title compound as an off-white solid. 1H NMR (DMSO-d6,
400MHz) δ 7.99 (d, J = 7.8 Hz, 1 H), 7.92 (d, J = 7.9 Hz, 1 H), 7.70 (t, J = 8.0 Hz, 1 H), 4.91 (s, 2H), 4.17 (s, 3H), 3.96 (brs, 2H), 3.65-3.62 (m, 6H). MS (ESI+): 427.0. HPLC (max plot) 97.6%; Rt 3.05 min. Example 14: 6-fluoro-1 -methyl-3-(morpholin-4-ylcarbonyl)-1 ,4- dihvdrothiochromenor4,3-clpyrazo -dioxide
Following the protocol outlined in Procedure AA, 6-fluoro-1 -methyl-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 6-fluoro-1 - methyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford the title compound as an off-white solid. 1H NMR (DMSO-d6, 400MHz) δ 7.92-7.83 (m, 2H), 7.57-7.53 (m, 1 H), 4.90 (s, 2H), 4.21 (s, 3H), 3.94 (brs, 2H), 3.65-3.62 (m, 6H). MS (ESI+): 366.0. HPLC (max plot) 97.2%; Rt 2.67 min. Example 15: 6-fluoro-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4- dihydrothiochromenor4,3-c1pyrazo -dioxide
Following the protocol outlined in Procedure AA, 6-fluoro-3-(morpholin-4-ylcarbonyl)-1 - phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 6-fluoro-1 - phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford the title compound as an off-white solid. 1H NMR (DMSO-d6, 400MHz) δ 7.63-7.56 (m, 4H), 7.52-7.43 (m, 3H), 6.64-6.62 (m, 1 H), 5.00 (s, 2H), 3.95-3.93 (m, 2H), 3.66-3.59 (m, 6H). MS (ESI+): 428.0. HPLC (max plot) 97.95%; Rt 3.83 min. Example 16: 8-fluoro-1 -methyl-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyraz -dioxide
Following the protocol outlined in Procedure AA, 8-fluoro-1 -methyl-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 8-fluoro-1 - methyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford the title compound as an off-white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.08 (dd, J = 8.7 Hz, J = 5.6 Hz, 1 H), 7.88 (dd, J = 10.0 Hz, J = 2.3 Hz, 1 H), 7.58-7.54 (m, 1 H), 4.82 (s, 2H), 4.26 (s, 3H), 3.92 (brs, 2H), 3.65-3.62 (m, 6H). MS (ESI+): 366.0. HPLC (max plot) 98.0%; Rt 2.85 min.
Example 17: 8-fluoro-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4- dihvdrothiochromenor4,3-clpyrazole 5,5-dioxide
Following the protocol outlined in Procedure AA, 8-fluoro-3-(morpholin-4-ylcarbonyl)-1 - phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 8-fluoro-1 - phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford the title compound as an off-white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.09 (dd, J = 8.7 Hz, J = 5.5 Hz, 1 H), 7.66-7.63 (m, 3H), 7.57-7.55 (m, 2H), 7.52-7.47 (m, 1 H), 6.43 (dd, J = 10.0 Hz, J = 2.4 Hz, 1 H), 4.93 (s, 2H), 3.93 (brs, 2H), 3.66-3.60 (m, 6H). MS (ESI+): 428.0. HPLC (max plot) 96.1 %; Rt 4.1 1 min.
Example 18: 6-bromo-1 -phenyl-1 ,4-dihvdrothiochromenof4,3-c1pyrazole-3-carboxylic acid 5,5-dioxide
Following the protocol outlined in Procedure AA, 6-bromo-1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide is obtained from 6-bromo- 1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford the title compound as an off-white solid. 1H NMR (DMSO-d6, 400MHz) δ 7.82 (dd, J = 8.0 Hz, J = 0.7 Hz, 1 H), 7.61 -7.57 (m, 3H), 7.48-7.45 (m, 2H), 7.38 (t, J = 8.0 Hz, 1 H), 5.01 (s, 2H), 3.96-3.94 (m, 2H), 3.66-3.59 (m, 6H). MS (ESI+): 488.0. HPLC (max plot) 98.2%; Rt 4.24 min. Example 19: 1 -(2-methylphenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
Following the protocol outlined in Procedure AA, 1-(2-methylphenyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -(2- methylphenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.00 (dd, J = 7.7 Hz, J = 1 .0 Hz, 1 H), 7.63-7.45 (m, 5H), 6.65 (d, J = 7.5 Hz, 1 H), 4.92 (s, 2H), 3.95-3.90 (m, 2H), 3.69-3.60 (m, 6H), 1.88 (s, 3H). MS (ESI+): 424.0. HPLC (max plot) 97.2%; Rt 4.1 1 min.
Example 20: 1 -(2-bromophenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
Following the protocol outlined in Procedure AA, 1-(2-bromophenyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -(2- bromophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford the title compound as an off-white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.01 (dd, J = 7.8 Hz, J = 1 .1 Hz, 1 H), 7.94 (dd, J = 7.7 Hz, J = 1 .4 Hz, 1 H), 7.79 (dd, J = 7.6 Hz, J = 1 .8 Hz, 1 H), 7.69-7.56 (m, 4H), 6.65 (d, J = 7.2 Hz, 1 H), 4.98-4.87 (m, 2H), 3.95-3.92 (m, 2H), 3.70-3.59 (m, 6H). MS (ESI+): 488.0. HPLC 8max plot) 98.7%; Rt 4.01 min.
Example 21 : 1 -(2-fluorophenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
Following the protocol outlined in Procedure AA, 1-(2-fluorophenyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -(2- fluorophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford 0.104 g (73%) of the title compound as an off-white solid. 1H NMR
(DMSO-de, 400MHz) δ 8.02 (dd, J = 7.7 Hz, J = 1 .4 Hz, 1 H), 7.82-7.70 (m, 2H), 7.67-7.49 (m, 4H), 6.84 (d, J = 7.5 Hz, J = 1 .4 Hz, 1 H), 4.94-4.89 (m, 2H), 3.90 (brs, 2H), 3.66-3.60 (m, 6H). MS (ESI+): 428.0. HPLC (max plot) 99.0%; Rt 3.75 min. Example 22: 1 -(2-chlorophenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazo -dioxide
Following the protocol outlined in Procedure AA, 1-(2-chlorophenyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -(2- chlorophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.01 (d, J = 7.4 Hz, 1 H), 7.83-7.78 (m, 2H), 7.74-7.55 (m, 4H), 6.68 (d, J = 7.7 Hz, 1 H), 4.98-4.86 (m, 2H), 3.93-3.84 (m, 2H), 3.70-3.61 (m, 6H). MS (ESI+): 444.0. HPLC (max plot) 99.3%; Rt 3.89 min.
Example 23: 1 -(2,3-dihydro-1 ,4-benzodioxin-6-yl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyraz -dioxide
Following the protocol outlined in Procedure AA, 1-(2,3-dihydro-1 ,4-benzodioxin-6-yl)-3- (morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -(2,3-dihydro-1 ,4-benzodioxin-6-yl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3- carboxylic acid 5,5-dioxide and morpholine to afford 0.103 g (77%) of the title compound as a yellow solid. 1H NMR (DMSO-d6, 400MHz) δ 8.05-8.02 (m, 1 H), 7.63-7.61 (m, 2H), 7.10 (d, J = 2.4 Hz, 1 H), 7.04 (d, J = 8.5 Hz, 1 H), 6.91 -6.90 (m, 2H), 4.87 (s, 2H), 4.34-4.33 (m, 4H), 3.95 (brs, 2H), 3.65-3.59 (m, 6H). MS (ESI+): 468.0. HPLC (max plot) 98.3%; Rt 3.85 min. Example 24: 1 -(2-methyH ,3-benzothiazol-6-yl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyra -dioxide
Following the protocol outlined in Procedure AA, 1-(2-methyl-1 ,3-benzothiazol-6-yl)-3- (morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -(2-methyl-1 ,3-benzothiazol-6-yl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford 0.03 g (76%) of the title compound as an off-white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.36 (d, J = 2.0 Hz, 1 H), 8.09 (d, J = 8.6 Hz, 1 H), 8.01 (dd, J = 7.8 Hz, J = 1 .0 Hz, 1 H), 7.63-7.51 (m, 3H), 6.79 (d, J = 7.8 Hz, 1 H), 4.91 (s, 2H), 3.96 -3.94 (m, 2H), 3.67-3.60 (m, 6H), 2.86 (s, 3H). MS (ESI+): 481 .0. HPLC (max plot) 97.2%; Rt 3.70 min. Example 25: 1 -(3-bromophenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
Following the protocol outlined in Procedure AA, 1-(3-bromophenyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -(3- bromophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford the title compound as a pale brown solid. 1H NMR (DMSO-d6, 400MHz) δ 8.03-8.01 (m, 1 H), 7.88-7.83 (m, 1 H), 7.67-7.60 (m, 2H), 7.57-7.50 (m, 2H), 6.91 -6.89 (m, 1 H), 4.89 (s, 2H), 3.93-3.91 (m, 2H), 3.66-3.59 (m, 6H). MS (ESI+): 488.0. HPLC (max plot) 96.7%; Rt 4.29 min.
Example 26: 1 -(3-chlorophenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
Following the protocol outlined in Procedure AA, 1-(3-chlorophenyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -(3- chlorophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford 0.12 g (78%) of the title compound as an off-white solid. 1H NMR (DMSO-de, 400MHz) δ 8.02 (dd, J = 7.7 Hz, J = 1 .9 Hz, 1 H), 7.77-7.60 (m, 4H), 7.48-7.46 (m, 1 H), 6.91 -6.89 (m, 1 H), 4.89 (s, 2H), 3.93-3.91 (m, 2H), 3.66-3.59 (m, 6H). MS (ESI+): 444.0. HPLC (max plot) 97.8%; Rt 4.22min.
Example 27: 1 -(4-bromophenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihvdrothiochromenor4,3-clpyrazole 5,5-dioxide
Following the protocol outlined in Procedure AA, 1-(4-bromophenyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -(4- bromophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford the title compound as an off-white solid.
1H NMR (DMSO-de, 400MHz) δ 7.78-7.76 (m, 1 H), 7.81 (dd, J = 6.7 Hz, J = 1 .7 Hz, 2H), 7.67- 7.63 (m, 2H), 7.51 (dd, J = 8.6 Hz, J = 1 .8 Hz, 1 H), 6.94-6.92 (m, 2H), 4.89 (s, 2H), 3.93-3.90 (m, 2H), 3.66-3.58 (m, 6H). MS (ESI+): 488.0. HPLC (max plot) 98.3%; Rt 3.85 min. Example 28: 1 -(4-fluorophenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazo -dioxide
Following the protocol outlined in Procedure AA, 1-(4-fluorophenyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -(4- fluorophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford 0.1 g (70%) of the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.01 (d, J = 7.7 Hz, 2H), 7.63-7.60 (m, 3H), 7.48-7.44 (m, 2H), 6.85 (d, J = 7.4 Hz, 1 H), 4.89 (s, 2H), 3.94-3.92 (m, 2H), 3.66-3.60 (m, 6H). MS (ESI+): 428.0. HPLC (max plot) 99.0%; Rt 3.89 min.
Example 29: 1 -(4-chlorophenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
I Following the protocol outlined in Procedure AA, 1-(4-chlorophenyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -(4- chlorophenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.03-8.01 (m, 1 H), 7.69-7.67 (m, 2H), 7.65-7.63 (m, 2H), 7.58 (d, J = 8.2 Hz, 1 H), 6.95-6.93 (m, 2H), 4.89 (s, 2H), 3.93-3.91 (m, 2H), 3.66-3.60 (m, 6H). MS (ESI+): 444.0. HPLC (max plot) 98.9%; Rt 4.25 min.
Example 30: 1 -(4-isopropylphenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
Following the protocol outlined in Procedure AA, 1-(4-isopropylphenyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -(4- isopropylphenyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.00 (dd, J = 7.6 Hz, J = 1 .7 Hz, 1 H), 7.64-7.55 (m, 2H), 7.49-7.42 (m, 4H), 6.84 (dd, J = 7.6 Hz, J = 1 .2 Hz, 1 H), 4.89 (s, 2H), 3.95-3.94 (m, 2H), 3.66-3.60 (m, 6H), 3.06-2.99 (m, 1 H). 1 .26 (d, J = 6.9 Hz, 6H). MS (ESI+): 452.0. HPLC (max plot) 96.0%; Rt 4.91 min. Example 31 : 1 -(4-methylpyridin-3-yl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
Following the protocol outlined in Procedure AA, 1-(4-methylpyridin-3-yl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -(4- methylpyridin-3-yl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide and morpholine to afford the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.36 (s, 1 H), 8.01 -7.98 (m, 2H), 7.77 (d, J = 8.1 Hz, 1 H), 7.65-7.58 (m, 2H), 6.91 (d, J = 7.2 Hz, 1 H), 4.88 (s, 2H), 3.92-3.91 (m, 2H), 3.67-3.61 (m, 6H), 2.49 (s, 3H). MS (ESI+): 425.0. HPLC (max plot) 98.4%; Rt 3.50 min.
Example 32: 3-(morpholin-4-ylcarbonyl)-1 -(tetrahydro-2H-pyran-4-yl)-1 ,4- dihydrothiochromenor4,3-c1pyrazo -dioxide
Following the protocol outlined in Procedure AA, 3-(morpholin-4-ylcarbonyl)-1 -(tetrahydro- 2H-pyran-4-yl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 - (tetrahydro-2H-pyran-4-yl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5- dioxide and morpholine to afford 0.05 g (86%) of the title compound as a white solid. 1H NMR (DMSO-de, 400MHz) δ 8.03 (d, J = 7.5 Hz, 1 H), 7.94-7.88 (m, 2H), 7.75-7.71 (m, 1 H), 5.05- 5.00 (m, 1 H), 4.78 (s, 2H), 3.98-3.95 (m, 4H), 3.66-3.65 (m, 6H), 3.60-3.55 (m, 2H), 2.18- 2.1 1 (m 2H), 2.09-1 .99 (m, 2H). MS (ESI+): 418.0. HPLC (max plot) 97.7%; Rt 3.03 min. Compounds described below are obtained following procedure AA
Example 182: 1 -r3-(5-Methvl-1 ,3,4-oxadiazol-2-vl)phenvll-3-(morpholin-4-vlcarbonvD-
1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
16 mg of the title compound as a white solid . 1H NMR (DMSO-c/6,
°¾"° 400 MHz): δ 8.21 -8.19 (d, J = 7.6 Hz,1 H), 8.06 (s, 1 H), 8.06-8.04
(d, J = 9.5 Hz, 1 H), 7.85-7.81 (t, J = 8.0 Hz, 1 H), 7.78-7.76 (d, J = 8.8 Hz, 1 H), 7.66-7.62 (t, J = 7.5 Hz, 1 H), 7.59-7.55 (t, J = 7.8 Hz, 1 H), 6.94-6.92 (d, J = 7.9 Hz, 1 H), 4.91 (s, 2H), 3.92 (m, 2H), 3.67 (m, 4H), 3.60 (m, 2H), 2.57 (s, 3H). MS (ESI+): 492.0. HPLC (max plot) 89.44%; Rt 3.33 min.
Example 183: H3-(5-Me :hvl-1 ,3,4-thiadiazol-2-vl)phenvll-3-(morpholin-4-vlcarbonvD-
1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
60 mg of the title compound as a white solid . 1H NMR (DMSO-c/6, 400 MHz): δ 8.16-8.14 (d , J = 8.0 Hz, 1 H ), 8.10 (s,1 H), 8.09-8.02 (m, 1 H), 7.79-7.76 (t , J = 7.9 Hz, 1 H), 7.71 -7.68 (m, 1 H), 7.66- 7.60 (m, 1 H), 7.60-7.56 (m, 1 H), 6.98-6.96 (d, J = 7.8 Hz, 1 H), 4.91 (s, 2H), 3.93 (m, 2H), 3.67 (m, 4H), 3.62-3.61 (m, 2H), 2.77 (s, 3H). MS (ESI+): 508.0. HPLC (max plot) 93.88%; Rt 3.54 min.
Example 196: H3-(3-Me :hvl-1 ,2,4-oxadiazol-5-vl)phenvll-3-(morpholin-4-vlcarbonvD-
1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
4 mg of the title compound as an off white solid. 1H NMR (DMSO- d6, 400 MHz): δ 8.32-8.30 (m, 1 H), 8.18 (s, 1 H), 8.04-8.02 (d, J = 8.0 Hz,1 H), 7.86-7.85 (m, 2H), 7.66-7.62 (m, 1 H), 7.59-7.55 (m, 1 H), 6.95-6.94 (d, J = 7.6 Hz, 1 H), 4.91 (s, 2H), 3.92-3.91 (m, 2H), 367 (m, 4H), 3.61 -3.60 (m, 2H), 2.41 (s, 3H). MS (ESI+): 492.0. HPLC (max plot) 95.31 %; Rt 3.87 min.
Example 213: A/,A/-Dimet hvl-1 -(5-{3-r3-(morpholin-4-vlcarbonvl)-5,5- dioxidothiochromenor4,3-clpvrazol-1 (4H)-vHphenvl}-1 ,2,4-oxadiazol-3-vl)methanamine
4.5 mg of the title compound as an off white solid. 1H NMR o o (DMSO-d6, 400 MHz): δ 8.40-8.35 (m, 2H), 8.15-8.13 (dd, J = 1 .4,
7.8 Hz, 1 H), 7.73-7.66 (m, 2H), 7.68-7.56 (m, 1 H),7.60-7.55 (m, 1 H), 7.50-7.45 (m, 1 H), 6.91 -6.89 (d, J = 7.5 Hz, 1 H), 4.77 (s, 2H), 4.19-4.21 (m, 2H), 3.90-3.85 ( m, 4H), 3.80-3.75 (m, 2H), 3.70 (m, 2H), 2.39 (s, 6H). MS (ESI+): 535.0. HPLC (max plot) 97.78%; Rt 2.80 min.
Example 312: 1-(2-lsopropylphenyl)-3-(morpholin-4-ylcarbonyl)-1,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
o o 69 mg of the title compound as a white solid. 1H NMR (400 MHz,
DMSO-d6) δ: 7.98 (d, J = 1 .2 Hz, 1 H), 7.65-7.60 (m, 4H), 7.44-7.43 (m, 2H), 6.63 (d, J = 7.2 Hz, 1 H), 4.92 (m, 2H), 3.68-3.60 (m, 8H),
<oJ 2.32-2.29 (m, 1 H), 1 .06 (t, J = 6.8 Hz, 3H), 0.87 (t, J = 6.8 Hz, 3H).
MS (ESI+): 452.0. HPLC (max plot): 99.3%; Rt 4.63 min.
Example 313: 1 -(2-Methoxvphenvl)-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
o o 90 mg (76%) of the title compound as a white solid. 1H NMR (400
MHz, DMSO-d6) δ: 7.98 (dd, J = 1 .3, 7.6 Hz, 1 H), 7.65-7.52 (m, 4H), 7.30 (d, J = 8.4 Hz, 1 H), 7.21 -7.17 (m, 1 H), 6.80 (d, J = 7.8 Hz, 1 H), 4.96-4.81 (m, 2H), 3.94 (m, 2H) 3.66-3.60 (m, 6H), 3.57 (s, 3H). MS (ESI+): 440.0. HPLC (max plot): 99.5%; Rt 3.80 min.
Example 176: 1 -(3-Fluorophenvl)-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
42 mg of the title compound as a white solid. 1H NMR (DMSO-c/6, 400 MHz): δ 8.03-8.02 (m, 1 H), 7.66-7.58 (m, 4H), 7.50 (m, 1 H), 7.35-7.33 (d, J = 7.7 Hz, 1 H), 6.91 -6.89 (d, J = 7.3 Hz, 1 H), 4.89 (s, 2H), 3.93 (m, 2H), 3.66 (m, 4H), 3.60 (m, 2H). MS (ESI+): 428.0. HPLC (max plot) 96.79%; Rt 3.97 min.
Example 176: 1 -(3-Cvanophenvl)-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
23 mg of the title compound. 1 H NMR (400 MHz, DMSO-d6) δ = o o
8.25 (s, 1 H), 8.10 (d, J = 7.7 Hz, 1 H), 8.03 (d, J = 7.5 Hz, 1 H), 7.86-7.77 (m, 2H), 7.68-7.58 (m, 2H), 6.89 (d, J = 7.7 Hz, 1 H), 4.90 (s, 1 H), 3.92 (bs, 2H), 3.67-3.61 (m, 6H). MS (ESI+): 435.0. HPLC: HPLC (max plot) 99.22%; Rt 3.66 min.
Example 130: 1 -r4-(Methvlsulfonvl)phenvll-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
°¾-° 36 mg of the title compound as a pale brown solid. 1H NMR
(DMSO-d6, 400 MHz): δ 8.15-8.13 (d, J = 8.6 Hz, 2H), 8.05-8.02 (dd, J = 1 .6, 7.7 Hz ,1 H), 7.84-7.82 (d, J = 8.6 Hz ,2H), 7.65-7.61 (m, 2H), 6.96-6.95 (d, J = 7.4 Hz, 1 H), 4.90 (s, 2H), 3.92 (m, 2H), 3.67 (m,4H), 3.61 -3.60 (m, 2H), 3.33 (s, 3H). MS (ESI+): 487.8. HPLC (max plot) 98.79%; Rt 3.21 min.
Example 66: A/-f4-r3-(Morpholin-4-vlcarbonvl)-5,5-dioxidothiochromenor4,3- clpvrazol-1 (4H)-vHbenzvl)methanesulfonamide
°¾"° 26 mg of the title compound. 1 H NMR (400 MHz, DMSO-d6) δ =
8.02 (d, J = 7.3 Hz, 1 H), 7.65-7.53 (m, 6H), 7.09 (d, J = 3.5 Hz, 1 H), 6.86 (d, J = 8.0 Hz, 1 H), 4.90 (s, 1 H), 5.00 (s, 1 H), 3.95 (brs, 2H), 3.66-3.61 (m, 6H), 2.61 (s, 3H). MS (ESI+): 517. HPLC (max plot) 96.19%; Rt 3.19 min.
Example 88: 3-(Morpholin-4-vlcarbonvl)-1 -pvridin-3-vl-1 ,4-dihvdrothiochromenor4,3- clpvrazole 5,5-dioxide
50 mg of the title compound as a pale brown solid. 1 H NMR (400 MHz, DMSO-d6): δ 8.82-8.80 (m, 2H), 8.06-8.02 (m, 2H), 7.68- 7.59 (m, 3H), 6.90-6.88 (m, 1 H), 4.91 (s, 2H), 3.93-3.91 (m, 2H), 3.67 (m, 4H), 3.61 -3.60 (m, 2H). MS (ESI+): 41 1 .0. HPLC (max plot) 96.65%; Rt 2.60 min.
Example 131 : 1 -(6-Me1 :hoxvPVridin-3-vD-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
26 mg of the title compound as an off white solid. 1H NMR
°¾''° (DMSO-de, 400 ΜΗζ):δ 8.42-8.41 (m, 1 H), 8.03-8.00 (m, 1 H),
7.92-7.89 (dd, J= 2.9, 8.8 Hz ,1 H), 7.65-7.62 (m, 2H), 7.05-7.03
<oJ (d, J = 8.8 Hz, 1 H), 6.98-6.96 (m, 1 H), 4.89 (s, 2H), 3.95-3.92 (m,
5H), 3.66 (m,4H), 3.61 -3.60 (m, 2H). MS (ESI+): 441 . HPLC (max
plot) 98.38%; Rt 3.52 min
Example 138: 1 -r3-(Methvlsulfonvl)phenvll-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
26 mg of the title compound as an off white solid. 1H NMR o .p (DMSO-de, 400 MHz): δ 8.16-8.14 (d, J = 7.5 Hz, 1 H), 8.06-8.02
(m, 2H), 7.95-7.87 (m, 2H), 7.68-7.58 (m, 2H), 6.92-6.90 (d, J = 7.8 Hz, 1 H), 4.91 (s, 2H), 3.89-3.88 (m, 2H), 3.67 (s,4H), 3.61 - 3.60 (m, 2H, 3.32 (s, 3H). MS (ESI+): 488.0. HPLC (max plot) 99.47%; Rt 3.22 min.
Example 73: 1 -Cvclopentvl-3-(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3- clpvrazole 5,5-dioxide 65 mg of the title compound as a white solid.1 H NMR (400 MHz,
DMSO-d6) δ = 8.02 (d, J = 6.9 Hz, 1H), 7.97 (d, J = 7.7 Hz, 1H), 7.89 (t, J = 7.6 Hz, 1H), 7.72 (t, J = 7.7 Hz, 1H), 5.30 (t, J = 5.5 Hz, 1H), 4.77 (s, 2H), 4.65 (t, J = 5.8 Hz, 1H), 3.94 (brs, 2H), 3.65-3.63 (m, 6H), 2.25-2.19 (m, 2H), 2.06-2.03 (m, 2H), 1.87-
1.86 (m, 2H), 1.71-1.70 (m, 2H).
MS (ESI+): 402.0. HPLC (max plot) 98.51%; Rt 3.65 min.
Example 194: 3-(Morpholin-4-vlcarbonvl)-1-r3-(morpholin-4-vlcarbonvl)cvclohexvll-1,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
6.9 mg of the title compound as an off white solid.1H NMR (DMSO-d6 ,400 MHz): δ 8.19-8.17 (d, J= 7.8 Hz, 1H), 7.75-7.73
Q p (d, J = 7.8 Hz, 1 H),7.65-7.61 (t, J = 7.6 Hz, 1 H), 7.51-7.49 (d, J =
7.9 Hz, 1H), 4.81-4.77 (m, 2H), 4.65-4.61 (m, 1H), 4.59 (m, 1H), 4.22-4.20 (m, 2H), 3.80 (m, 6H), 3.68-3.62 (m, 4H), 3.52 (m, 2H), 2.7 (m, 1H), 2.49-2.46 (m, 1H), 2.17-2.10 (m, 4H), 1.9 (m, 1H), 1.8-1.6 (m, 3H). MS (ESI+): 529.0. HPLC (max plot) 96.46%; Rt 3.24 min.
Example 193: 3-(Morpholin-4-vlcarbonvl)-1 -r3-(piperidin-1 -vlcarbonvl)cvclohexvll-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
12 mg of the title compound as an off white semi solid.1H NMR (DMSO-d6, 400 MHz): δ 8.18-8.17 (d, J= 6.8 Hz, 1H), 7.77-7.73
Q p (m, 1 H), 7.64-7.61 (t, J = 7.7 Hz, 1 H), 7.53-7.51 (d, J = 7.8 Hz,
1H), 4.79-4.75 (d , J= 16.5 Hz, 1 H), 4.69-4.65 (d, J= 16.5 Hz, 1H), 4.59-4.57 (m, 1H), 3.59-3.43 (m, 4H), 2.77-2.71 (m, 1H), 2.49-2.40 (m, 1H), 2.18-2.07 (m, 4H), 1.88-1.85 (m, 1H), 1.70- 1.64 (m, 3H). MS (ESI+): 527.0. HPLC (max plot) 97.6%; Rt 3.96 min
Example 170: 1-(4,4-DifluorocvclohexvD-3-(morpholin-4-vlcarbonvl)-1,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
°¾''° 61 mg of the title compound as a white solid.1H NMR (DMSO-d6,
400 MHz): δ 8.04-8.03 (d, J= 7.4 Hz, 1H), 7.94-7.88 (m, 2H), 7.76-7.72 (m, 1H), 5.03 (m, 1H), 4.77 (s, 2H), 3.89-3.88 (m, 2H), 3.65-3.63 (m, 6H), 2.16-2.14 (m, 8H). MS (ESI+): 452.0. HPLC
F (max plot) 98.29%; Rt4.15 min. Example 171 : 1 -(3,3-DimethvlcvclohexvD-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
61 mg of the title compound as a pale pink solid. NMR (DMSO-d6, 400 MHz): δ 8.04-8.02 (d, J = 7.8 Hz, 1 H), 7.93-7.90 (m, 1 H), 7.85-7.83 (d, J = 7.8 Hz, 1 H), 7.72-7.70 (m, 1 H), 4.92-4.85 (m, 1 H),4.76 (s, 2H),3.90 (m, 2H), 3.64 (m, 6H), 2.05-2.02 (m, 1 H), 1 .88-1 .86 (m,1 H), 1 .71 -1 .65 (m, 4H), 1 .41 -1 .37 (m, 1 H), 1 .34-1.30
(m, 1 H), 1 .26 (s, 3H), 1 .22 (s, 3H). MS (ESI+): 444.0. HPLC (max plot) 92.55%; Rt 4.99 min.
Example 127: 1 -(4-MethvlcvclohexvD-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
17 mg of the title compound as a white solid. 1H NMR (DMSO-c/6, o o 400 MHz): δ 8.03-8.01 (d, J = 7.5 Hz, 1 H), 7.93-7.88 (m, 1 H),
7.85-7.83 (d, J = 7.7 Hz ,1 H), 7.74-7.70 (t, J = 7.8 Hz ,1 H), 4.77 (s, 2H), 4.68 (m, 1 H), 3.96-3.92 (m, 2H), 3.65-3.64 (m, 6H), 2.04- 2.01 (m, 2H), 1.95 (m, 1 H), 1.90-1 .89 (m, 2H), 1 .70-1 .57 (m, 2H), 1 .48 (m, 2H), 1.28-1 .25 (m, 3H). MS (ESI+): 430.3. HPLC (max plot) 97.73%; Rt 5.99 min.
Example 94: 1 -(4-ieri-ButvlcvclohexvD-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
54 mg of the title compound as a white solid. 1H NMR (400 MHz,
°'s'° DMSO-de) δ = 8.03-8.01 (d, J = 7.8 Hz, 1 H), 7.94-7.90 (m, 1 H),
7.86-7.84 (d, J = 7.8 Hz ,1 H), 7.74-7.70 (t, J = 7.5 Hz ,1 H), 4.77 (s, 2H),4.68 (m, 1 H), 3.95 (m, 2H), 3.64 (m, 6H), 2.12-2.09 (d, J = 1 1 .2 Hz, 2H), 1 .95-1.85 (m, 4H), 1.32-1 .26 (m, 2H), 1 .16-1.13 (m, 1 H), 0.88 (s, 9H). MS (ESI+): 472.3. HPLC (max plot) 97.00%; Rt 5.63 min.
Example 98: 4-r3-(Morpholin-4-vlcarbonvl)-5,5-dioxidothiochromenor4,3-clpvrazol-1
(4H)-vllcvclohexanol
0.009 g of the title compound as a pale brown solid. 1H NMR (DMSO-de, 400 MHz) δ 8.03-8.001 (d, J = 7.8 Hz, 1 H), 7.93-7.74 (m, 2H), 7.74-7.70 (m, 1 H), 4.75 (s, 2H), 4.71 -4.70 (d, J = 4.2 Hz, 1 H), 3.90 (m, 2H), 3.65-3.63 (m, 6H), 3.55 (m, 2H), 2.00-1 .91 (m, 6H), 1 .51 -1 .42 (m, 2H). MS (ESI+): 432.0. HPLC (max plot): 92.66%; Rt 2.67 min
Example 99: 3-(Morpholin-4-vlcarbonvl)-1 -(tetrahvdro-2H-pvran-3-vl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
MSC2324368A, MC006_300
176 mg (74%) of the title compound as a white solid.
1 H NMR (DMSO-d6, 400 MHz) δ 8.04-8.02 (d, J = 7.4 Hz, 1 H),
7.92 (m, 2H), 7.75-7.71 (m, 1 H), 4.88 (m, 1 H), 4.78 (s, 2H), 4.03-
4.02 (m, 1 H), 3.90 (m, 3H), 3.75-3.60 (m, 7H), 3.40 (m, 1 H), 2.21 -
2.15 (m, 2H), 1 .84-1 .79 (m, 2H). MS (ESI+): 418.0: HPLC (max plot): 98.53%; Rt 3.27 min
Example 78: 1 -Cvcloheptvl-3-(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3- clpvrazole 5,5-dioxide
38 mg of the title compound as a white solid. 1H NMR (400 MHz,
°¾"° DMSO-de): δ 8.03-8.01 (dd, J = 1 .1 , 7.8 Hz, 1 H), 7.93-7.89 (m,
1 H), 7.85-7.83 (d, J = 7.5 Hz ,1 H), 7.73-7.70 (m, 1 H), 4.96-4.92 (m, 1 H), 4.76 (s, 2H), 3.93 (m, 2H), 3.64 (bs, 6H), 2.08-2.04 (m, 4H), 1 .81 -1 .77 (m, 2H), 1 .60-1 .57 (m, 6H). MS (ESI+): 430.3. HPLC (max plot) 95.39%; Rt 4.69 min.
Example 128: 7-Bromo-1 -cvclohexvl-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
27 mg of the title compound as an off white solid. 1H NMR o. .o (DMSO-de, 400 MHz): δ 8.1 1 -8.09 (m, 2H), 7.80-7.78 (d, J = 9.0
Hz, 1 H), 4.82 (s, 2H), 4.70-4.64 (m, 1 H), 3.92 (s, 2H), 3.65-3.64 (m, 6H), 2.04-2.01 (m, 2H), 1 .90-1.81 (m, 4H), 1 .69-1 .66 (m, 1 H),
° 1 .54-1.51 (m, 2H), 1 .48 (m, 1 H). MS (ESI+): 494.0. HPLC (max plot) 97.50%; Rt 4.95 min.
Example 158: 3-(Morp iolin-4-vlcarbonvl)-1 -phenvl-7-(trifluoromethvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
82 mg of the title compound as a white solid. 1H NMR (DMSO- d6,400 MHz): δ 8.20 (s, 1 H), 8.04-8.02 (d , J = 8.3 Hz, 1 H), 7.64- 7.63 (m, 3H), 7.58-7.56 (m, 2H), 7.04-7.02 (d, J = 8.5 Hz, 1 H), 5.03 (s, 2H), 3.93 (m, 2H), 3.67 (m, 4H), 3.61 (m, 2H). MS
(ESI+): 477.8. HPLC (max plot) 99.17%; Rt 4.77 min.
Example 113: 8-Methoxv-3-(morpholin-4-vlcarbonvl)-1 -phenvl-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
23 mg of the title compound as a pale yellow solid. 1H NMR (DMSO-de, 400 MHz): δ 7.94-7.92 (d, J = 8.8 Hz, 1 H), 7.65-7.64 (m, 3H), 7.57-7.54 (m, 2H), 7.16-7.14 (m, 1 H), 6.23-6.22 (d, J = 2.4 Hz, 1 H), 4.83 (s, 2H), 3.94 (s, 2H), 3.66 (m, 4H), 3.53 (m, 2H), 3.32 (s, 3H). MS (ESI+): 440. HPLC (max plot) 94.21 %; Rt 4.02 min.
Example 132 : 3-(Morpholin-4-vlcarbonvl)-1 -phenvl-1 ,4-dihvdropvrazolor3',4':4,5lthio pvranor2,3-blpvridine 5,5-dioxide
130 mg of the title compound as an off white solid. 1H NMR (DMSO-d6, 400 MHz): δ 8.71 -8.69 (dd, J = 1 .4, 4.7 Hz ,1 H), 7.64- 7.59 (m, 4H), 7.56-7.53 (m, 2H), 7.19-7.16 (dd, J= 1 .4, 6.8 Hz ,1 H), 5.00 (s, 2H), 3.93-3.92 (m, 2H), 3.66 (m, 4H), 3.60 (m, 2H). MS (ESI+): 41 1 .0. HPLC (max plot) 99.52%; Rt 3.13 min.
Example 211 : 3-(Morpholin-4-vlcarbonvl)-1 -r4-(morpholin-4-vlmethvl)phenvll-1 ,4- dihvdropvrazolor3',4':4,51thiopvranor2,3-blpvridine 5,5-dioxide
45 mg of the title compound as a pale brown solid. 1H NMR (DMSO-d6, 400 MHz): δ 8.70-8.69 (dd, J = 1 .4, 4.7 Hz, 1 H), 7.62- 7.58 (dd, J = 1 .4, 4.7 Hz, 1 H), 7.55-7.53 (d, J = 8.4 Hz, 2H), 7.50- 7.48 (d, J = 8.4 Hz, 2H), 7.20-7.17 (dd, J = 1 .3, 8.2 Hz, 1 H), 5.00 (s, 2H), 3.93 (m, 2H), 3.66-3.61 (m, 4H), 3.61 -3.42 (m, 8H), 2.40
(m, 4H). MS (ESI+): 510.3. HPLC (max plot) 95.80%; Rt 4.19 min.
Example 79 : 3-(Morpholin-4-vlcarbonvl)-1 -cvclohexvl-1 ,4- dihvdropvrazolor3',4':4,51thio pvranor2,3-blpvridine 5,5-dioxide
17 mg (75%) of the title compound as an off white solid. 1 H NMR (400 MHz, DMSO-d6): δ 8.78-8.77 (d, J = 4.6 Hz, 1 H), 8.31 -8.29 (d, J = 8.1 Hz, 1 H), 7.92-7.89 (dd, J = 4.7, 8.1 Hz, 1 H), 4.88 (s, 2H), 4.69-4.63 (m, 1 H), 3.92 (s, 2H), 3.65 (s, 6H), 2.06-2.02 (m, 2H), 1 .90-1 .81 (m, 4H), 1 .70-1 .66 (m, 1 H), 1 .56-1 .46 (m, 2H),
1 .25-1 .22 (m, 1 H). MS (ESI+): 417.0. HPLC (max plot) 98.54%; Rt 3.65 min.
Example 150: 3-(Morpholin-4-vlcarbonvl)-1 -phenvl-1 ,4- dihvdropvrazolor3',4':4,51thiopvranor3,2-clpvridine 5,5-dioxide 16 mg of the title compound as a pale brown solid. 1H NMR
(DMSO-de, 400 MHz): δ 8.83-8.82 (d, J = 5.0 Hz, 1 H), 8.0-7.97 (m, 2H), 7.66-7.62 (m, 3H), 7.61 -7.60 (m, 2H), 5.03 (s, 2H), 3.93 (m, 2H), 3.67 (m, 4H), 3.62-3.61 (m, 2H). MS (ESI+): 41 1 .0. HPLC (max plot) 96.9%; Rt 3.28 min.
Example 192: 3-(Morpholin-4-vlcarbonvl)-1 -phenvl-1 ,4- dihvdrothienor3',2':5,61thiopvranor4,3-clpvrazole 5,5-dioxide
101 mg (83%) of the title compound as a brown solid. 1H NMR o. .o
(DMSO-d6, 400 MHz): δ 8.01 -8 (d, J = 5.0 Hz, 1 H), 7.64-7.60 (m, 5H), 6.36-6.35 (d, J = 5.0 Hz, 1 H), 4.98 (s, 2H), 3.95 (m, 2H), 3.66-3.60 (m, 4H), 3.32 (m, 2H). MS (ESI+): 416.0. HPLC (max plot) 97.91 %; Rt 3.82 min.
Example 195: 1 -Methvl-5-r3-(morpholin-4-vlcarbonvl)-5,5- dioxidothienor3',2':5,6lthiopvranor4,3-clpvrazol-1 (4H)-vllpvridin-2 (1 H)-one
2 mg of the title compound as an off white solid. 1H NMR (DMSO- d6, 400 MHz): δ 8.35-8.34 (d, J = 2.6 Hz, 1 H), 8.09-8.07 (d, J = 5.1 Hz, 1 H), 7.65-7.62 (dd, J = 2.8, 9.6 Hz, 1 H), 6.92-6.91 (d, J = 5.1 Hz,1 H), 6.55-6.52 (d, J = 9.4 Hz, 1 H), 4.96 (s, 2H), 3.93 (m, 2H), 3.65 (m, 4H), 3.6 (m, 2H), 3.47 (s, 3H). MS (ESI+): 447.0. HPLC
(max plot) 93.44%; Rt 2.49 min.
Example 201 : 1 -Cvclohexvl-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothienor3',2':5,61thiopvranor4,3-clpvrazole 5,5-dioxide
74 mg of the title compound as an off white solid. 1H NMR o. .o (DMSO-d6, 400 MHz): δ 8.26-8.25 (d, J = 5.0 Hz, 1 H), 7.68-7.66
(d, J = 5.0 Hz, 1 H), 4.86 (m, 2H), 4.68-4.63 (m, 1 H), 3.94 (m, 2H), 3.63 (m, 6H), 2.01 -1 .99 (m, 2H), 1 .83-1.8 (m, 4H), 1 .69-1.66 (m, 1 H), 1.58-1 .48 (m, 2H), 1 .24-1.21 (m, 2H), 1 .07 (m, 1 H). MS (ESI+): 422.0. HPLC (max plot) 98.29%; Rt 4.29 min.
Example 205: 3-(Morpholin-4-vlcarbonvl)-1 -phenvl-1 ,4- dihvdrothienor2',3':5,61thiopvranor4,3-clpvrazole 5,5-dioxide
o o 62 mg of the title compound as a pale yellow solid. 1H NMR
(DMSO-d6, 400 MHz): δ 7.75-7.74 (d, J = 5.3 Hz, 1 H), 7.69-7.66
° (m, 5H), 7.53-7.52 (d, J = 5.3 Hz, 1 H), 4.90 (s, 2H), 3.95 (m, 2H),
3.66 (m, 4H), 3.61 -3.60 (m, 2H). MS (ESI+): 416.0. HPLC (max
0 (ESI+): 400.0. HPLC (max plot) 96.59%; Rt 3.14 min.
Examples described below are obtained following procedure T, described above:
chromenor4,3-c1pyrazole 5,5-dioxide o o 49 mg of the title compound as a white solid. 1 H NMR (DMSO-d6) δ 8.04-8.01 (m, 1 H), 7.67-7.53 (m, 7H), 6.85-6.82 (m, 1 H), 4.91 (s, 2H), 4.57-4.31 (m, 2H), 3.93-3.81 (m, 1 H), 3.57-3.44 (m, 2H),
° 3.31 -3.26 (m, 0.5H), 3.04-2.91 (m, 1 H), 2.66-2.58 (m, 0.5H), 1 .1 1
(dd, J = 6.3, 28.8 Hz, 3H). HPLC (max plot) 99.6%; Rt 3.50 min.
Example 338: 3-r(3-Methvlmorpholin-4-vl)carbonvll-1 -phenvl-1 ,4-dihvdrothio
chromenor4,3-clpvrazole 5,5-dioxide
o o 36 mg of the title compound as a white solid. 1 H NMR (DMSO-d6) δ 8.04-8.01 (m, 1 H), 7.67-7.53 (m, 7H), 6.84 (d, J = 7.5 Hz, 1 H), 4.90 (s, 2H), 4.71 -4.20 (m, 2H), 3.96-3.38 (m, 4.5H), 3.24-3.10 (m, 0.5H), 1 .32-1 .30 (m, 3H). HPLC (max plot) 99.5%; Rt 3.48 min. MS (ESI+): 424.1.
Example 333: {4-r(5,5-Dioxido-1 -phenvl-1 ,4-dihvdrothiochromenor4,3-clpvrazol-3- vDcarbonvllmorpholin-2-vl}methanol
73 mg of the title compound as a off-white powder. 1H NMR (DMSO-de) δ 8.04-8.01 (m, 1 H), 7.66-7.54 (m, 7H), 6.85-6.82 (m, 1 H), 4.92-4.91 (m, 2H), 4.91 -4.74 (m, 1 H), 4.64-4.32 (m, 2H), 3.96-3.83 (m, 1 H), 3.56-3.27 (m, 4.5H), 3.13-2.92 (m, 1 H), 2.78- 2.67 (m, 0.5H). HPLC (max plot) 91.9%; Rt 2.98 min. MS (ESI+):
440.1.
Example 334: 3-(1 ,4-Oxazepan-4-vlcarbonvD-1 -phenvl-1 ,4-dihvdrothiochromenor4,3- clpvrazole 5,5-dioxide
o p 58 mg of the title compound as a off-white powder. 1 H NMR
(DMSO-d6) δ 8.04-8.01 (m, 1 H), 7.67-7.52 (m, 7H), 6.87-6.83 (m, 1 H), 4.90 (s, 2H), 3.98-3.93 (m, 2H), 3.77-3.66 (m, 6H), 1 .93-1.85 (m, 2H). HPLC (max plot) 99.3%; Rt 3.51 min. MS (ESI+): 423.9. m.p. = 190-195°C.
Example 124: 1 -{3-r(4-Methvlpiperazin-1 -vl)carbonvHphenvl}-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
o o
85 mg of the title compound as an off white solid. 1H NMR (DMSO-d6, 400 MHz): δ 8.03 (dd, J = 1.3, 7.8 Hz, 1 H), 7.72-7.57 (m, 5H), 7.46 (s, 1 H), 6.91 -6.89 (d, J = 7.9 Hz, 1 H), 4.89 (s, 2H), 3.93-3.91 (m, 2H), 3.66 (m, 4H), 3.60-3.59 (m, 4H), 3.27 (m, 2H), 2.49-2.48 (m, 2H), 2.31 (m, 5H). MS (ESI+): 536.3.0. HPLC (max plot) 98.02%; Rt 2.42 min.
Example 125: 3-(Morpholin-4-vlcarbonvl)-1 -r3-(piperidin-1 -vlcarbonvl)phenvll-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
0.135 g of the title compound as an off white solid. 1H NMR (DMSO-d6, 400 MHz); δ 8.03-8.01 (d, J = 7.8 Hz, 1 H), 7.72-7.56 (m, 5H), 7.44 (s, 1 H), 6.90 -6.88 (d, J = 7.7 Hz, 1 H), 4.89 (s, 2H), 3.93 (m, 2H), 3.66 (m, 4H), 3.61 -3.60 (m, 2H), 3.53 (m, 2H), 3.32 (m, 2H), 1.55 (m, 4H), 1 .33 (m, 2H). MS (ESI+): 521 .3.0. HPLC
(max plot) 96.49%; Rt 3.67 min.
Example 126: A/-(2-Methoxvethvl)-3-r3-(morpholin-4-vlcarbonvl)-5,5- dioxidothiochromenor4,3-clpvrazol-1 (4H)-vHbenzamide
40 mg of the title compound as an off white solid. 1H NMR
Q. o (DMSO-d6, 400 MHz): δ 8.77-8.76 (m, 1 H), 8.1 1 -8.10 (d, J = 5.3
Hz, 1 H), 8.03-8.00 (d, J = 1 1 .2 Hz, 2H), 7.72-7.70 (d, J = 6.6 Hz, 2H), 7.65-7.61 (t, J = 7.6 Hz, 1 H), 7.58-7.55 (t, J = 7.7 Hz, 1 H), 6.83-6.81 (d, J = 7.8 Hz, 1 H), 4.91 (s, 2H), 3.92 (m, 2H), 3.67 (m, 4H), 3.60 (m, 2H), 3.43-3.40 (m, 4H), 3.23 (s, 3H). MS (ESI+): 51 1 .0. HPLC (max plot) 98.31 %; Rt 3.07 min.
Example 142: 1 -{3-r(4-Methoxvpiperidin-1 -vl)carbonvllphenvl}-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
37 mg of the title compound as a off white solid. 1H NMR (DMSO-
Qs"° d6, 400 MHz): δ 8.03-8.01 (d, J = 7.7 Hz, 1 H), 7.72-7.57 (m, 5H),
7.48 (s, 1 H), 6.90-6.88 (d, J = 7.7 Hz, 1 H), 4.89 (s, 2H), 3.93 (m, 2H), 3.86 (m, 1 H), 3.66 (m, 3H), 3.61 -3.60 (m, 2H), 3.59 (m, 2H), 3.39-3.37 (m, 2H), 3.22 (s, 3H), 3.1 1 (m, 1 H), 1 .83 (m, 1 H), 1 .67 (m, 1 H), 1 .44 (m, 1 H), 1.34 (m, 1 H). MS (ESI+): 550.8. HPLC (max plot) 90.67%; Rt 3.31 min.
Example 143: 1 -{3-r3-(Morpholin-4-vlcarbonvl)-5,5-dioxidothiochromenor4,3-clpvrazol-
1 (4H)-vHbenzovl>piperidin-4-ol
°¾"° 25 mg of the title compound as a white solid. 1H NMR (DMSO- d6,400 MHz): δ 8.03-8.01 (d, J = 7.2 Hz, 1 H), 7.70-7.58 (m, 5H), 7.46 (s, 1 H), 6.90-6.88 (d, J = 7.8 Hz, 1 H), 4.89 (s, 2H), 4.77-4.76 (d, J = 3.9 Hz, 1 H), 3.93 (m, 3H), 3.66-3.61 (m, 5H), 3.60 (m, 2H),
HO-O- 3.42 (m, 1 H), 3.21 (m, 1 H), 3.08 (m, 1 H), 1.75 (m, 1 H), 1.58 (m,
dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide o ο 56 mg of the title compound as a off white solid. 1H NMR (DMSO- d6, 400 MHz): δ 8.03-8.01 (t, J = 1 .7 Hz, 1 H), 7.66-7.59 (m, 6H), 6.94-6.91 (t, J = 7.4 Hz, 1 H), 4.90 (s, 2H), 3.93 (m, 2H), 3.66-3.60 (m, 14H). MS (ESI+): 522.8. HPLC (max plot) 91 .1 1 %; RT 3.00 o min.
Example 148: 3-r3-(Morpholin-4-vlcarbonvl)-5,5-dioxidothiochromenor4,3-clpvrazol-1
(4H)-vH-A/-(tetrahvdro-2H-pvran-4-vl)benzamide
52 mg of the title compound as a white solid. 1H NMR (DMSO- d6,400 MHz): δ 8.55-8.53 (d, J = 7.6 Hz, 1 H), 8.12-8.1 1 (d, J = 7.1 Hz, 1 H), 8.03-8.01 (m, 2H), 7.73-7.71 (m, 2H), 7.69-7.61 (m, 1 H), 7.65-7.55 (m, 1 H), 6.83-6.81 (d, J = 7.8 Hz, 1 H), 4.91 (s, 2H), 4.00 (m, 1 H), 3.99-3.84 (m, 4H), 3.67 (m, 4H), 3.61 -3.60 (m, 2H), 3.32 (m, 2H), 1 .75 (m, 2H), 1 .59-1 .52 (m, 2H). MS (ESI+):
537.0. HPLC (max plot) 96.23%; Rt 3.16 min.
Example 149: 3-r3-(Morpholin-4-vlcarbonvl)-5,5-dioxidothiochromenor4,3-clpvrazol-1
(4H)-vH-A/-pvridin-3-vlbenzamide
24.5 mg of the title compound as a white solid. 1H NMR (DMSO- d6,400 MHz): δ 10.62 (s, 1 H), 8.90 (s, 1 H), 8.32-8.31 (d, J = 4.6 Hz, 1 H), 8.25-8.23 (d, J = 6.8 Hz, 1 H), 8.17-8.15 (m, 2H), 8.04- 8.02 (d, J = 7.8 Hz, 1 H), 7.80-7.79 (m, 1 H), 7.64-7.58 (m, 2H), 7.41 -7.38 (m, 2H), 6.89-6.87 (d, J = 7.7 Hz, 1 H) ,4.92 (s, 2H), 3.93 (m, 2H), 3.67 (m, 4H), 3.61 (m, 2H). MS (ESI+): 530.0. HPLC
(max plot) 93.53%; Rt 2.73 min.
Example 151 : 3-(Morpholin-4-vlcarbonvl)-1 -r4-(piperidin-1 -vlcarbonvl)phenvll-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
77 mg of the title compound as a white solid. 1H NMR (DMSO- d6,400 MHz): δ 8.02-8.0 (d, J = 7.7 Hz, 1 H), 7.66-7.58 (m, 6H), 6.91 -6.89 (d, J = 7.6 Hz, 1 H), 4.87 (s, 2H), 3.92 (m, 2H), 3.65 (m, 4H), 3.60 (m, 4H), 3.31 (m, 2H), 1 .61 -1 .48 (m, 6H). MS (ESI+): o 520.8. HPLC (max plot) 95.89%; Rt 3.72 min.
Example 159: 1 -{3-r(3-Methoxvpiperidin-1 -vl)carbonvllphenvl}-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Procedure AC
Example 141 : {3-f3-(Morpholin-4-ylcarbonyl)-5,5-dioxidothiochromenof4,3-c1pyrazol-1 (4H)-yl1phenyl}methanol
To a solution of aluminium chloride (5.13 g; 38.49 mmol; 4.93 eq.) in THF (30 mL) stirred for 25 min at 4°C is added morpholine (5.40 ml; 61 .36 mmol; 7.86 eq.) and the reaction mixture is stirred at 4°C for 1 h. Ethyl 1 -[3-(hydroxymethyl)phenyl]-1 ,4-dihydrothio chromeno[4,3- c]pyrazole-3-carboxylate 5,5-dioxide (3.1 1 g; 7.81 mmol; 1 eq.) is added and the reaction mixture is allowed to warm up to rt. After 22 h, the reaction mixture is cooled down to 0°C then water is added slowly (total volume 25 mL). After 30 min stirring, the product is extracted with DCM. The organic phase is washed with an aqueous solution of Rochelle salts (-0.7 m; pH= 5), brine then dried over MgS04. The solvent is removed under reduced pressure to afford 3.39 g (99%) of the title compound as a pale yellow solid. HPLC (max plot) 95.6%; Rt 3.08 min. MS (ESI+): 440.0.
Compounds described below are obtained following procedure AC
Procedure AD Example 33: 3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4-dihydrothiochromenof4,3- clpyrazole 5,5-dioxide
1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide (150.00 mg; 0.44 mmol; 1.00 Eq) is suspended in DCM (4.00 ml) and 2 drops of DMF and then Oxalyl chloride (3 mL) is added dropwise. The reaction mixture is stirred at room temperature for 30min. The solution is evaporated to dryness. The residue is suspended in DCM (4.00 ml) and morpholine (350.00 μΙ_; 4.02 mmol; 9.12 Eq) is added dropwise. The reaction mixture is stirred at rt for 30min then diluted with aq. solution of HCI 0.05 M. The two layers are separated. The aqueous layer is extracted with DCM (2x). The organic layers are washed with a saturated solution of NaHC03 and brine, dried over MgS04 and evaporated to give foam. The foam is recrystallised in EtOH to the title compound as a white solid. 1H NMR (DMSO-de, 300MHz) δ 8.04-8.01 (m, 1 H), 7.67-7.53 (m, 7H), 6.85-6.82 (m, 1 H), 4.91 (s, 2H), 3.98-3.94 (m, 2H), 3.68-3.61 (m, 6H). UPLC/MS: (ES+): 410.1 , (ES-): 408.1 . HPLC (max plot) 100.0%; Rt 3.36 min.
Example 34: 1 -methyl-3-(morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromenof4,3- clpyrazole 5,5-dioxide
Following the protocol outlined in Procedure AD, 1-methyl-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -methyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-3-carboxylic acid 5,5-dioxide, oxalyl chloride and morpholine to afford 0.62 g (83%) of the title compound as a white solid. 1H NMR (DMSO-d6, 300MHz) δ 8.07-8.02 (m, 2H), 7.92-7.87 (m, 1 H), 7.76-7.71 (m, 1 H), 4.81 (s, 2H), 4.26 (s, 3H), 3.99-3.93 (m, 2H), 3.70-3.60 (m, 6H). UPLC/MS: (ES+): 347.9, (ES-): 346.1. HPLC (max plot) 99.9%; Rt 2.15 min. Compounds described described below are obtained following procedure AD:
ylmethyl)cvclopropynphenyl)-1 ,4-dihvdrothiochromenor4,3-c1pyrazole 5,5-dioxide
phenvll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Procedure AE
Example 250: 3-(Morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4-dihydrothiochromenof4,3- clpyrazole-6-carboxamide 5,5-dioxide
To a solution of 6-cyano-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3-carboxylate 5,5- dioxide (50 mg, 0.135 mmol) in dry DCM (10 mL) are added morpholine (0.02 mL, 0.156 mmol) and TEA (0.03 mL, 0.196 mmol) after which reaction mixture is cooled to 0°C.
EDC.HCI (38 mg, 0.196 mmol) and HOBt (2 mg, 0.013 mmol) are then added to the reaction mixture which is stirred at RT for 12 h under nitrogen. After this time, DCM is added and organic phase is washed with Na2C03 sat, dried over Na2S04 concentrated under reduced pressure and purified by silica gel column chromatography (3% MeOH in DCM) to afford the title compound as a pale yellow solid. 1H NMR (DMSO-c/6, 400 MHz): δ 7.89 (s, 1 H), 7.63- 7.60 (m, 3H), 7.55-7.44 (m, 4H), 6.84-6.82 (d, J = 7.8 Hz, 1 H), 5.74 (s, 2H), 4.78 (s, 2H), 3.97 (m, 2H), 3.66-3.61 (m, 6H). MS (ESI+): 453.0. HPLC (max plot) 96.54%; Rt 3.98 min.
Procedure AF
Example 35: 1 -methyl-3-(morpholin-4-ylcarbonyl)-8-nitro-1 ,4-dihydrothiochromenof4,3- clpyrazole 5,5-dioxide
A solution of 1 -methyl-3-(morpholin-4-ylcarbonyl)-8-nitro-1 ,4-dihydrothiochromeno[4,3- c]pyrazole (0.084 g, 0.23 mmol) in acetic acid is heated at 100 °C under nitrogen. Hydrogen peroxide 30% in water (0.5 mL, 3.6 mmol, 15 Eq) is added and the reaction mixture is heated for 30 minutes. After 30 minutes, the solvent is removed under reduced pressure. 10% aqueous NaHC03 is added to the residue. The mixture is stirred for few minutes and then extracted with DCM. The organic layer is concentrated and purified by column
chromatography to afford the title compound as a yellow solid. 1H NMR (DMSO-d6, 400MHz) δ 8.66 (s, 1 H), 8.48 (dd, J = 8.5 Hz, J = 2.3 Hz, 1 H), 8.28 (J = 1 1 .8 Hz, 1 H), 4.96 (s, 2H), 4.33 (s, 3H), 3.94 (brs, 2H), 3.66-3.63 (m, 6H). MS (ESI+): 393.0. HPLC (max plot) 90.8%; Rt 3.08 mm. Example 36: 3-(morpholin-4-ylcarbonyl)-8-nitro-1 -phenyl-1 ,4-dihydrothiochromenof4,3- clpyrazole 5,5-dioxide
Following the protocol outlined in Procedure AF, 3-(morpholin-4-ylcarbonyl)-8-nitro-1 -phenyl- 1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3-(morpholin-4- ylcarbonyl)-8-nitro-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole and hydrogen peroxide to afford of the title compound as a yellow solid. 1H NMR (DMSO-d6, 400MHz) δ 8.38 (dd, J =
8.5 Hz, J = 2.2 Hz, 1 H), 8.27 (d, J = 8.6 Hz, 1 H), 7.70-7.59 (m, 5H), 7.51 (d, J = 2.1 Hz, 1 H),
5.06 (s, 2H), 3.95-3.93 (m, 2H), 3.67-3.60 (m, 6H). MS (ESI+): 455.0. HPLC (max plot) 95.5%; Rt 4.18 min.
Procedure AG
Example 37: 1 -ethyl-3-(morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromenof4,3- clpyrazole 5,5-dioxide
To a solution of 3-(morpholin-4-ylcarbonyl)-2,4-dihydrothiochromeno[4,3-c]pyrazole 5,5- dioxide (0.400 g, 1 .2 mmol) in acetonitrile (10 mL) is added potassium carbonate (0.49 g, 3.6 mmol) followed by ethyl iodide (0.56 g, 3.6 mmol). The reaction mixture is heated at 60 °C overnight. The crude reaction mixture is filtered through a celite pad and the filtrate concentrated under reduced pressure. The residue is purified by preparative HPLC to afford the title compound as an off-white solid. 1H NMR (DMSO-d6, 400 MHz): δ 8.02 (d, J = 7.72 Hz, 1 H), 7.94 (d, J = 7.84 Hz, 1 H), 7.89 (t, J = 7.52 Hz, 1 H), 7.72 (t, J = 7.64 Hz, 1 H), 4.79 (s, 2H), 4.57 (q, J = 7.12 Hz, 2H), 3.94 (brs, 2H), 3.66-3.63 (m, 6H), 1 .46 (t, J = 7.16 Hz, 3H). MS (ESI+): 362.0. HPLC (max plot) 95.0%; Rt 2.99 min.
Example 38: 1 -(4-methoxybenzyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-clpyrazole 5,5-dioxide
Following the protocol outlined in Procedure AG, 1-(4-methoxybenzyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3- (morpholin-4-ylcarbonyl)-2,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and 4- methoxybenzyl bromide to afford the title compound as a white solid. 1H NMR (DMSO-d6, 300MHz) δ 8.01 -7.98 (m, 1 H), 7.84-7.76 (m, 2H), 7.70-7.65 (m, 1 H), 7.08 (d, J = 8.8 Hz, 2H), 6.91 (d, J = 8.8 Hz, 2H), 5.79 (s, 2H), 4.84 (s, 2H), 3.96-3.93 (m, 2H), 3.71 (s, 3H), 3.70-3.60 (m, 6H) UPLC/MS: (ES+): 454.0, (ES-): 452.1. HPLC (max plot) 100.0%; Rt 3.40min. Example 39: 3-(morpholin-4-ylcarbonyl)-1 -propyl-1 ,4-dihydrothiochromenof4,3- clpyrazole 5,5-dioxide
Following the protocol outlined in Procedure AG, 3-(morpholin-4-ylcarbonyl)-1 -propyl-1 ,4- dihydrothio chromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3-(morpholin-4-ylcarbonyl)- 2,4-dihydrothio chromeno[4,3-c]pyrazole 5,5-dioxide and propyl bromide to afford the title compound as an off-white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.02 (d, J = 7.8 Hz, 1 H), 7.95 (d, J = 7.7 Hz, 1 H), 7.88 (t, J = 7.7 Hz, 1 H), 7.89 (t, J = 7.8 Hz, 1 H), 4.79 (s, 2H), 4.51 (t, J = 7.1 Hz, 2H), 3.93 (brs, 2H), 3.65 - 3.62 (m, 6H), 1 .97 - 1 .81 (m, 2H), 0.86 (t, J = 7.2 Hz, 3H). MS (ESI+): 376.0. HPLC (max plot) 99.0%; Rt 3.39 min.
Example 40: 1 -benzyl-3-(morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromenof4,3- clpyrazole 5,5-dioxide
Following the protocol outlined in Procedure AG, 1-benzyl-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydro thiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3-(morpholin-4-ylcarbonyl)- 2,4-dihydrothio chromeno[4,3-c]pyrazole 5,5-dioxide and benzyl bromide to afford the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 7.98 (d, J = 7.7 Hz, 1 H), 7.75- 7.74 (m, 2H), 7.67-7.63 (m, 1 H), 7.36-7.26 (m, 3H), 7.10 (d, J = 7.4 Hz, 1 H), 5.87 (s, 2H), 4.84 (s, 2H), 4.02-3.92 (m, 2H), 3.65 - 3.62 (m, 6H). MS (ESI+): 424.0. HPLC (max plot) 99.0%; Rt 3.92 min. Example 41 : 3-(morpholin-4-ylcarbonyl)-1 -(2-phenylethyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
Following the protocol outlined in Procedure AG, 3-(morpholin-4-ylcarbonyl)-1 -(2- phenylethyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3- (morpholin-4-ylcarbonyl)-2,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and (2- bromoethyl)benzene to afford the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.03-7.98 (m, 2H), 7.87 (t, J = 7.5 Hz, 1 H), 7.71 (t, J = 7.6 Hz, 1 H), 7.20-7.13 (m, 3H), 7.06 (d, J = 7.6 Hz, 1 H), 4.85 (t, J = 6.5 Hz, 2H), 4.74 (s, 2H), 3.61 -3.29 (m, 8H), 3.08 (t, J = 6.5 Hz, 2H). MS (ESI+): 438.0. HPLC (max plot) 98.4%; Rt 4.02 min.
Example 42: N,N-dimethyl-2-f3-(morpholin-4-ylcarbonyl)-5,5-dioxidothiochromenof4,3- clpyrazol-1 (4H)-yllethanamine
Following the protocol outlined in Procedure AG, N,N-dimethyl-2-[3-(morpholin-4-ylcarbonyl)- 5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4H)-yl]ethanamine is obtained from 3-(morpholin-4- ylcarbonyl) -2,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and 2-bromo-N,N- dimethylethanamine to afford the title compound as a white solid. 1H NMR (DMSO-d6,
400MHz) δ 8.05-8.01 (m, 2H), 7.89 (t, J = 7.6 Hz, 1 H), 7.71 (t, J = 7.6 Hz, 1 H), 4.77 (s, 2H), 4.61 (t, J = 6.4 Hz, 1 H), 3.93 (br, 2H), 3.65-3.63 (m, 6H), 2.73 (t, J = 6.5 Hz, 1 H), 2.13 (s, 6H). MS (ESI+): 405.0. HPLC (max plot) 97.9%; Rt 2.00 min. Example 43: tert-butyl 4-{r3-(morpholin-4-ylcarbonyl)-5,5-dioxidothiochromenor4,3- c1pyrazol-1(4H)-yl1methyl}piperidin -1 -carboxylate
Following the protocol outlined in Procedure AG, tert-butyl 4-{[3-(morpholin-4-ylcarbonyl)-5,5- dioxidothiochromeno[4,3-c]pyrazol-1 (4H)-yl]methyl}piperidine-1 -carboxylate is obtained from 3-(morpholin-4-ylcarbonyl)-2,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and tert-butyl 4-(bromomethyl)piperidine-1 -carboxylate to afford the title compound as a white solid. 1H NMR (DMSO-de, 400MHz) δ 8.03-7.98 (m, 2H), 7.89-7.86 (m, 1 H), 7.71 (t, J = 8.0 Hz, 1 H), 4.78 (s, 2H), 4.48 (d, J = 7.2 Hz, 2H), 3.91 -3.85 (m, 3H), 3.65-3.63 (m, 6H), 2.66-2.62 (m, 2H), 2.04 (t, J = 3.6 Hz, 2H), 1 .47-1 .44 (m, 2H), 1 .35 (s, 9H), 1 .14-1.08 (m, 2H). MS (ESI+): 431 .0. HPLC (max plot) 96.8%; Rt 4.41 min.
Example 44: 1 -(3-methoxypropyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihvdrothiochromenor4,3-clpyrazole 5,5-dioxide
Following the protocol outlined in Procedure AG, 1-(3-methoxypropyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3- (morpholin-4-ylcarbonyl)-2,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and 1 -bromo-3- methoxypropane to afford the title compound as an off-white solid. 1H NMR (DMSO-d6,
400MHz) δ 8.03-7.98 (m, 2H), 7.90-7.86 (m, 1 H), 7.73-7.70 (m, 1 H), 4.78 (s, 2H), 4.59 (t, J = 7.0 Hz, 2H), 3.93 (m, 2H), 3.65-3.63 (m, 6H), 3.27-3.21 (m, 2H), 3.13 (s, 3H), 2.09 (t, J = 6.28 Hz, 2H). MS (ESI+): 406.0 HPLC (max plot) 97.2%; Rt 3.07 min. Example 45: 3-(morpholin-4-ylcarbonyl)-1 -(tetrahydrofuran-2-ylmethyl)-1 ,4-dihydrothio chromenor4,3-c1pyrazole 5,5-dioxi
Following the protocol outlined in Procedure AG, 3-(morpholin-4-ylcarbonyl)-1 - (tetrahydrofuran-2-ylmethyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3-(morpholin-4-ylcarbonyl)-2,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and 2- (bromomethyl)tetrahydrofuran to afford the title compound as an off-white solid. 1H NMR (DMSO-d6, 400MHz) 8 8.17 (d, J = 7.9 Hz, 1 H), 8.00 (d, J = 7.1 Hz, 1 H), 7.87 (t, J = 6.9 Hz, 1 H), 7.70 (t, J = 7.6 Hz, 2H), 4.84-4.80 (m, 2H), 4.77-4.73 (m, 2H), 4.34-4.31 (m, 1 H), 3.92 (brs, 2H), 3.69-3.56 (m, 8H), 2.49 (m, 2H), 2.03 (t, J = 6.6 Hz, 2H). MS (ESI+): 418.0. HPLC (max plot) 95.0%; Rt 3.14 min.
Example 46: 2-f3-(morpholin-4-ylcarbonyl)-5,5-dioxidothiochromenof4,3-c1pyrazol- 1 (4H)-yl1ethanol
Following the protocol outlined in Procedure AG, 2-[3-(morpholin-4-ylcarbonyl)-5,5- dioxidothio chromeno[4,3-c]pyrazol-1 (4H)-yl]ethanol is obtained from 3-(morpholin-4- ylcarbonyl)-2,4-dihydro thiochromeno[4,3-c]pyrazole 5,5-dioxide and 2-bromoethanol to afford the title compound as a pale brown solid. 1H NMR (DMSO-d6, 400MHz) δ 8.26 (d, J = 7.9 Hz, 1 H), 8.01 (d, J = 7.7 Hz, 1 H), 7.87 (t, J = 7.7 Hz, 1 H), 7.71 (t, J = 7.6 Hz, 1 H), 5.22 (t, J = 5.2 Hz, 1 H), 4.78 (s, 2H), 4.54 (t, J = 5.2 Hz, 2H), 3.95-3.93 (m, 4H), 3.66-3.62 (m, 6H). MS (ESI+): 378.0. HPLC (max plot) 93.9%; Rt 2.32 min. Example 47: 3-(morpholin-4-ylcarbonyl)-1 -(pyridin-2-ylmethyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
Following the protocol outlined in Procedure AG, 3-(morpholin-4-ylcarbonyl)-1 -(pyridin-2- ylmethyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3-(morpholin- 4-ylcarbonyl)-2,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and 2-
(bromomethyl)pyridine to afford the title compound as a pale brown solid. 1H NMR (DMSO- d6, 400MHz) δ 8.53 (d, J = 4.7 Hz, 1 H), 8.00-7.97 (m, 2H), 7.82-7.67 (m, 3H), 7.36-7.33 (m, 1 H), 7.24 (d, J = 7.8 Hz, 1 H), 5.89 (s, 2H), 4.83 (s, 2H), 3.88 (m, 2H), 3.65-3.58 (m, 6H). MS (ESI+): 425.0. HPLC (max plot) 97.5%; Rt 2.55 min.
Example 48: 1 -butyl-3-(morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromenof4,3- clpyrazole 5,5-dioxide
Following the protocol outlined in Procedure AG, 1-butyl-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3-(morpholin-4-ylcarbonyl)- 2,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and 1 -bromobutane to afford the title compound as an off-white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.02 (d, J = 7.8 Hz, 1 H), 7.95 (d, J = 7.7 Hz, 1 H), 7.88 (t, J = 7.7 Hz, 1 H), 7.89 (t, J = 7.8 Hz, 1 H), 4.79 (s, 2H), 4.51 (t, J = 7.1 Hz, 2H), 3.93 (brs, 2H), 3.65-3.62 (m, 6H), 1 .97-1 .81 (m, 2H), 0.86 (t, J = 7.2 Hz, 3H). MS (ESI+): 376.0. HPLC (max plot) 99.0%; Rt 3.39 min. Example 49: 1 -(cvclopentylmethyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazo -dioxide
Following the protocol outlined in Procedure AG, 1-(cyclopentylmethyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3- (morpholin-4-ylcarbonyl)-2,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and
(bromomethyl)cyclopentane to afford the title compound as an off-white solid. 1H NMR (DMSO-de, 400MHz) δ 8.01 (dd, J = 7.7 Hz, J = 2.1 Hz, 1 H), 7.88 (t, J = 7.4 Hz, 1 H), 7.70 (t, J = 7.7 Hz, 1 H), 4.78 (m, 2H), 4.50 (d, J = 7.5 Hz, 2H), 3.93 (brs, 2H), 3.65-3.62 (m, 6H), 2.42- 2.35 (m, 1 H), 1.60-1 .57 (m, 4H), 1 .54-1 .50 (m, 2H), 1 .47-1.44 (m, 2H). MS (ESI+): 376.0. HPLC (max plot) 982%; Rt 4.29 min.
Example 50: 1 -isobutyl-3-(morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromenof4,3- clpyrazole 5,5-dioxide
Following the protocol outlined in Procedure AG, 1-isobutyl-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3-(morpholin-4-ylcarbonyl)- 2,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and 1 -bromo-2-methylpropane to afford the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz) δ 8.00 (d, J = 7.9 Hz, 2H), 7.88 (t, J = 7.6 Hz, 1 H), 7.70 (t, J = 7.7 Hz, 1 H), 4.78 (s, 2H), 4.40 (d, J = 7.4 Hz, 2H), 3.92 (brs, 2H), 3.65-3.62 (m, 6H), 2.15-2.08 (m, 1 H), 0.82 (d, J = 7.4 Hz, 6H). MS (ESI+): 390.0. HPLC (max plot) 98.3%; Rt 3.74 min.
Example 51 : 1 -(cvclohexylmethyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihvdrothiochromenor4,3-clpyrazo -dioxide
Following the protocol outlined in Procedure AG, 1-(cyclohexylmethyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3- (morpholin-4-ylcarbonyl)-2,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and
(bromomethyl)cyclophexane to afford the title compound as a white solid. 1H NMR (DMSO- d6, 400ΜΗζ)δ 8.02-7.98 (m, 2H), 7.88 (t, J = 7.6 Hz, 1 H), 7.70 (t, J = 7.6 Hz, 1 H), 4.77 (s, 2H), 4.42 (d, J = 7.3 Hz, 2H), 3.92-3.89 (m, 2H), 3.65-3.62 (m, 6H), 1 .86-1 .80 (m, 1 H), 1 .60- 1 .54 (m, 6H), 1.50-1 .47 (m, 3H), 1 .09-0.99 (m, 2H). MS (ESI+): 430.0. HPLC (max plot) 97.4%; Rt 4.56 min.
Example 52: 3-(morpholin-4-ylcarbonyl)-1 -(tetrahydro-2H-pyran-4-ylmethyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazo -dioxide
Following the protocol outlined in Procedure AG, 3-(morpholin-4-ylcarbonyl)-1 -(tetrahydro- 2H-pyran-4-ylmethyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3- (morpholin-4-ylcarbonyl)-2,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and 4- (bromomethyl)tetrahydro-2H-pyran to afford the title compound as an off-white solid. 1H NMR (DMSO-de, 400MHz) δ 8.02-8.00 (m, 2H), 7.90-7.86 (m, 1 H), 7.71 (t, J = 7.7 Hz, 1 H), 4.78 (s, 2H), 4.48 (d, J = 7.3 Hz, 2H), 3.90-3.89 (m, 2H), 3.79-3.76 (m, 2H), 3.65-3.63 (m, 6H), 3.18 (d, J = 1 1 .8 Hz, 2H), 2.12-2.07 (m, 1 H), 1 .47-1.40 (m, 2H), 1.35-1 .30 (m, 3H). MS (ESI+): 432.0. HPLC (max plot) 97.1 %; Rt 3.04 min.
Example 53: 1 -(2-methoxyethyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
Following the protocol outlined in Procedure AG, 1-(2-methoxyethyl)-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3- (morpholin-4-ylcarbonyl)-2,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and 1 -bromo-2- methoxyethane to afford the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz)8 8.14 (d, J = 7.9 Hz, 1 H), 8.01 (d, J = 7.8 Hz, 1 H), 7.87 (t, J = 7.6 Hz, 1 H), 7.71 (t, J = 7.6 Hz, 1 H), 4.78 (s, 2H), 4.67 (t, J = 5.12 Hz, 2H), 3.93-3.85 (m, 4H), 3.66-3.64 (m, 2H), 3.21 (s, 3H). MS (ESI+): 392.0. HPLC (max plot) 94.2%; Rt 2.97 min. Example 54: 3-f3-(morpholin-4-ylcarbonyl)-5,5-dioxidothiochromenof4,3-c1pyrazol- 1(4H)-vnpropan-1 -ol
Following the protocol outlined in Procedure AG, 3-[3-(morpholin-4-ylcarbonyl)-5,5- dioxidothiochromeno[4,3-c]pyrazol-1 (4H)-yl]propan-1 -ol is obtained from 3-(morpholin-4- ylcarbonyl)-2,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and 3-bromopropan-1 -ol to afford the title compound as a white solid. 1H NMR (DMSO-d6, 400MHz)8 8.03 - 8.01 (m, 2H), 7.88 (t, J = 7.9 Hz, 1 H), 7.71 (t, J = 7.8 Hz, 1 H), 4.78 (s, 2H), 4.74 (t, J = 4.8 Hz, 1 H), 4.59 (t, J = 7.1 Hz, 1 H), 3.92 (brs, 2H), 3.65-3.63 (m, 6H), 3.49-3.48 (m, 2H), 2.05-1 .99 (m, 2H). MS (ESI+): 392.0. HPLC (max plot) 99.0%; Rt 2.45 min.
Example 55: 3-(morpholin-4-ylcarbonyl)-1 -(2-pyridin-2-ylethyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
Following the protocol outlined in Procedure AG, 13-(morpholin-4-ylcarbonyl)-1 -(2-pyridin-2- ylethyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3-(morpholin-4- ylcarbonyl)-2,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and 2-(2-bromoethyl)pyridine to afford the title compound as a white solid. 1H NMR (DMSO-d6, 400ΜΗζ)δ 8.50 (d, J = 4.6 Hz, 1 H), 8.07 (d, J = 7.8 Hz, 1 H), 8.02 (d, J = 7.7 Hz, 1 H), 7.89 (t, J = 7.1 Hz, 1 H), 7.75-7.70 (m, 2H), 7.30-7.22 (m, 2H), 4.98 (t, J = 6.7 Hz, 2H), 4.75 (s, 2H), 3.61 -3.58 (m, 6H), 3.50- 3.48 (m, 2H), 3.40-3.37 (m, 2H). MS (ESI+): 439.0. HPLC (max plot) 98.7%; Rt 2.12 min.
Compounds described below are obtained following protocole outlined in proced AG.
Example 231 : Methyl 5-ff3-(morpholin-4-ylcarbonyl)-5,5-dioxidothiochromenof4,3-
vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide vl>-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
20 mg (27%) of the title compound as a pale yellow foam. 1 H NMR (DMSO-d6): δ 8.04 (d, J = 8.2, 1 H), 8.00-7.84 (m,
°¾''° 2H), 7.75 (d, J = 6.5 Hz, 2H), 7.41 (s, 1 H), 6.20 (s, 1 H),
5.49 (s, 1 H), 4.78 (s, 2H), 4.23 (s, 2H), 3.93 (s, 2H), 3.66 (s, 5H), 3.30-3.21 (m, 1 H), 2.84 (d, J = 3.1 Hz, 4H), 2.45- 2.33 (m, 1 H), 2.27 (s, 2H). HPLC (max plot) 98.5%; Rt 2.00 min. MS (ESI+): 497.2.
Example 288: 1 -f 1 -Γ2-(1 H-lmidazol-1 -vl)ethvllpvrrolidin-3-vl>-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
40 mg of the title compound as a white foam. 1 H NMR (DMSO-d6) δ 8.04 (d, J = 7.5 Hz, 1 H), 8.00-7.83 (m, 2H),
°¾''° 7.74 (t, J = 7.4 Hz, 1 H), 7.65 (s, 1 H), 7.20 (s, 1 H), 6.85 (s,
1 H), 5.48 (s, 1 H), 4.78 (s, 2H), 4.08 (t, J = 6.1 Hz, 2H), 3.94 (s, 2H), 3.66 (s, 5H), 3.28 (d, J = 9.4 Hz, 1 H), 2.93 (dd, J = 9.7, 4.7 Hz, 1 H), 2.87-2.73 (m, 4H), 2.43 (d, J = 8.2 Hz, 1 H), 2.25 (d, J = 7.6 Hz, 1 H). HPLC (max plot) 86.7%; Rt 1 .55 min. MS (ESI+): 497.2.
Example 310: 1 -i1 -f2-r(3S)-3 -Fluoropvrrolidin-1 -vllethvl}pvrrolidin-3-vD-3-
(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
50 mg of the title compound as a pale yellow foam. 1H NMR (DMSO-de): δ 8.03 (dd, J = 7.8 Hz, 1 .1 , 1 H), 7.97 (d, J = 7.5 Hz, 1 H), 7.89 (t, J = 7.6 Hz, 1 H), 7.73 (t, J = 7.6 Hz,
°¾''° 1 H), 5.47 (s, 1 H), 5.25 (s, 1 H), 5.06 (s, 1 H), 4.86-4.71 (m,
2H), 3.96 (s, 2H), 3.66 (s, 6H), 3.27 (d, J = 8.2 Hz, 1 H), 2.92-2.71 (m, 5H), 2.59 (dt, J = 15.7, 8.4 Hz, 5H), 2.47- 2.36 (m, 1 H), 2.28 (dd, J = 15.3, 7.2 Hz, 2H), 2.10-2.08 (m, 1 H), 1 .94-1 .69 (m, 1 H).. HPLC (max plot) 100.0%; Rt 1.77 min. MS (ESI+): 517.9.
Example 308: 1 -i1 -f2-r(3R)-3 -Fluoropvrrolidin-1 -vllethvl}pvrrolidin-3-vD-3-
(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide 36 mg of the title compound as a pale yellow foam. 1 H
NMR (DMSO-d6): δ 8.03 (d, J = 7.6 Hz, 1 H), 8.00-7.83 (m,
°¾'·° 2H), 7.73 (t, J = 7.7 Hz, 1 H), 5.47 (s, 1 H), 5.25 (s, 1 H),
5.07 (s, 1 H), 4.78 (s, 2H), 3.96 (s, 2H), 3.66 (s, 5H), 3.27 (d, J = 8.7 Hz, 1 H), 2.93-2.70 (m, 5H), 2.69-2.53 (m, 4H), 2.42 (d, J = 8.9 Hz, 1 H), 2.35-2.16 (m, 2H), 2.16-1.97 (m, 1 H), 1 .94-1 .70 (m, 2H). HPLC (max plot) 100.0%; Rt 1 .69 min. MS (ESI+): 517.8.
Example 311 : 1 -f 1 -r2-(3,3-Difluoroazetidin-1 -vl)ethvllpvrrolidin-3-vl>-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
50 mg of the title compound as a pale yellow foam. 1H NMR (DMSO-de): δ 8.04 (dd, J = 7.8 Hz, 1 .2, 1 H), 7.99- 7.85 (m, 2H), 7.74 (dd, J = 1 1 .4, 4.9 Hz, 1 H), 5.47 (s, 2H), 4.78 (s, 2H), 3.95 (s, 2H), 3.66 (s, 5H), 3.57 (t, J = 12.5 Hz, 4H), 3.25 (s, 1 H), 2.83 (d, J = 37.8 Hz, 3H), 2.65 (s, 2H),
F 2.47-2.37 (m, 1 H), 2.24 (d, J = 5.6 Hz, 1 H). HPLC (max plot) 98.2%; Rt 2.45 min. HPLC (max plot) 66.3%; Rt 2.19 min. MS (ESI+): 521 .8.
Example 255: 1 -Γ1 -(2-Methoxvethvl)pvrrolidin-3-vll-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
o o
MS (ESI+): 461.2. HPLC (max plot) 97.52%; Rt 2.31 min
\
Example 256: 1 -Γ1 -(3-Methoxvpropvl)PVrrolidin-3-vll-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
7 mg of the title compound as a pale yellow solid. 1H NMR o o (DMSO-de, 400 MHz): δ 8.03-8.01 (m, 1 H), 7.96-7.94 (m,
1 H), 7.90-7.86 (m, 1 H), 7.74-7.70 (m, 1 H), 5.46 (m,1 H), 4.81 -4.76 (s, 2H), 3.95 (m, 2H), 3.65 (m, 6H), 3.36-3.35 (m, 2H), 3.26 (s, 3H), 3.26 (m, 1 H), 3.20 (m, 2H), 2.20 (m, 1 H), 1 .69-1 .65 (m, 2H). MS (ESI+): 475.0. HPLC (max plot) 94.52%; Rt 2.41 min Example 121 : 2-f4-f3-(Morpholin-4-ylcarbonyl)-5,5-dioxidothiochromenof4,3- clpyrazol-1 (4H)-yllpiperidin-1 -vDethanol
21 mg of the title compound as an off white solid. 1H NMR (DMSO-d6, 400 MHz): δ 8.04-8.03 (d, J = 1.1 Hz, 1 H), 8.03- 7.85 (m, 2H), 7.74-7.70 (t, J = 7.7 Hz, 1 H), 4.78 (s, 2H), 4.73-4.71 (m, 1 H), 4.44-4.41 (t, J = 5.4 Hz, 1 H), 3.98 (m, 2H), 3.65 (s, 6H), 3.53-3.50 (t, J = 1 1 .7 Hz, 2H), 2.49-2.48 (m, 2H), 2.26-2.20 (m, 2H), 2.16-2.1 1 (m, 2H), 2.01 -1 .98
(d, J = 10.8 Hz, 2H). MS (ESI+): 461.0. HPLC (max plot) 98.47%; Rt 2.16 min
Example 101 : 1 -f1 -(2-Methoxyethyl)piperidin-4-vn-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
10 mg of the title compound as an off white solid. 1H NMR (400 MHz, DMSO-de): δ 8.03-8.02 (d, J = 6.8 Hz, 1 H), 7.91 -7.85 (m, 2H), 7.74-7.70 (t, J = 7.8 Hz, 1 H), 4.78 (s, 2H), 4.71 (m, 1 H), 3.98 (m, 2H), 3.65 (s, 6H), 3.46-3.42 (t, J = 6.8 Hz, 2H), 3.23 (s, 3H), 3.00-2.97 (d, J = 1 1 .7 Hz , 2H), 2.53-2.52 (m, 2H), 2.27-2.21 (m, 2H), 2.15-2.10 (m, 2H), 2.01 -1 .99 (d, J = 9.8 Hz, 2H). MS (ESI+): 475.3.
HPLC (max plot): 90.61 %; Rt 2.37 min.
Example 175: 3-(Morpholin-4-ylcarbonyl)-1 -f1 -(2-morpholin-4-ylethyl)piperidin-3-vn- 1 ,4-dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
50 mg of the title compound as a off-white solid. 1 H NMR (300 MHz, DMSO): δ 8.05 (dd, J = 7.8, 1 .2 Hz, 1 H), 7.98-
7.89 (m, 1 H), 7.85 (d, J = 7.6 Hz, 1 H), 7.79-7.68 (m, 1 H), 5.06-4.55 (m, 3H), 4.00-3.84 (m, 2H), 3.77-3.56 (m, 6H), 3.55-3.46 (m, 4H), 3.32-3.30 (m, 2H), 3.28-3.15 (m, 1 H), 2.90 (d, J = 10.7 Hz, 1 H), 2.46-2.24 (m, 7H), 2.21 -1 .85 (m,
3H), 1 .84-1 .61 (m, 2H). . HPLC (max plot) 98.6%; Rt 1 .63 min. MS (ESI+): 529.4.
Example 263: 3-iMorpholin-4-ylcarbonyl)-1 -f1 -r2-i1 H-pyrazol-1 -yl)ethvnpiperidin-3- vD-1 ,4-dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide 73 mg of the title compound as a white foam. 1 H NMR
(DMSO-d6) δ 8.07-8.04 (m, 1 H), 7.96-7.90 (m, 1 H), 7.79- 7.73 (m, 3H), 7.41 -7.40 (m, 1 H), 6.20 (m, 1 H), 4.78 (s, 2H), 4.75-4.67 (m, 1 H), 4.26-4.21 (m, 2H), 3.91 -3.89 (m, 2H), 3.66 (s, 6H), 3.18-3.15 (m, 1 H), 2.89-2.74 (m, 3H), 2.45-
2.42 (m, 1 H), 2.14-1 .65 (m, 5H). HPLC (max plot) 98.3%; Rt 2.07 min. MS (ESI+): 510.8.
Example 273: 1 -{1 -r2-(3,3-Difluoroazetidin-1 -yl)ethvnpiperidin-3-yl)-3-(morpholin-4- ylcarbonvD-1 ,4-dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
37 mg of the title compound as a white solid. 1H NMR (DMSO-de) δ 8.07-8.04 (m, 1 H), 7.95-7.84 (m, 2H), 7.78- 7.73 (m, 1 H), 4.79 (s, 3H), 3.93-3.90 (m, 2H), 3.70-3.63 (m, 6H), 3.55 (t, J = 12.5 Hz, 4H), 3.20-3.16 (m, 1 H), 2.92- 2.89 (m, 1 H), 2.67-2.62 (m, 2H), 2.46-2.37 (m, 3H), 2.14-
1 .69 (m, 5H). HPLC (max plot) 97.7%; Rt 2.00 min. MS (ESI+): 535.8.
Example 265: 3-(Morpholin-4-ylcarbonyl)-1 -Π -(tetrahydrofuran-3-ylmethyl)piperidin- 3-νΠ-1 ,4-dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
36 mg of the title compound as a white solid. 1H NMR (DMSO-de) δ 8.07-8.04 (m, 1 H), 7.96-7.91 (m, 1 H), 7.84- 7.72 (m, 2H), 4.84-4.73 (m, 3H), 3.95-3.87 (m, 2H), 3.74- 3.54 (m, 8H), 3.40-3.33 (m, 2H), 3.21 -3.13 (m, 1 H), 2.95- 2.86 (m, 1 H), 2.43-2.28 (m, 4H), 2.16-1.71 (m, 6H), 1 .58-
1 .43 (m, 1 H). HPLC (max plot) 97.1 %; Rt 1 .80 min. MS (ESI+): 500.8.
Example 281 : 1 -{1 -f2-(4-Fluoropiperidin-1 -yl)ethyl1piperidin-3-yl}-3-(morpholin-4- ylcarbonvD-1 ,4-dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
38 mg of the title compound as a beige solid. 1H NMR (DMSO-de): δ 8.06 (dd, J = 7.8, 1 .2 Hz, 1 H), 7.96-7.91 (m, 1 H), 7.86-7.81 (m, 1 H), 7.78-7.73 (m, 1 H), 4.79 (s, 3H), 4.74-4.52 (m, 1 H), 3.93-3.90 (m, 2H), 3.70-3.62 (m, 6H), 3.23-3.20 (m, 1 H), 2.91 -2.88 (m, 1 H), 2.55-2.46 (m, 4H),
2.45-2.36 (m, 3H), 2.29-2.21 (m, 2H), 2.14-1 .89 (m, 3H), 1 .85-1 .55 (m, 6H). HPLC (max plot) 100%; Rt 1.86 min. MS (ESI+): 545.9.
Example 282: 1 -(1 -f2-ri3S)-3 -Fluoropvrrolidin-1 -vllethvl}piperidin-3-vD-3-(morpholin-
4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide (mixture 2 diasteriomers
19 mg of the title compound as a white solid. 1H NMR (DMSO-de): δ 8.06 (dd, J = 7.8, 1 .2 Hz, 1 H), 7.96-7.90 (m, 1 H), 7.85-7.83 (m, 1 H), 7.78-7.72 (m, 1 H), 5.26-5.02 (m, 1 H), 4.79 (s, 3H), 3.93-3.90 (m, 2H), 3.69-3.62 (m, 6H), 3.23-3.19 (m, 1 H), 2.94-2.73 (m, 3H), 2.63-2.38 (m, 6H),
2.29-1.70 (m, 8H). HPLC (max plot) 100%; Rt 1.58 min. MS (ESI+): 532.3.
Example 283: 1 -i1 -f2-r(3R)-3 -Fluoropvrrolidin-1 -vllethvl}piperidin-3-vD-3-(morpholin-
4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
20 mg of the title compound as a white solid. 1H NMR (DMSO-de): δ 8.06 (dd, J = 7.8, 1 .2 Hz, 1 H), 7.96-7.90 (m,
°¾''° 1 H), 7.85-7.83 (m, 1 H), 7.78-7.72 (m, 1 H), 5.27-5.02 (m,
1 H), 4.79-4.74 (m, 3H), 3.93-3.90 (m, 2H), 3.70-3.63 (m, 6H), 3.23-3.20 (m, 1 H), 2.93-2.90 (m, 1 H), 2.86-2.73 (m, 2H), 2.63-2.38 (m, 6H), 2.29-2.21 (m, 1 H), 2.17-1 .70 (m, 7H). HPLC (max plot) 100%; Rt 1.58 min. MS (ESI+): 532.3.
Example 284: 1 -f 1 -r2-(3,3-Difluoropiperidin-1 -vl)ethvllpiperidin-3-vl>-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
44 mg of the title compound as a white solid. 1H NMR (DMSO-de): δ 8.06 (dd, J = 7.8, 1 .3 Hz, 1 H), 7.95-7.90 (m, 1 H), 7.84-7.81 (m, 1 H), 7.78-7.73 (m, 1 H), 4.79-4.73 (m, 3H), 3.93-3.91 (m, 2H), 3.70-3.62 (m, 6H), 3.24-3.21 (m, 1 H), 2.93-2.89 (m, 1 H), 2.69-2.61 (m, 2H), 2.58-2.46 (m,
4H), 2.43-2.38 (m, 3H), 2.12-1.55 (m, 9H) HPLC (max plot) 98.8%; Rt 2.14 min. MS (ESI+): 564.3.
Example 294: 1 -Γ1 -(2-Cvclohexvlethvl)piperidin-3-vll-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide 32 mg of the title compound as a off-white solid. 1H NMR
(DMSO-de) δ 8.06 (dd, J = 1 .2, 7.8 Hz, 1 H), 7.95-7.89 (m,
°¾''° 1 H), 7.84-7.81 (m, 1 H), 7.78-7.73 (m, 1 H), 4.82-4.75 (m,
3H), 3.93-3.90 (m, 2H), 3.69-3.62 (m, 6H), 3.14-3.1 1 (m, 1 H), 2.90-2.86 (m, 1 H), 2.41 -2.27 (m, 3H), 2.15-2.1 1 (m, 1 H), 2.00-1 .57 (m, 9H), 1 .34-1.07 (m, 6H), 0.91 -0.80 (m, 2H). HPLC (max plot) 99.3%; Rt 3.01 min. ). MS (ESI+): 527.4.
Example 295: 1 -f 1 -r(5-Methvl-1 ,2,4-oxadiazol-3-vl)methvllpiperidin-3-vl}-3-
(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
20 mg of the title compound as a white solid. 1H NMR (DMSO-de) δ 8.05 (dd, J = 1 .2, 7.8 Hz, 1 H), 7.95-7.89 (m, 1 H), 7.86-7.83 (m, 1 H), 7.78-7.73 (m, 1 H), 4.85-4.78 (m, 3H), 3.91 -3.88 (m, 2H), 3.78-3.75 (m, 2H), 3.70-3.62 (m, 6H), 3.24-3.21 (m, 1 H), 2.94-2.91 (m, 1 H), 2.61 -2.57 (m, 4H), 2.26-1 .73 (m, 5H). HPLC (max plot) 92.7%; Rt 6.56 min. HPLC (max plot) 95.2%; Rt 6.56 min. MS (ESI+): 513.2.
Example 296: 3-(Morpholin-4-vlcarbonvl)-1 -f 1 -Γ3-(1 H-pvrrol-1 -vl)propvllpiperidin-3- vl>-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
1 1 mg of the title compound as a white solid. 1H NMR
Q. ,,0 (DMSO-de) δ 8.10-8.05 (m, 1 H), 7.97-7.92 (m, 1 H), 7.87- 7.84 (m, 1 H), 7.78-7.73 (m, 1 H), 6.71 (t, J = 2.1 Hz, 2H), 5.93 (t, J = 2.1 Hz, 2H), 4.87-4.79 (m, 3H), 3.91 -3.87 (m, 4H), 3.69-3.62 (m, 6H), 3.10-3.07 (m, 1 H), 2.88-2.84 (m, 1 H), 2.37-2.08 (m, 4H), 2.00-1 .75 (m, 6H). HPLC (max plot) 98.6%; Rt 8.02 min. MS (ESI+): 524.3.
Example 297: 1 -f1 -r2-(1 H-lmidazol-1 -vl)ethvllpiperidin-3-vl>-3-(morpholin-4-vl carbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
41 mg of the title compound as a white solid. 1H NMR (DMSO-de) δ 8.06 (dd, J = 1 .2, 7.8 Hz, 1 H), 7.97-7.91 (m, 1 H), 7.78-7.71 (m, 2H), 7.65 (t, J = 1 .0 Hz, 1 H), 7.19 (t, J = 1 .2 Hz, 1 H), 6.88 (t, J = 1 .0 Hz, 1 H), 4.79-4.69 (m, 3H),
4.1 1 -4.06 (m, 2H), 3.92-3.89 (m, 2H), 3.69-3.62 (m, 6H), 3.20-3.17 (m, 1 H), 2.94-2.90 (m, 1 H), 2.83-2.66 (m, 2H),
2.55-2.45 (m, 1 H), 2.14-1 .60 (m, 5H). HPLC (max plot) 99.7%; Rt 6.04 min. MS (ESI+): 51 1.3.
Example 133: 1-ri-(2-Methoxvethvl)piperidin-3-vll-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
13.2 mg of the title compound as an off white solid. 1H NMR (DMSO-d6, 400 MHz): δ 8.05-8.03 (m, 1 H), 7.92 (m, 1 H), 7.82 (m, 1 H), 7.73 (m, 1 H), 4.77 (s, 3H), 3.89 (m, 2H), 3.65-3.64 (m, 6H), 3.42 (m, 2H), 3.18 (m, 4H), 2.95 (m, 1 H), 2.66 (m, 2H), 2.49 (m, 2H), 2.22 (m, 2H), 1.98 (m,
1 H), 1 .85 (m, 2H). MS (ESI+): 475.3. HPLC (max plot) 91.17%; Rt 2.34 min.
Example 134: 2-{3-r3-(Morpholin-4-vlcarbonvl)-5,5-dioxidothiochromenor4,3- clpvrazol-1 (4H)-vllpiperidin-1 -vl}ethanol
14 mg of the title compound as an off white solid. 1H NMR (DMSO-d6, 400 MHz): δ 8.04-8.02 (d, J = 7.9 Hz, 1 H), 7.92-7.90 (m, 1 H), 7.83-7.81 (d, J = 7.9 Hz, 1 H), 7.75-7.73 (m, 1 H), 4.77 (m, 3H), 4.42-4.40 (t, J = 5.3 Hz, 1 H), 3.89 (m, 2H), 3.64 (m, 6H), 3.51 -3.45 (m, 2H), 3.20 (m, 1 H), 2.90-2.87 (m, 1 H), 2.44 (m, 3H), 2.09-2.05 (m, 2H), 1.95
(m, 1 H), 1 .75-1 .72 (m, 2H). MS (ESI+): 461.2. HPLC (max plot) 97.14%; Rt 2.15 min.
Example 172: 1-ri-(3-Methoxvpropvl)piperidin-3-vll-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
14 mg of the title compound as a pale brown solid. 1H NMR (DMSO-de, 400 MHz): δ 8.05-8.03 (m, 1 H), 7.94-7.90 (m, 1 H), 7.82-7.80 (d, J = 7.9 Hz, 1 H), 7.75-7.71 (t, J = 7.7 Hz, 1 H), 4.77 (s, 2H), 3.89 (m, 2H), 3.65-3.64 (m, 6H), 3.18 (m, 1 H), 3.18 (s, 3H), 3.13-3.10 (m, 1 H), 2.88-2.85 (m, 1 H), 2.49 (m, 1 H), 2.41 -2.30 (m, 3H), 2.12 (m, 1 H), 1 .86-1 .98
(m, 2H), 1.84-1.76 (m, 2H), 1.7-1.6 (m, 2H). MS (ESI+): 489.0. HPLC (max plot) 94.24%; RT 2.44 min
Example 173: 1-n-(3-Methv butvl)piperidin-3-vll-3-(morpholin-4-vlcarbonvD-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide 23 mg of the title compound as a pale brown solid. 1H NMR
(DMSO-d6, 400 MHz): δ 8.05-8.03 (d, J = 7.8 Hz, 1 H), 7.91 -7.89 (m, 1 H), 7.82-7.80 7.75-7.71 o ο (d, J = 7.8 Hz, 1 H),
(t, J = 7.8 Hz, 1 H), 4.77 (bs, 3H), 3.89 (m, 2H), 3.64 (m, 6H), 3.12-3.10 (m, 1 H), 2.88-2.85 (m, 1 H), 2.48-2.27 (m, 3H), 2.10 (m, 1 H), 1 .94-1 .91 (m, 2H), 1 .85-1 .66 (m, 2H), 1 .54-1 .57 (m, 1 H), 1 .31 -1.22 (m, 2H), 0.84-0.82 (d, J = 6.7 Hz, 6H). MS (ESI+): 487.0. HPLC (max plot) 95.39%; Rt 3.03 min
Example 174: 1 -(1 -Benzvlpiperidin-3-vD-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
9 mg of the title compound as an off white solid. 1H NMR (DMSO-d6, 400 MHz): δ 8.02-8.0 (dd, J = 1 .2, 7.8 Hz, 1 H), o o 7.88-7.85 (t, J = 7.8 Hz, 1 H), 7.73-7.69 (t, J = 7.6 Hz, 1 H),
7.60-7.58 (d, J = 7.8 Hz, 1 H), 7.33-7.29 (m, 4H), 7.23-7.20 (m, 1 H), 4.79-4.69 (m, 3H), 3.88 (m, 2H), 3.68-3.62 (m, 6H), 3.42 (m, 1 H), 3.32 (m, 1 H), 3.05-3.02 (m, 1 H), 2.91 - 2.88 (m, 1 H), 2.34-2.28 (m, 1 H), 2.10-1 .96 (m, 3H), 1 .82- 1 .72 (m, 2H). MS (ESI+): 507.0. HPLC (max plot) 92.29%; Rt 2.94 min
Example 219: 3-(Morpholin-4-vlcarbonvl)-1 -Γ1 -(2-phenvlethvl)piperidin-3-vll-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
21 mg of the title compound as a white solid. 1H NMR (DMSO-de, 400 m Hz): δ 8.05-8.03 (dd, J = 1 .2, 7.8 Hz, o o 1 H), 7.93-7.90 (t, J = 7.4 Hz, 1 H), 7.83-7.81 (d, J = 8.0 Hz,
1 H), 7.75-7.71 (t, J = 7.6 Hz, 1 H), 4.77 (s, 2H), 3.89 (m, 2H), 3.64 (m, 6H), 3.12-3.10 (m, 1 H), 2.89-2.86 ( m, 1 H),
°^ Q- -O 2.36-2.34 (m,3H), 2.1 1 (m,1 H), 1.95 (m, 2H),1 .77-1 .71 (m,
2H), 1 .33-1 .30 (m, 2H), 0.91 (s, 9H). MS (ESI+): 501 .3. HPLC (max plot) 96.24%; Rt 3.40 min.
Example 220: 1 -Γ1 -(3,3-Dimethvlbutvl)piperidin-3-vll-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide 21 mg of the title compound as a white solid. 1H NMR
(DMSO-de, 400 m Hz): δ8.05-8.03 (dd, J = 1 .2, 7.8 Hz, 1 H), 7.93-7.90 (t, J = 7.4 Hz, 1 H), 7.83-7.81 (d, J = 8.0 Hz, 1 H), 7.75-7.71 (t, J = 7.6 Hz, 1 H), 4.77 (s, 2H), 3.89 (m, 2H), 3.64 (m, 6H), 3.12-3.10 (m, 1 H), 2.89-2.86 (m, 1 H), 2.36-2.34 (m,3H), 2.1 1 (m,1 H), 1.95 (m, 2H),1 .77-1 .71 (m, 2H), 1 .33-1 .30 (m, 2H), 0.91 (s, 9H). MS (ESI+): 501 .3. HPLC (max plot) 96.24%; Rt 3.40 min
Example 222: 3-(Morpholin-4-vlcarbonvl)-1 -Γ1 -(3,3,3-trifluoropropvl)piperidin-3-vll-
1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
13 mg of the title compound as an off white solid. 1H NMR (CDCI3, 400 MHz): δ 8.18-8.16 (d, J = 7.7 Hz,1 H), 7.79- 7.76 (t, J = 7.6 Hz,1 H), 7.64-7.59 (m, 2H), 4.77-4.61 (m, 3H), 4.15 (s, 2H), 3.80 (m,6H), 3.19-2.98 (m, 1 H), 2.95-
2.74 (m, 1 H), 2.73-2.68 (m, 2H), 2.61 -2.55 (m, 1 H), 2.36- 2.29 (m, 2H), 2.18-2.09 (m, 3H), 1 .96-1.93 (m, 1 H), 1 .78-
1 .75 (m, 1 H). MS (ESI+): 513.0. HPLC (max plot) 97.57%; Rt 2.76 min
Example 223: 3-(Morpholin-4-vlcarbonvl)-1 -{1 -r4,4,4-trifluoro-3-
(trifluoromethvl)butvllpiperidin-3-vl>-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5- dioxide
10 mg of the title compound as a white solid. 1H NMR (DMSO-d6, 400 MHz): δ 8.05-8.03 (m, 1 H), 7.90-7.86 (m, 1 H), 7.83-7.81 (d, J = 7.4 Hz, 1 H), 7.75-7.71 (m, 1 H), 4.85- 4.77 (m, 3H), 3.98-3.96 (m, 1 H), 3.89 (m, 2H), 3.65-3.64 (m, 6H), 3.14-3.1 1 (m, 1 H), 2.87-2.85 (m,1 H), 2.48 (m, 1 H), 2.14-2.1 1 (m, 2H), 2.07-2.02 (m, 1 H), 1 .94-1 .89 (m,
3H), 1 .78 (m, 2H), MS (ESI+): 595.0. HPLC (max plot) 95.52%; Rt 3.59 min.
Example 225: 1 -{1 -r2-(2-Met hoxvethoxv)ethvllpiperidin-3-vl}-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide 74 mg (74%) of the title compound as colorless semi solid.
1H NMR (CDCI3, 400 MHz): δ 8.17-8.15 (d, J = 6.8 Hz, 1 H), o ο 7.77-7.75 (m, 1 H), 7.69-7.67 (d, J = 7.8 Hz, 1 H), 7.64-7.60
(m, 1 H), 4.79-4.60 (m, 3H), 4.16 (m, 2H), 3.80 (m, 6H), 3.65-3.59 (m, 4H), 3.53-3.50 (m, 2H), 3.34 (s, 3H), 3.29 (m, 1 H), 3.04 (m, 1 H), 2.76-2.73 (m, 2H), 2.71 -2.68 (m, o- 1 H), 2.58-2.53 (m, 1 H), 2.17-2.08 (m, 2H), 2.07-1 .89 (m, 2H). MS (ESI+): 519.3. HPLC (max plot) 98.77%; Rt 2.59 min
Example 253: A/,A/-Dimethvl-2-{3-r3-(morpholin-4-vlcarbonvl)-5,5- dioxidothiochromenor4,3-clpvrazol-1 (4H)-vllpiperidin-1 -vl}ethanamine
13 mg of the title compound as a pale yellow gummy solid. 1H NMR (CDCI3, 400 MHz): δ 8.15-8.13 (d, J = 7.6 Hz, 1 H), 7.85 (m, 2H), 6.64-7.62 (m, 1 H), 4.94 (m, 1 H), 4.72-4.62 (m, 2H), 4.14 (m, 2H), 3.80 (m, 7H), 3.27-3.25 (m, 1 H), 3.02-2.99 (m, 1 H), 2.78 (m, 4H), 2.63 (m, 6H), 2.20-2.17 (m, 2H), 2.05-1 .92 (m, 3H). MS (ESI+): 488.3. HPLC (max plot) 95.34; Rt 3.79 min.
Example 258: 1 -Γ1 -(3-MethoxvpropvDazepan-4-vll-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
14 mg of the title compound as a brown solid. 1H NMR o o
(CDCIs, 400 MHz): δ 8.17-8.15 (m, 1 H), 7.80-7.78 (m, 1 H), 7.65-7.61 (m, 2H), 5.07 (m, 1 H), 4.65 (s, 2H), 4.14 (bs, 2H), 3.75 (m, 6H), 3.48-3.46 (m, 2H), 3.34 (s, 3H), 3.03- 2.82 (m, 6H), 2.42 (m, 2H), 2.30 (m, 2H), 2.02 (m, 2H), 1 .92 (m, 2H). MS (ESI+): 503.3. HPLC (max plot) 99.02%; Rt 2.57 min
Example 259: 1 -(2-lsopropv phenvl)-3-(morpholin-4-vlcarbonvD-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
0. .0
13.9 mg of the title compound as a brown solid. 1 H NMR (400 MHz, CDCI3): δ 8.17-8.15 (m, 1 H), 7.80-7.78 (m, 1 H), 7.65-7.61 (m, 2H), 5.07 (m, 1 H), 4.65 (s, 2H), 4.14 (brs, 2H), 3.75 (m, 6H), 3.47 (t, 2H), 3.34 (s, 3H), 3.03-2.82 (m, l 6H), 2.42 (m, 2H), 2.30 (m, 2H), 2.02 (m, 2H), 1.92 (m, 2H). MS (ESI+): 503.3. HPLC (max plot): 99.0%; Rt 2.57 min.
Example 309: 6-Chloro-3-(morpholin-4-vlcarbonvl)-1 -Γ1 -(2-morpholin-4-vlethvl) piperidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
35 mg of the title compound as a beige solid. 1 H NMR (300 MHz, DMSO-de): δ 7.84-7.90 (m, 1 H), 7.76-7.78 (m, 2H), 4.91 (s, 2H), 4.66 (bs, 1 H), 3.94 (bs, 2H), 3.66 (bs, 6H), 3.49-3.52 (m, 4H), 3.14-3.18 (m, 1 H), 2.86-2.90 (m,
1 H), 1 .69-2.47 (m, 14H). MS (ESI+): 563.8.
Example 386: Enantiomer B of 6-chloro-3-(morpholin-4-vlcarbonvl)-1 -Γ1 -(2- morpholin-4-vlethvl) piperidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5- dioxide
Obtained from enantiomer B of 6-chloro-1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give 853 mg (75%) of the title compound as a beige solid. 1 H NMR (300 MHz, DMSO-d6): δ 7.91 -7.82 (m, 1 H), 7.82-7.72 (m, 3H), 4.91 (s, 2H), 4.74-4.58 (m, 1 H), 4.03-3.83 (m, 2H), 3.79-3.57 (m, 6H), 3.57-3.41 (m, 4H), 3.22-3.08 (m, 1 H),
2.97-2.78 (m, 1 H), 2.50-2.44 (m, 1 H), 2.44-2.22 (m, 7H), 2.19-1 .83 (m, 3H), 1 .83-1.54 (m, 2H). MS (ESI): 564.5. HPLC (max plot) 99.4%; Rt 6.21 min. [a]25 D +1.17 (1 .1 , EtOH).
Example 441 : Enantiomer B of 1 -f 1 -r3-(3,3-difluoropvrrolidin-1 -vl)-3- oxopropvllpiperidin-3-vl}-3-(morpholin-4-vlcarbonvD-1 ,4-dihvdrothiochromenor4,3- clpvrazole 5,5-dioxide
Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)- 1 -[piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give 70 mg of the title compound as a white powder. 1H NMR (DMSO-d6, 300 MHz): δ 8.06 (dd, J = 1 .1 , 7.8 Hz, 1 H), 7.94 (t, J = 7.3 Hz, 1 H), 7.83 (d, J = 8.0 Hz, o<; 1 H), 7.75 (t, J = 7.5 Hz, 1 H), 4.84-4.67 (m, 3H), 3.98-3.85 (m, 3H), 3.74-3.60 (m, 8H), 3.48 (t, J = 7.4 Hz, 1 H), 3.24- 3.15 (m, 1 H), 2.96-2.85 (m, 1 H), 2.74-2.57 (m, 2H), 2.49- 2.26 (m, 5H), 2.18-1.59 (m, 5H). MS (ESI+): 578.6. HPLC
(max plot) 99.6%; Rt 2.32 min
Example 450: Enantiomer B of 3-(morpholin-4-vlcarbonvl)-1 -Γ1 -(2-pvrrolidin-1 - vlethvl)piperidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give40 mg of the title compound as a yellow foam. 1H NMR (DMSO-d6! 300 MHz): δ 8.06 (d, J = 7.6 Hz, 1 H), 7.91 (d, J = 7.3 Hz, 1 H), 7.85 (d, J = 7.8 Hz, 1 H), 7.75 (t, J = 7.5 Hz, 1 H), 4.79 (s, 3H), 3.96-3.86 (m, 2H), 3.73-3.59 (m, 4H),
3.34 (s, 8H), 3.27-3.16 (m, 1 H), 2.96-2.86 (m, 1 H), 2.45- 2.33 (m, 4H), 2.22-1 .86 (m, 3H), 1 .85-1.68 (m, 2H), 1 .67- 1 .56 (m, 3H). MS (ESI+): 514.4. HPLC (max plot) 92.8%; Rt 5.91 min
Example 362: Enantiomer B of 1 -f 1 -r2-(3,3-difluoroazetidin-1 -vl)ethvllpiperidin-3-vD-
3-(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give160 mg of the title compound as a pale yellow foam. 1 H NMR (300 MHz, DMSO-d6): δ 8.05 (dd, J = 7.8, 1 .2 Hz, 1 H), 7.98-7.81 (m, 2H), 7.75 (dd, J = 1 1 .7, 4.4 Hz, 1 H), 4.79 (s, 3H), 3.91 (d, J = 2.3 Hz, 2H), 3.66 (s, 6H), 3.54 (t, J = 12.5
Hz, 4H), 3.17 (d, J = 10.1 Hz, 1 H), 2.89 (d, J = 1 1 .0 Hz, 1 H), 2.64 (t, J = 6.5 Hz, 2H), 2.47-2.33 (m, 3H), 2.21 -1.85 (m, 3H), 1.77 (s, 2H). HPLC (max plot) 100.0%; Rt 2.59 min. MS (ESI+): 536.3.
Example 363: Enantiomer B of 1 -f 1 -r2-(4-fluoropiperidin-1 -vl)ethvllpiperidin-3-vl>-3-
(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give210 mg (74%) of the title compound as a pale yellow foam. 1 H NMR (300 MHz, DMSO-d6): δ 8.05 (dd, J = 7.8, 1 .1 Hz,
1 H), 7.92 (dd, J = 1 1 .4, 3.9 Hz, 1 H), 7.84 (d, J = 7.7 Hz, 1 H), 7.75 (t, J = 7.5 Hz, 1 H), 4.79 (s, 3H), 4.73 (d, J = 10.5 Hz, 1 H), 4.54 (d, J = 3.2 Hz, 1 H), 3.91 (d, J = 3.6 Hz, 2H), 3.66 (s, 6H), 3.22 (d, J = 9.6 Hz, 1 H), 2.90 (d, J = 10.8 Hz, 1 H), 2.61 -2.35 (m, 8H), 2.27 (s, 2H), 2.17-1.87 (m, 4H), 1 .87-1 .53 (m, 6H). HPLC (max plot) 79.1 %; Rt 2.30 min. MS (ESI+): 546.4.
Example 364 : Enantiomer B of 1 -(1 -f2-r3-fluoropvrrolidin-1 -vllethvl}piperidin-3-vD-
3-(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give190 mg of the title compound as a yellow solid. 1H NMR (300 MHz, DMSO-de) δ 8.05 (dd, J = 7.8, 1.2 Hz, 1 H), 7.99-7.88 (m, 1 H), 7.83 (d, J = 7.5 Hz, 1 H), 7.75 (t, J = 7.6 Hz, 1 H), 5.24 (s, 1 H), 5.05 (s, 1 H), 4.79 (s, 3H), 3.91 (s, 2H), 3.66
(s, 6H), 3.33 (s, 4H), 3.21 (d, J = 10.8 Hz, 1 H), 3.00-2.67 (m, 3H), 2.67-2.35 (m, 9H), 2.26 (d, J = 7.1 Hz, 1 H), 2.19- 1.57 (m, 8H). HPLC (max plot) 67.6%; Rt 1 .82 min. MS (ESI+): 532.4.
Example 221 : 1 -Γ1 -(2-fluoroethvl)piperidin-3-vll-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)- 1 -[piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give 30 mg of the title compound as a pale brown solid. 1H NMR (400 MHz, CDCI3) δ = 8.18-8.17 (dd, J= 7.7, 0.9 Hz 1 H),7.79-7.75 (m,1 H), 7.65-7.61 (t, J = 6.7 Hz, 1 H), 4.79-4.61 (m, 4H), 4.55-4.53 (t, J = 4.7 Hz, 1 H), 4.16 (m, 2H), 3.80 (m, 6H), 3.30-3.27 (m, 1 H), 3.03-3.06
(m, 1 H), 2.87-2.84 (m,2H), 2.77-2.80 (m, 1 H), 2.68-2.63 (m, 1 H), 2.24-2.09 (m, 2H), 2.17 (m, 1 H), 1 .92 (m,1 H), 1 .57 (m,1 H). HPLC (max plot): 97.23%; Rt 2.32 min. MS (ESI+): 463.0. Example 367: Enantiomer B of 1 -(1 -{2-r(3R)-3-fluoropvrrolidin-1 -vllethvl}piperidin-3- vD-3-(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give135 mg (48%) of the title compound as a yellow foam solid. 1 H NMR (300 MHz, DMSO) δ 8.06 (dd, J = 7.8, 1 .2 Hz, 1 H), 7.92 (dd, J = 10.8, 4.4 Hz, 1 H), 7.84 (d, J = 7.5 Hz, 1 H),
7.75 (t, J = 7.6 Hz, 1 H), 5.30 (s, 1 H), 5.1 1 (s, 1 H), 4.79 (s, 3H), 3.90 (s, 2H), 3.61 (m, 6H), 3.24 (m, 2H), 3.04-2.54 (m, 7H), 2.09 (m, 4H), 1 .97-1 .63 (m, 4H). MS (ESI+): 532.3
Example 370: Enantiomer B of 1 -f 1 -r2-(2,2-dimethvlmorpholin-4-vl)ethvllpiperidin-3- vl>-3-(morpholin-4-vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give130
°¾"° mg (74%) of the title compound as a white foam. 1 H NMR
(DMSO-d6) δ 8.06 (dd, J = 1 .2, 7.8 Hz, 1 H), 7.97-7.89 (m, 1 H), 7.87-7.81 (m, 1 H), 7.75 (t, J = 7.56 Hz, 1 H), 4.79 (s, 3H), 4.00-3.86 (m, 2H), 3.72-3.60 (m, 6H), 3.53-3.45 (m, 2H), 3.30-3.21 (m, 1 H), 2.96-2.85 (m, 1 H), 2.48-2.31 (m, 4H), 2.30-2.21 (m, 2H), 2.19-1 .65 (m, 8H), 1 .06 (d, J = 3.3 Hz, 6H). HPLC (max plot) 100.0%; Rt 2.37 min. MS (ESI+): 558.5.
Example 377: Enantiomer B of 1 -f 1 -r2-(3-methvlmorpholin-4-vl)ethvllpiperidin-3-vl}-
3-(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4-
°¾''° dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give190 mg (84%) of the title compound as a white solid. 1 H NMR (DMSO-d6) δ 8.06 (dd, J = 1 .2, 7.8 Hz, 1 H), 8.00-7.82 (m, 2H), 7.80-7.71 (m, 1 H), 4.79 (s, 3H), 3.96-3.87 (m, 2H), 3.73-3.61 (m, 4H), 3.61 -3.57 (m, 1 H), 3.52 (dd, J = 3.3, 10.6 Hz, 1 H), 3.44-3.38 (m, 1 H), 3.28-3.18 (m, 2H), 302-
vlethvl)piperidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide Obtained from enantiomer B of 1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give195 mg of the title compound as a white solid. 1H NMR (DMSO-
°¾''° d6) δ 8.05 (dd, J = 7.8, 1 .2 Hz, 1 H), 7.98-7.89 (m, 1 H), 7.85
(d, J = 7.6 Hz, 1 H), 7.79-7.68 (m, 1 H), 5.06-4.55 (m, 3H), 4.00-3.84 (m, 2H), 3.77-3.56 (m, 6H), 3.55-3.46 (m, 4H), 3.32-3.30 (m, 2H), 3.28-3.15 (m, 1 H), 2.90 (d, J = 10.7 Hz, 1 H), 2.46-2.24 (m, 7H), 2.21 -1 .85 (m, 3H), 1 .84-1 .61 (m, 2H). HPLC (max plot) 99.5%; Rt 1 .54 min. [a]25D -3.79 (c 1.06, DCM).
Example 468: Enantiomer B of 3-(morpholin-4-vlcarbonvl)-1 -Γ1 -pvridin-4-vlpiperidin-
3-vll-l ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)- 1 -[piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give 85 mg of the title compound as a white solid. 1H NMR (DMSO-d6, 300 MHz): δ 8.14-8.12 (d, J = 6.0 Hz, 2H), 8.07-8.05 (d, J = 6.0 Hz, 1 H), 7.88-7.83 (m, 2H), 7.76-7.71 (m, 1 H), 6.85-6.84 (d, J = 3.0 Hz, 2H), 4.91 (bs, 1 H), 4.81 (s, 2H), 4.28-4.24 (d, J = 12.0 Hz, 1 H), 3.95- 3.88 (m, 3H), 3.66-3.60 (m, 5H), 3.52-3.47 (m, 1 H), 3.1 1 - 3.04 (m, 1 H), 2.23-1 .80 (m, 5H). MS (ESI+): 494.2. HPLC (max plot) 98.0%; Rt 2.12 min
Example 406: 6-Fluoro-3-(morpholin-4-vlcarbonvl)-1 -f 1 -Γ2-(1 H-pvrazol-1 - vl)ethvHpiperidin-3-vl>-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
62 mg of the title compound as a white powder. 1H NMR (DMSO-d6, 300 MHz): δ 7.98-7.91 (m, 1 H), 7.73-7.72 (m, 1 H), 7.62-7.56 (m, 1 H), 7.41 (m, 1 H), 6.21 -6.20 (m, 1 H), 4.90 (s, 2H), 4.64 (bs, 1 H), 4.24 (bs, 2H), 3.90 (bs, 2H), 3.66 (bs, 6H), 3.15-3.12 (m, 1 H), 2.88-2.74 (m, 3H), 2.49-
N 2.41 (m, 1 H), 2.09-1.66 (m, 6H). MS (ESI+): 529.3. HPLC (max plot) 96.5%; Rt 2.00 min.
Example 413: 6-fluoro-3-(morpholin-4-vlcarbonvl)-1 -Γ1 -(2-morpholin-4- vlethvl)piperidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide 27 mg of the title compound as a white powder. 1H NMR
(DMSO-d6, 300 MHz): δ 8.27 (m, 2H), 7.92-7.99 (m, 1 H), 7.56-7.66 (m, 2H), 4.90 (s, 2H), 4.71 (br s, 1 H), 3.92 (br s, 2H), 3.66 (b s, 6H), 3.21 (br s, 1 H), 2.89 (m, 2H), 2.73 (s, 1 H), 1 .70-2.43 (m, 14H). MS (ESI+): 548.4.
Example 414: 1 -f1 -r2-i3,3-Difluoroazetidin-1 -vl)ethvllDiDeridin-3-vl)-6-fluoro-3-
(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
37 mg of the title compound as a white powder. 1H NMR (DMSO-d6, 300 MHz): δ 7.92-7.90 (m, 1 H), 7.66-7.56 (m, 2H), 4.90 (s, 2H), 4.74 (bs, 1 H), 3.91 (bs, 2H), 3.66 (bs, 6H), 3.58-3.49 (t, J = 12 Hz, 4H), 3.15-3.12 (m, 1 H), 2.90- 2.87 (m, 1 H), 2.65-2.61 (m, 2H), 2.44-2.37 (m, 2H), 2.12- 1 .66 (m, 6H). MS (ESI+): 519.3. HPLC (max plot) 97.7%; Rt 2.05 min
Example 349: Enantiomer A of 6-fluoro-3-(morpholin-4-vlcarbonvl)-1 -Γ1 -(2- morpholin-4-vlethvl)piperidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5- dioxide hydrochloride salt
Obtained from enantiomer A of 6-fluoro-1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give93 mg of the title compound as a white powder. 1H NMR (DMSO-d6, 300 MHz): δ 7.87-7.93 (m, 2H), 7.58-7.64 (m, 1 H), 5.28 (br s, 1 H), 4.92 (br s, 2H), 3.09-3.84 (m, 24H), 1 .91 -2.28 (m, 4H) MS (ESI+): 548.4. HPLC (max plot) 98.1 %; Rt 2.27 min. HPLC (chiralpack OZ-3, MeOH/0.1 % DEA, max plot): Rt 22.54 min.
Example 350: Enantiomer B of 6-fluoro-3-(morpholin-4-vlcarbonvl)-1 -Γ1 -(2- morpholin-4-vlethvl)piperidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5- dioxide hydrochloride salt
Obtained from enantiomer B of 6-fluoro-1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give20 mg of the title compound as a white powder. MS (ESI+): 548.4. HPLC (max plot) 99.7%; Rt 2.23 min. HPLC (chiralpack OZ-3, MeOH/0.1 % DEA, max plot): 100.0%, Rt
18.14 min. [a]25 D -0.34 (1.2, EtOH).
Example 428: Enantiomer B of 6-methoxv-1 -Π -(2-methoxvethvl)piperidin-3-vll-3-
(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 6-methoxy-1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give37 mg of the title compound as a white solid. 1H NMR (DMSO- d6, 300 MHz): δ 7.86-7.80 (t, J = 9.0 Hz, 1 H), 7.41 -7.30 (m, 2H), 4.71 (s, 2H), 4.66-4.62 (m, 1 H), 3.94 (s, 5H), 3.65 (s, 6H), 3.44-3.41 (t, J = 6.0 Hz, 2H), 3.20 (s, 3H), 3.16-3.13 (m, 1 H), 2.90-2.87 (m, 1 H), 2.58-2.53 (m, 2H), 2.46-2.39 (m, 1 H), 2.10-1 .69 (m, 5H). MS (ESI+): 505.4. HPLC (max plot) 99.1 %; Rt 1 .68 min.
Example 467: Enantiomer B of 1 -Π -(2-methoxvethvl)piperidin-3-vll-6-methvl-3-
(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 6-methyl-1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give33 mg (34%) of the title compound as a white solid. 1H NMR
QsrS (DMSO-d6, 300 MHz): δ 7.80-7.75 (m, 1 H), 7.63-7.61 (m,
1 H), 7.54-7.51 (m, 1 H), 4.79 (s, 2H), 4.66 (m, 1 H), 3.95 (m, 2H), 3.66 (s, 6H), 3.44-3.41 (m, 2H), 3.19 (s, 3H), 3.13 (m, 1 H), 2.90-2.87 (m, 1 H), 2.68 (s, 3H), 2.55 (m, 2H), 2.47- 2.40 (m, 1 H), 2.06-1 .65 (m, 5H). MS (ESI+): 489.3. HPLC (max plot) 97.7%; Rt 2.05 min
Example 394: Enantiomer B of 7-methoxv-1 -Π -(2-methoxvethvl)piperidin-3-vll-3-
(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 7-methoxy-1 -[1 -(2-
Q. .p chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give30 mg (94%) of the title compound as a white foam. 1H NMR (DMSO-d6, 300 MHz): δ 10.70 (s, 1 H), 7.97 (d, J = 9.1 Hz, 1 H), 7.52 (d, J = 2.6 Hz, 1 H), 7.42 (d, J = 8.3 Hz, 1 H), 5.34 (s, 1 H), 4.77 (s, 2H), 3.94 (s, 3H), 3.89-3.53 (m, 13H),
3.53-3.37 (m, 3H), 3.15-3.00 (m, 2H), 2.08 (t, J = 34.5 Hz, 4H).. MS (ESI+): 505.3. HPLC (max plot) 98.7%; Rt 2.39 mm
Procedure AH
Example 348: Enantiomer A of 3-(morpholin-4-ylcarbonyl)-1 -f1 -(2-morpholin-4- ylethyl)piperidin-3-vn-1 ,4-dihvdrothiochromenor4,3-c1pyrazole 5,5-dioxide
Enantiomer A of 1 -[1 -(2-chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide (274 mg; 0.57 mmol; 1.00 eq.), morpholine (199 μΙ; 2.29 mmol; 4.00 eq.), sodium iodide (85 mg; 0.57 mmol; 1 .00 eq.) and K2C03 (237 mg; 1 .72 mmol; 3.00 eq.) are taken up in ACN (6 mL). The reaction mixture is stirred at 60°C overnight. The reaction mixture is diluted in DCM and washed with water, brine, then dried over MgS04 and evaporated Purification by flash chromatography (DCM/MeOH 0 to 5%) followed by dissolution in ACN : water and freeze drying gives the title compound as a white solid. 1H NMR (DMSO-d6, 300 MHz): δ 8.05 (dd, J = 1 .2, 7.8 Hz, 1 H), 7.94 (td, J = 1 .3, 7.8 Hz, 1 H), 7.88-7.81 (m, 1 H), 7.80-7.70 (m, 1 H), 5.05-4.62 (m, 3H), 4.05-3.79 (m, 2H), 3.79- 3.58 (m, 6H), 3.56-3.42 (m, 4H), 3.32-3.08 (m, 3H), 2.91 (d, J = 10.8 Hz, 1 H), 2.46-2.22 (m, 8H), 2.20-1 .60 (m, 6H). MS (ESI+): 530.46. HPLC (max plot) 99.4%; Rt 1 .56 min. [a]25D +4.20 (c 1 .09, DCM),
Compounds described below are obtained following protocole outlined in procedure
AH
Example 290: 3-(Morpholin-4-ylcarbonyl)-1 -Π -(2-morpholin-4-ylethyl)piperidin-4-vn-1 ,4- dihvdrothiochromenor4,3-clpyrazole 5,5-dioxide
42 mg of the title compound as a white powder. 1 H NMR (DMSO-d6) δ δ 8.04 (d, J = 7.6 Hz, 1 H), 7.90 (q, J = 7.8 Hz, 2H), 7.74 (t, J = 7.3 Hz, 1 H), 4.79 (s, 2H), 4.73 (s, 1 H), 3.98 (s, 2H), 3.66 (s, 5H), 3.60 - 3.48 (m, 4H), 3.00 (d, J = 1 1.0 Hz, 2H),
2.47 - 2.33 (m, 6H), 2.31 - 2.00 (m, 5H). HPLC (max plot) 74.2%; Rt 1 .65 min. MS (ESI+): 529.9.
Example 429: Enantiomer B of 1 -f1 -r3-(3,3-difluoroazetidin-1 -vl)-3-oxopropvllpiperidin-
3-vl>-3-(morpholin-4-vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)-1 - [piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-
Q o dioxide to give 25 mg of the title compound as a white solid. 1H
NMR (DMSO-d6! 300 MHz): δ 8.06 (d, J = 7.8 Hz, 1 H), 7.98- 7.89 (m, 1 H), 7.86-7.71 (m, 2H), 4.82-4.67 (m, 3H), 4.57 (t, J = 12.7 Hz, 2H), 4.24 (t, J = 12.8 Hz, 2H), 3.94-3.87 (m, 2H), 3.73- 3.58 (m, 5H), 3.21 -3.10 (m, 1 H), 2.94-2.82 (m, 1 H), 2.74-2.54
(m, 2H), 2.48-2.25 (m, 3H), 2.19-1.65 (m, 6H). MS (ESI+):
564.3. HPLC (max plot) 98.4%; Rt 2.65 min
Example 433: Enantiomer B of methyl 3-{3-r3-(morpholin-4-vlcarbonvl)-5,5- dioxidothiochromenor4,3-clpvrazol-1 (4H)-vllpiperidin-1 -vl}propanoate
Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)-1 - [piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-
Qs"° dioxide to give 90 mg (75%) of the title compound as a yellow foam. 1H NMR (DMSO-d6, 300 MHz): δ 8.06 (d, J = 7.5 Hz, 1 H), 7.94 (t, J = 7.2 Hz, 1 H), 7.89-7.71 (m, 2H), 4.89-4.65 (m, 3H),
— o- 4.02-3.76 (m, 3H), 3.75-3.50 (m, 9H), 3.27-3.10 (m, 1 H), 3.08- 2.79 (m, 2H), 2.78-2.55 (m, 2H), 2.47-2.31 (m, 1 H), 2.26-1.53 (m, 5H). MS (ESI+): 503.4. HPLC (max plot) 93.9%; Rt 1.93 min
Example 434: Enantiomer B of 6-Fluoro-1-ri-(2-methoxvethvl)piperidin-3-vll-3-
(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 6-fluoro-1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give73 mg of the title compound as a white powder. 1H NMR (DMSO-c/6, 300 MHz): δ 8.02-7.89 (m, 1 H), 7.71 -7.51 (m, 2H), 4.89 (s, 2H), 4.79-4.61 (m, 1 H), 3.99-3.82 (m, 2H), 3.79-3.55 (m, 6H), 3.50- 3.37 (m, 2H), 3.19 (s, 3H), 3.18-3.10 (m, 1 H), 2.96-2.81 (m, 1 H),
2.66-2.52 (m, 2H), 2.48-2.35 (m, 1 H), 2.19-2.00 (m, 2H), 2.00- 1 .58 (m, 1 H), 1.83-1.58 (m, 2H). MS (ESI+): 493.4. HPLC (max plot) 100.0%; Rt 1.92 min Example 438: Enantiomer B of 2-methoxv-A-methvl-A/-(2-f3-r3-(morpholin-4- vlcarbonvD-5,5-dioxidothiochromenor4,3-clpvrazol-1 (4H)-vllpiperidin-1 - vDethvDethanamine
Obtained from enantiomer B of 1 -[1 -(2-chloroethyl)piperidin-3- yl]-3-(morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3- c]pyrazole 5,5-dioxide to give14 mg of the title compound as a o o beige solid. 1H NMR (DMSO-d6, 300 MHz): δ 8.05 (d, J = 7.4
Hz, 1 H), 7.94 (t, J = 7.3 Hz, 1 H), 7.85 (d, J = 7.8 Hz, 1 H), 7.75 (t, J = 7.5 Hz, 1 H), 4.85-4.67 (m, 3H), 3.98-3.85 (m, 2H), 3.75-
0" 3.58 (m, 7H), 3.29-3.18 (m, 2H), 3.16 (s, 3H), 2.96-2.83 (m, 1 H), 2.57-2.48 (m, 4H), 2.43-2.32 (m, 2H), 2.16 (s, 3H), 2.14-1.61 (m, 6H). MS (ESI+): 532.6. HPLC (max plot) 100.0%; Rt 1 .75 min.
Example 439: Enantiomer B of 1 -f1 -r2-(3-methoxvPVrrolidin-1 -vl)ethvllpiperidin-3-vl}-3-
(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 1 -[1 -(2-chloroethyl)piperidin-3- yl]-3-(morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3- c]pyrazole 5,5-dioxide to give15 mg of the title compound as a
Q o yellow solid. 1H NMR (DMSO-d6, 300 MHz): δ 8.05 (dd, J = 1 .1 ,
7.8 Hz, 1 H), 7.94 (tr, J = 7.7 Hz, 1 H), 7.84 (d, J = 7.7 Hz, 1 H), 7.75 (t, J = 7.5 Hz, 1 H), 4.84-4.70 (m, 3H), 3.96-3.86 (m, 2H), 3.85-3.75 (m, 1 H), 3.73-3.57 (m, 7H), 3.26-3.16 (m, 2H), 3.12 (d, J = 2.7 Hz, 3H), 2.96-2.84 (m, 1 H), 2.70-2.53 (m, 2H), 2.47- 2.31 (m, 4H), 2.20-1 .47 (m, 8H). MS (ESI+): 544.6. HPLC (max plot) 100.0%; Rt 1.75 min
Example 444: Enantiomer B of A/-(2-f3-r3-(morpholin-4-vlcarbonvl)-5,5- dioxidothiochromenor4,3-clpvrazol-1 (4H)-vllpiperidin-1 -vl}ethvl)acetamide
Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)-1 - . o [piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5- dioxide to give61 mg of the title compound as a white solid. 1H NMR (DMSO-d6, 300 MHz): δ 8.05 (d, J = 7.7 Hz, 1 H), 7.95 (t, J = 7.3 Hz, 1 H), 7.85 (d, J = 7.6 Hz, 1 H), 7.82-7.71 (m, 2H), 4.83- o 4.71 (m, 3H), 3.94-3.86 (m, 2H), 3.72-3.60 (m, 5H), 3.27-3.02 (m, 4H), 2.93-2.83 (m, 1 H), 2.48-2.33 (m, 3H), 2.19-1 .84 (m, 2.94-2.84 (m, 1 H), 2.66-2.55 (m, 5H), 2.47-2.36 (m, 2H), 2.19- 1 .62 (m, 6H). MS (ESI+): 576.6. HPLC (max plot) 99.7%; Rt 6.17 min.
Example 460: Enantiomer B of 1 -f1 -r2-(4-methoxvpiperidin-1 -vl)ethvllpiperidin-3-vl}-3-
(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 1 -[1 -(2-chloroethyl)piperidin-3- yl]-3-(morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3- c]pyrazole 5,5-dioxide to givel 15 mg of the title compound as a q o white solid. 1H NMR (DMSO-d6, 300 MHz): δ 8.05 (d, J = 7.8 Hz,
1 H), 7.97-7.89 (m, 1 H), 7.84 (d, J = 7.9 Hz, 1 H), 7.8 (t, J = 7.8 Hz, 1 H), 4.83-4.70 (m, 3H), 3.96-3.87 (m, 2H), 3.73-3.61 (m, 5H), 3.28-3.22 (m, 1 H), 3.20 (s, 3H), 3.16-3.04 (m, 2H), 2.94- 2.84 (m, 1 H), 2.71 -2.60 (m, 2H), 2.46-2.33 (m, 4H), 2.16-1.85 (m, 6H), 1.85-1 .63 (m, 4H), 1 .40-1.25 (m, 2H). MS (ESI+):
558.6. HPLC (max plot) 100.0%; Rt 1.77 min
Example 463: Enantiomer B of 1 -(2-{3-r3-(morpholin-4-vlcarbonvl)-5,5- dioxidothiochromenor4,3-clpvrazol-1 (4H)-vllpiperidin-1 -vl}ethvl)piperidin-4-ol
Obtained from enantiomer B of 1 -[1 -(2-chloroethyl)piperidin-3- yl]-3-(morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3- c]pyrazole 5,5-dioxide to give60 mg of the title compound as a o o white solid. 1H NMR (DMSO-d6, 300 MHz): δ δ 8.05 (d, J = 7.9
Hz, 1 H), 7.98-7.89 (m, 1 H), 7.84 (d, J = 7.4 Hz, 1 H), 7.75 (t, J = 7.4 Hz, 1 H), 4.83-4.69 (m, 3H), 4.55-4.46 (m, 1 H), 3.96-3.87 (m, 2H), 3.72-3.60 (m, 5H), 3.28-3.18 (m, 2H), 2.94-2.85 (m, 1 H), 2.75-2.62 (m, 2H), 2.46-2.3 (m, 4H), 2.17-1.85 (m, 5H), 1.84- 1 .54 (m, 5H), 1.39-1.20 (m, 3H). MS (ESI+): 544.5. HPLC (max plot) 100.0%; Rt 1.63 min
Example 465: Enantiomer B of 3-(morpholin-4-vlcarbonvl)-1-ri-(2-piperidin-1 - vlethvl)piperidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 1 -[1 -(2-chloroethyl)piperidin-3- yl]-3-(morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3- c]pyrazole 5,5-dioxide to give90 mg (82%) of the title compound as a yellow solid. 1H NMR (DMSO-d6, 300 MHz): δ 8.06 (d, J =
7.8 Hz, 1 H), 7.97-7.88 (m, 1 H), 7.84 (d, J = 7.8 Hz, 1 H), 7.80- dioxide Obtained from enantiomer B of 6-methoxy-1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to givel O mg of the title compound as a beige solid. 1H NMR (DMSO-c/6, 300 MHz): δ 8.15 (s, 1 H), 7.85-7.80 (t, J = 9.0 Hz, 1 H), 7.42-7.31 (m, 2H), 5.22-4.99 (m, 2H), 4.71 (s, 2H), 4.65 (m, 1 H), 3.94 (s, 5H), 3.65 (s, 6H), 3.50 (m, 2H), 3.06-2.73 (m, 4H), 2.51 (m, 1 H), 2.34-1.63 (m, 9H). MS (ESI+): 548.5. HPLC (max plot) 95.3%; Rt 1.53 min
Example 471 : Enantiomer B of 6-methvl-3-(morpholin-4-vlcarbonvl)-1 -ri -(2-morpholin-
4-vlethvl)piperidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 6-methyl-1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give83 mg (75%) of the title compound as a white powder. 1H NMR
(DMSO-d6, 300 MHz): δ 7.79-7.74 (m, 1 H), 7.65-7.62 (m, 1 H), 7.54-7.51 (m, 1 H), 4.79 (s, 2H), 4.70-4.63 (m, 1 H), 3.95 (m, 2H), 3.66 (s, 7H), 3.52-3.49 (m, 4H), 3.18-3.16 (m, 2H), 2.90-2.87 (m, 1 H), 2.68 (s, 3H), 2.43-1.64 (m, 12H). MS (ESI+): 544.4. HPLC (max plot) 94.9%; Rt 1 .88 min
Example 472: Enantiomer B of 7-fluoro-3-(morpholin-4-vlcarbonvl)-1 -ri -(2-morpholin-4- vlethvl)piperidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 7-fluoro-1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to givel O mg of the title compound as a yellow foam. 1H NMR (DMSO-c/6, 300 o. P MHz): δ 7.99-7.86 (m, 2H), 7.82 (t, J = 8.6 Hz, 1 H), 4.90-4.67 fs YF (m, 3H), 4.77 (d, J = 10.4 Hz, 1 H), 3.95-3.85 (m, 2H), 3.72-3.62
(m, 6H), 3.55-3.42 (m, 4H), 3.21 (d, J = 10.1 Hz, 1 H), 2.90 (d, J = 9.9 Hz, 1 H), 2.45-2.27 (m, 7H), 2.16-1 .86 (m, 4H), 1 .85-1.60 (m, 2H). MS (ESI+): 548.5. HPLC (max plot) 66.6%; Rt 1 .97 min. HPLC (Chiralpack IA, EtOH/0.1 %DEA, max plot): 99.57%, Rt 8.87 min (enantiomer A: Rt 7.81 min). [a]25 D -1 .87 (1 .1 , MeOH) Example 474: Enantiomer B of 7-fluoro-1 -f1 -f2-(4-methoxypiperidin-1 - yl)ethvnpiperidin-3-yl)-3-(morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromenof4,3- clpyrazole 5,5-dioxide
Obtained from enantiomer B of 7-fluoro-1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give60 mg (61 %) of the title compound as a white foam. 1H NMR (DMSO- d6, 300 MHz): δ 7.95-7.86 (m, 2H), 7.85-7.76 (m, 1 H), 4.84 (s, 2H), 4.80-4.67 (m, 1 H), 3.95-3.87 (m, 2H), 3.71 -3.61 (m, 6H), 3.19 (s, 4H), 3.15-3.05 (m, 1 H), 2.88 (d, J = 10.0 Hz, 1 H), 2.68- 2.57 (m, 2H), 2.45-2.30 (m, 2H), 2.20-1.84 (m, 6H), 1 .82-1.62 (m, 4H), 1.38-1 .22 (m, 4H).. MS (ESI+): 576.4. HPLC (max plot) 57.0%; Rt 2.07 min
Example 382: Enantiomer B of 1 -f1 -f2-(3,3-difluoroazetidin-1 -yl)ethvnpiperidin-3-yl)-7- methoxy-3-(morpholin-4-ylcarbonyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole 5,5- dioxide
Obtained from enantiomer B of 7-methoxy-1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give75 mg of the title compound as a white foam. 1H NMR (DMSO-c/6, 300 MHz): δ 7.80 (d, J = 8.8 Hz, 1 H), 7.50 (d, J = 2.7 Hz, 1 H), 7.45 (dd, J = 8.7, 2.8 Hz, 1 H), 4.73 (d, J = 16.4 Hz, 3H), 3.93 (s, 5H), 3.65 (s, 6H), 3.54 (t, J = 12.5 Hz, 4H), 3.15 (d, J = 8.8 Hz, 1 H),
2.89 (d, J = 9.5 Hz, 1 H), 2.64 (t, J = 6.2 Hz, 2H), 2.39 (t, J = 8.2 Hz, 3H), 2.15-1 .63 (m, 5H).. MS (ESI+): 566.4. HPLC (max plot) 98.9%; Rt 2.48 min.
Example 383: Enantiomer B of 7-methoxy-3-(morpholin-4-ylcarbonyl)-1 -f1 -(2- morpholin-4-ylethyl)piperidin-3-vn-1 ,4-dihvdrothiochromenor4,3-c1pyrazole 5,5-dioxide
Obtained from enantiomer B of 7-methoxy-1 -[1 -(2- chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide to give90 mg (82%) of the title compound as a white foam. 1H NMR (DMSO- d6, 300 MHz): δ 7.79 (d, J = 8.6 Hz, 1 H), 7.48 (dd, J = 13.1 , 2.6
Hz, 2H), 4.74 (d, J = 13.4 Hz, 3H), 3.93 (s, 5H), 3.62 (d, J = MHz): δ 8.04-7.92 (m, 3H), 4.90 (s, 2H), 4.86-4.70 (m, 1 H),
3.98-3.84 (m, 2H), 3.75-3.58 (m, 6H), 3.58-3.42 (m, 4H), 3.29- 3.16 (m, 1 H), 2.95-2.84 (m, 1 H), 2.46-2.23 (m, 7H), 2.20-1.57 (m, 6H). MS (ESI+): 614.3. HPLC (max plot) 99.9%; Rt 5.01 min
Example 353: Enantiomer A of 6-fluoro-3-(morpholin-4-vlcarbonvl)-1-ri-(tetrahvdro-2H-
PVran-4-vl)pvrrolidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide hydrochloride salt
Obtained from enantiomer A of 6-fluoro-3-(morpholin-4- ylcarbonyl)-1 -pyrrolidin-3-yl-1 ,4-dihydrothio chromeno[4,3- clpyrazole 5,5-dioxide to give 217 mg (81 %) of the title compound as a pink solid. 1H NMR (DMSO-c/6, 300 MHz): δ 1 1 .86-1 1 .76 (m, 1 H), 7.99-7.90 (m, 1 H), 7.78-7.72 (m, 1 H), 7.66-7.57 (m, 1 H), 5.79-5.66 (m, 1 H), 4.96-4.89 (m, 2H), 4.24- 4.12 (m, 1 H), 4.04-3.87 (m, 4H), 3.68-3.56 (m, 8H), 3.37-3.23 (m, 4H), 2.82-2.70 (m, 2H), 2.13-1.71 (m, 4H). MS (ESI+): 505.33. HPLC (max plot) 98.2%; Rt 2.27 min. HPLC (Chiralcel OJ-H, MeOH/01 %DEA, max plot): Rt 5.49 min. [a]25 D +12.53 (c 1 .1 , EtOH)
Example 354: Enantiomer B of 6-fluoro-3-(morpholin-4-vlcarbonvl)-1 -f1-r2-(tetrahvdro-
2H-pvran-4-vl)ethvHpvrrolidin-3-vl>-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5- dioxide hydrochloride salt
Obtained from enantiomer B of 6-fluoro-3-(morpholin-4- ylcarbonyl)-1 -pyrrolidin-3-yl-1 ,4-dihydrothio chromeno[4,3- clpyrazole 5,5-dioxide to give 210 mg (85%) of the title
O O F compound as a pink powder. 1H NMR (DMSO-c/6, 300 MHz): δ i 1 1 .48-1 1 .36 (m, 1 H), 7.99-7.89 (m, 1 H), 7.77-7.71 (m, 1 H),
7.65-7.58 (t, J = 7.5 Hz, 1 H), 5.82-5.68 (m, 1 H), 4.94-4.89 (m, 2H), 4.03-3.80 (m, 4H), 3.67-3.59 (m, 8H), 3.39-3.21 (m, 4H), 2.86-2.56 (m, 3H), 1 .79-1.51 (m, 6H), 1.27-1 .12 (m, 2H). MS (ESI+): 533.4. HPLC (max plot) 97.5%; Rt 2.55 min. [a]25 D - 13.18 (c 1.56, EtOH). HPLC (Chiralcel OJ-H, MeOH/0.1 % DEA, max plot): 98.94%; Rt 9.01 min.
Example 355: Enantiomer B of 6-fluoro-3-(morpholin-4-vlcarbonvl)-1-ri-(tetrahvdro-2H-
PVran-4-vl)pvrrolidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide hydrochloride salt
Obtained from enantiomer B of 6-fluoro-3-(morpholin-4- ylcarbonyl)-1 -pyrrolidin-3-yl-1 ,4-dihydrothio chromeno[4,3- clpyrazole 5,5-dioxide to give 178 mg (72%) of the title compound as a white powder. 1H NMR (DMSO-c/6, 300 MHz): δ 1 1 .86-1 1 .76 (m, 1 H), 7.99-7.90 (m, 1 H), 7.78-7.72 (m, 1 H), 7.66-7.57 (m, 1 H), 5.79-5.66 (m, 1 H), 4.96-4.89 (m, 2H), 4.24- 4.12 (m, 1 H), 4.04-3.87 (m, 4H), 3.68-3.56 (m, 8H), 3.37-3.23 (m, 4H), 2.82-2.70 (m, 2H), 2.13-1.71 (m, 4H). MS (ESI+): 505.4. HPLC (max plot) 97.9%; Rt 2.31 min. HPLC (Chiralcel OJ-H, MeOH/0.1 % DEA, max plot): 98.21 %; Rt 5.96 min. [a]25 D -13.78 (c 1.09, EtOH).
Example 356: Enantiomer A of 6-fluoro-3-(morpholin-4-vlcarbonvl)-1 -f-1 -r2-(tetrahvdro-
2H-pvran-4-vl)ethvHpvrrolidin-3-vl>-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5- dioxide hydrochloride salt
Obtained from enantiomer A of 6-fluoro-3-(morpholin-4- ylcarbonyl)-1 -pyrrolidin-3-yl-1 ,4-dihydrothio chromeno[4,3- clpyrazole 5,5-dioxide to give 230 mg (86%) of the title compound as a pink solid. 1H NMR (DMSO-c/6, 300 MHz): δ 1 1 .48-1 1 .36 (m, 1 H), 7.99-7.89 (m, 1 H), 7.77-7.71 (m, 1 H), 7.65-7.58 (t, J = 7.5 Hz, 1 H), 5.82-5.68 (m, 1 H), 4.94-4.89 (m, 1 H), 4.03-3.80 (m, 4H), 3.67-3.59 (m, 8H), 3.39-3.21 (m, 4H), 2.86-2.56 (m, 3H), 1 .79-1.51 (m, 6H), 1.27-1 .12 (m, 2H). MS (ESI+): 533.43. HPLC (max plot) 96.4%; Rt 2.51 min. HPLC (Chiralcel OJ-H, MeOH/01 %DEA, max plot): Rt 1 1.20 min. [a]25 D +12.77 (c 1 .38, EtOH).
Example 343: Enantiomer A of 6-fluoro-3-(morpholin-4-vlcarbonvl)-1 -f1 -r2-(tetrahvdro-
2H-pvran-4-vl)ethvHpiperidin-3-vl>-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide hydrochloride salt
Obtained from enantiomer A of 6-fluoro-3-(morpholin-4-
°'s2jL ylcarbonyl)-1 -[piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3- c]pyrazole 5,5-dioxide to give 167 mg of the title compound as an off white solid. 1H NMR (DMSO-d6, 300 MHz): δ 10.78 (bs, 1 H), 7.96-7.84 (m, 2H), 7.64-7.58 (m, 1 H), 5.32 (bs, 1 H), 4.91 (s, 2H), 3.84-3.79 (m, 5H), 3.68-3.57 (m, 7H), 3.30-3.16 (m, 5H),
3.01 -2.99 (m, 1 H), 2.23-2.03 (m, 4H), 1.69-1 .35 (m, 5H), 1 .23- 1 .15 (m, 2H). MS (ESI+): 547.4. HPLC (max plot) 97.7%; Rt 2.61 min.
Example 344: Enantiomer B of 6-fluoro-3-(morpholin-4-ylcarbonyl)-1 -f1 -f2-(tetrahvdro- 2H-pyran-4-yl)ethvnpiperidin-3-yl)-1 ,4-dihvdrothiochromenor4,3-c1pyrazole 5,5-dioxide
Obtained from enantiomer B of 6-fluoro-3-(morpholin-4- ylcarbonyl)-1 -[piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3- c]pyrazole 5,5-dioxide to give 152 mg of the title compound as a white solid. 1H NMR (DMSO-d6, 300 MHz): δ 10.75 (bs, 1 H), 7.96-7.84 (m, 2H), 7.64-7.58 (m, 1 H), 5.32 (bs, 1 H), 4.91 (s, 2H), 3.83-3.79 (m, 5H), 3.68-3.57 (m, 7H), 3.30-3.13 (m, 5H),
3.01 -2.99 (m, 1 H), 2.23-2.03 (m, 4H), 1.69-1 .54 (m, 5H), 1 .23- 1 .12 (m, 2H). MS (ESI+): 547.4. HPLC (max plot) 100.0%; Rt 2.63 min
Procedure AJ
Example 360: 1 -{3-f2-(1 H-lmidazol-1 -yl)ethoxy1phenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihvdrothiochromenor4,3-clpyrazole 5,5-dioxide
To a suspension of 3-[3-(morpholin-4-ylcarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4H)-yl]phenol (206.5 mg; 0.49 mmol; 1 eq.), potassium carbonate (401 .6 mg; 2.91 mmol; 5.99 eq.) and sodium iodide (1 1.7 mg; 0.08 mmol; 0.16 eq.) in DMF (4 ml) is added N-{2- chloroethyl)-imidazole hydrochloride (158.4 mg; 0.95 mmol; 1.95 eq.). The suspension is stirred at 80°C 2 days then in the microwave at 120°C for 30 min. The reaction mixture is diluted with water and the product is extracted with EtOAc. The combined organic layer is washed with water then with brine, dried over MgS04 and the solvent removed under vacuum to afford a brown residue. After purification by flask chromatography (silica;
DCM/MeOH 98/2 to 0/100), it affords the title compound as a fluffy yellow powder. 1 H NMR (DMSO-d6): δ 8.07-7.98 (m, 1 H), 7.73-7.55 (m, 3H), 7.55-7.44 (m, 1 H), 7.28-7.13 (m, 3H), 7.09-7.00 (m, 1 H), 6.93-6.83 (m, 2H), 4.10 (s, 2H), 4.44-4.22 (m, 4H), 4.00-3.87 (m, 2H), 3.75-3.55 (m, 6H). HPLC (max plot) 93.5%; Rt 2.48 min. MS (ESI+): 520.4.
Example 340: 3-(Morpholin-4-ylcarbonyl)-1 -{3-f2-(1 H-pyrazol-1 -yQethoxylphenylM ,4- dihvdrothiochromenor4,3-c1pyrazole 5,5-dioxide
Following the protocol outlined in procedure AJ, 3-(morpholin-4-ylcarbonyl)-1 -{3-[2-(1 /-/- pyrazol-1 -yl)ethoxy]phenyl}-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3-[3-(morpholin-4-ylcarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4H)-yl]phenol and 1 -(2-bromo ethyl)-1 /-/-pyrazole to afford the title compound as a white powder. 1 H NMR (DMSO-d6) δ 8.07-7.97 (m, 1 H), 7.82-7.75 (m, 1 H), 7.70-7.54 (m, 2H), 7.54-7.46 (m, 1 H), 7.46-7.41 (m, 1 H), 7.22-7.14 (m, 1 H), 7.14-7.08 (m, 1 H), 7.08-7.00 (m, 1 H), 6.92-6.84 (m, 1 H), 6.26-6.18 (m, 1 H), 4.90 (s, 2H), 4.55-4.45 (m, 2H), 4.45-4.34 (m, 2H), 4.01 -3.88 (m, 2H), 3.76-3.56 (m, 6H). HPLC (max plot) 96.2%; Rt 4.14 min. MS (ESI+): 520.3.
Example 341 : 1 -f3-(2-Methoxyethoxy)phenvn-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-clpyrazole 5,5-dioxide
Following the protocol outlined in procedure AJ, 1 -[3-(2-methoxyethoxy) phenyl]-3- (morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3-[3-(morpholin-4-ylcarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4H)-yl]phenol and 2-bromoethyl methylether to afford the title compound as a white solid. 1 H NMR (DMSO- d6) 5 8.09-7.96 (m, 1 H), 7.71 -7.56 (m, 2H), 7.56-7.44 (m, 1 H), 7.29-7.1 1 (m, 2H), 7.1 1 -6.97 (m, 1 H), 6.97-6.82 (m, 1 H), 4.90 (s, 2H), 4.25-4.08 (m, 2H), 4.05-3.87 (m, 2H), 3.79-3.53 (m, 8H), 3.29 (s, 3H). HPLC (max plot) 99.5%; Rt 3.53 min. MS (ESI+): 484.3. m.p. = [142- 144]°C on Optimelt.
Procedure AK: Example 168 : 1 -f4-f(4-Methoxypiperidin-1 -yl)methvnphenyl)-3-(morpholin-4- ylcarbonvD-1 ,4-dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
To a solution of 4-[3-(morpholin-4-ylcarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4/-/)- yl]benzyl methanesulfonate (230 mg; 0.44 mmol; 1 eq.) in DMF (10 mL) are added K2C03 (184 mg; 1 .33 mmol; 3 eq.) and 4-methoxypiperidine (102 mg; 0.89 mmol; 2 eq.) . The reaction mixture is stirred at 85°C for 30 min then diluted with water, extracted with
EtOAc,washed with brine and dried over MgSCv The solvent is removed and the residue is purified by MD-Autoprep to afford the title compound as a white solid. 1 H NMR (DMSO-d6) δ 8.07-8.04 (m, 1 H), 7.70-7.50 (m, 6H), 6.88-6.85 (m, 1 H), 4.94 (s, 2H), 4.01 -3.98 (m, 2H), 3.71 -3.62 (m, 8H), 3.27 (s, 3H), 3.27-3.22 (m, 1 H), 2.76-2.70 (m, 2H), 2.23-2.14 (m, 2H), 1 .92-1 .84 (m, 2H), 1 .55-1.44 (m, 2H). HPLC (max plot) 100%; Rt 2.23 min. MS (ESI+): 537.0.
Compounds described below are obtained following protocole outlined in proced AK
vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide o o 276 mg of the title compound as a white powder. 1H NMR
(DMSO-de) δ 8.08-7.97 (m, 1 H), 7.69-7.44 (m, 6H), 6.88- 6.78 (m, 1 H), 4.91 (s, 2H), 4.05-3.91 (m, 2H), 3.87 (bs, 2H), 3.78-3.55 (m, 10H). HPLC (max plot) 97.8%; Rt 2.15 min. MS (ESI+): 514.8. m.p. = [218-220]°C on Optimelt.
Example 272: 1 -{4-r(3-Methoxvazetidin-1 -vl)methvllphenvl}-3-(morpholin-4-vlcarbonvD-
1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
317 mg (81 %) of the title compound as an off-white powder. 1 H NMR (DMSO-d6) δ 8.06-8.00 (m, 1 H), 7.68- 7.43 (m, 6H), 6.86-6.79 (m, 1 H), 4.90 (s, 2H), 4.07-3.90 (m, 3H), 3.75-3.58 (m, 8H), 3.58-3.49 (m, 2H), 3.17 (s, 3H), 2.98-2.87 (m, 2H). HPLC (max plot) 97.6%; Rt 2.13
min. MS (ESI+): 508.8.
Example 278: 1 -r4-(Methoxvme1 :hvl)phenvll-3-(morpholin-4-vlcarbonvD-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
93.9 mg of the title compound as a white powder. 1H NMR (DMSO-de) δ 8.06-7.98 (m, 1 H), 7.69-7.48 (m, 6H), 6.92- 6.82 (m, 1 H), 4.91 (s, 2H), 4.55 (s, 2H), 4.04-4.89 (m, 2H), 3.76-3.56 (m, 6H), 3.38 (s, 3H). HPLC (max plot) 99.7%; Rt 3.36 min. MS (ESI+): 454.1. CHN analysis:
[C23H23N305S] Corrected: C60.91 %,H5.1 1 %,N9.27%; Found: C60.30%,H5.06%,N9.22%.
Example 234: 1 -{3-r(4-Methoxvpiperidin-1 -vl)methvllphenvl}-3-(morpholin-4-vl carbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
1 16 mg of the title compound as a white powder. 1H NMR (DMSO-de) δ 8.07-7.98 (m, 1 H), 7.70-7.45 (m, 5H), 7.38- 7.31 (m, 1 H), 6.86-6.78 (m, 1 H), 4.91 (s, 2H), 4.03-3.86 (m, 2H), 3.77-3.56 (m, 6H), 3.51 (bs, 2H), 3.19 (s, 3H), 3.18-3.04 (m, 1 H), 2.70-2.53 (m, 2H), 2.14-1 .96 (m, 2H), 1 .81 -1 .65 (m, 2H), 1 .19-1.39 (m, 2H). HPLC (max plot)
98.6%; Rt 2.23 min. MS (ESI+): 537.0.
Example 236: 3-(Morpholin-4-vlcarbonvl)-1 -r3-(thiomorpholin-4-vlmethvl)phenvll-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide o o 96 mg of the title compound as a white solid. 1H NMR
(DMSO-de) δ 8.08-7.98 (m, 1 H), 7.71 -7.45 (m, 5H), 7.40- 7.30 (m, 1 H), 6.88-6.75 (m, 1 H), 4.91 (s, 2H), 4.04-3.85 (m, 2H), 3.80-3.48 (m, 8H), 2.67-2.41 (m, 8H). HPLC (max plot) 98.3%; Rt 2.24 min. MS (ESI+): 524.7.
Example 243: 1 -(3-f r3-(Methvlsulfonvl)pvrrolidin-1 -vllmethvl}phenvl)-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
51 mg of the title compound as a white powder. 1H NMR (DMSO-de) δ 8.08-7.97 (m, 1 H), 7.71 -7.53 (m, 4H), 7.53- 7.45 (m, 1 H), 7.45-7.37 (m, 1 H), 6.91 -6.78 (m, 1 H), 4.91 (s, 2H), 4.05-3.86 (m, 2H), 3.82-3.55 (m, 9H), 2.86 (s, 3H), 2.84-2.70 (m, 2H), 2.62-2.47 (m, 2H), 2.16-1 .94 (m, 2H).
HPLC (max plot) 96.8%; Rt 2.16 min. MS (ESI+): 571 .0.
Example 244: 1 -{3-r(3,3-Difluoropiperidin-1 -vl)methvllphenvl}-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
1 1 mg of the title compound as an off-white powder. 1H
°s'° NMR (DMSO-de) δ 8.10-7.95 (m, 1 H), 7.72-7.45 (m, 5H),
7.45-7.33 (m, 1 H), 6.90-6.78 (m, 1 H), 4.91 (s, 2H), 4.09- 3.83 (m, 2H), 3.83-3.52 (m, 8H), 2.71 -2.54 (m, 2H), 2.44- 2.29 (m, 2H), 1.99-1 .72 (m, 2H), 1 .67-1 .47 (m, 2H). HPLC (max plot) 96.8%; Rt 2.35 min. MS (ESI+): 543.1.
Example 245: 3-(Morpholin-4-vlcarbonvl)-1 -r3-(pvrrolidin-1 -vlmethvl)phenvll-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
23 mg of the title compound as a white powder. 1H NMR (DMSO-de) δ 8.08-7.97 (m, 1 H), 7.71 -7.51 (m, 4H), 7.51 - 7.42 (m, 1 H), 7.42-7.33 (m, 1 H), 6.90-6.78 (m, 1 H), 4.90 (s, 2H), 4.04-3.84 (m, 2H), 3.80-3.51 (m, 8H), 2.46-2.29 (m, 4H), 1.75-1 .54 (m, 4H). HPLC (max plot) 96.6%; Rt
2.06 min. MS (ESI+): 493.0
Example 247: 1 -{3-Γ(1 ,1 -Dioxidothiomorpholin-4-vl)methvllphenvl}-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide o o 88 mg of the title compound as a white solid. 1H NMR
(DMSO-de) δ 8.10-7.96 (m, 1 H), 7.75-7.48 (m, 5H), 7.48- 7.38 (m, 1 H), 6.90-6.76 (m, 1 H), 4.91 (s, 2H), 4.06-3.85 b (m, 2H), 3.85-3.51 (m, 8H), 3.12-3.16 (m, 4H), 3.16-2.72
^s=o (m, 4H). HPLC (max plot) 69.0%; Rt 2.81 min. MS (ESI-): o
555.1.
Example 248: H3-(Methoxvme1 :hvl)phenvll-3-(morpholin-4-vlcarbonvD-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
70 mg of the title compound as a white solid. 1 H NMR (DMSO-d6) δ 8.09-7.95 (m, 1 H), 7.74-7.52 (m, 4H), 7.52- 7.40 (m, 2H), 6.89-6.79 (m, 1 H), 4.91 (s, 2H), 4.51 (s, 2H), 4.03-3.86 (m, 2H), 3.77-3.53 (m, 6H), 3.29 (s, 3H). HPLC (max plot) 99.6%; Rt 3.36 min. MS (ESI+): 453.7. m.p. = [161 -164]°C on Optimelt. CHN analysis: [C23H23N305S]
Corrected: C60.91 %,H5.1 1 %,N9.27%; Found:
C60.28%,H5.08%,N8.95%.
Example 260: 1 -{3-r(4,4-Difluoropiperidin-1 -vl)methvllphenvl}-3-(morpholin-4- vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide (hydrochloride salt) o p 43 mg of the title compound as a yellow solid. 1H NMR
(DMSO-de) δ 1 1 .27-10.92 (bs, 1 H), 8.10-7.98 (m, 1 H), 7.94-7.48 (m, 6H), 7.00-6.88 (m, 1 H), 4.92 (s, 2H), 4.56- 4.33 (m, 2H), 4.03-3.86 (m, 2H), 3.86-3.32 (m, 8H), 3.25- 2.93 (m, 2H), 2.50-2.20 (m, 4H). HPLC (max plot) 94.3%;
F
Rt 2.41 min. MS (ESI+): 542.7.
Example 261 : 1 -{3-r(3,3-Difluoroazetidin-1 -vl)methvllphenvl}-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
o o 21 mg of the title compound as a white powder. 1H NMR
(DMSO-de) δ 8.08-7.98 (m, 1 H), 7.72-7.53 (m, 4H), 7.53- 7.45 (m, 1 H), 7.45-7.38 (m, 1 H), 6.86-6.77 (m, 1 H), 4.91 (s, 2H), 4.03-3.87 (m, 2H), 3.86-3.75 (m, 2H), 3.75-3.48 (m, 10H). HPLC (max plot) 96.0%; Rt 2.20 min. MS
F
(ESI+): 514.7.
Example 262: 1 -{3-r(3-Methoxvazetidin-1 -vl)methvllphenvl}-3-(morpholin-4-vlcarbonvD-
1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide o p 25 mg of the title compound as a yellow solid.1H NMR
(DMSO-de) δ 11.08-10.68 (m, 1 H), 8.13-7.98 (, 1 H), 7.88- 7.51 (m, 6H), 6.94-6.78 (m, 1H), 4.92 (bs, 2H), 4.57-4.36 (m, 2H), 4.36-4.08 (m, 2H), 4.08-3.80 (m, 2H), 3.80-3. (m, o 8H), 3.55-3.40 (m, 1H), 3.22 (s, 3H). HPLC (max plot) /
96.4%; Rt2.15 min. MS (ESI+): 508.7.
Example 266: 1 -{3-r(3-MethoxvPVrrolidin-1 -vl)methvllphenvl}-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
303 mg of the title compound as a yellow solid.1H NMR (DMSO-de) δ 8.07-7.98 (m, 1H), 7.70-7.51 (m, 4H), 7.51- 7.44 (m, 1H), 7.41-7.34 (m, 1H), 6.87-6.79 (m, 1H), 4.91 (s, 2H), 4.01-3.88 (m, 2H), 3.88-3.76 (m, 1H), 3.76-3.55 (m, 8H), 3.11 (s, 3H), 2.71-2.58 (m, 1H), 2.58-2.45 (m, 1H), 2.45-2.30 (m, 2H), 2.01-1.84 (m, 1H), 1.69-1.52 (m,
1H). HPLC (max plot) 99.9%; Rt2.13 min. MS (ESI+): 522.8.
Example 235: 1 -(3-f r3-(3-Methvlbutoxv)PVrrolidin-1 -vllmethvl}phenvl)-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
97 mg of the title compound as a yellow powder.1H NMR o o (DMSO-de) δ 8.08-7.97 (m, 1H), 7.70-7.42 (m, 6H), 7.42- 7.34 (m, 1H), 6.89-6.79 (m, 1H), 4.91 (s, 2H), 4.07-3.82 (m, 3H), 3.82-3.53 (m, 8H), 3.33-3.18 (m, 2H), 2.77-2.61 (m, 1H), 2.45-2.29 (m, 2H), 2.04-2.82 (m, 1H), 2.71-1.42 (m, 2H), 1.43-1.25 (m, 2H), 0.91-0.76 (m, 6H). HPLC (max plot) 96.2%; Rt 3.26 min. MS (ESI+): 579.1.
Example 237: 1 -{3-r3-(Morpholin-4-vlcarbonvl)-5,5-dioxidothiochromenor4,3-clpvrazol-
1 (4H)-vHbenzvl)piperidin-4-ol
101 mg (100%) of the title compound as a yellow solid.1H
°s'° NMR (DMSO-de) δ 8.08-7.97 (m, 1H), 7.74-7.43 (m, 5H),
7.41-7.29 (m, 1H), 6.90-6.76 (m, 1H), 4.91 (bs, 2H), 4.61- 4.47 (m, 1H), 4.03-3.87 (m, 2H), 3.78-3.56 (m, 6H), 3.50 (bs, 2H), 3.47-3.36 (m, 1H), 2.70-2.56 (m, 2H), 2.13-1.90
OH (m, 2H), 1.74-1.51 (m, 2H), 1.39-1.15 (m, 2H). HPLC (max plot) 97.5%; Rt 2.46 min. m. p. = [121 -130]°C on Optimelt. MS (ESI+): 523.1.
Example 242: 1 -f3-r(4-Fluoropiperidin-1 -vl)methvllphenvl}-3-(morpholin-4-vlcarbonvD-
1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
53 mg of the title compound as a yellow solid. 1H NMR (DMSO-de) δ 8.09-7.97 (m, 1 H), 7.73-7.45 (m, 5H), 7.41 - 7.30 (m, 1 H), 6.89-6.77 (m, 1 H), 4.91 (s, 2H), 4.81-4.48 (m, 1 H), 4.03-3.86 (m, 2H), 3.79-3.58 (m, 6H), 3.54 (s, 2H), 2.52-2.38 (m, 2H), 2.35-2.17 (m, 2H), 1 .88-1 .50 (m,
F 4H). HPLC (max plot) 97.1 %; Rt 2.28 min. MS (ESI+):
525.1.
Example 291 : 1 -Γ3-(1 H-lmidazol-1 -vlmethvl)phenvll-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
37 mg of the title compound as a white powder. 1H NMR (DMSO-de) δ 8.07-7.99 (m, 1 H), 7.80-7.74 (m, 1 H), 7.70- 7.59 (m, 2H), 7.59-7.48 (m, 3H), 7.48-7.43 (m, 1 H), 7.23- 7.16 (m, 1 H), 6.91 -6.87 (m, 1 H), 6.83-6.78 (m, 1 H), 5.29 (s, 2H), 4.90 (s, 2H), 3.97-3.86 (m, 2H), 3.76-3.55 (m, 6H).
HPLC (max plot) 99.6%; Rt 2.13 min. MS (ESI+): 490.2.
Example 292: 3-(Morpholin-4-vlcarbonvl)-1 -Γ3-(1 H-pvrazol-1 -vlmethvl)phenvll-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
27 mg (1 1 %) of the title compound as a white solid. 1H NMR (DMSO-de) δ 8.06-7.98 (m, 1 H), 7.87-7.81 (m, 1 H), 7.69-7.41 (m, 6H), 7.39-7.33 (m, 1 H), 6.86-6.77 (m, 1 H), 6.28-6.22 (m, 1 H), 5.44 (s, 2H), 4.89 (s, 2H), 3.98-3.83 (m, 2H), 3.76-3.54 (m, 6H). HPLC (max plot) 99.4%; Rt 3.22
min. MS (ESI+): 490.2.
Example 432: 1 -{4-r(2-Methvlmorpholin-4-vl)methvHphenvl}-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
°¾"° 123 mg (95%) of the title compound as a white powder.1 H
NMR (DMSO-d6! 300 MHz): δ 8.06-7.98 (m, 1 H), 7.69-7.44 (m, 6H), 7.88-7.78 (m, 1 H), 4.91 (s, 2H), 4.04-3.87 (m, 2H), 3.83-3.38 (m, 1 1 H), 2.79-2.59 (m, 2H), 2.15-2.02 (m, 1 H), 1 .85-1 .73 (m, 1 H), 1 .09-1.00 (m, 3H). MS (ESI+): 523.4. HPLC (max plot) 98.4%; Rt 2.21 min
min
Procedure AL
Example 357: 1 -f4-f(3-Methylmorpholin-4-yl)methvnphenyl)-3-(morpholin-4- ylcarbonylH ,4-dihvdrothiochromenor4,3-c1pyrazole 5,5-dioxide
To a solution of {4-[3-(morpholin-4-ylcarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4H)- yl]phenyl}methanol (123 mg; 0.28 mmol; 1 eq.) and DIEA (330 μΙ; 1 .93 mmol; 2.56 eq.) in DCM (13 mL) is added at 0°C methanesulfonlyl chloride (75 μΙ; 0.97 mmol; 1.3 eq.). The solution is stirred for 30 min and allowed to warm up to rt. After this time, a suspension of sodium iodide (32 mg; 0.21 mmol; 0.28 eq.), K2C03 (336 mg; 2.43 mmol; 3.22 eq.) and 3- methylmorpholine (166 μΙ; 1 .51 mmol; 2 eq.) in DMF (50 mL) is added on the sulfonylchloride mixture. The resulting suspension is stirred at 80°C for 2h after which time water is added after return to RT.. The product is extracted with DCM and the combined organic layer is washed with brine, dried over MgS04 and purified by MD-Autoprep then triturated in a mixture of DCM and pentane to afford the title compound as a orange powder. 1 H NMR (DMSO-d6): δ 8.02-7.98 (m, 1 H), 7.69-7.43 (m, 6H), 6.87-6.79 (m, 1 H), 4.91 (s, 2H), 4.18- 4.03 (m, 1 H), 4.03-3.88 (m, 2H), 3.79-3.56 (m, 8H), 3.56-3.41 (m, 1 H), 3.33-3.24 (m, 2H), 3.24-3.10 (m, 1 H), 2.52-2.66 (m, 1 H), 2.50-2.36 (m, 1 H), 2.29-2.09 (m, 1 H), 1 .03 (d, J = 6.3 Hz, 3H). HPLC (max plot) 98.1 %; Rt 2.09 min. HPLC (max plot) 76.8%; Rt 2.15 min. MS (ESI+): 523.4.
Compounds described below are obtained following protocole outlined in procedure AL
vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide 12 mg of the title compound as a pale brown solid. 1H NMR
O o
(DMSO-d6, 400 MHz): δ 8.70-8.70 (m, 1 H), 8.04-7.98 (m, 2H), 7.67-7.58 (m, 3H), 6.91 -6.89 (d, J = 7.7 Hz, 1 H), 4.90 (s, 2H), 3.92 (m, 2H), 3.73 (m, 2H), 3.67-3.60 (m, 7H), 3.31 (m, 1 H), 2.49 (m, 4H). MS (ESI+): 523.0. HPLC (max plot) 96.64%; Rt 2.16 min.
Example 178: 3-(Morpholin-4-vlcarbonvl)-1 -r3-(piperidin-1 -vlmethvl)phenvll-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
o o off white solid. ΊΗ NMR (DMSO-d6, 400 MHz): δ 8.02-8.0 (d, J
= 7.2 Hz, 1 H), 7.64-7.47 (m, 5H), 7.33 (s, 1 H), 6.82-6.80 (d, J = 7.8 Hz, 1 H), 4.89 (s, 2H), 3.93 (m, 2H), 3.67 (m, 4H), 3.60 (m, 2H), 3.47 (m, 2H), 2.27 (m, 4H), 1 .36 (m, 6H). MS (ESI+): 507.0. HPLC (max plot) 95.51 %; Rt 2.73 min
Example 179: /V,/V-Dimet hvl-1 -{3-r3-(morpholin-4-vlcarbonvl)-5,5- dioxidothiochromenor4,3-clpvrazol-1 (4H)-vllphenvl}methanamine
o o white solid. ΊΗ NMR (DMSO-d6, 400 MHz): δ 8.02-8.00 (d, J =
7.6 Hz, 1 H), 7.64-7.48 (m, 5H), 7.36 (s, 1 H), 6.82-6.81 (d, J = 7.5 Hz, 1 H), 4.89 (s, 2H), 3.92 (m, 2H), 3.66 (m, 4H), 3.60 (m, 2H), 3.44 (m, 2H), 2.1 1 (m, 6H). MS (ESI+): 467.0. HPLC (max plot) 98.03%; Rt 2.49 min.
Example 168: 1 -{4-r(4-Methoxvpiperidin-1 -vl)methvllphenvl}-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
24 mg of the title compound as an off white solid. 1H NMR (DMSO-d6, 400 MHz): δ 8.01 -7.99 (d, J = 7.5 Hz, 1 H), 7.64- o o
7.60 (m, 1 H), 7.57-7.51 (m, 3H), 7.47-7.45 (d, J = 8.2 Hz, 1 H), 6.82-6.80 (d, J = 7.8 Hz, 1 H), 4.89 (s, 2H), 3.94 (m, 2H), 3.66 (m, 4H), 3.66 (m, 2H), 3.60 (m, 2H), 3.21 (s, 3H), 3.21 -3.19 (m, 2H), 2.66 (m, 3H), 2.15-2.1 1 (m, 2H), 1.82 (m, 2H), 1 .45-1 .42 (m, 2H). MS (ESI+): 537.0. HPLC (max plot) 94.67%; Rt 2.70 min
Example 169: 3-(Morpholin-4-vlcarbonvl)-1 -r4-(piperidin-1 -vlmethvl)phenvll-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide 24 mg of the title compound as an off white solid. 1H NMR
(DMSO-d6, 400 MHz): δ 8.01 -7.99 (d, J = 7.5 Hz, 1 H), 7.64- 7.60 (m, 1 H), 7.57-7.50 (m, 3H), 7.47-7.45 (m, 2H), 6.83-6.81 (d, J = 7.7 Hz, 1 H), 4.89 (s, 2H), 3.94 (m, 2H), 3.66 (m, 4H), 3.6 (m, 2H), 3.54 (m, 2H), 2.36 (m, 4H), 1 .51 (m, 4H), 1 .40 (m, 2H).
MS (ESI+): 507.0. HPLC (max plot) 96.42%; Rt 2.69 min
Example 426: 2-Methoxv-A-methvl-A/-f4-r3-(morpholin-4-vlcarbonvl)-5,5- dioxidothiochromenor4,3-clpvrazol-1 (4H)-vHbenzvl)ethanamine
Qs"° 80 mg of the title compound as a yellow solid. 1H NMR (DMSO- d6, 300 MHz): δ 8.06-7.97 (m, 1 H), 7.69-7.43 (m, 6H), 6.87-6.78 (m, 1 H), 4.90 (s, 2H), 4.04-4.88 (m, 2H), 3.77-3.56 (m, 8H), 3.48 (t, J = 5.9 Hz, 2H), 3.25 (s, 3H), 2.58 (t, J = 5.9 Hz, 2H), 2.22 (s, 3H). MS (ESI+): 51 1.3. HPLC (max plot) 97.5%; Rt
/ 6.88 min
Example 430: 1 -f4-r(3-Fluoroazetidin-1 -vl)methvllphenvl}-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
°¾"° 68 mg of the title compound as a white powder. 1H NMR
(DMSO-d6, 300 MHz): δ 8.07-7.96 (m, 1 H), 7.70-7.56 (m, 2H), 7.56-7.41 (m, 4H), 6.87-6.76 (m, 1 H), 5.37-5.05 (m, 1 H), 4.90 (s, 2H), 4.06-3.85 (m, 2H), 3.76 (s, 2H), 3.73-3.51 (m, 8H), 3.29-3.20 (m, 1 H), 3.20-3.10 (m, 1 H). MS (ESI+): 497.33.
F HPLC (max plot) 98.5%; Rt 7.03 min
Example 431 : 2-Methoxv-A-f4-r3-(morpholin-4-vlcarbonvl)-5,5- dioxidothiochromenor4,3-clpvrazol-1 (4H)-vHbenzvl)ethanamine
Qs"° 89 mg (76%) of the title compound as a white powder.
1H NMR (DMSO-d6, 300 MHz): δ 8.07-7.97 (m, 1 H), 7.69-7.51 (m, 4H), 7.51 -7.42 (m, 2H), 6.89-6.82 (m, 1 H), 4.90 (s, 2H), 4.01 -3.90 (m, 2H), 3.83 (s, 2H), 3.74-3.56 (m, 6H), 3.43 (t, J =
HN 5.7 Hz, 2H), 3.25 (s, 3H), 3.24-3.17 (m, 1 H), 2.69 (t, J = 5.7 Hz,
/ 2H). MS (ESI+): 497.4. HPLC (max plot) 97.3%; Rt 2.03 min
Example 455: A/-f4-r3-(Morpholin-4-vlcarbonvl)-5,5-dioxidothiochromenor4,3- clpvrazol-1 (4H)-vllbenzvl}tetrahvdro-2H-pvran-3 -amine 83 mg of the title compound as a brown powder. 1H NMR
°¾"° (DMSO-d6! 300 MHz): δ 8.09-7.96 (m, 1 H), 7.71 -7.51 (m, 4H),
7.51 -7.41 (m, 2H), 6.89-6.77 (m, 1 H), 4.90 (s, 2H), 4.08-3.89 <oJ Q (m, 2H), 3.89-3.77 (m, 3H), 3.77-3.54 (m, 7H), 3.31 -3.17 (m,
1 H), 3.10-2.96 (m, 1 H), 2.62-2.43 (m, 2H), 2.04-1 .87 (m, 1 H), 1 .72-1 .55 (m, 1 H), 1 .55-1.36 (m, 1 H), 1 .36-1 .18 (m, 1 H). MS (ESI+): 523.23. HPLC (max plot) 99.6%; Rt 2.15 min
Intermediate X: Ethvl 1 -r4-(morpholin-4-vlmethvl)phenvll-1 ,4- dihvdropvrazolor3',4':4,51thiopvranor2,3-blpvridine-3-carboxvlate 5,5-dioxide
¾ -P 120 mg of the title compound. 1H NMR (DMSO-d6, 400 MHz): δ
8.70-8.70 (d, J = 3.3 Hz, 1 H), 7.63-7.59 (m, 1 H), 7.56-7.54 (m,
9 N"N 2H), 7.50-7.48 (m, 2H), 7.20-7.18 (d, J = 7.0 Hz, 1 H), 5.09 (s,
2H), 4.39-4.34 (m, 2H), 3.59 (m, 6H), 2.40 (m, 4H), 1 .34-1 .31 (t, J = 7.1 Hz, 3H). MS (ESI+): 469.0
Example 137: 3-(Morpholin-4-ylcarbonyl)-1 -f4-(morpholin-4-ylmethyl)phenyl1-1 ,4- dihvdrothiochromenor4,3-c1pyra -dioxide
To a suspension of 1 -[4-(hydroxymethyl)phenyl]-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3- carboxylic acid 5,5-dioxide (5.29 g; 14.29 mmol; 1 eq.) in DCE (212 mL) at 0°C are added dropwise thionyl chloride (3.17 mL; 42.88 mmol; 3 eq.) over 15 min then DMF (2 mL). The reaction mixture is stirred at 40°C for 6h and then at rt overnight. The solvent is removed under reduced pressure and the residue is taken up in DCE (106 mL). The resulting solution is added dropwise to a solution of morpholine (26 mL) in DCE (106 mL) at 0°C over 30 min after which reaction mixture is let to warm to rt and then heated to 50°C for 4h30. The solvent is removed under reduced pressure. The residue is taken up in DCM and washed with water, brine, dried over MgS04 and evaporated under vacuum. The residue is triturated in ether and then filtered off to afford 5.77 g (79%) of the title compound as an off-white solid. 1H NMR (DMSO-de) δ 8.04-8.01 (m, 1 H), 7.66-7.48 (m, 6H), 6.85-6.82 (m, 1 H), 4.91 (s, 2H), 3.97-3.94 (m, 2H), 3.68-3.60 (m, 12H), 2.43-2.40 (m, 4H). HPLC (max plot) 99.4%; Rt 1 .94 min; MS (ESI+): 509.0. CHN analysis: [C26H28N405S] Corrected: C61.40%, H5.55%, N1 1 .02%; Found: C61 .27%, H5.62%, N10.95%.
Procedure AM
Example 56: 3-(morpholin-4-ylcarbonyl)-1 -(piperidin-4-ylmethyl)-1 ,4- dihydrothiochromenor4,3-clpyrazole 5,5-dioxide
To a solution of tert-butyl 4-{[3-(morpholin-4-ylcarbonyl)-5,5-dioxidothiochromeno[4,3- c]pyrazol-1 (4H)-yl]methyl}piperidine-1 -carboxylate (0.1 g, 0.21 mmol) in DCM (2.0 mL) is added TFA (0.1 19 g, 1.05 mmol, 5 Eq) and the reaction mixture is stirred at room
temperature overnight. The crude reaction mixture is washed with sodium bicarbonate then brine and dried over MgSCv The crude residue is purified by flash chromatography to afford the title compound as a pale brown solid. 1H NMR (DMSO-d6, 400MHz) δ 8.03-7.98 (m, 2H), 7.88 (t, J = 7.5 Hz, 1 H), 7.73 - 7.70 (m, 1 H), 4.78 (s, 2H), 4.47 (t, J = 7.1 Hz, 2H), 3.91 (s, 2H), 3.66-3.63 (m, 6H), 2.98-2.95 (m, 2H), 2.00 (brs, 1 H), 1 .75-1 .69 (m, 1 H), 1 .48 - 1 .40 (m, 2H), 1 .24-1 .17 (m, 3H). MS (ESI+): 431 .0. HPLC (max plot) 97.2%; Rt 2.16 min.
Example described below is obtained following procedure AM:
Procedure AN
Example 57: 4-benzyl-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4- dihvdrothiochromenor4,3-clpyrazole 5,5-dioxide
To a solution of 3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide (100 mg; 0.24 mmol; 1.0 eq.) in THF (4.0 mL) is added NaH (55% w/w in mineral oil) (12.79 mg; 0.29 mmol; 1 .2 Eq.) . After 15 min stirring, benzyl bromide (34.81 μΙ_; 0.29 mmol; 1.2 eq.) is added and the reaction mixture is stirred at room temperature for 3h. The reaction is quenched with water and the product extracted with EtOAc. The combined organic phases are washed with brine, dried over MgS04 and concentrated under reduced pressure. The crude residue is recrystallized from EtOH and dried under vaccum to afford the title compound as an off-white solid. 1H NMR (DMSO-d6, 300MHz) δ 8.01 -7.98 (m, 1 H), 7.63-7.58 (m, 4H), 7.53-7.46 (m, 3H), 7.12-7.07 (m, 3H), 6.89-6.86 (m, 2H), 6.66-6.64 (m, 1 H), 5.29-5.25 (m, 1 H), 3.93-3.88 (m, 1 H), 3.63-3.53 (m, 5H), 3.45-3.36 (m, 2H), 3.26-3.20 (m, 1 H), 2.76-2.69 (m, 1 H). UPLC/MS: (ES+): 500.2, (ES-): 498.3. HPLC (max plot) 97.6%; Rt 4.32 min. Example 58: 4-(cvclopropylmethyl)-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4- dihydrothio chromenor4,3-c1pyraz le 5,5-dioxide
Following the protocol outlined in Procedure AN, 4-(cyclopropylmethyl)-3-(morpholin-4- ylcarbonyl)-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3- (morpholin-4-yl carbonyl)-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and cyclopropylmethyl bromide to afford the title compound as a white solid. UPLC/MS: (ES+): 464.1. HPLC (max plot) 98.1 %; Rt 4.01 min.
Example 59: 4-ethyl-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
Following the protocol outlined in Procedure AN, 4-ethyl-3-(morpholin-4-ylcarbonyl)-1 -phenyl- 1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3-(morpholin-4-yl carbonyl)-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and iodoethane to afford the title compound as a white solid. 1H NMR (DMSO-d6, 300MHz) δ 8.03-8.00 (m, 1 H), 7.67-7.53 (m, 7H), 6.84-6.81 (m, 1 H), 4.85-4.80 (m, 1 H), 3.99-3.95 (m, 2H), 3.80-3.50 (m, 6H), 2.08-1 .95 (m, 1 H), 1 .53-1 .38 (m, 1 H), 0.82 (t, J = 7.4 Hz, 3H). HPLC (max plot) 99.8%; Rt 3.67 min. Example 60: 4,4-dimethyl-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4- dihydrothiochromenor4,3-c1pyrazo -dioxide
Following the protocol outlined in Procedure AN, 4,4-dimethyl-3-(morpholin-4-ylcarbonyl)-1 - phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3-(morpholin-4- yl carbonyl)-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and iodomethane to afford the title compound as a white solid. 1H NMR (DMSO-d6, 300MHz) δ 8.06-8.03 (m, 1 H), 7.67-7.56 (m, 5H), 7.51 -7.48 (m, 2H), 6.83-6.80 (m, 1 H), 3.72-3.65 (m, 4H), 3.59-3.50 (m, 4H), 1.60 (s, 6H). HPLC (max plot) 100%; Rt 3.40 min. Example 112 : 4-(3-Methoxypropyl)-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4-dihydro thiochromenor4,3-clpyrazole 5,5-dioxide
Following the protocol outlined in procedure AN, 4-(3-methoxypropyl)-3-(morpholin-4- ylcarbonyl)-1 -phenyl-1 ,4-dihydro thiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3- (morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and 1 - bromo-3-methoxypropane to afford the title compound as a white solid. HPLC (max plot) 98.4%; Rt 3.64 min. MS (ESI+): 482.0.
Example 111 : 4-Benzyl-1 -methyl-3-(morpholin-4-ylcarbonyl)-1 ,4-dihydrothio
chromenor4,3-c1pyrazole 5,5-dioxide
Following the protocol outlined in procedure AN, 4-benzyl-1 -methyl-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothio chromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 1 -methyl-3- (morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and benzyl bromide to afford the title compound as a white solid. 1H NMR (DMSO-d6) δ 8.05-8.02 (m, 1 H), 7.96-7.93 (m, 1 H), 7.89-7.84 (m, 1 H), 7.76-7.70 (m, 1 H), 7.17-7.07 (m, 3H), 6.88-6.85 (m, 2H), 5.20 (q, J = 5.0 Hz, 1 H), 4.19 (s, 3H), 3.84-3.79 (m, 1 H), 3.65-3.50 (m, 5H), 3.39- 3.18 (m, 3H), 2.62-2.55 (m, 1 H). HPLC (max plot) 100.0%; Rt 3.35 min. MS (ESI+): 438.2.
Example 316: 4-Fluoro-3-(morpholin-4-ylcarbonyl)-1 -(tetrahydro-2H-pyran-4-yl)-1 ,4- dihvdrothiochromenor4,3-clpyrazole 5,5-dioxide
Following the protocol outlined in procedure AN, 4-fluoro-3-(morpholin-4-ylcarbonyl)-1 - (tetrahydro-2/-/-pyran-4-yl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 3-(morpholin-4-ylcarbonyl)-1 -(tetrahydro-2H-pyran-4-yl)-1 ,4-dihydrothiochromeno[4,3- c]pyrazole 5,5-dioxide and /V-fluoro-/V-chloromethyl-triethylenediamine-bis(tetrafluoroborate) to afford the title compound as a white solid. HPLC (max plot) 90.0%; Rt 3.12 min. MS (ESI+): 435.8.
Procedure AO Intermediate AO : terf-Butyl {3-r3-(morpholin-4-ylcarbonyl)-5,5-dioxido-1 -phenyl-1 ,4- dihvdrothiochromenor4,3-c1pyraz -4-vnpropyl)carbamate
To a solution of 3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide (150 mg; 0.37 mmol; 1 eq.) in THF (3 mL) is added potassium
bis(trimethylsilyl)amide (879.19 μΙ; 0.5 M; 0.44 mmol; 1.2 eq.) and then 3-(boc-amino)propyl bromide (104.68 mg; 0.44 mmol; 1 .20 eq.) The reaction mixture is stirred at rt for 2 days. The reaction is not complete even after addition of 2 eq. of 3-(boc-amino)propyl bromide. It is stopped by addition of water. The product is extracted with EtOAc and the combined organic phases are washed with brine, dried over MgS04 and concentrated under reduced pressure, to afford 217 mg (quant) of the title compound. HPLC (max plot) 83.1 %; Rt 4.08 min. MS (ESI-): 565.5.
Procedure AP
Example 123: 1 -Π -(Methylsulfonyl)piperidin-4-vn-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-clpyrazole 5,5-dioxide
To a solution of 3-(morpholin-4-ylcarbonyl)-1 -piperidin-4-yl-1 ,4-dihydrothiochromeno[4,3- c]pyrazole 5,5-dioxide (30 mg, 0.066 mmol) in THF (10 mL) is added triethylamine (40 Dl, 0.26 mmol) and the reaction mass is cooled to 0°C after which methane sulfonyl chloride (0.01 mL, 0.099 mmol) is slowly added. The reaction mixture is slowly warmed to RT then stirred for 12 h. After this time, water is added to the reaction mixture that is then extracted with EtOAc. The organic layer is separated, dried under sodium sulphate and concentrated under reduced pressure. Compound is then purified by neutral alumina column
chromatography (0.2% MeOH in chloroform) to afford the title compound as an off white solid. 1H NMR (DMSO-d6, 400 MHz): δ 8.20-8.18 (d, J = 7.0 Hz, 1 H), 7.78-7.75 (m, 1 H), 7.67- 7.64 (m, 1 H), 7.52-7.49 (m, 1 H), 4.70 (m, 3H), 4.18 (m, 2H), 4.05 (m, 2H), 3.81 (s, 6H), 2.99- 2.94 (t , J = 1 1 .4 Hz, 2H), 2.80 (s, 3H), 2.47-2.42 (m, 2H), 2.24-2.18 (m, 2H). MS (ESI+): 495.0. HPLC (max plot) 93.19%; Rt 3.18 min. Compounds described below are obtained following protocole outlined in Procedure AP
General procedure AQ Example 152: A/,A/-Dimethyl-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4- dihvdrothiochromenof4,3-c1pyrazol-7 -amine 5,5-dioxide
7-bromo-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5- dioxide (100 mg, 0.20 mmol, 1 eq.), NaOiBu (280 mg, 0.29 mmol, 1 .4 eq.) are taken in degassed toluene in a sealed tube. Tris(dibenylidene acetone)dipalladium(O) (5 mg, 0.005 mmol, 0.025 eq.), 2-ditertiary butyl phosphino-2',4',6'-triisopropyl biphenyl (3.5 mg, 0.008 mmol, 0.04 eq.) are then added followed by dimethylamine in THF (3 ml_, 2 M) and the reaction mixture is heated at 90°C for 16 h. After this time, reaction mixture is filtered through a celite pad, evaporated and purified by silica gel flash chromatography to afford the title compound as a pale brown solid. 1H NMR (DMSO-c/6, 400 MHz): δ 7.61 -7.59 (m, 3H), 7.51 - 7.49 (m, 2H), 7.10 (s, 1 H), 6.81 -6.79 (dd, J = 2.6, 9.0 Hz, 1 H), 6.61 -6.59 (d, J = 9.0 Hz, 1 H), 4.76 (s, 2H), 3.96 (m, 2H), 3.65 (m, 4H), 3.59 (m, 2H), 2.97 (s, 6H). MS (ESI+): 453.0. HPLC (max plot) 91 .39%; Rt 4.20 min.
Compounds described below are obtained following protocole outlined in procedure AQ
19 mg of the title compound as a pale brown solid. 1H NMR
(DMSO-d6, 400 MHz): δ 8.01 -8.0 (d, J = 2.1 Hz, 1 H), 7.62- o ο
7.59 (m, 2H), 7.44-7.40 (t, J = 8.2 Hz, 1 H), 7.19-7.17 (m, 1 H), 7.06 (s, 1 H), 6.91 -6.89 (m, 1 H), 6.84-6.82 (d, J = 8.8 Hz, 1 H), 4.88 (s, 2H), 3.93 (m, 2H), 3.72-3.69 (m, 4H), 3.66 (m, 4H), 3.61 -3.60 (m, 2H), 3.17-3.15 (m, 4H), MS (ESI+): 495.0.
HPLC (max plot) 98.46%; Rt 3.72 min
Example 155: 3-(Morpholin-4-vlcarbonvl)-1 -(4-morpholin-4-vlphenvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
3 mg of the title compound as an off white solid. 1H NMR (DMSO-d6, 400 MHz): δ 8.00-7.98 (t, J = 3.2 Hz, 1 H), 7.61 - 7.59 (m, 2H), 7.35-7.33 (m, 2H), 7.1 1 -7.09 (m, 2H), 6.93-6.91 (t, J = 4.6 Hz, 1 H), 4.87 (s, 2H), 3.95 (m, 2H), 3.76-3.75 (m, 4H), 3.65 (m, 4H), 3.60 (m, 2H), 3.24-3.23 (m, 4H). MS
(ESI+): 495.0. HPLC (max plot) 94.20%; Rt 3.61 min.
Example 166: {3-r3-(Morpholin-4-vlcarbonvl)-5,5-dioxidothiochromenor4,3-clpvrazol-1
(4H)-vllphenvl}phenvlamine
4 mg of the title compound as a pale brown solid. 1H NMR o o
(DMSO-d6, 400 MHz): δ 8.54 (s, 1 H), 8.02-8.0 (m, 1 H), 7.68- 7.65 (m, 2H), 7.45-7.41 (m, 1 H), 7.25-7.17 (m, 3H), 7.06-7.01 (m, 4H), 6.91 -6.85 (m, 2H), 4.87 (s, 2H), 3.94 (s, 2H), 3.66 (m, 2H), 3.66 (m, 4H), 3.61 -3.60 (m, 2H). MS (ESI+): 501 .0.
HPLC (max plot) 99.16%; Rt 4.71 min
Example 181 : 3-(Morpholin-4-vlcarbonvl)-1 -(3-pvrrolidin-1 -vlphenvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
12 mg of the title product as a pale brown solid. 1H NMR (DMSO-d6,400 MHz): δ 8.0-7.98 (dd, J = 2.6, 5.3 Hz,1 H), o o
7.63-7.59 (m, 2H), 7.35-7.31 (t, J = 7.8 Hz, 1 H), 6.98-6.95 (dd, J = 3.9, 6.2 Hz, 1 H), 6.75-6.73 (t, J = 7.4 Hz, 1 H), 6.58- 6.56 (m, 2H), 4.88 (s, 2H), 3.95 (m, 2H), 3.66 (m, 4H), 3.61 (m, 2H), 3.24-3.21 (m, 4H), 1 .96-1.92 (m, 4H). MS (ESI+): 479.0. HPLC (max plot) 99.33%; Rt 4.71 min
Example 368: 3-(Morpholin-' t-vlcarbonvD-1 -(1 -phenvlpvrrolidin-3-vD-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide 5 mg of the title compound as a white powder. MS (ESI+):
479.2. HPLC (max plot) 96.2%; Rt 4.58 min
Example 218: 3-(Morpholin-4 t-vlcarbonvl)-1 -(1 -phenvlpiperidin-3-vl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
7 mg of the title compound as an off white solid. 1H NMR (CDCIs, 400 MHz) δ 8.19-8.16 (dd, J = 7.7, 0.9 Hz, 1 H), 8.88- o o 8.70 (m,1 H), 8.68-8.65 (m, 2H), 7.37-7.27 (m, 2H), 6.98-6.92
(m, 2H), 6.90 (m,1 H), 4.88 (m,1 H), 4.76-4.63 (m, 2H), 4.18- 4.16 (m, 2H), 3.98-3.96 (m, 1 H), 3.80-3.74 (m,7H), 3.32-3.26 (t, J = 10.5 Hz, 1 H), 2.89-2.86-(m, 1 H), 2.29-2.25 (m,2H), 2.06-2.03 (m, 1 H), 1.95-2.0 (m,1 H). MS (ESI+): 493.0; HPLC (max plot) 99.09%; Rt 3.78 min.
Example 484: Enantiomer B of 3-(morpholin-4-vlcarbonvl)-1 -ri -pvridin-3-vlpiperidin-3- vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
7 mg of the title compound as a beige solid. 1H NMR (DMSO- d6, 300 mHz) δ 8.35-8.36 (d, J = 3 Hz, 1 H), 8.05-8.07 (d, J = o o 3 Hz, 1 H), 7.99-8.00 (m, 1 H), 7.88-7.89 (d, J = 3 Hz, 2H),
7.71-7.78 (m, 1 H), 7.36-7.40 (m, 1 H), 7.08-7.22 (m, 1 H), 4.97 (bs, 1 H), 4.81 (s, 2H), 4.10-4.12 (m, 1 H), 3.92 (m, 2H), 3.77- 3.81 (m, 1 H), 3.62-3.66 (m, 5H), 3.27-3.31 (m, 1 H), 2.83-2.92 (m, 1 H), 1.90-2.22 (m, 5H). MS (ESI+): 494.2. HPLC (max plot) 95.05%; Rt 2.18 min.
Intermediate AQ-1 : W-Methv -3-(morpholin-4-vlcarbonvl)-1 -phenvl-1 ,4- dihvdrothiochromenor4,3-clpvrazol-6-amine
102 mg (76%) yield of the title compound. MS (ESI+): 407.0.
Example 156: W-(2-Methoxvethvl)-3-(morpholin-4-vlcarbonvl)-1 -phenvl-1 ,4- dihvdrothiochromenor4,3-clpvrazol-8-amine 5,5-dioxide 9 mg of the title compound as a pale brown solid. 1H NMR
(DMSO-d6! 400 MHz): δ 7.63-7.54 (m, 4H), 7.53-7.52 (m, 2H), 6.77-6.74 (t, J = 5.6 Hz, 1 H), 6.71 -6.68 (dd, J = 2.0, 8.7 Hz, 1 H), 5.88 (s, 1 H), 4.68 (s, 2H), 3.94 (m, 2H), 3.65 (m, 4H), 3.59 (m, 2H), 3.19 (s, 3H), 3.17-3.12 (m, 2H), 2.49 (m, 2H). MS (ESI+): 483.0. HPLC (max plot) 95.75%; Rt 3.63 min procedure AR
Example 129: 8-Methyl-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4- dihydrothiochromenor4,3-clpyraz -dioxide
8-bromo-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5- dioxide (160 mg, 0.32 mmol) is dissolved in 1 ,4-Dioxane:water (4:2) to which is added methyltrifluoroborate potassium salt (80 mg, 0.65 mmol) and K2C03 (90 mg, 0.65 mmol). The reaction mixture is degassed for 5 min and is added S-phos (6.5 mg, 0.016 mmol) followed by palladium acetate (3.6 mg, 0.016 mmol). The reaction mixture is heated under microwave for 2 h at 120°C. After this time, the reaction mass is concentrated and purified by silica gel flash chromatography to afford the title compound as an off white solid. 1H NMR (DMSO-d6, 400 MHz): δ 7.90-7.88 (d, J = 8.0 Hz, 1 H), 7.64-7.62 (m, 3H), 7.54-7.52 (m, 2H), 7.43-6.55 (d, J = 7.5 Hz, 1 H), 6.55 (s, 1 H), 4.85 (s, 2H), 3.94 (m, 2H), 3.66 (m, 4H), 3.62 (m, 2H), 2.1 1 (s, 3H). MS (ESI+): 424.0. HPLC (max plot) 91 .94%; Rt 4.17 min.
Compounds described below are obtained following protocole outlined in procedure AR
Example 136: 1 -f1 -(Methylsulfonyl)piperidin-3-vn-3-(morpholin-4-ylcarbonyl)-1 ,4- dihvdrothiochromenor4,3-clpyrazole 5,5-dioxide Q. ο 21 mg of the title compound as a white solid. 1H NMR (DMSO-c/6,
400 MHz): δ 8.02-8.01 (d, J = 7.8 Hz, 1 H), 7.65-7.59 (m, 2H), 7.55-7.36 (m, 3H), 7.36 (s, 1 H), 6.82-6.80 (d, J = 7.8 Hz, 1 H), 4.90 (s, 2H), 3.93 (m, 2H), 3.67 (m, 4H), 3.60 (m, 2H), 3.52 (m, 2H), 3.47 (m, 4H), 2.31 (bs, 4H). MS (ESI+): 509.0. HPLC (max plot) 95.71 %; Rt 2.49 min
Intermediate AR-1 : 6 -Met l-3-(morpholin-4-vlcarbonvl)-1 -phenvl-1 ,4- dihvdrothiochromenor4,3-clpvrazole
40 mg (93%) of the title compound. ΊΗ NMR (DMSO-d6, 400 MHz): δ 7.48-7.45 (m, 3H), 7.42-7.39 (m, 2H), 7.07-7.05 (d, J = 7.5 Hz, 1 H), 6.81 (t, J = 7.7 Hz, 1 H), 6.67-6.65 (d, J = 7.5 Hz, 1 H), 4.18-4.16 (m, 4H), 3.81 (m, 4H), 3.75-3.74 (m, 2H), 2.42 (s, 3H).
Example 202: 6-Methvl-3-(morpholin-4-vlcarbonvl)-1 -phenvl-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
13 mg of the title compound. 1H NMR (DMSO-c/6, 400 MHz): δ 7.59-7.58 (m, 3H), 7.46-7.43 (m, 2H), 7.38-7.37 (m, 2H), 6.69- 6.67 (t, J = 5.1 Hz, 1 H), 4.89 (s, 2H), 3.97 (m, 2H), 3.66 (m, 4H), 3.61 (m, 2H), 2.65 (s, 3H). MS (ESI+): 424.0. HPLC (max plot) 96.76%; Rt 4.22 min.
Example 139: 7-Methvl-3-(morpholin-4-vlcarbonvl)-1 -phenvl-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
19 mg of the title compound as an off white solid. 1H NMR
°¾"° (DMSO-d6, 400 MHz): δ 7.83 (s, 1 H), 7.63-7.61 (m, 3H), 7.53- 7.50 (m, 2H), 7.39-7.37 (d, J = 8.3 Hz, 1 H), 6.71 -6.69 (d, J = 8.0 Hz, 1 H), 4.86 (s, 2H), 3.95 (m, 2H), 3.66 (m, 4H), 3.60 (m, 2H), 2.38 (s, 3H). MS (ESI+): 424.0. HPLC (max plot) 93.68%; Rt 4.18 min
Example 162: 3-(Morpholin-4-vlcarbonvl)-8-(morpholin-4-vlmethvl)-1 -phenvl-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
15.5 mg of the title compound as an off white solid. 1H NMR (DMSO-d6, 400 MHz): δ 7.96-7.94 (d, J = 8.0 Hz, 1 H), 7.64-7.62 (m, 3H), 7.54-7.52 (m, 3H), 6.86 (s, 1 H), 4.87 (s, 2H), 3.94 (m, 2H), 3.66 (m, 4H), 3.60 (m, 2H), 3.42 (m, 4H), 3.30 (m, 2H), 2.13 (m, 4H), MS (ESI+): 508.8. HPLC (max plot) 96.17%; Rt 2.54 mm
Procedure AS
Example 114: 8-f(4-Methylpiperazin-1 -yl)carbonvn-3-(morpholin-4-ylcarbonyl)-1 - phenyl-1 ,4-dihydrothiochrome -c1pyrazole 5,5-dioxide
To a s o l u t i o n 8-bromo-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4-dihydrothiochromeno[4,3- c]pyrazole 5,5-dioxide (200 mg, 0.4 mmol) in toluene (10 mL) is added Na2C03 (65 mg, 0.6 mmol) and /V-methyl piperidine (961 mg, 0.6 mmol). The reaction mixture is purged with nitrogen for 15 min after which it is purged with carbonmonoxide followed by palladium acetate (4.4 mg, 0.02 mmol) and Xanthphos (1 1 mg, 0.02 mmol). The reaction mixture is heated at 1 10°C and refluxed for 12 h under carbonmonoxide atmosphere. After this time, solvents are removed under reduced pressure and compound purified by silica gel flash chromatography to afford the title compound as an off white solid. 1H NMR (DMSO-c/6, 400 MHz): δ 8.08-8.06 (d, J = 7.6 Hz, 1 H), 7.63-7.61 (m, 4H), 7.57-7.55 (m, 2H), 6.71 (s, 1 H), 4.93 (s, 2H), 3.94 (m, 2H), 3.66-3.60 (m, 6H), 3.45 (bs, 2H), 3.00 (bs, 2H), 2.21 (m, 2H), 2.16 (s, 3H), 2.05 (bs, 2H). MS (ESI+): 536.0. HPLC (max plot) 95.74%; Rt 2.45 min.
Example 115: A/,A/-Dimethyl-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4-
Following new Procedure AS, /V,/V-dimethyl-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole-8-carboxamide 5,5-dioxide is obtained from 8-bromo-3- (morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and Λ/,/V-dimethylamine to afford the title compound as an off white solid. 1H NMR (DMSO-c/6, 400 MHz): δ 8.08-8.06 (d, J = 8.0 Hz, 1 H), 7.65-7.54 (m, 6H), 6.75 (s, 1 H), 4.94 (s, 2H), 3.94 (m, 2H), 3.66 (m, 4H), 3.60 (m, 2H), 2.84 (s, 3H), 2.62 (s, 3H). MS (ESI+): 481. HPLC (max plot) 95.16%; Rt 3.19 min.
Example 116: 3,8-Bis(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4-dihydrothiochromenof4,3- clpyrazole 5,5-dioxide
Following new Procedure AS, 3,8-bis(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 8-bromo-3-(morpholin-4- ylcarbonyl)-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and morpholine to afford the title compound as an off white solid. 1H NMR (DMSO-c/6, 400 MHz): δ 8.09-8.07 (d, J = 8.0 Hz, 1 H), 7.67-7.64 (m, 4H), 7.57-7.54 (m, 2H), 6.75 (s, 1 H), 4.93 (s, 2H), 3.94 (m, 2H), 3.66 (m, 4H), 3.61 (m, 2H), 3.49 (m, 4H), 3.3 (m, 2H), 3.03 (m, 2H). MS (ESI+): 523.0. HPLC (max plot) 95.86%; Rt 3.17 min.
Example 117: 3-(Morpholin-4-ylcarbonyl)-1 -phenyl-8-(piperidin-1 -ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
Following new Procedure AS, 3-(morpholin-4-ylcarbonyl)-1 -phenyl-8-(piperidin-1 -ylcarbonyl)- 1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide is obtained from 8-bromo-3-(morpholin- 4-ylcarbonyl)-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and piperidine to afford the title compound as an off white solid. 1H NMR (DMSO-c/6, 400 MHz): δ 8.07-8.05 (d, J = 8.0 Hz, 1 H), 7.63-7.53 (m, 6H), 6.68 (s, 1 H), 4.93 (s, 2H), 3.94 (m,2H), 3.66 (m, 4H), 3.61 (m, 2H), 3.42 (m, 2H), 2.98 (m, 2H), 1 .54 (m, 2H), 1 .40 (m, 2H), 1.22 (m, 2H). MS (ESI+): 521 .0. HPLC (max plot) 93.95%; Rt 3.89 min.
Procedure AT Example 157: 1 -Biphenyl-3-yl-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
1 -(3-Bromophenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5- dioxide (100 mg, 0.20 mmol), phenylboronic acid (37 mg, 0.31 mmol), cesium fluoride (124 mg, 0.82 mmol) are taken in dioxane-water (2:1 ) and bubbled with nitrogen for 5 min. Then bis(triphenyl phosphine)dichloro palladium(ll) (21 g, 0.03 mmol) is added to reaction mass and heated under microwave irradiation for 1 h at 90 C. The reaction mixture is filtered through a celite pad, concentrated under reduced pressure and purified by flash
chromatography to afford the title compound as a pale yellow solid. 1H NMR (DMSO-c/6, 400 MHz): δ 8.03-8.01 (m,1 H), 7.95-7.93 (d, J = 8.0 Hz, 1 H),7.83 (s, 1 H), 7.72-7.70 (m, 4H), 7.68- 7.60 (m, 2H), 7.59-7.47 (m, 3H), 7.45-7.40 (m, 1 H), 4.91 (s, 2H), 3.96 (m, 4H), 3.62-3.61 (m, 2H). MS (ESI+): 486.0. HPLC (max plot) 98.53%; Rt 4.84 min.
Compounds described below are obtained following protocole outlined in procedure AT
Example 160: 1 -(2'-Methylbiphenyl-3-yl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihvdrothiochromenor4,3-clpyrazole 5,5-dioxide
54 mg of the title compound as a pale yellow solid. 1H NMR
(DMSO-d6, 400 MHz): δ 8.01 -8.00 (d, J = 3.6 Hz, 1 H), 7.72-7.70 (m, 1 H), 7.68-7.55 (m, 4H), 7.43 (s, 1 H), 7.29-7.21 (m, 4H), 6.97-6.95 (dd, J = 3.7, 6.2 Hz, 1 H), 4.90 (s, 2H), 3.95 (m, 2H), 3.66 (m, 4H), 3.61 -3.60 (m, 2H), 2.21 (s, 3H). MS (ESI+): 500.0. HPLC (max plot)
97.85%; Rt 5.10 min.
Example 161 : 1 -(2'-Methylbiphenyl-4-yl)-3-(morpholin-4-ylcarbonyl)-1 ,4- dihvdrothiochromenor4,3-clpyrazole 5,5-dioxide 35 mg of the title compound as a pale yellow solid. 1H NMR
(DMSO-d6, 400 MHz): δ 8.04-8.01 (d, J = 8.7 Hz, 1 H), 7.66-7.58 (m, Ν\ -N' 6H), 7.34-7.31 (m, 4H), 6.94-6.92 (d, J = 7.3 Hz, 1 H), 4.91 (s, 2H),
3.68-3.63 (m, 6H), 2.30 (s, 3H). MS (ESI+): 499.8. HPLC (max plot) 97.87%; Rt 5.15 min
Example 197: 1 -r3-(3-Furvl)phenvll-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
63 mg of the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 8.35 o o (s, 1 H), 8.02-8 (m, 1 H), 7.90-7.88 (d, J = 7.9 Hz, 1 H),7.86 (s,1 H),
7.76 (s, 1 H), 7.63-7.59 (m, 1 H), 7.57 (m, 3H), 7.36-7.34 (d, J = 7.6 Hz, 1 H), 7.07 (s, 1 H), 6.91 -6.89 (d, J = 8.6 Hz, 1 H), 4.91 (s, 2H), 3.95-3.94 (m, 2H), 3.67 (m, 4H), 3.62-3.61 (m, 2H). MS
(ESI+):476.0. HPLC (max plot) 98.26%; Rt 4.5 min.
Example 184: 1 -Γ3-ί3,5- Dimethvlisoxazol-4-vl)phenvll-3-(morpholin-4-vlcarbonvD-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
o o 38 mg of the title compound as a white solid. 1H NMR (DMSO-c/6,
400 MHz): δ 8.03-8.01 (m, 1 H), 7.65-7.60 (m, 3H), 7.57-7.53 (m, 2H), 6.95-6.94 (d, J = 7.0 Hz, 1 H), 4.9 (s, 2H), 3.95 (m, 2H), 3.66
° i / ° (m, 4H), 3.62-3.61 (m, 2H), 2.37 (s, 3H), 2.18 (s, 3H). MS (ESI+):
505.0. HPLC (max plot) 97.82%; Rt 4.14 min
Example 185: 1 -Γ3-(1 -Methvl-1 H-pvrazol-4-vl)phenvll-3-(morpholin-4-vlcarbonvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
17 mg of the title compound as a pale brown solid. 1H NMR (DMSO-d6, 400 MHz): δ 8.01 -8.0 (m, 1 H), 7.84-7.63 (m, 2H), 7.63- 7.58 (m, 2H), 7.58-7.55 (m, 3H), 7.29-7.26 (m, 1 H), 6.91 -6.89 (m, 1 H), 4.90 (s, 2 H), 3.95 (m, 2H), 3.83 (s, 3H), 3.67 (m, 4H), 3.62
(m, 2H). MS (ESI+): 490.0. HPLC (max plot) 97.49%; Rt 3.64 min
Example 186: 5-{3-r3-(Morpholin-4-vlcarbonvl)-5,5-dioxidothiochromenor4,3-clpvrazol-
1 (4H)-vllphenvl}pvrimidin-2 -amine
o o 51 mg of the title compound as a pale brown solid. 1H NMR
(DMSO-d6, 400 MHz): δ 8.63 (s, 2H), 8.02-8.0 (d , J = 7.4 Hz, 1 H), 7.90-7.88 (m, 2H), 7.65-7.58 (m, 3H), 7.40-7.38 (d, J = 7.9 Hz, 1 H), 6.95-6.93 (d, J = 7.7 Hz, 1 H), 6.89 (s, 2H), 4.91 (s, 2H), 3.96 (m, 2H), 3.67 (m, 4H), 3.61 (m, 2H). MS (ESI+): 503.0. HPLC
(max plot) 98.86%; Rt 2.88 min
Example 187: 3-(Morpholin-4-vlcarbonvl)-1 -(3-pvridin-4-vlphenvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
12 mg of the title compound as a pale brown solid. 1H NMR o o (DMSO-d6, 400 MHz): δ 8.66-8.65 (d, J = 4.6 Hz, 2H), 8.09-8.07
(d, J = 8.2 Hz, 1 H), 8.03-8.02 (d, J = 8.3 Hz, 2H), 7.78-7.76 (m, 3H), 7.63-7.58 (m, 3H), 6.94-6.92 (d, J = 7.8 Hz, 1 H), 4.92 (s, 2H), 3.95 (bs, 2H), 3.67 (bs, 4H), 3.61 (bs, 2H). MS (ESI+): 487.0. HPLC (max plot) 97.27%; Rt 2.68 min
Example 188: 3-(Morpholin-4-vlcarbonvl)-1 -f3-ri -(2-morpholin-4-vlethvl)-1 H-pvrazol-4- vllphenvl}-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
25 mg of the title compound as a white solid. 1H NMR (DMSO-c/6, 400 MHz): δ 8.30 (s, 1 H), 8.02-8.0 (m, 1 H), 7.98 (s,1 H), 7.84- 7.83 (d, J = 7.9 Hz, 1 H), 7.76 (s, 1 H), 7.61 -7.55 (m, 3H), 7.28- 7.27 (d, J = 7.2 Hz, 1 H), 6.92-6.90 (d, J = 8.0 Hz, 1 H), 4.90 (s, 2H), 4.22-4.19 (t, J = 6.4 Hz, 2H), 3.95 (m, 2H), 3.67 (m, 4H), 3.62-3.61 (m, 2H), 3.52-3.50 (m, 4H), 2.72-2.68 (t, J = 6.5 Hz,
2H), 2.38 (m, 4H). MS (ESI+): 589.0. HPLC (max plot) 99.69%; Rt 3.04 min.
Example 198: 3-(Morpholin-4-vlcarbonvl)-1 -(3-pvridin-3-vlphenvl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
48 mg of the title compound. 1H NMR (DMSO-d6, 400 MHz): δ 8.94 (s, 1 H), 8.61 -8.59 (d, J = 4.7 Hz, 1 H), 8.15-8.13 (d, J = 8.0 Hz, 1 H), 8.03-7.97 (m, 3H),7.75-7.71 (t, J = 7.9 Hz, 1 H),7.65- 7.48 (m, 4H), 6.96-6.95 (d, J = 7.7 Hz, 1 H), 4.91 (s, 2H), 3.96 (m, 2H), 3.67 (m, 4H), 3.62-3.61 (m, 2H). MS (ESI+): 487.0. HPLC (max plot) 99.58%; Rt 2.68 min.
Procedure AU
Example 164: {3-f3-(Morpholin-4-ylcarbonyl)-5,5-dioxidothiochromenof4,3-c1pyrazol-1 (4H)-yl1phenyl)amine
1 -(3-bromophenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5- dioxide (150 mg, 0.31 mmol), cupric acetate (6.1 mg, 0.031 mmol), cesium carbonate (200 mg, 0.616 mmol) and acetyl acetone (13 D l_, 0.123 mmol) are taken in a sealed tube to which is added a solution of DMF purged with NH3 gas. The reaction mixture is heated to 90°C for 24 h. After this time, reaction mixture is concentrated under reduced pressure and purified by silica gel column chromatography (100% EtOAc) to afford the title compound as a pale brown solid. 1H NMR (DMSO-d6, 400 MHz): δ 7.99-7.97 (m, 1 H), 7.62-7.60 (m, 1 H), 7.24-7.20 (t, J = 7.8 Hz, 1 H), 6.98-6.95 (m, 1 H), 6.75-6.73 (d, J = 9.3 Hz, 1 H), 6.58-6.56 (m, 2H), 5.57 (s, 2H), 4.87 (s, 2H), 3.95 (m, 2H), 3.66 (m, 6H). MS (ESI+): 425.0.; HPLC (max plot) 94.69%; Rt 2.65 min.
Example 165: 3-(Morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4-dihydrothiochromenof4,3- clpyrazol-7 -amine 5,5-dioxide
Following the protocol outlined in Procedure AU, 3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazol-7-amine 5,5-dioxide is obtained from 7-bromo-3- (morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and NH3 gas to afford the title compound as a pale brown solid. 1H NMR (DMSO-c/6, 400 MHz): δ 7.60-7.58 (m, 3H), 7.49-7.47 (m, 2H), 7.16 (s, 1 H), 6.54 (m, 1 H), 6.47 (m, 1 H), 6.15 (s, 2H), 4.72 (s, 2H), 3.95 (m, 2H), 3.65 (m, 4H), 3.59 (m, 2H). MS (ESI+): 425.0. HPLC (max plot) 95.93%; Rt 3.36 min.
Example 65: 3-(Morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4-dihydrothiochromenof4,3- clpyrazol-8-amine 5,5-dioxide
Following the protocol outlined in Procedure AU, 3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4- dihydrothiochromeno[4,3-c]pyrazol-8-amine 5,5-dioxide is obtained from 8-bromo-3- (morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide and NH3 gas to afford the title compound as a pale brown solid. 1 H NMR (400 MHz, DMSO-d6) δ = 7.61 -7.58 (m, 4H), 7.50-7.48 (m, 2H), 6.62 (dd, J = 8.6, 2.1 Hz, 1 H), 6.04 (s, 2H), 6.00 (d, J = 1 .9 Hz, 1 H), 4.65 (s, 2H), 3.92 (bs, 2H), 3.65-3.59 (m, 6H). MS (ESI+): 425.0. HPLC (max plot) 94.64%; Rt 3.1 1 min. Examples described below are obtained following protocole outlined in procedure Z, described above:
10.3 mg of the title compound as an off white solid. 1H NMR
(DMSO-de, 400 MHz) δ 8.17-8.15 (dd, J = 7.7, 1 .1 Hz, 1 H),7.79-7.75 (t, J = 7.5 Hz, 1 H), 7.67-7.61 (m, 1 H), 4.82 (m, 1 H), 4.75-58 (m, 2H), 4.16 (m, 2H), 3.80-(m, 6H), 3.19-3.17 (m,1 H), 2.97-2.94 ( m, 1 H), 2.54-2.48 (m, 1 H), 2.4 ( s, 3H), 2.18-2.17-(m, 3H), 2.14-2.10 (m, 2H). MS (ESI+): 431.0; HPLC (max plot) 94.65%; Rt 2.29 min
Example 405: 3-(Morpholin-4-vlcarbonvl)-1 -f 1 -r2-(tetrahvdro-2H-pvran-4-vl)ethvll azetidin-3-vl>-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
107 mg of the title compound as a white foam. 1H NMR
°¾''° (DMSO-de) δ 8.04-8.01 (m, 1 H), 7.92-7.83 (m, 2H), 7.76-7.70
(m, 1 H), 5.54-5.45 (quint, J = 6.75 Hz, 1 H), 4.79 (s, 2H), 3.95- 3.78 (m, 6H), 3.67 (s, 6H), 3.45-3.40 (m, 2H), 3.30-3.21 (m, 2H), 1 .57-1 .53 (m, 3H), 1 .28-1 .1 1 (m, 4H), 2.53 (m, 2H). HPLC (max plot) 98.0%; Rt 6.13 min. MS (ESI+): 501.2.
Example 299: 2-{3-r3-(Morpholin-4-vlcarbonvl)-5,5-dioxidothiochromenor4,3-clpvrazol-
1 (4H)-vllpvrrolidin-1 -vl}ethvl acetate
270 mg of the title compound as a brown foam.. HPLC (max plot) 99.0%; Rt 2.28 min. (ESI+): 465.2:
Example 300: 3-(Morpholin-4-vlcarbonvl)-1 -Γ1 -(tetrahvdro-2H-pvran-4-vl)pvrrolidin-3- vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
47 mg of the title compound as a white foam. 1H NMR (DMSO- de) δ 8.03 (d, J = 7.7 Hz, 1 H), 8.00-7.95 (m, 1 H), 7.93-7.86 (m, 1 H), 7.73 (t, J = 7.7 Hz, 1 H), 5.54-5.42 (m, 1 H), 4.85-4.72 (m, 2H), 4.01 -3.94 (m, 2H), 3.88-3.80 (m, 2H), 3.71 -3.62 (m, 6H), 3.36-3.25 (m, 4H), 2.92-2.88 (m, 1 H), 2.79 (t, J = 6.7 Hz, 2H),
2.48-2.15 (m, 3H), 1 .83-1.73 (m, 2H), 1.47-1 .27 (m, 2H). HPLC (max plot) 100%; Rt 2.20 min. MS (ESI+): 487.2.
Example 303: 3-(Morpholin-4-vlcarbonvl)-1 -Γ1 -(tetrahvdrofuran-3-vlmethvl)pvrrolidin-3- vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
vl)ethvHpvrrolidin-3-vl>-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide 32 mg of the title compound as a yellow oil. 1H NMR (DMSO- d6) δ 7.68-7.61 (m, 1 H), 7.38 (d, J = 7 Hz, 1 H), 7.25-7.21 (m, 1 H), 5.27-5.18 (m, 1 H), 4.68-4.66 (m, 2H), 4.14-4.06 (m, 2H), 3.92-3.84 (m, 4H), 3.74-3.68 (m, 8H), 3.38-3.20 (m, 2H), 3.00- 2.93 (m, 1 H), 2.84-2.48 (m, 6H), 1 .58-1 .39 (m, 4H). HPLC (max plot) 96.2%; Rt 2.51 min. MS (ESI+): 533.3.
Example 402: Enantiomer A of 3-(morpholin-4-vlcarbonvl)-1 -r-1 -(tetrahvdro-2H-pvran-
4-vl)pvrrolidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer A of 3-(morpholin-4-ylcarbonyl)-1 - pyrrolidin-3-yl-1 ,4-dihydrothio chromeno[4,3-c]pyrazole 5,5- dioxide to give 55 mg of the title compound as a white foam. 1H NMR (DMSO-d6, 300 MHz): δ 8.03 (d, J = 6.7 Hz, 1 H), 7.97 (d, J = 7.8 Hz, 1 H), 7.90 (t, J = 7.7 Hz, 1 H), 7.73 (t, J = 7.3 Hz, 1 H), 5.47 (s, 1 H), 4.78 (s, 2H), 3.97 (s, 2H), 3.84 (d, J = 1 1 .6 Hz, 2H), 3.67 (s, 5H), 3.32-3.23 (m, 3H), 2.91 (dd, J = 9.6, 5.1 Hz, 1 H), 2.79 (t, J = 6.9 Hz, 2H), 2.47-2.1 1 (m, 4H), 1 .78 (d, J
= 12.4 Hz, 2H), 1 .49-1 .27 (m, 2H). MS (ESI+): 487.4. HPLC (max plot) 70.1 %; Rt 1 .92 min.
Example 403: Enantiomer B of 3-(morpholin-4-vlcarbonvl)-1 -ri -(tetrahvdro-2H-pvran-4- vl)PVrrolidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)-1 - pyrrolidin-3-yl-1 ,4-dihydrothio chromeno[4,3-c]pyrazole 5,5- dioxide to give 58 mg of the title compound as a white foam. 1H NMR (DMSO-d6, 300 MHz): δ 8.03 (dd, J = 7.8, 1 .2 Hz, 1 H), 7.97 (d, J = 7.6 Hz, 1 H), 7.89 (t, J = 7.7 Hz, 1 H), 7.74 (dd, J = 10.9, 4.2 Hz, 1 H), 5.47 (s, 1 H), 4.78 (d, J = 1 .1 Hz, 2H), 4.00- 3.93 (m, 2H), 3.84 (d, J = 1 1 .3 Hz, 2H), 3.67 (s, 6H), 3.31 -3.24 (m, 3H), 2.91 (dd, J = 9.5, 5.1 , 1 H), 2.79 (t, J = 6.8 Hz, 2H),
2.47-2.12 (m, 4H), 1 .78 (d, J = 12.3 Hz, 2H), 1 .49-1 .27 (m, 2H).. MS (ESI+): 487.4. HPLC (max plot) 66.1 %; Rt 1 .86 min.
Example 285: 3-(morpholin-4-vlcarbonvl)-1 -f 1 -r2-(tetrahvdro-2H-pvran-4-vl)ethvll piperidin-4-vl}-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide 65 mg of the title compound as a white solid. 1H NMR (DMSO- d6) δ δ 8.04 (d, J = 7.7 Hz, 1 H), 7.96-7.83 (m, 2H), 7.73 (t, J = 7.3 Hz, 1 H), 4.76 (d, J = 16.0 Hz, 3H), 3.97 (s, 2H), 3.82 (dd, J = 1 1 .0, 3.5 Hz, 2H), 3.66 (s, 5H), 3.27 (t, J = 1 1.5 Hz, 2H), 2.97 (d, J = 6.0 Hz, 2H), 2.43-2.27 (m, 2H), 2.23-1 .95 (m, 6H), 1 .66-
1 .30 (m, 5H), 1.28-1 .03 (m, 3H). HPLC (max plot) 98.8%; Rt 2.10 min. MS (ESI+): 529.3.
Example 305: 3-(morpholin-4-vlcarbonvl)-1 -Γ1 -(tetrahvdro-2H-pvran-4-vl
methvl)piperidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
56 mg of the title compound as a white solid. 1 H NMR (DMSO- d6) δ 8.06 (dd, J = 1 .2, 7.8 Hz, 1 H), 7.93-7.88 (m, 1 H), 7.84- 7.81 (m, 1 H), 7.78-7.72 (m, 1 H), 4.82-4.75 (m, 3H), 3.93-3.90 (m, 2H), 3.85-3.77 (m, 2H), 3.69-3.62 (m, 6H), 3.27-3.19 (m, 2H), 3.13-3.10 (m, 1 H), 2.87-2.84 (m, 1 H), 2.37-2.30 (m, 1 H),
2.25-2.15 (m, 3H), 2.04-1.53 (m, 7H), 1 .16-1 .03 (m, 2H). HPLC (max plot) 100%; Rt 1 .81 min. MS (ESI+): 514.9.
Example 415: 3-(Morpholin-4-vlcarbonvl)-1 -(1 -oxetan-3-vlpiperidin-3-vl)-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
21 mg of the title compound as a white solid. 1H NMR (DMSO- d6) δ 1 H NMR (300 MHz, DMSO) δ 8.17-7.91 (m, 2H), 7.91 - 7.66 (m, 2H), 5.02-4.67 (m, 3H), 4.62-4.29 (m, 4H), 3.88 (s, 2H), 3.65 (s, 7H), 3.56-3.44 (m, 2H), 3.00 (d, J = 9.7 Hz, 1 H), 2.75 (d, J = 8.1 Hz, 2H), 2.29 (t, J = 10.4 Hz, 1 H), 2.22-2.07 (m, 1 H), 2.04-1 .59 (m, 5H). HPLC (max plot) 98.4%; Rt 5.92 min. MS (ESI+): 473.3.
Example 224: 3-(Morpholin-4-vlcarbonvl)-1 -f 1 -r2-(tetrahvdro-2H-pvran-4-vl)ethvll piperidin-3-vl>-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
120 mg of the title compound as a white solid. 1H NMR q. .p (DMSO-de) δ 8.06 (dd, J = 7.8, 1 .2 Hz, 1 H), 7.95-7.90 (m, 1 H),
7.84-7.82 (m, 1 H), 7.78-7.73 (m, 1 H), 4.79 (s, 3H), 3.93-3.90 (m, 2H), 3.82-3.77 (m, 2H), 3.70-3.62 (m, 6H), 3.29-3.21 (m, 2H), 3.16-3.09 (m, 1 H), 2.92-2.85 (m, 1 H), 2.42-2.28 (m, 3H), 2.18-2.09 (m, 1 H), 2.01 -1.88 (m, 2H), 1 .83-1 .66 (m, 2H), 1 .57- 1 .44 (m, 3H), 1 .39-1 .31 (m, 2H), 1 .19-1 .05 (m, 2H). HPLC (max plot) 99.3%; Rt 2.00 min. MS (ESI+): 528.8. CHN
analysis: [C27H36N405S] Corrected:
C61 .34%,H6.86%,N10.60%; Found:
C61 .13%,H6.67%,N10.44%.
Example 293: 3-(Morpholin-4-vlcarbonvl)-1 -Γ1 -(tetrahvdro-2H-pvran-4-vl)piperidin-3-vll-
1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
1 1 mg of the title compound as a white solid. 1 H NMR (DMSO-
°¾''° d6) δ 8.06 (dd, J = 1 .2, 7.8 Hz, 1 H), 7.98-7.82 (m, 1 H), 7.82- 7.72 (m, 2H), 4.79-4.73 (m, 3H), 3.93-3.84 (m, 4H), 3.69-3.63 (m, 6H), 3.29-3.16 (m, 3H), 2.94-2.91 (m, 1 H), 2.59-2.50 (m, 2H), 2.24-2.12 (m, 2H), 2.04-1 .65 (m, 5H), 1 .51 -1 .39 (m, 2H). HPLC (max plot) 97.8%; Rt 1 .73 min. MS (ESI+): 501 .3.
Example 374: Enantiomer B of 3-(morpholin-4-vlcarbonvl)-1 -M -(tetrahvdro-2H-pvran-4- vl) piperidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)-1 - [piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5- dioxide to give 42 mg of the title compound as a white fluffy solid. 1H NMR (300 MHz, DMSO) δ 8.05 (dd, J = 7.8, 1 .2 Hz, 1 H), 7.94 (dd, J = 1 1 .5, 4.0 Hz, 1 H), 7.86-7.66 (m, 2H), 4.77 (m, 3H), 4.02-3.78 (m, 4H), 3.66 (m, 2H), 3.22 (m, 5H), 2.92 (d,
J = 1 1.0 Hz, 1 H), 2.69-2.53 (m, 4H), 2.18 (m, 2H), 2.06-1.76 (m, 2H), 1.67 (m, 3H), 1 .56-1 .29 (m, 2H). HPLC (max plot) 99%; Rt 2.19 min. MS (ESI+): 501 .5.
Example 451 : Enantiomer B of 1 -ri '-methvl-1 ,4'-bipiperidin-3-vll-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)-1 - [piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5- . o dioxide to give 43 mg of the title compound as a white solid. 1H
NMR (DMSO-d6, 300 MHz): δ 8.07-8.04 (m, 1 H), 7.97-7.92 (m, 1 H), 7.82-7.72 (m, 2H), 4.79-4.72 (m, 3H), 3.91 (m, 2H), 3.66 (s, 6H), 3.17-3.13 (m, 2H), 2.91 -2.79 (m, 3H), 2.57-2.50 (m, 1 H), 2.35-1 .44 (m, 14H). MS (ESI+): 514.4. HPLC (max plot) 98.5%; Rt 1 .52 min
Example 459: Enantiomer B of 1 -ri '-methvl-1 ,3'-bipiperidin-3-vll-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)-1 - [piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5- dioxide to give 21 mg of the title compound as an off-white. 1H NMR (DMSO-d6! 300 MHz): δ 7.97-7.92 (m, 1 H), 7.68-7.56 (m, 2H), 4.90 (s, 2H), 4.77 (bs, 1 H), 3.91 (bs, 2H), 3.66-3.17 (m,
17H), 2.96 (bs, 1 H), 2.73 (m, 3H), 2.12-1.74 (m, 6H). MS (ESI+): 514.3. HPLC (max plot) 98.9%; Rt 1.58 min
Example 466: Enantiomer B of 3-(morpholin-4-vlcarbonvl)-1 -ri -(pvridin-3- vlmethvl)piperidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)-1 - [piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5- . o dioxide to give 162 mg of the title compound as a white solid.
1H NMR (DMSO-d6, 300 MHz): δ 8.53 (m, 1 H), 8.46-8.44 (m, 1 H), 8.04-8.01 (m, 1 H), 7.90-7.85 (m, 1 H), 7.77-7.70 (m, 1 H), 7.65-7.62 (m, 1 H), 7.39-7.35 (m, 1 H), 4.82-4.76 (m, 3H), 3.90 (m, 2H), 3.71 -3.55 (m, 8H), 3.08-3.05 (m, 1 H), 2.91 -2.87 (m, 1 H), 2.43-1 .73 (m, 7H). MS (ESI+): 508.3. HPLC (max plot) 99.5%; Rt 1 .60 min.
Example 473: Enantiomer B of 3-(morpholin-4-vlcarbonvl)-1 -ri -(pvridin-4- vlmethvl)piperidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)-1 - [piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5- q. o dioxide to give 187 mg (77%) of the title compound as a white solid. 1H NMR (DMSO-d6, 300 MHz): δ 8.50-8.52 (m, 2H), 8.04- 8.02 (m, 1 H), 7.95-7.90 (m, 1 H), 7.77-7.69 (m, 2H), 7.37-7.36
O-/ (m, 1 H), 4.84-4.76 (m, 3H), 3.89 (m, 2H), 3.71 -3.54 (m, 8H), 3.06-3.03 (m, 1 H), 2.90-2.86 (m, 1 H), 2.44-2.37 (m, 1 H), 2.15- 1 .83 (m, 6H). MS (ESI+): 508.3. HPLC (max plot) 98.5%; Rt 1 .57 min.
Example 361 : Enantiomer 3 of 3-(morpholin-4-vlcarbonvl)-1 -ri -(tetrahvdro-2H-pvran-4- vlmethvl) piperidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)-1 - [piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5- dioxide to give 120 mg of the title compound as a white foam.
Q. .p 1 H NMR (DMSO-d6): δ 8.05 (d, J = 7.8 Hz, 1 H), 7.89 (d, J =
7.2 Hz, 1 H), 7.82 (d, J = 7.6 Hz, 1 H), 7.75 (t, J = 7.6 Hz, 1 H), 5.76 (s, 1 H), 4.79 (s, 3H), 3.91 (s, 2H), 3.81 (s, 2H), 3.66 (s, 6H), 3.22 (t, J = 1 1 .6 Hz, 2H), 3.1 1 (d, J = 9.3 Hz, 1 H), 2.85 (d, J = 10.7 Hz, 1 H), 2.33 (t, J = 10.6 Hz, 1 H), 2.19 (dd, J = 14.2, 10.0 Hz, 3H), 2.07-1.86 (m, 2H), 1.85-1 .48 (m, 5H), 1 .10 (d, J = 10.6 Hz, 2H). HPLC (max plot) 72.7%; Rt 1 .94 min. MS (ESI+): 515.3.
Example 416: Enantiomer A of 3-(morpholin-4-vlcarbonvl)-1 -M -(tetrahvdro-2H-pvran-4- vl)azepan-4-vH-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer A of 1 -azepan-4-yl-3-(morpholin-4- vlcarbonvD-1 ,4-dihydrothiochromenor4,3-c|pyrazole 5,5-dioxide to give 31 mg of the title compound as a red oil. 1 H NMR (DMSO-d6) δ 8.08 (d, J = 6.5 Hz, 1 H), 7.75-7.70 (m, 1 H), 7.57- 7.52 (m, 2H), 4.96-4.86 (m, 1 H), 4.59 (s, 2H), 4.14-3.93 (m, 4H), 3.72 (s, 6H), 3.36-3.27 (t, J = 7.5 Hz, 2H), 2.92-2.63 (m, 4H), 2.32-2.16 (m, 4H), 1 .73-1 .51 (m, 5H), 1 .87-.85 (m, 2H). HPLC (max plot) 97.8%; Rt 2.39 min. MS (ESI+): 515.4.
Example 417: Enantiomer B of 3-(morpholin-4-vlcarbonvl)-1 -M -(tetrahvdro-2H-pvran-4- vl)azepan-4-vH-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 1 -azepan-4-vl-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide to give 42.2 mg of the title compound as a red oil. 1H NMR (DMSO-de) δ 8.08 (d, J = 6.5 Hz, 1 H), 7.75-7.70 (m, 1 H), 7.57- 7.52 (m, 2H), 4.96-4.86 (m, 1 H), 4.59 (s, 2H), 4.14-3.93 (m, 4H), 3.72 (s, 6H), 3.36-3.27 (t, J = 7.5 Hz, 2H), 2.92-2.63 (m, 4H), 2.32-2.16 (m, 4H), 1 .73-1 .51 (m, 5H), 1 .87-.85 (m, 2H). HPLC (max plot) 97.8%; Rt 2.35 min. MS (ESI+): 515.4. MS (ESI+): 515.4.
Example 404: 6-Fluoro-3-(morpholin-4-vlcarbonvl)-1 -Γ1 -(tetrahvdrofuran-3- vlmethvl)piperidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide 33 mg of the title compound as a beige solid. 1H NMR (DMSO- d6, 300 MHz): δ 8.00-7.92 (m, 1 H), 7.65-7.55 (m, 2H), 4.90 (s, 2H), 4.71 (bs, 1 H), 3.91 (bs, 2H), 3.73-3.54 (m, 8H), 3.38-3.35 (m, 1 H), 3.18-3.09 (m, 1 H), 2.94-2.85 (m, 1 H), 2.42-1 .45 (m, 12H). MS (ESI+): 519.3. HPLC (max plot) 93.8%; Rt 1 .82 min
Example 280: 6-Fluoro-3-(morpholin-4-ylcarbonyl)-1 -{1 -f2-(tetrahydro-2H-pyran-4- yl)ethvnpiperidin-3-yl)-1 ,4-dihvdrothiochromenor4,3-c1pyrazole 5,5-dioxide
29.1 mg of the title compound as a white fluffy solid. 1H NMR (DMSO-de) δ 7.89-7.97 (m, 1 H), 7.54-7.63 (m, 2H), 4.88 (s, 2H), 4.71 (bs, 1 H), 3.90 (bs, 1 H), 3.76-3.80 (m, 3H), 3.64 (s, 5H), 3.19-3.27 (m, 2H), 3.06-3.09 (d, J = 9.0 Hz, 1 H), 2.85- 2.88 (d, J = 9.0 Hz, 1 H), 1 .09-2.37 (m, 16H). HPLC (max plot)
98.7%; Rt 2.05 min. MS (ESI+): 546.9.
Example 307: Enantiomer A of 3-(morpholin-4-ylcarbonyl)-1 -f1 -f2-(tetrahvdro-2H- PVran-4-yl)ethvnpiperidin-3-yl)-1 ,4-dihvdrothiochromenor4,3-c1pyrazole 5,5-dioxide hydrochloride salt
Obtained from enantiomer A of 3-(morpholin-4-ylcarbonyl)-1 - [piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5- dioxide to give 165 mg of the title compound as a white solid. 1 H NMR (DMSO-d6) δ 10.58 (s, 1 H), 8.06 (dd, J = 1 1.0, 4.4 HZ, 2H), 7.91 (dd, J = 1 1.5, 3.8 Hz, 1 H), 7.77 (t, J = 7.8 Hz, 1 H), 5.35 (s, 1 H), 4.80 (s, 2H), 3.94 - 3.51 (m, 10H), 3.51 -
3.37 (m, 1 H), 3.25 (m, 3H), 3.03 (s, 1 H), 2.10 (m, 4H), 1 .60 (m, 4H), 1 .17 (m, 2H). HPLC (max plot) 98.7%; Rt 2.31 min. MS (ESI+): 529.5. [a]25D +15.53 (c 1.25, EtOH).
Example 306: Enantiomer B of 3-(morpholin-4-ylcarbonyl)-1 -f1 -f2-(tetrahvdro-2H- PVran-4-yl)ethvnpiperidin-3-yl)-1 ,4-dihvdrothiochromenor4,3-c1pyrazole 5,5-dioxide hydrochloride salt
Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)-1 - [piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5- dioxide to give 142 mg of the title compound as a white solid. 1H NMR (DMSO-de) δ 10.58 (s, 1 H), 8.06 (dd, J = 1 1 .0, 4.4, 2H), 7.91 (dd, J = 1 1.5, 3.8, 1 H), 7.77 (t, J = 7.8, 1 H), 5.35 (s,
1 H), 4.80 (s, 2H), 3.94 - 3.51 (m, 10H), 3.51 - 3.37 (m, 1 H), 3.25 (m, 3H), 3.03 (s, 1 H), 2.10 (m, 4H), 1.60 (m, 4H), 1 .17 (m,
2H). HPLC (max plot) 99.1 %; Rt 2.30 min. MS (ESI+): 529.5. [a]25D -18.50 (c 1.23, EtOH).
Example 425: Enantiomer B of 6-Fluoro-3-(morpholin-4-ylcarbonyl)-1 -f1 -(tetrahvdro- 2H-pyran-3-yl)piperidin-3-vn-1 ,4-dihvdrothiochromenor4,3-c1pyrazole 5,5-dioxide
Obtained from enantiomer B of 6-fluoro-3-(morpholin-4- ylcarbonyl)-1 -[piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3- c]pyrazole 5,5-dioxide to give 156 mg of the title compound as a white solid. 1H NMR (DMSO-d6, 300 MHz): δ 8.00-7.93 (m, 1 H), 7.62-7.55 (m, 2H), 4.89 (s, 2H), 4.64 (m, 1 H), 3.91 -3.82 (m, 3H), 3.66 (s, 6H), 3.23-3.16 (m, 3H), 2.90-2.87 (m, 1 H),
2.66-2.56 (m, 1 H), 2.30-1.42 (m, 1 1 H). MS (ESI+): 519.4. HPLC (max plot) 95.9%; Rt 1.88 min
Example 427: Enantiomer B of 6-fluoro-3-(morpholin-4-ylcarbonyl)-1 -f1 -(tetrahvdro-2H- PVran-4-yl)piperidin-3-vn-1 ,4-dihvdrothiochromenor4,3-c1pyrazole 5,5-dioxide
Obtained from enantiomer B of 6-fluoro-3-(morpholin-4- ylcarbonyl)-1 -[piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3- c]pyrazole 5,5-dioxide to give 152 mg of the title compound as a white solid. 1H NMR (DMSO-d6, 300 MHz): δ 8.01 -7.93 (m, 1 H), 7.62-7.55 (m, 2H), 4.90 (s, 2H), 4.69 (m, 1 H), 3.91 -3.84 (m, 4H), 3.66 (s, 5H), 3.28-3.13 (m, 3H), 2.93-2.89 (m, 1 H),
2.56 (m, 2H), 2.22-1 .40 (m, 10H). MS (ESI+): 519.4. HPLC (max plot) 96.8%; Rt 1.79 min
Example 301 : 6-Chloro-3-(morpholin-4-ylcarbonyl)-1 -{1 -f2-(tetrahydro-2H-pyran-4- yl)ethvnpiperidin-3-yl)-1 ,4-dihvdrothiochromenor4,3-c1pyrazole 5,5-dioxide
83 mg of the title compound as a beige foam. 1H NMR (DMSO- d6) δ 7.82-7.87 (m, 1 H), 7.72-7.77 (m, 2H), 4.89 (s, 2H), 4.65 (bs, 1 H), 3.91 (m, 2H), 3.75-3.80 (m, 2H), 3.64 (m, 5H), 3.18- 3.29 (m, 2H), 3.04-3.06 (d, 1 H), 2.83-2.87 (m, 1 H), 1 .05-2.37 (m, 16H). HPLC (max plot) 99.6%; Rt 2.80 min. MS (ESI+):
563.3.
Example 389: Enantiomer B of 7-methoxy-3-(morpholin-4-ylcarbonyl)-1 -f1 -(tetrahydro- 2H-pyran-3-yl)piperidin-3-vn-1 ,4-dihvdrothiochromenor4,3-c1pyrazole 5,5-dioxide Obtained from enantiomer B of 7-methoxy-3-(morpholin-4- ylcarbonyl)-1 -[piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3- . ,p c]pyrazole 5,5-dioxide to give 1H NMR (DMSO-c/6, 300 MHz): δ
7.74 (d, J = 9.7 Hz, 1 H), 7.50 (t, J = 2.5 Hz, 2H), 4.76 (s, 2H), 4.70-4.58 (m, 1 H), 3.96-3.82 (m, 6H), 3.72-3.58 (m, 6H), 3.27- 3.08 (m, 3H), 2.88 (s, 1 H), 2.65-2.55 (m, 1 H), 2.55-2.45 (m, 2H), 2.27 (s, 1 H), 2.07 (s, 1 H), 2.02-1 .74 (m, 3H), 1 .71 -1.36 (m, 4H).. MS (ESI+): 531.3. HPLC (max plot) 98.6%; Rt 2.18 min
Example 395: Enantiomer B of 7-methoxv-3-(morpholin-4-vlcarbonvl)-1 -ri -
(tetrahvdrofuran-3-vlmethvl)piperidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole
5,5-dioxide
Obtained from enantiomer B of 7-methoxy-3-(morpholin-4- ylcarbonyl)-1 -[piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3- c]pyrazole 5,5-dioxide to give the title compound. 1H NMR (DMSO-d6, 300 MHz): δ 7.76 (dd, J = 8.8, 3.7 Hz, 1 H), 7.58- 7.42 (m, 2H), 4.78-4.65 (m, 3H), 3.95-3.88 (m, 4H), 3.79-3.48 (m, 7H), 3.44-3.33 (m, 2H), 3.24-3.05 (m, 1 H), 3.02-2.80 (m,
1 H), 2.46-2.24 (m, 3H), 2.17-2.05 (m, 1 H), 2.03-1 .37 (m, 6H). MS (ESI+): 531.4. HPLC (max plot) 64.2%; Rt 2.28 min.
Example 369: Enantiomer B of 7-methoxv-3-(morpholin-4-vlcarbonvl)-1 -f1 -r2-
(tetrahvdro-2H-pvran-4-vl)ethvllpiperidin-3-vl>-1 ,4-dihvdrothiochromenor4,3-clpvrazole
5,5-dioxide
Obtained from enantiomer B of 7-methoxy-3-(morpholin-4- ylcarbonyl)-1 -[piperidin-3-yl]-1 ,4-dihydrothiochromeno[4,3- c]pyrazole 5,5-dioxide to give 60 mg of the title compound as a q *o white foam. 1H NMR (DMSO-d6, 300 MHz): δ 7.77 (d, J = 8.8,
1 H), 7.50 (d, J = 2.7, 1 H), 7.45 (dd, J = 8.7, 2.8, 1 H), 4.74 (d, J ^N \ N-N _ = 10.0, 3H), 3.93 (m, 4H), 3.79 (m, 2H), 3.65 (m, 5H), 3.23 (dd,
J = 17.5, 6.1 , 2H), 3.10 (d, J = 9.4, 1 H), 2.88 (d, J = 10.7, 1 H), 2.35 (m, 3H), 2.10 (s, 1 H), 2.04-1 .61 (m, 4H), 1 .53 (m, 3H), 1 .35 (m, 2H), 1.21 -1 .04 (m, 2H). MS (ESI+): 559.33. HPLC (max plot) 99.8%; Rt 2.76 min
Example 408: 3-(Morpholin-4-vlcarbonvl)-1 -f 1 -r2-(tetrahvdro-2H-pvran-4- vl)ethvllpiperidin-3-vl}-1,4-dihvdropvrazolor3',4,:4,5lthiopvranor2,3-blpvridine 5,5- dioxide
100 mg of the title compound as a white solid.1H NMR
(DMSO-d6, 300 MHz): δ 9.00-8.65 (m, 1 H), 8.28 (d, J = 8.3 Hz, 1 H), 7.93 (dd, J = 8.2, 4.7 Hz, 1 H), 4.90 (s, 2H), 4.74 (s, 1 H), 3.97-3.86 (m, 2H), 3.84-3.73 (m, 2H), 3.72-3.57 (m, 6H), 3.31- 3.19 (m, 2H), 3.16-3.05 (m, 1H), 2.96-2.81 (m, 1H), 2.45-2.21 (m, 3H), 2.19-2.04 (m, 1H), 2.03-1.63 (m, 4H), 1.60-1.42 (m, 3H), 1.39-1.24 (m, 2H), 1.21-1.00 (m, 2H). MS (ESI+): 530.39. HPLC (max plot) 94.8%; Rt 1.60 min
Example 379: Enantiomer A of 3-(morpholin-4-vlcarbonvl)-1-M-(tetrahvdro-2H-pvran-3- vl)piperidin-3-vll-1,4-dihvdropvrazolor3',4,:4,5lthiopvranor2,3-blpvridine 5,5-dioxide
Obtained from enantiomer A of 3-(morpholin-4-ylcarbonyl)-1- [piperidin-3-yl]-1,4-dihydropyrazolo[3',4':4,5]thiopyrano[2,3- b]pyridine 5,5-dioxide to give 32 mg of the title compound as a o..0 white solid.1H NMR (DMSO-d6, 300 MHz): δ 8.84-8.73 (m, 1H),
8.28-8.16 (m, 1H), 8.00-7.91 (m, 1H), 4.90 (s, 2H), 4.74-4.57 (m, 1H), 3.98-3.77 (m, 3H), 3.77-3.54 (m, 7H), 3.26-3.04 (m, 3H), 2.96-2.81 (m, 1H), 2.68-2.52 (m, 1H), 2.37-2.18 (m, 1H), 2.18-2.03 (m, 1H), 2.00-1.73 (m, 3H), 1.73-1.55 (m, 2H), 1.55- 1.32 (m, 3H). MS (ESI+): 502.4. HPLC (max plot) 94.1%; Rt 5.98 min
Example 381: Enantiomer 3 of 3-(morpholin-4-vlcarbonvl)-1-ri-(tetrahvdro-2H-pvran-3- vl)piperidin-3-vll-1,4-dihvdropvrazolor3',4':4,5lthiopvranor2,3-blpvridine 5,5-dioxide
Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)-1- [piperidin-3-yl]-1,4-dihydropyrazolo[3',4':4,5]thiopyrano[2,3- b]pyridine 5,5-dioxide to give 32 mg of the title compound as a o..0 white solid.1H NMR (DMSO-d6, 300 MHz): δ 8.84-8.73 (m, 1H),
8.28-8.16 (m, 1H), 8.00-7.91 (m, 1H), 4.90 (s, 2H), 4.74-4.57 (m, 1H), 3.98-3.77 (m, 3H), 3.77-3.54 (m, 7H), 3.26-3.04 (m, 3H), 2.96-2.81 (m, 1H), 2.68-2.52 (m, 1H), 2.37-2.18 (m, 1H), 2.18-2.03 (m, 1H), 2.00-1.73 (m, 3H), 1.73-1.55 (m, 2H), 1.55- 1.32 (m, 3H). MS (ESI+): 502.4. HPLC (max plot) 94.1%; Rt 5.98 min. Example 371 : Enantiomer A of 3-(morpholin-4-vlcarbonvl)-1 -Γ1 -(tetrahvdro-2H-pvran-4- vlmethvl)piperidin-3-vll-1 ,4-dihvdropvrazolor3',4,:4,5lthiopvranor2,3-blpvridine 5,5- dioxide
Obtained from enantiomer A of 3-(morpholin-4-ylcarbonyl)-1 - [piperidin-S-yll-l ^-dihydropyrazolo^'^'^.Slthiopyranop.S- b]pyridine 5,5-dioxide to give 52 mg (84%) of the title compound as a white fluffy solid. 1H NMR (DMSO-c/6, 300 MHz): δ 8.84-8.78 (m, 1 H), 8.31 -8.23 (m, 1 H), 7.96-7.88 (m, 1 H), 4.90 (s, 2H), 4.83-4.67 (m, 1 H), 3.97-3.86 (m, 2H), 3.86- 3.74 (m, 2H), 3.74-3.57 (m, 6H), 3.29-3.16 (m, 2H), 3.16-3.04 (m, 1 H), 2.91 -2.77 (m, 1 H), 2.41 -2.27 (m, 1 H), 2.27-2.07 (m, 3H), 2.07-1 .87 (m, 2H), 1 .87-1 .47 (m, 5H), 1 .19-0.98 (m, 2H). MS (ESI+): 516.3. HPLC (max plot) 58.6%; Rt 1.58 min
Example 376: Enantiomer 3 of 3-(morpholin-4-vlcarbonvl)-1 -M -(tetrahvdro-2H-pvran-4- vlmethvl)piperidin-3-vll-1 ,4-dihvdropvrazolor3',4':4,5lthiopvranor2,3-blpvridine 5,5- dioxide
Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)-1 - [piperidin-S-y -l ^-dihydropyrazolo^'^'^.Slthiopyranop.S- b]pyridine 5,5-dioxide to give 36 mg of the title compound as a white powder. 1H NMR (DMSO-d6, 300 MHz): δ 8.84-8.78 (m, 1 H), 8.31 -8.23 (m, 1 H), 7.96-7.88 (m, 1 H), 4.90 (s, 2H), 4.83- 4.67 (m, 1 H), 3.97-3.86 (m, 2H), 3.86-3.74 (m, 2H), 3.74-3.57 (m, 6H), 3.29-3.16 (m, 2H), 3.16-3.04 (m, 1 H), 2.91 -2.77 (m, 1 H), 2.41 -2.27 (m, 1 H), 2.27-2.07 (m, 3H), 2.07-1 .87 (m, 2H), 1 .87-1 .47 (m, 5H), 1 .19-0.98 (m, 2H). MS (ESI+): 516.5. HPLC (max plot) 90.8%; Rt 6.29 min.
Procedure AW: Compounds below obtained by separation of racemic mixture by chiral chromatography following procedures outlined above. The chiral centers have been drawn arbitrarily up or dawn. Enantiomers have been named "enantiomer A" or "enantiomer B" arbitrarily.
Intermediate AW.1 : Enantiomer A of terf-butyl 3-f3-(morpholin-4-ylcarbonyl)-5,5- dioxidothiochromenof4,3-c1pyrazol-1 (4H)-vnpyrrolidine-1 -carboxylate (c 1 .2, MeOH)
Intermediate AW.6: Enantiomer B of 3-(morpholin-4-vlcarbonvl)-1 -rpiperidin-3-vll-1 ,4- dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
°s*° Purified on a Chiralcel OD-H to give 4.85 g (95%) of the title compound as a white solid. DPO00284N02. MS (ESI+): 417.2. HPLC (max plot) 97.6%; Rt 2.16 min. HPLC (chiralcel OD-H,
O- Γ NH
EtOH/0.1 % DEA, max plot): 99.40%; Rt 12.40 min
Intermediate AW.7: Enantiomer A of 6-fluoro-3-(morpholin-4-vlcarbonvl)-1 -rpiperidin-
3-vH-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Purified on a Chiralcel OD-H to give 1 .04 g (91 %) of the title compound as a white solid. DPO00283F01 . HPLC (chiralcel
O-/ Γ NH OD-H, MeOH/0.1 % DEA, max plot): 98.62%; Rt 1.38 min
Intermediate AW.8: Enantiomer B of 6-fluoro-3-(morpholin-4-vlcarbonvl)-1 -rpiperidin-
3-vH-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Purified on a Chiralcel OD-H to give 1 .03 g (90%) of the title compound as a white solid. DPO00283F02. HPLC (chiralcel
O-/ Γ NH OD-H, MeOH/0.1 % DEA, max plot): 100.0%; Rt 6.67 min
Intermediate AW.9: Enantiomer B of 6-methoxv -3-(morpholin-4-vlcarbonvl)-1 - rpiperidin-3-vH-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Purified on a Chiralcel OD-H to give 850 mg (80%) of the title compound as a white solid. HPLC (chiralcel OD-H, EtOH/0.1 % DEA, max plot): 97.36%; Rt 18.02 min (enantiomer A: Rt 5.41
0~s f NH min).
Intermediate AW.10: Enantiomer B of 7-fluoro-3-(morpholin-4-vlcarbonvl)-1 - rpiperidin-3-vH-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
o. P Purified on a Chiralcel OD-H to give 1 .20 g of the title fs YF compound as a white solid. HPLC (max plot) 96.5%; Rt 2.39 min. HPLC (chiralcel OD-H, EtOH/0.1 % TEA, max plot):
0-/ Γ NH
100.0%; Rt 17.51 min (enantiomer A: Rt 5.12 min)
Intermediate AW.11 : Enantiomer B of 7-methoxv-3-(morpholin-4-vlcarbonvl)-1 -
dioxidothiochromenor4,3-clpvrazol-1(4H)-vHazepane-1-carboxvlate
vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide Purified on a Chiralpak AY-H to give 153 mg (quant) of the title compound as a. 1H NMR (300 MHz, DMSO): δ 8.16-8.00 (m, 1 H), 7.99-7.89 (m, 1 H), 7.88-7.80 (m, 1 H), 7.80-7.63 (m, 1 H), 4.94-4.68 (m, 3H), 4.62 (t, J = 4.8 Hz, 1 H), 4.46 (t, J = 4.8 Hz, 1 H), 4.00-3.83 (m, 2H), 3.75-3.55 (m, 5H), 3.20 (d, J = 10.2 Hz, 1 H), 2.93 (d, J = 10.5 Hz, 1 H), 2.77 (t, J = 4.7 Hz, 1 H), 2.68 (t, J = 4.8 Hz, 1 H), 2.62-2.49 (m, 2H), 2.14 (d, J = 10.3 Hz, 2H), 2.03-1.52 (m, 3H). HPLC (max plot) 96.7%; Rt 2.26 min. . HPLC (chiralpack AY, 50% hexane/50% EtOH/0.1 % TEA, max plot): 96.28%; Rt 19.87 min (enantiomer A: Rt 14.79 min).
Example 409: Enantiomer A of 1 -f1 -r2-(4-fluoropiperidin-1 -vl)ethvllpvrrolidin-3-vl}-3-
(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Purified on a Chiralpak AD-H to give 18 mg of the title compound as a white powder. 1H NMR (DMSO-c/6, 300 MHz): δ 8.03 (dd, J = 7.8, 1 .2 Hz, 1 H), 7.97 (d, J = 7.7 Hz, 1 H), 7.93-7.85 (m, 1 H), 7.74 (dd, J = 10.9, 4.3 Hz, 1 H), 5.51 -5.40 (m, 1 H), 4.76 (s, 2H), 4.77-4.67 (m, 1 H), 4.62-4.52- (m, 1 H), 4.00-3.93 (m, 2H), 3.72-3.62 (m, 5H), 3.28 (dd, J = 9.6, 7.4 Hz, 1 H), 2.86 (dd, J = 9.7, 5.2 Hz, 1 H), 2.76 (t, J = 6.8 Hz, 2H), 2.60 (dd, J = 13.0, 6.4 Hz, 4H), 2.42 (t, J = 6.7 Hz, 3H), 2.34-2.17 (m, 3H), 1 .92-1.57 (m, 4H).. MS (ESI+): 532.4. HPLC (max plot) 100.0%; Rt 1 .80 min. HPLC (chiralpack AD- H, EtOH, max plot): 100.0%; Rt 8.01 min.
Example 410: Enantiomer B of 1 -f1 -r2-i4-fluoropiperidin-1 -vl)ethvllPvrrolidin-3-vl)-3-
(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Purified on a Chiralpak AD-H to give 18 mg of the title compound as a white powder. 1H NMR (DMSO-c/6, 300 MHz): δ 8.03 (dd, J = 7.8, 1 .2 Hz, 1 H), 7.97 (d, J = 7.7 Hz, 1 H), 7.93-7.85 (m, 1 H), 7.74 (dd, J = 10.9, 4.3 Hz, 1 H), 5.51 -5.40 (m, 1 H), 4.76 (s, 2H), 4.77-4.67 (m, 1 H), 4.62-4.52 (m, 1 H), 4.00-3.93 (m, 2H), 3.72-3.62 (m, 5H), 3.28 (dd, J = 9.6, 7.4 Hz, 1 H), 2.86 (dd, J = 9.7, 5.2 Hz, 1 H), 2.76 (t, J = 6.8 Hz, 2H), 2.60 (dd, J = 13.0, 6.4 Hz, 4H), 2.42 (t, J = 6.7 Hz, 3H), 2.34-2.17 (m, 3H), 1 .92-1.57 (m, 4H).. MS (ESI+): 532.4.
HPLC (max plot) 99.5%; Rt 2.1 1 min. HPLC (chiralpack AD- H, EtOH, max plot): 100.0%; Rt 13.27 min
Example 411 : Enantiomer A of 1 -f 1 -Γ2-(1 H-imidazol-1 -vDethvllpiperidin-3-vl}-3-
(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
o o Purified on a Chiralcel OD-H to give 8 mg of the title
compound as a white powder. MS (ESI+): 51 1 .31 . HPLC (max plot) 95.3%; Rt 1 .47 min. HPLC (chiralcel OD-H, EtOH, max plot): 100.0%; Rt 7.09 min
Example 412: Enantiomer B of 1 -ί1 -Γ2-(1 H-imidazol-1 -vl)ethvllpiperidin-3-vl)-3-
(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
o, o Purified on a Chiralcel OD-H to give 8 mg of the title
compound as a white powder. MS (ESI+): 51 1 .31 . HPLC (max plot) 94.4%; Rt 1 .46 min. HPLC (chiralcel OD-H, EtOH, max plot): 100.0%; Rt 10.21 min
Example 423: Enantiomer A of 3-(morpholin-4-vlcarbonvl)-1 -f1 -r2-(tetrahvdro-2H-
PVran-4-vl)ethvllpiperidin-3-vl}-1 ,4-dihvdropvrazolor3',4,:4,5lthiopvranor2,3- blpvridine 5,5-dioxide
Purified on a Chiralpak AY-H to give 21 mg of the title compound as a white solid. 1H NMR (DMSO-c/6, 300 MHz): δ 8.85-8.76 (m, 1 H), 8.34-8.22 (m, 1 H), 7.99-7.87 (m, 1 H), 4.90 (s, 2H), 4.82-4.67 (m, 1 H), 3.97-3.85 (m, 2H), 3.85-3.74 (m, 2H), 3.74-3.57 (m, 6H), 3.30-3.17 (m, 2H), 3.17-3.03 (m, 1 H), 2.95-2.77 (m, 1 H), 2.45-2.22 (m, 3H), 2.22-2.03 (m, 1 H), 2.03-1.83 (m, 2H), 1 .83-1.61 (m, 2H), 1 .61 -1 .40 (m, 3H), 1 .40-1 .26 (m, 2H), 1 .21 -1.00 (m, 2H). MS (ESI+): 530.5. HPLC (max plot) 91 .9%; Rt 6.16 min. HPLC (chiralpak AY-H, 60% EtOH/40% isOH, max plot): 100.0%; Rt 18.17 min
Example 422: Enantiomer B of 3-(morpholin-4-vlcarbonvl)-1 -f1 -r2-(tetrahvdro-2H-
PVran-4-vl)ethvllpiperidin-3-vl}-1 ,4-dihvdropvrazolor3',4,:4,5lthiopvranor2,3- blpvridine 5,5-dioxide Purified on a Chiralpak AY-H to give 30 mg of the title
compound as a white solid. 1H NMR (DMSO-c/6, 300 MHz): δ 8.85-8.76 (m, 1 H), 8.34-8.22 (m, 1 H), 7.99-7.87 (m, 1 H), 4.90 (s, 2H), 4.82-4.67 (m, 1 H), 3.97-3.85 (m, 2H), 3.85-3.74 (m, 2H), 3.74-3.57 (m, 6H), 3.30-3.17 (m, 2H), 3.17-3.03 (m, 1 H),
C] N-N. _ 2.95-2.77 (m, 1 H), 2.45-2.22 (m, 3H), 2.22-2.03 (m, 1 H), o-y CN' 2.03-1.83 (m, 2H), 1 .83-1.61 (m, 2H), 1 .61 -1 .40 (m, 3H),
1 .40-1 .26 (m, 2H), 1 .21 -1.00 (m, 2H). MS (ESI+): 530.5. HPLC (max plot) 93.2%; Rt 6.15 min. HPLC (chiralpak AY-H, 60% EtOH/40% isOH, max plot): 100.0%; Rt 27.10 min
Example 347: Enantiomer A of 1-ri-(2-methoxvethvl)piperidin-3-vll-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Purified on a Chiralpak AY-H to give 240 mg of the title compound as a pale yellow solid. 1H NMR (DMSO-c/6, 300 MHz): δ 8.05 (dd, J = 1.2, 7.8 Hz, 1 H), 7.99-7.89 (m, 1 H), 7.87-7.80 (m, 1 H), 7.79-7.71 (m, 1 H), 4.95-4.67 (m, 3H), 4.04- 3.85 (m, 2H), 3.75-3.58 (m, 6H), 3.44 (t, J = 5.6 Hz, 2H), 3.27- 3.1 1 (m, 4H), 2.90 (d, J = 12.0 Hz, 1 H), 2.64-2.53 (m, 2H),
2.47-2.36 (m, 1 H), 2.20-1.61 (m, 6H). MS (ESI+): 475.37. HPLC (max plot) 96.7%; Rt 1 .79 min. HPLC (Chiralpak AY-H, MeOH/01 %DEA, max plot): 100.0%; Rt 8.19 min.
Example 346: Enantiomer B of 1-ri-(2-methoxvethvl)piperidin-3-vll-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Purified on a Chiralpak AY-H to give 220 mg of the title compound as a pale yellow solid. 1H NMR (DMSO-c/6, 300 MHz): δ 8.05 (dd, J = 1.2, 7.8 Hz, 1 H), 7.98-7.89 (m, 1 H), 7.87-7.80 (m, 1 H), 7.79-7.70 (m, 1 H), 4.91 -4.66 (m, 3H), 4.01 - 3.85 (m, 2H), 3.74-3.55 (m, 5H), 3.44 (t, J = 5.6 Hz, 2H), 3.25- 3.15 (m, 4H), 2.90 (d, J = 10.7 Hz, 1 H), 2.66-2.53 (m, 2H),
2.47-2.36 (m, 1 H), 2.25-1.61 (m, 6H). MS (ESI+): 475.33. HPLC (max plot) 96.6%; Rt 1 .76 min. HPLC (Chiralpak AY-H, MeOH/01 %DEA, max plot): 100.0%; Rt 14.03 min
Example 464: Enantiomer B of 1 -i1-r2-(3,3-difluoroazetidin-1 -vl)ethvHpiperidin-3-vD-
6-fluoro-3-(morpholin-4-vlcarbonvl)-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-
Procedure AX
Example 418: Enantiomer B of 1 -f1 -(3-furoyl)piperidin-3-vn-3-(morpholin-4-ylcarbonyl)- 1 ,4-dihvdrothiochromenor4,3-c1pyrazole 5,5-dioxide
To a solution of Enantiomer B of 3-(morpholin-4-ylcarbonyl)-1 -[piperidin-3-yl]-1 ,4- dihydrothiochromeno [4,3-c]pyrazole 5,5-dioxide (30 mg; 0.07 mmol; 1 eq.) in DCM (0.45 mL) is added N, /V-diiso propylethylamine (25 μΙ; 0.14 mmol; 2 eq.) followed by 3-furoyl chloride (14 mg; 0.1 1 mmol; 1.5 eq.) and the reaction mixture is stirred at rt overnight. The solvent is concentrated and the residue is purified by flash chromatography (eluent
MeOH/EtOAc 0 to 10%) to afford 20 mg (54%) of the title compound as a white foam. 1 H NMR (DMSO-d6): δ 8.04 (d, J = 7.7 Hz, 2H), 7.86 (s, 1 H), 7.75 (d, J = 7.8 Hz, 2H), 6.67 (s, 1 H), 4.85 (s, 1 H), 4.79 (s, 2H), 3.91 (s, 2H), 3.64 (d, J = 9.7 Hz, 5H), 2.26 (s, 2H), 1.95-1 .61 (m, 2H). HPLC (max plot) 99.4%; Rt 3.02 min. MS (ESI+): 51 1 .30.
Compounds described below are obtained following protocol outlined in procedure
AX
Example 61 : 3-(Morpholin-4-ylcarbonyl)-1 -f3-(morpholin-4-ylcarbonyl)phenvn-1 ,4- dihvdrothiochromenor4,3-clpyrazole 5,5-dioxide
dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide 40 mg of the title compound as a white foam. 1H NMR
°¾"° (DMSO-de) δ 8.05 (m, 1 H), 7.99-7.86 (m, 2H), 7.75 (m, 1 H),
5.68-5.55 (m, 1 H), 4.80 (m, 2H), 3.96-3.82 (m, 3H), 3.73-3.50 (m, 8H), 2.64-2.40 (m, 2H), 2.19-2.08 (m, 2H), 1 .77-1 .55 (m,
0 6H), 1 .28-1 .05 (m, 2H), 1 .03-0.82 (m, 2H). HPLC (max plot)
99.6%; Rt 3.49 min. MS (ESI+): 527.4.
Example 287: 3-(Morpholin-4-vlcarbonvl)-1 -Γ1 -(tetrahvdro-2H-pvran-4-vlacetvl)
PVrrolidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
35 mg (83%) of the title compound as a white foam. 1 H NMR (DMSO-d6): δ 8.05 (d, J = 7.6 Hz, 1 H), 7.93 (q, J = 8.1 Hz, 2H), 7.75 (t, J = 7.2 Hz, 1 H), 5.61 (s, 1 H), 4.88-4.71 (m, 2H), 4.10-3.97 (m, 1 H), 3.85 (dd, J = 18.3, 14.1 Hz, 5H), 3.59 (d, J = 34.1 Hz, 7H), 3.30-3.19 (m, 2H), 2.36-2.14 (m, 2H), 1 .89 (s,
0
1 H), 1 .58 (s, 2H), 1.19 (dd, J = 16.0, 8.9 Hz, 3H). HPLC (max plot) 100%; Rt 2.49 min. MS (ESI+): 528.8.
Example 419: Enantiomer B of 3-(morpholin-4-vlcarbonvl)-1 -M -(tetrahvdro-2H-pvran-4- vlcarbonvl) piperidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)-1 - [piperidin-3-yl]-1 ,4-dihydropyrazolo[3',4':4,5]thiopyrano[2,3- b]pyridine 5,5-dioxide to give 27 mg (71 %) of the title compound as a white foam. 1 H NMR (DMSO-d6) δ : 8.13-7.82 (m, 3H), 7.75 (d, J = 7.7 Hz, 1 H), 4.72 (d, J = 4.3 Hz, 4H), 4.29-3.54 (m, 12H), 3.39 (s, 2H), 3.24-2.59 (m, 5H), 2.24 (s, 2H), 1 .62 (t, J =
7.1 Hz, 7H). HPLC (max plot) 99.6%; Rt 2.73 min. MS (ESI+): 529.30.
Example 420: Enantiomer B of 3-(morpholin-4-vlcarbonvl)-1 -M -(tetrahvdro-2H-pvran-4- vlacetvl) piperidin-3-vll-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)-1 - [piperidin-3-yl]-1 ,4-dihydropyrazolo[3',4':4,5]thiopyrano[2,3- b]pyridine 5,5-dioxide to give 35 mg (90%) of the title compound as a white foam. 1 H NMR (DMSO-d6) δ 8.13-7.81 (m, 3H), 7.74 (t, J = 7.6 Hz, 1 H), 4.99-4.54 (m, 4H), 4.27-4.07 (m, 1 H), 3.98-
3.77 (m, 4H), 3.74-3.55 (m, 7H), 3.30-2.93 (m, 3H), 2.40-2.05 (m, 4H), 1.91 -1 .42 (m, 5H), 1 .32-0.97 (m, 2H). HPLC (max plot) 98.4%; Rt 4.08 min. MS (ESI+): 543.30.
Example 421 : Enantiomer B of 1 -ri -(cvclohexvlacetvl)piperidin-3-vH-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)-1 - [piperidin-3-yl]-1 ,4-dihydropyrazolo[3\4^4,5]thiopyrano[2,3- b]pyridine 5,5-dioxide to give 38 mg (98%) of the title compound as a white foam. 1 H NMR (300 MHz, DMSO-d6) δ 8.05-7.80 (m, 3H), 7.74 (t, J = 7.7 Hz, 1 H), 4.97-4.51 (m, 4H), 4.25-3.88 (m, 4H), 3.72-3.60 (m, 5H), 3.23-2.96 (m, 2H), 2.38-2.00 (m, 4H), 1 .92-1 .77 (m, 1 H), 1 .77-1 .44 (m, 6H), 1 .25-0.75 (m, 6H). HPLC (max plot) 98.4%; Rt 4.08 min. MS (ESI+): 441 .
Example 447: Enantiomer B of 1 -ri -(methoxvacetvl)piperidin-3-vll-3-(morpholin-4- vlcarbonvD-1 ,4-dihvdrothiochromenor4,3-clpvrazole 5,5-dioxide
°¾"° Obtained from enantiomer B of 3-(morpholin-4-ylcarbonyl)-1 - [piperidin-3-yl]-1 ,4-dihydropyrazolo[3',4':4,5]thiopyrano[2,3- b]pyridine 5,5-dioxide to give 30 mg (82%) of the title compound as a white foam. MS (ESI+): 489.4. HPLC (max plot) 100.0%; Rt o s 2.90 min
Example 276: A/-Cvclohexyl-3-f3-(morpholin-4-ylcarbonyl)-5,5-
To a solution of 3-(morpholin-4-ylcarbonyl)-1 -pyrrolidin-3-yl-1 ,4-dihydrothiochromeno[4,3- c]pyrazole 5,5-dioxide hydrochloride (50 mg; 0.1 1 mmol; 1 eq.) and Λ/,/V-diisopropyl ethylamine (21 .59 μΙ; 0.13 mmol; 1.10 eq.) in DCM (0.5 ml) is added cyclohexyl isocyanate (15.68 mg; 0.13 mmol; 1.1 eq.) and the reaction mixture is stirred at rt for 20 min.
Aminomethyl resin is added and the reaction mixture is stirred at rt overnignt. The resin is filtered off and the solvent removed under reduced pressure. The crude residue is purified by flash chromatography (eluting from 0 to 10% EtOAc in MeOH) to afford after concentration of the desired fractions 45 mg (75%) of the title compound as a white solid. HPLC (max plot) 99.7%; Rt 3.68 min. MS (ESI+): 528.3. Example 189: 3-(Morpholin-4-ylcarbonyl)-1 -r3-(1 ,3-thiazol-2-yl)phenvn-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
1 -(3-bromophenyl)-3-(morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5- dioxide (100 mg, 0.20 mmol, 1 eq.) is taken in THF in and bubbled with nitrogen for 5 minutes. To this are added thiazolyl zinc bromide (2 ml_), tetrakis(triphenyl
phosphine)palladium(O) (12 mg, 0.010 mmol, 0.05 eq.) and the reaction mixture is heated under sealed condition at 65°C for 4 h. The reaction mixture is filtered through a celite pad, concentrated under reduced pressure and purified by flash chromatography to afford the title compound as a pink solid. 1H NMR (DMSO-d6, 400 MHz): δ 8.18-8.16 (d, J = 7.7 Hz, 1 H), 8.07 (s, 1 H), 8.04-8.02 (d, J = 7.7 Hz, 1 H), 7.96-7.95 (d, J = 3.2 Hz, 1 H), 7.87-7.86 (d , J = 3.2 Hz, 1 H), 7.76-7.72 (t, J = 7.9 Hz, 1 H), 7.65-7.56 (m, 3H), 6.98-6.96 (d, J = 7.7 Hz, 1 H), 4.91 (s, 2H), 3.93 (m, 2H), 3.67 (m, 4H), 3.62-3.61 (m, 2H). MS (ESI+): 493.0. HPLC (max plot) 98.44%; Rt 4.02 min.
Example 199: 1 -f3-(5-Ethyl-1 ,2,4-oxadiazol-3-yl)phenvn-3-(morpholin-4-ylcarbonyl)-1 ,4- dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
To a solution of /V'-hydroxy-3-[3-(morpholin-4-ylcarbonyl)-5,5-dioxidothiochromeno[4,3- c]pyrazol-1 (4H)-yl]benzenecarboximidamide (150 mg, 0.32 mmol) in dry EtOAc is added propionic acid (13 μΙ_, 0.32 mmol) under nitrogen followed by TEA (0.13 ml_, 0.963 mmol) and propane phosphonic acid cyclic anhydride (0.51 ml_, 0.80 mmol) at 0°C under nitrogen. The reaction mixture is heated to 80°C for 12 h under nitrogen and concentrated under vacuum. Solid residue is purified by silica gel column chromatography (1 .2% MeOH in DCM) to afford the title compound as an off white solid. 1H NMR (DMSO-c/6, 400 MHz): δ 8.24-8.22 (d, J = 7.4 Hz, 1 H), 8.05-8.02 (m, 2H), 7.81 -7.77 (m, 2H),7.64 (m, 1 H), 7.57 (m, 1 H), 6.93- 6.91 (d, J = 7.9 Hz, 1 H), 4.91 (s, 2H), 3.92-3.90 (m, 2H), 3.67 (m, 4H), 3.61 -3.60 (m, 2H), 3.02-3.0 (m, 2H), 1.33-1 .29 (t, J = 7.6 Hz, 3H). MS (ESI+): 506.0. HPLC (max plot) 97.13%; Rt 4.34 min.
Example 200: 1 -r3-(5-Methyl-1 H-1 ,2,4-triazol-3-yl)phenvn-3-(morpholin-4-ylcarbonyl)-
1 ,4-dihydrothiochromenor4,3-c1pyrazole 5,5-dioxide
To a solution of 3-[3-(morpholin-4-ylcarbonyl)-5,5-dioxidothiochromeno[4,3-c]pyrazol-1 (4/-/)- yl]benzonitrile (100 mg, 0.23 mmol) in dry toluene is added acetic azide (34 mg, 0.46 mmol) and K2C03 (158 mg, 0.1 15 mmol) under nitrogen. The reaction mixture is heated to 1 10°C for 12 h under nitrogen after which it is concentrated under vacuum. The solid residue is purified by Preparative HPLC to afford the title compound as an off white solid. 1H NMR (DMSO-d6, 400 MHz): δ 8.21 -8.19 (d, J = 7.7 Hz, 1 H), 8.03-7.98 (m, 2H), 7.73-7.69 (m, 1 H), 7.64-7.56 (m, 3H), 6.92-6.90 (d, J = 7.8 Hz, 1 H), 4.91 (s, 2H), 3.93 (m, 2H),3.75-3.67 (m, 4H), 3.62-3.61 (m, 2H), 2.37 (s, 3H). MS (ESI+): 491 .0. HPLC (max plot) 98.76%; Rt 2.96 mm. Example 238: 1 -f4-(Morpholin-4-ylmethyl)phenvn-1 ,4-dihydrothiochromenof4,3- clpyrazole-3-carboxylic acid 5,5-dioxide
To a suspension of 1 -[4-(hydroxymethyl)phenyl]-1 ,4-dihydrothiochromeno[4,3-c]pyrazole-3- carboxylic acid 5,5-dioxide (30 mg; 0.08 mmol; 1 eq.) in DCE (2 ml) at 0°C is added thionyl chloride (15 μΙ; 0.2 mmol; 2.5 eq.). The reaction mixture is stirred for 15 min, the solvent is removed then a solution of morpholine (300 μΙ; 10 V) in DCE (2 mL) is added. After overnight stirring, the solvent is removed and the crude residue is purified by Autoprep to afford the title compound as a white fluffy solid. 1H NMR (DMSO-d6) δ 8.02 (dd, J = 1 .3, 7.7 Hz, 1 H), 7.69- 7.41 (m, 5H), 6.93-6.72 (m, 1 H), 4.97 (s, 2H), 3.76-3.53 (m, 5H), 3.32-3.30 (m, 2H), 2.46- 2.32 (m, 3H). HPLC (max plot) 91 .4%; Rt 2.26 min. MS (ESI+): 439.98.
Example 212: A/-Methyl-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4- dihvdrothiochromenof4,3-c1pyrazol-6-amine 5 5-dioxide
To a solution of /V-methyl-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4-dihydrothiochromeno[4,3- c]pyrazol-6-amine (90 mg, 0.22 mmol) in THF: H20 (1 :1 , 10 mL) is added oxone (545 mg, 0.88 mmol) and the reaction mixture is stirred at RT for 3 h. After this time, EtOAc is added to the reaction mixture that is washed with water. The organic layer is separated, dried over
Na2S04, concentrated under reduced pressure. The solid residue is purified by silica gel flash chromatography (40% EtOAc in pet. ether) the title compound as a white solid. 1H NMR (DMSO-d6, 400 MHz): δ 7.59-7.56 (m, 3H), 7.47-7.44 (m, 2H), 7.26-7.22 (t, J = 8.1 Hz,1 H), 6.80-6.74 (m, 2H), 5.98-5.96 (d, J = 7.6 Hz,1 H), 4.87 (s, 2H), 3.95-3.94 (m, 2H), 3.65 (m, 4H), 3.61 -3.59 (m, 2H), 2.83-2.82 (d, J = 4.7 Hz, 3H). MS (ESI+): 439.0. HPLC (max plot) 95.63%; Rt 4.39 min.
Example 440: Enantiomer B of 1 -(2-f3-f3-(morpholin-4-ylcarbonyl)-5,5- dioxidothiochromenof4,3-c1pyrazol-1 (4H)-vnpiperidin-1 -yl)ethyl)pyrrolidin-2-one
A solution of 2-pyrrolidone (35 mg; 0.42 mmol; 2 eq.) with NaH (10 mg; 0.42 mmol; 2 eq.) in ACN at 0°C is added to a solution of enantiomer B of 1 -[1 -(2-chloroethyl)piperidin-3-yl]-3- (morpholin-4-ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide (100 mg; 0.21 mmol; 1 eq.) and Nal (31 mg; 0.21 mmol; 1 eq.) in ACN (2 mL). Reaction mixture is heated to 60°C for 18h after which DCM is added and organic phase is washed with water and brine. It is dried over MgS04 then purified by MD-Autoprep to give 1 1 mg (9%) of the title compound as a white solid. 1H NMR (DMSO-d6, 300 MHz): δ 8.05 (d, J = 7.7 Hz, 1 H), 8.00-7.82 (m, 2H), 7.81 -7.67 (m, 1 H), 4.89-4.64 (m, 3H), 4.00-3.83 (m, 2H), 3.83-3.56 (m, 8H), 3.22-3.12 (m, 1 H), 2.99-2.82 (m, 1 H), 2.67-2.34 (m, 4H), 2.29-2.15 (m, 2H), 2.15-1.54 (m, 8H). MS (ESI+): 528.5. HPLC (max plot) 97.6%; Rt 1 .86 min.
Example 454: Enantiomer B of 1 -(1 -f2-f(1 -methylpiperidin-4-yl)oxy1ethyl)piperidin-3-yl)- 3-(morpholin-4-ylcarbonyl)-1 ,4-dihvdrothiochromenof4,3-c1pyrazole 5,5-dioxide
A solution of enantiomer B of 1 -[1 -(2-chloroethyl)piperidin-3-yl]-3-(morpholin-4-ylcarbonyl)- 1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide (100 mg; 0.21 mmol; 1 eq.) and NaH (18 mg; 0.42 mmol; 2 eq.) in acetonitril (2 mL) at 0°C is added to a solution of 1 -methyl-4- piperidinol (49 μΙ; 0.42 mmol; 2 eq.) and Nal (31 mg; 0.21 mmol; 1 eq.) in ACN (2 mL) .
Reaction mixture is heated to 60°C for 18h after which DCM is added and organic phase is washed with water and brine. It is dried over MgS04 then purified by MD-Autoprep to give the title compound as a yellow oil. 1H NMR (DMSO-d6, 300 MHz): δ 8.06 (d, J = 7.9 Hz, 1 H), 7.98-7.87 (m, 1 H), 7.86-7.70 (m, 2H), 4.87-4.70 (m, 3H), 3.97-3.84 (m, 2H), 3.84-3.76 (m, 1 H), 3.76-3.56 (m, 6H), 3.55-3.47 (m, 2H), 3.37-3.16 (m, 3H), 3.15-2.93 (m, 4H), 2.91 -2.70 (m, 3H), 2.63-2.54 (m, 1 H), 2.30-1.59 (m, 10H). MS (ESI+): 558.3. HPLC (max plot) 75.1 %; Rt 1.74 min
Example 452: Enantiomer B of 2-f3-f3-(morpholin-4-ylcarbonyl)-5,5- dioxidothiochromenof4,3-c1pyrazol-1 (4H)-vnpiperidin-1 -yl)ethanamine
To a solution of enantiomer B of 1 -[1 -(2-chloroethyl)piperidin-3-yl]-3-(morpholin-4- ylcarbonyl)-1 ,4-dihydrothiochromeno[4,3-c]pyrazole 5,5-dioxide (90 mg; 0.19 mmol; 1 .00 eq.) in CH3CN (0.90 ml) is added aq ammonia (181 .88 μΙ; 2.82 mmol; 15.00 eq.) and the reaction is stirred at 135°C for 15 min under microwave irradiation which after purification by MD-
Autoprep affords the title compound as a white solid. 1H NMR (DMSO-c/6, 300 MHz): δ 8.05 (d, J = 7.8 Hz, 1 H), 7.96 (t, J = 7.1 Hz, 1 H), 7.87 (d, J = 7.6 Hz, 1 H), 7.75 (t, J = 7.4 Hz, 1 H), 4.79 (q, J = 16.2 Hz, 3H), 3.90 (s, 2H), 3.66 (s, 6H), 3.15 (d, J = 9.7 Hz, 2H), 2.90 (q, J = 13.0 Hz, 3H), 2.73-2.53 (m, 2H), 2.27-2.02 (m, 2H), 2.00-1 .59 (m, 3H). MS (ESI+): 460.3. HPLC (max plot) 55.4%; Rt 2.09 min. Procedure AY
Example 487: 4-(Methoxymethyl)-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4- dihydropyrazolor4,3-ciri ,21benzothiazine 5,5-dioxide
A mixture of 2-bromo-/V-(methoxymethyl)-/V-[3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 H-pyrazol- 4-yl]benzenesulfonamide (240 mg; 0.45 mmol; 1.00 eq.), palladium acetate (20 mg; 0.09 mmol; 0.20 eq.), triphenylphosphine (94 mg; 0.36 mmol; 0.80 eq.) and Cs2C03 (584 mg; 1.79 mmol; 4.00 eq.) is flushed with N2 for 10 minutes. Toluene (50 mL) is added and the resulting mixture is stirred at reflux for 2 hours.After this time, reaction mixture is filtered through a short plug of celite, ished with ethyl acetate. Combined organic phase are ished with NaHC03 then brine, dried over sodium sulfate and concentrated in vacuo and purified by flash chromatography to give the title compound as a white solid. 1H NMR (300 MHz, DMSO- d6): δ 8.03 (dd, J = 1 .3, 7.5 Hz, 1 H), 7.88-7.46 (m, 7H), 7.04-6.94 (m, 1 H), 5.15 (s, 2H), 3.69 (s, 6H), 3.64-3.54 (m, 2H), 2.89 (s, 3H). HPLC (max plot) 83.4%; Rt 3.71 min. MS (ESI+) 423.2.
Example 488: 4-Methyl-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4-dihvdropyrazolof4,3- ciri,21benzothiazine 5,5-dioxide
Following protocol outlined in procedure AY, 4-methyl-3-(morpholin-4-ylcarbonyl)-1 -phenyl- 1 ,4-dihydropyrazolo[4,3-c][1 ,2]benzothiazine 5,5-dioxide is obtained from 2-bromo-/V-methyl- /V-[3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 /-/-pyrazol-4-yl]benzenesulfonamide to give 4 mg (19%) of the title compound as a white solid. 1 H NMR (300 MHz, DMSO-d6): δ 8.04-7.98 (m, 1 H), 7.76-7.55 (m, 7H), 7.00-6.92 (m, 1 H), 3.80-3.66 (m, 6H), 3.66-3.57 (m, 2H), 3.16 (s, 3H), HPLC (max plot) 100.0%; Rt 3.45 min. MS (ESI+) 425.3.
Example 489: 3-(Morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4-dihvdropyrazolof4,3- ciri,21benzothiazine 5,5-dioxide
To a solution of 4-(methoxymethyl)-3-(morpholin-4-ylcarbonyl)-1 -phenyl-1 ,4- dihydropyrazolo[4,3-c][1 ,2]benzothiazine 5,5-dioxide (85 mg; 0.19 mmol; 1.00 eq.) in 1 ,4- dioxane (3 mL) is added HCI (0.75 ml_; 1 M; 0.75 mmol; 4.00 eq.) after which reaction mixture is stirred at 100°C for 90 min under microwave irradiation (*2). DCM is added to the reaction mixture that is neutralized to pH 6 with NaHC03, extracted with DCM, dried over MgS04 and purified by MD-Autoprep to give 8 mg (10%) of the title compound as an off white solid. 1 H NMR (300 MHz, DMSO-d6): δ 10.94 (s, 1 H), 8.00-7.91 (m, 1 H), 7.71 -7.50 (m, 7H), 6.99-6.86 (m, 1 H), 3.83-3.55 (m, 8H). HPLC (max plot) 97.4%; Rt 3.27 min. MS (ESI+) 41 1 .2.
Example 486: 3-(Morpholin-4-ylcarbonyl)-1 -phenyl-4H- imidazo Γ5, 1 -cl Π , 41
benzothiazine 5,5-dioxide
Following protocol outlines in procedure Q 3-(Morpholin-4-ylcarbonyl)-1 -phenyl-4/-/- imidazo [5, 1 -c] [1 , 4] benzothiazine 5,5-dioxide is obtained from 3-(morpholin-4-ylcarbonyl)-1 -phenyl- 4H- imidazo [5, 1 -c] [1 , 4] benzothiazine to give 16 mg (73%) of the title compound. 1 H NMR (DMSO-d6, 400 MHz) δ 8.04-8.02 (m,1 H),7.61 -7.58 (m, 2H),7.55-7.52 (m, 3H),7.50-7.43 (m, 2H), 6.99-6.97 (m, 1 H), 5.24 (s, 2H), 4.15 (m, 2H), 3.63 (m, 6H). MS (ESI+): 410.0, HPLC (max plot) 94.7%; Rt 3.73 min.
Example 600: Biological assays Pi3K alpha
The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid
phosphorylation may be tested in the following binding assay. The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125l, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin. To a 384 wells MTP containing 5 μΙ of the test compound of Formula (I) (solubilized in 2% DMSO; to yield a final concentration of 20, 5, 1 .25, 0.3125, 0.0781 , 0.0195, 0.0049, 0.0012, 0.0003 and 0.00075 μΜ of the test compound), the following assay components are added: 1 ) 5 μΙ_ of lipid micelles 2) 5 μΙ_ of Kinase buffer ([33Ρ]γΑΤΡ 30 μΜ/200 nCi, MgCI2 10 mM, DTT 1 mM, Na3V04 100 μΜ, Cholic acid sodium salt 0.1 %, beta Glycerophosphate 1 mM in Hepes 40 mM, pH 7.4) and 3) 5 μΙ_ (30ng) of Human recombinant GST-PI3K (in Hepes 40mM, pH 7.4). After incubation at 30°C for 120 minutes, with gentle agitation, the reaction is stopped by addition of 60 μΙ_ of a solution containing 75 μg of neomycin-coated PVT SPA beads, ATP 5 mM and EDTA 5 mM in PBS. The assay is further incubated 30°C for 60 minutes with gentle agitation to allow binding of phospholipids to neomycin-SPA beads. After precipitation of the neomycin-coated PVT SPA beads for 5 hours, radioactive Ptdlns(3)P is quantified by scintillation counting in a Wallac MicroBeta™ plate counter.
Pi3K beta
The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid
phosphorylation may be tested in the following binding assay. The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125l, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin. To a 384 wells MTP containing 5 μΙ of the test compound of Formula (I) (solubilized in 2% DMSO; to yield a final concentration of 20, 5, 1 .25, 0.3125, 0.0781 , 0.0195, 0.0049, 0.0012, 0.0003 and 0.00075 μΜ of the test compound), the following assay components are added: 1 ) 5 μΙ_ of lipid micelles 2) 5 μΙ_ of Kinase buffer ([33Ρ]γΑΤΡ 70 μΜ/300 nCi, MgCI24 mM, DTT 1 mM, Na3V04 0.1 μΜ, Cholic acid sodium salt 0.2% in Hepes 40 mM, pH 7.4) and 3) 5 μΙ_ (12ng) of Human recombinant GST-PI3K (in Hepes 40mM, pH 7.4). After incubation at 30°C for 120 minutes, with gentle agitation, the reaction is stopped by addition of 60 μΙ_ of a solution containing 75 μg of neomycin-coated PVT SPA beads, ATP 5 mM and EDTA 5 mM in PBS. The assay is further incubated at 30°C for 60 minutes with gentle agitation to allow binding of phospholipids to neomycin-SPA beads. After precipitation of the neomycin-coated PVT SPA beads for 5 hours, radioactive Ptdlns(3)P is quantified by scintillation counting in a Wallac MicroBeta™ plate counter.
Pi3K delta
The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid
phosphorylation may be tested in the following binding assay. The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125l, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin. To a 384 wells MTP containing 5 μΙ of the test compound of Formula (I) (solubilized in 2% DMSO; to yield a final concentration of 20, 5, 1 .25, 0.3125, 0.0781 , 0.0195, 0.0049, 0.0012, 0.0003 and 0.00075 μΜ of the test compound), the following assay components are added: 1 ) 5 μΙ_ of lipid micelles 2) 5 μΙ_ of Kinase buffer ([33Ρ]γΑΤΡ260 μΜ/300 nCi, MgCI24 mM, DTT 4 mM, Na3V04 0.4 μΜ in Hepes 40 mM, pH 7.4) and 3) 5 μΙ_ (50ng) of Human recombinant GST-PI3K (in Hepes 40mM, pH 7.4). After incubation at room temperature for 120 minutes, with gentle agitation, the reaction is stopped by addition of 60 μΙ_ of a solution containing 75 μg of neomycin-coated PVT SPA beads, ATP 6.5 mM and EDTA 6.5 mM in PBS. The assay is further incubated at room temperature for 60 minutes with gentle agitation to allow binding of phospholipids to neomycin-SPA beads. After precipitation of the neomycin-coated PVT SPA beads for 5 hours, radioactive Ptdlns(3)P is quantified by scintillation counting in a Wallac MicroBeta™ plate counter.
Pi3K gamma The efficacy of compounds of the invention in inhibiting the PI3K induced-lipid phosphorylation may be tested in the following binding assay. The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125l, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin. To a 384 wells MTP containing 5 μΙ of the test compound of Formula (I) (solubilized in 2% DMSO; to yield a final concentration of 20, 5, 1 .25, 0.3125, 0.0781 , 0.0195, 0.0049, 0.0012, 0.0003 and 0.00075 μΜ of the test compound), the following assay components are added: 1 ) 5 μΙ_ of lipid micelles 2) 5 μΙ_ of Kinase buffer ([33Ρ]γΑΤΡ 30 μΜ/200 nCi, MgCI2 10 mM, DTT 1 mM, Na3V04 100 μΜ, Cholic acid sodium salt 0.1 %, beta Glycerophosphate 1 mM in Hepes 40 mM, pH 7.4) and 3) 5 μΙ_ (30ng) of Human recombinant GST-PI3K (in Hepes
40mM, pH 7.4). After incubation at 30°C for 120 minutes, with gentle agitation, the reaction is stopped by addition of 60 μΙ_ of a solution containing 75 μg of neomycin-coated PVT SPA beads, ATP 5 mM and EDTA 5 mM in PBS. The assay is further incubated 30°C for 60 minutes with gentle agitation to allow binding of phospholipids to neomycin-SPA beads. After precipitation of the neomycin-coated PVT SPA beads for 5 hours, radioactive Ptdlns(3)P is quantified by scintillation counting in a Wallac MicroBeta™ plate counter.
The values indicated in Table I below refer to the best IC50 (μΜ) obtained with the four above described isoforms of PI3K, i.e. the amount necessary to achieve 50% inhibition of said target.
Example 512: Mechanistic-on target cell assay
The cellular activity of the examples was measured by Flow Cytometry assay format using a Ramos B-lymphocyte cell line (ATCC #CRL-1923). These cells were incubated overnight in 5% serum and next day serum-starved to reduce background of AKT phosphorylation, pre- incubated with test compounds for 20 min and then stimulated with anti-human IGM antibody (JacksonlmmunoResearch # 109 006 129) (10ug/ml final) for 15 minutes. The reaction was stopped by fixing the cells with Paraformaldehyde 4% (final) for 10 minutes at room temperature. Cells were washed once with Phosphate Buffer Saline (PBS), permabilized in PBS-Triton X-100 0.2% for 15 minutes at room temperature washed twice with PBS and once with PBS-4% serum. The cells were incubated anti p-AKT (Ser 473) (Cell Signalling #4058L) (1 /70 dilution) in PBS-4% serum for one hour at room temperature. After two washes in PBS-4% serum, cells were stained with a mixture of Mouse anti-human IgM -APC (BD Pharmingen # 551062) (1 :50), anti rabbit IgG-Alexa 488 (Invitrogen Ref. A-45558A) (1 :200) and Goat IgG (5mg/ml, 10 mg) (Zymed #02-6202) (1 :200) for 30 minutes at 4°C. Cells were washed twice in PBS and resuspended in PBS. The cell suspension was passed on a FC500 flow cytometer (Beckman Coulter), gating on the I GM positive cells and measuring the AKT phosphorylation.
Examples of inhibitory activities for compounds according to the invention are set out in Table I below.
Table I
Example 511 : Preparation of a pharmaceutical formulation
Formulation 1 - Tablets
A compound of formula (I) is admixed as a dry powder with a dry gelatin binder in an approximate 1 :2 weight ratio. A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into 240-270 mg tablets (80-90 mg of active compound according to the invention per tablet) in a tablet press.
Formulation 2 - Capsules
A compound of formula (I) is admixed as a dry powder with a starch diluent in an
approximate 1 :1 weight ratio. The mixture is filled into 250 mg capsules (125 mg of active compound according to the invention per capsule).
Formulation 3 - Liquid
A compound of formula (I) (1250 mg), sucrose (1.75 g) and xanthan gum (4 mg) are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously prepared solution of microcrystalline cellulose and sodium carboxymethyl cellulose (1 1 :89, 50 mg) in water. Sodium benzoate (10 mg), flavor, and color are diluted with water and added with stirring. Sufficient water is then added to produce a total volume of 5 ml_.
Formulation 4 - Tablets A compound of formula (I) is admixed as a dry powder with a dry gelatin binder in an approximate 1 :2 weight ratio. A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into 450-900 mg tablets (150-300 mg of active compound according to the invention) in a tablet press.
Formulation 5 - Injection
A compound of formula (I) is dissolved in a buffered sterile saline injectable aqueous medium to a concentration of approximately 5 mg/mL.

Claims

Claims:
1 . A compound of Formula ( ):
(I*) wherein
Xi denotes a nitrogen atom or CR3,
X2, X5 are independently from one another nitrogen or carbon atoms,
U denotes an aromatic 6-membered ring having optionally 1 , 2 or 3 nitrogen atoms, including X5, or an unsaturated or aromatic 5-membered ring having 1 to 3 heteroatoms selected from N, S or O, including the meaning of X5,
Z denotes an unsaturated or aromatic 5-membered heterocyclic ring having 2 nitrogen atoms, including the meaning of X2.
T denotes S, SO or S02,
R1 denotes H, A, Hal, CN, N02, N(R6)2, OR6, Ar, Het, Y, -NR6COR6, CON(R6)2, - NR6COAr, NR6COHet, COHet, -NR6S02R6, C02R6, including C02Y,
R2 denotes H, Ar, Het, A, Cyc,
R3 denotes H, Y,
R4 denotes H, Y, (CH2)nAr, (CH2)nCyc, (CH2)nHet, (CH2)nOY, (CH2)nNHY,
(CH2)nNH2, or if is CR3, also Hal,
R5 denotes H, Y or Ar, when R5 is Y and r is 2, two R5 groups may be linked together to provide with the morpholine group to which they are linked, a bridged system.
R6 is H, A, Cyc or Ar.
u is 0, 1 , 2, 3, or 4,
r is 0, 1 or 2, is 1 or 2, denotes a monocyclic or fused bicyclic, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF3, N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, -C02R6, CON(R6)2, COHet, -NHCOR6, -NHS02A, -NHS02Ar, - NHS02-N(R6)2, N(H)1-qAqCOR6, N(H)1-qAqS02-N(H)2-m(A)m, -N(H)1-qAqCON(H)2. m(A)m, -S02A, -S02Ar, -S02N(H)2-m(A)m, -S02Het, -(CH2)n-N(R6)2, -(CH2)n- OR6, -(CH2)n-N(R6)S02A, -(CH2)n-N(R6)S02R6, Het2, -(CH2)n-Het2, -(CHY)n- Het2; denotes a monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 , 2, 3 or 4 N, O and/or S atoms and eventually comprising a S02 or a CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF3, N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, -C02R6, CON(R6)2, -NHCOR6, -NHS02A, -NHS02R6, -NHS02- N(H)2-m(A)m, N(H)1-qAqCOR6, N(H)1-qAqS02-N(H)2-m(A)m, -N(H)1-qAqCON(H)2- m(A)m, -S02A, -S02Ar, -S02N(H)2-m(A)m, COHet, -S02Het, -(CH2)n-N(H)2-m(A)m, -(CH2)n-OR6, -(CH2)n-N(R6)S02A, -(CH2)n-N(R6)S02R6, Het2, -(CH2)n-Het2; - (CHY)n-Het2;
denotes a saturated or unsaturated carbocyclic ring having 3 to 8 carbon atoms, which is unsubstituted, mono-substituted, di-substituted or tri- substituted by Hal, OCF3, N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, CON(R6)2, -NHCOR6, -NHS02A, -NHS02R6, -NHS02-N(H)2-m(A)m, N(H)1- qAqCOR6, N(H)1-qAqS02-N(H)2-m(A)m, -N(H)1-qAqCON(H)2-m(A)m, -COOR6, - S02A, -S02Ar, -S02N(H)2-m(A)m, -S02Het, -(CH2)p-N(H)2-m(A)m, -(CH2)n-OR6, - (CH2)n-N(R6)S02A, -(CH2)n-N(R6)S02R6, Het2, -(CH2)n-Het2; -(CHY)n-Het2; is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by Hal, Ar, Het, Cyc, OR6, -CN, - C02Y, C02H or N(R6)2 and wherein one or more, preferably 1 to 7 non- adjacent CH2-groups may be replaced by O, NR6, CO, CONR6, NR6CO, OCO, - and/or by -CH=CH- or -C=C- groups, or denotes cycloalkyl or
cycloalkylalkylen having 3-7 ring C atoms;
Y denotes a branched or linear alkyl having 1 to 8 carbon atoms. denotes F, CI, Br or I, is 0 or 1 , is 0, 1 or 2, n is 1 , 2, 3, or 4 and pharmaceutically acceptable derivatives, solvates, tautomers, salts, hydrates and stereoisomers thereof, including mixtures thereof in all ratios,
with the proviso that compound of formula (B1 ) is excluded:
2. A compound of Formula ( ) according to claim 1 wherein the moiety
in Formula (I*) is selected from the following groups:
Wherein R1, R2, R3, R4, T, are as defined above.
And wherein
U1, U2, U3, and U4 denote CR1 or one or two of U1, U2, U3 and U4 are independently N, and the remaining are CR1, or one of U1 and U4 is S, U2-U3 form together a group CR1 and the remaining is CR1, or one of U1 and U4 is S, U2-U3 form together a group CR1 and the remaining is N, or denotes the following group
wherein U1 denotes N, U2-U3 form together a group CR1, U4 is CR1, X5 is N, and Z, X1, X2, R2, T, are as above defined.
3. A compound of Formula ( ) according to claims 1 or 2 wherein R2 is selected from H, a branched or linear CrC6-alkyl or one of the following groups:
513
514
516
517
518
519
520
521
522
523
4. A compound of Formula ( ) according to claim 1 wherein the compound is of Formula (I):
(I)
R2 denotes H, Ar, Het, A, Cyc,
R3, R4 denote independantly from one another H, Y, (CH2)nAr, (CH2)nCyc, (CH2)nHet R5 denotes H, Y or Ar,
U1, U2, U3, and U4 denote CR1 or one or two of U1, U2, U3 and U4 are independently N, and the remaining are CR1
R1 denotes H, A, Hal, CN, N02, N(R6)2, OR6, Ar, Het, Y, -NR6COR6, CON(R6)2
T denotes S, - SO or S02.
r denotes 0, 1 or 2, denotes a monocyclic or fused bicyclic, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF3, N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, -C02R6, CON(R6)2, COHet, -NHCOR6, -NHS02A, -NHS02Ar, - NHS02-N(R6)2, N(H)1-qAqCOR6, N(H)1-qAqS02-N(H)2-m(A)m, -N(H)1-qAqCON(H)2 m(A)m, -S02A, -S02Ar, -S02N(H)2-m(A)m, -S02Het, -(CH2)n-N(R6)2, -(CH2)n- OR6, -(CH2)n-N(R6)S02A, -(CH2)n-N(R6)S02R6, Het2, -(CH2)n-Het2; -(CHY)n- Het2:
Het denotes a monocyclic or bicyclic saturated, unsaturated or aromatic
heterocyclic ring having 1 , 2, 3 or 4 N, O and/or S atoms which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF3,
N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, -C02R6, CON(R6)2, -NHCOR6, -NHS02A, -NHS02R6, -NHS02-N(H)2-m(A)m, N(H)1-qAqCOR6, N(H)1-qAqS02- N(H)2-m(A)m, -N(H)1-qAqCON(H)2-m(A)m, -S02A, -S02Ar, -S02N(H)2-m(A)m, COHet, -S02Het, -(CH2)n-N(H)2-m(A)m, -(CH2)n-OR6, -(CH2)n-N(R6)S02A, - (CH2)n-N(R6)S02R6, Het2, -(CH2)n-Het2; -(CHY)n-Het2;
Cyc denotes a saturated carbocyclic ring having 1 to 8 carbon atoms, which is unsubstituted, mono-substituted, di-substituted or tri-substituted by Hal, OCF3, N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, CON(R6)2, -NHCOR6, - NHS02A, -NHS02R6, -NHS02-N(H)2-m(A)m, N(H)1-qAqCOR6, N(H)1-qAqS02- N(H)2-m(A)m, -N(H)1-qAqCON(H)2-m(A)m, -COOR6, -S02A, -S02Ar, -S02N(H)2- m(A)m, -S02Het, -(CH2)p-N(H)2-m(A)m, -(CH2)n-OR6, -(CH2)n-N(R6)S02A, -(CH2)n- N(R6)S02R6. Het2, -(CH2)n-Het2; -(CHY)n-Het2;
A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by Hal, Ar, Het, Cyc, OR6, -CN, - C02Y or N(R6)2 and wherein one or more, preferably 1 to 7 non-adjacent CH2- groups may be replaced by O, NR6, CONR6- and/or by -CH=CH- or -C≡C- groups, or denotes cycloalkyl or cycloalkylalkylen having 3-7 ring C atoms;
Y denotes a branched or linear alkyl having 1 to 8 carbon atoms.
R6 is H, A, Cyc, or Ar.
Hal denotes F, CI, Br or I, q is O or l , m is 0, 1 or 2, n is 1 , 2, 3, or 4 and pharmaceutically acceptable derivatives, solvates, tautomers, salts, hydrates and stereoisomers thereof, including mixtures thereof in all ratios,
with the proviso that compound of formula (B1 ) is excluded:
A compound of Formula ( ) according to claim 1 wherein the compounds is selected from the following group:
528
6. A compound of Formula ( ):
(I*) wherein
Xi denotes a nitrogen atom or CR3,
X2, X5 are independently from one another nitrogen or carbon atoms, U denotes an aromatic 6-membered ring having optionally 1 , 2 or 3 nitrogen atoms, including X5, or an unsaturated or aromatic 5-membered ring having 1 to 3 heteroatoms selected from N, S or O, including the meaning of X5,
Z denotes an unsaturated or aromatic 5-membered heterocyclic ring having 2 nitrogen atoms, including the meaning of X2.
T denotes S, SO or S02,
R1 denotes H, A, Hal, CN, N02, N(R6)2, OR6, Ar, Het, Y, -NR6COR6, CON(R6)2, - NR6COAr, NR6COHet, COHet, -NR6S02R6, C02R6, including C02Y,
R2 denotes H, Ar, Het, A, Cyc,
R3 denotes H, Y,
R4 denotes H, Y, (CH2)nAr, (CH2)nCyc, (CH2)nHet, (CH2)nOY, (CH2)nNHY,
(CH2)nNH2, or if X, is CR3, also Hal,
R5 denotes H, Y or Ar, when R5 is Y and r is 2, two R5 groups may be linked
together to provide with the morpholine group to which they are linked, a bridged system.
R6 is H, A, Cyc or Ar.
u is 0, 1 , 2, 3, or 4,
r is 0, 1 or 2,
g is 1 or 2,
Ar denotes a monocyclic or fused bicyclic, unsaturated or aromatic carbocyclic ring having 6 to 14 carbon atoms, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF3, N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, -C02R6, CON(R6)2, COHet, -NHCOR6, -NHS02A, -NHS02Ar, - NHS02-N(R6)2, N(H)1-qAqCOR6, N(H)1-qAqS02-N(H)2-m(A)m, -N(H)1-qAqCON(H)2- m(A)m, -S02A, -S02Ar, -S02N(H)2-m(A)m, -S02Het, -(CH2)n-N(R6)2, -(CH2)n- OR6, -(CH2)n-N(R6)S02A, -(CH2)n-N(R6)S02R6, Het2, -(CH2)n-Het2, -(CHY)n- Het2; denotes a monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 , 2, 3 or 4 N, O and/or S atoms and eventually comprising a S02 or a CO group, which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, OCF3, N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, -C02R6, CON(R6)2, -NHCOR6, -NHS02A, -NHS02R6, -NHS02- N(H)2-m(A)m, N(H)1-qAqCOR6, N(H)1-qAqS02-N(H)2-m(A)m, -N(H)1-qAqCON(H)2- m(A)m, -S02A, -S02Ar, -S02N(H)2-m(A)m, COHet, -S02Het, -(CH2)n-N(H)2-m(A), -(CH2)n-OR6, -(CH2)n-N(R6)S02A, -(CH2)n-N(R6)S02R6, Het2, -(CH2)n-Het2; - (CHY)n-Het2;
Cyc denotes a saturated or unsaturated carbocyclic ring having 3 to 8 carbon atoms, which is unsubstituted, mono-substituted, di-substituted or tri- substituted by Hal, OCF3, N02, CN, perfluoroalkyl, A, OR6, N(R6)2, COR6, CON(R6)2, -NHCOR6, -NHS02A, -NHS02R6, -NHS02-N(H)2-m(A)m, N(H)1- qAqCOR6, N(H)1-qAqS02-N(H)2-m(A)m, -N(H)1-qAqCON(H)2-m(A)m, -COOR6, - S02A, -S02Ar, -S02N(H)2-m(A)m, -S02Het, -(CH2)p-N(H)2-m(A)m, -(CH2)n-OR6, - (CH2)n-N(R6)S02A, -(CH2)n-N(R6)S02R6, Het2, -(CH2)n-Het2; -(CHY)n-Het2;
A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by Hal, Ar, Het, Cyc, OR6, -CN, - C02Y, C02H or N(R6)2 and wherein one or more, preferably 1 to 7 non- adjacent CH2-groups may be replaced by O, NR6, CO, CONR6, NR6CO, OCO, - and/or by -CH=CH- or -C≡C- groups, or denotes cycloalkyl or
cycloalkylalkylen having 3-7 ring C atoms;
Y denotes a branched or linear alkyl having 1 to 8 carbon atoms.
Hal denotes F, CI, Br or I, q is 0 or 1 , m is 0, 1 or 2, n is 1 , 2, 3, or 4 and pharmaceutically acceptable derivatives, solvates, tautomers, salts, hydrates and stereoisomers thereof, including mixtures thereof in all ratios, for use as a
medicament.
7. A compound of Formula ( ) according to claim 1 for the prevention and/or treatment of the diseases associated to Phosphoinositide 3-kinases disorders.
8. A compound according to claim 7 wherein the disease is inflammatory disease, autoimmune disorder, cancer or multiple sclerosis and related disorders.
9. A compound according to claim 8 wherein the autoimmune disease is selected from the group consisting of Asthma, Rheumatoid arthritis, Acute disseminated
encephalomyelitis (ADEM), Addison's disease, Alopecia areata, Ankylosing spondylitis, Antiphospholipid antibody syndrome (APS), Autoimmune hemolytic anemia, Autoimmune hepatitis, Autoimmune inner ear disease, Bullous pemphigoid, Behget's disease, Coeliac disease, Anti-transglutaminase, Chagas disease, Chronic obstructive pulmonary disease, Crohns Disease, Dermatomyositis, Diabetes mellitus type 1 , Endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome (GBS), Hashimoto's disease, Hidradenitis suppurativa, Kawasaki disease, IgA nephropathy, Idiopathic thrombocytopenic purpura, Interstitial cystitis, Lupus erythematosus, Mixed Connective Tissue Disease, Morphea, Multiple sclerosis (MS), Myasthenia gravis, Narcolepsy, Neuromyotonia, Pemphigus vulgaris, Pernicious anaemia, Psoriasis, Psoriatic Arthritis, Polymyositis, Primary biliary cirrhosis, Rheumatoid arthritis, Schizophrenia, Scleroderma, Sjogren's syndrome, Stiff person syndrome, Temporal arteritis, Ulcerative Colitis, Vasculitis, Vitiligo, Wegener's granulomatosis
10. A kit consisting of separate packs of :
(a) an effective amount of a compound of the formula ( ) and/or pharmaceutically usable derivatives, solvates, salts, hydrates and stereoisomers thereof, including mixtures thereof in all ratios, and
(b) an effective amount of a further medicament active ingredient.
1 1 . A Pharmaceutical compositions containing at least one of the compounds of Formula ( ) according to any one of claims 1 to 5.
12. A pharmaceutical composition according to claim 1 1 wherein compounds of formula ( ) are combined with at least one further medicament used in the treatment of inflammatory diseases or immune disorders.
13. A pharmaceutical composition according to claim 12 wherein compounds of Formula ( ) are combined with at least one further immunomodulating agents.
14. A process for producing compounds of Formula ( ) according to claims 1 to 5,
comprising the reaction of a compound of Formula (Ι ) wherein X-i , X2, X5, R1, R2, R4, T, U, Z and u are as d
With compound D*:
Wherein R5, g and r are as defined in claim 1 .
15. A process for producing compounds of Formula (I*) according to claims 1 to 5, wherein compounds of Formula ( ) wherein T is S is oxydised to compounds of Formula ( ) wherein T is S02.
EP10775841.9A 2009-11-13 2010-11-12 Tricyclic pyrazol amine derivatives Active EP2499146B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10775841.9A EP2499146B1 (en) 2009-11-13 2010-11-12 Tricyclic pyrazol amine derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09175933 2009-11-13
US26185409P 2009-11-17 2009-11-17
PCT/EP2010/067412 WO2011058149A1 (en) 2009-11-13 2010-11-12 Tricyclic pyrazol amine derivatives
EP10775841.9A EP2499146B1 (en) 2009-11-13 2010-11-12 Tricyclic pyrazol amine derivatives

Publications (2)

Publication Number Publication Date
EP2499146A1 true EP2499146A1 (en) 2012-09-19
EP2499146B1 EP2499146B1 (en) 2016-09-21

Family

ID=41796476

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10775841.9A Active EP2499146B1 (en) 2009-11-13 2010-11-12 Tricyclic pyrazol amine derivatives

Country Status (14)

Country Link
US (1) US9073940B2 (en)
EP (1) EP2499146B1 (en)
JP (1) JP5735526B2 (en)
KR (1) KR20130049766A (en)
CN (1) CN102695710B (en)
AR (1) AR078979A1 (en)
AU (1) AU2010317883B2 (en)
CA (1) CA2778174C (en)
EA (1) EA201290305A1 (en)
ES (1) ES2607952T3 (en)
IL (1) IL219602A (en)
MX (1) MX2012005518A (en)
WO (1) WO2011058149A1 (en)
ZA (1) ZA201202641B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9044451B2 (en) 2010-07-19 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of delta tocopherol for the treatment of lysosomal storage disorders
DE102011055815A1 (en) 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamide-substituted heteroaryl-pyrazoles and their use
EP2790705B1 (en) 2011-12-15 2017-12-06 Novartis AG Use of inhibitors of the activity or function of pi3k
DE102012016908A1 (en) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris (hetero) aryl-pyrazoles and their use
EP2920161B1 (en) 2012-11-16 2019-08-14 THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Tocopherol and tocopheryl quinone derivatives as correctors of lysosomal storage disorders
WO2014121901A1 (en) 2013-02-07 2014-08-14 Merck Patent Gmbh Polymorphic forms
ES2849434T3 (en) * 2013-06-24 2021-08-18 Merck Patent Gmbh Pyrazole compounds as modulators of FRSH and uses thereof
WO2015196335A1 (en) * 2014-06-23 2015-12-30 Tocopherx, Inc. Pyrazole compounds as modulators of fshr and uses thereof
EP3341376B1 (en) 2015-08-26 2020-12-23 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Condensed tricyclic compounds as protein kinase inhibitors
TW201837036A (en) 2017-01-10 2018-10-16 德商拜耳廠股份有限公司 Heterocycle derivatives as pesticides
AR113206A1 (en) 2017-01-10 2020-02-19 Bayer Cropscience Ag HETEROCYCLIC DERIVATIVES AS PESTICIDES
CN108434150B (en) * 2018-02-09 2020-03-10 天津医科大学总医院 Application of ZSTK474 in preparing medicine for treating EAN
EP3608326A1 (en) * 2018-08-10 2020-02-12 Irbm S.P.A. Tricyclic inhibitors of hepatitis b virus
CN113754678B (en) * 2020-06-02 2023-03-10 江苏恒瑞医药股份有限公司 Dihydrothiochromene pyrazole derivative, preparation method and medical application thereof
CN113754685B (en) * 2020-06-02 2023-06-16 江苏恒瑞医药股份有限公司 Dihydrothiochromene pyrazole derivative, preparation method and application thereof in medicine
CN116033828A (en) 2020-07-02 2023-04-28 拜耳公司 Heterocyclic derivatives as pest control agents
CN115835863A (en) * 2020-07-09 2023-03-21 江苏恒瑞医药股份有限公司 Oxaazabicyclic derivatives, preparation method and application thereof in medicines
US20230234962A1 (en) 2020-07-29 2023-07-27 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Oxa-azaspiro derivative, and preparation method therefor and pharmaceutical use thereof
JP2024518685A (en) 2021-03-29 2024-05-02 アイオンクチュラ・ソシエテ・アノニム PI3K-DELTA INHIBITORS FOR USE IN TREATMENT REGIMENS - Patent application
AU2022250707A1 (en) 2021-03-29 2023-10-12 Ionctura Sa A pi3k-delta inhibitor for the treatment of pancreatic cancer
GB202117511D0 (en) * 2021-12-03 2022-01-19 Ionctura Sa Treatment regimens
CN114524827B (en) * 2022-02-22 2024-07-09 深圳市儿童医院 Pyrazole derivative for treating severe neurosis and application thereof
CN114524828B (en) * 2022-02-22 2024-07-09 深圳市儿童医院 Thiazole derivative for treating severe neurosis and application thereof
CN115491252B (en) * 2022-09-29 2023-05-02 江苏四新界面剂科技有限公司 Low-foam wetting agent for precious stone cutting and preparation method thereof
WO2024184266A1 (en) 2023-03-03 2024-09-12 Ionctura Sa Combination of roginolisib and hdac inhibitor in the treatment of haematological malignancy
WO2024184233A1 (en) 2023-03-03 2024-09-12 Ionctura Sa Combination of roginolisib and bcl-2 inhibitor in the treatment of haematological malignancy
GB202308807D0 (en) 2023-06-13 2023-07-26 Ionctura Sa Combinations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816467A (en) 1987-01-09 1989-03-28 Farmitalia Carlo Erba S.R.L Heteroaryl 3-oxo-propanenitrile derivatives, pharmaceutical compositions and use
GB8814586D0 (en) * 1988-06-20 1988-07-27 Erba Carlo Spa Tricyclic 3-oxo-propanenitrile derivatives & process for their preparation
GB8907799D0 (en) * 1989-04-06 1989-05-17 Erba Carlo Spa Heteroaryl-3-oxo-propanenitrile derivatives useful in the treatment of rheumatoid arthritis and other autoimmune diseases
GB8916290D0 (en) * 1989-07-17 1989-08-31 Erba Carlo Spa Heteroaryl-3-oxo-propanenitrile derivatives useful in stimulating myelopoiesis
JP3542826B2 (en) 1994-07-11 2004-07-14 帝国臓器製薬株式会社 Novel bicyclic compound fused [2,1-d] isoxazole-3-carboxylic acid derivative
GB9720901D0 (en) * 1997-10-01 1997-12-03 Pharmacia & Upjohn Spa Condensed benzothiopyranic compounds
FR2800375B1 (en) * 1999-11-03 2004-07-23 Sanofi Synthelabo TRICYCLIC DERIVATIVES OF PYRAZOLECARBOXYLIC ACID, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
CA2493843C (en) 2002-07-10 2012-04-17 Applied Research Systems Ars Holding N.V. Azolidinone-vinyl fused-benzene derivatives
EP1581529A1 (en) 2002-12-20 2005-10-05 Warner-Lambert Company Benzoxazines and derivatives thereof as inhibitors of pi3ks
GB0305152D0 (en) 2003-03-06 2003-04-09 Novartis Ag Organic compounds
GB0320197D0 (en) 2003-08-28 2003-10-01 Novartis Ag Organic compounds
BRPI0516557A (en) 2004-10-07 2008-09-09 Boehringer Ingelheim Int pi3 kinases
CA2633500A1 (en) 2005-12-20 2007-07-05 President And Fellows Of Harvard College Compounds, screens, and methods of treatment
WO2008035356A2 (en) 2006-09-20 2008-03-27 Glenmark Pharmaceuticals Limited Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
WO2009010824A1 (en) * 2007-07-13 2009-01-22 Glenmark Pharmaceuticals, S.A. Dihydrochromenopyrazole derivatives as vanilloid receptor ligands
WO2009071895A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
AR071112A1 (en) * 2008-03-31 2010-05-26 Genentech Inc INHIBITORS OF BENZOPIRANO AND BENZOXEPINA QUINASASPI3K INHIBITORS, USEFUL AS ANTI-AGENT AGENTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011058149A1 *

Also Published As

Publication number Publication date
JP5735526B2 (en) 2015-06-17
ES2607952T3 (en) 2017-04-04
AR078979A1 (en) 2011-12-14
EP2499146B1 (en) 2016-09-21
ZA201202641B (en) 2013-06-26
US9073940B2 (en) 2015-07-07
WO2011058149A1 (en) 2011-05-19
KR20130049766A (en) 2013-05-14
JP2013510825A (en) 2013-03-28
MX2012005518A (en) 2012-06-19
EA201290305A1 (en) 2012-12-28
IL219602A (en) 2017-04-30
CN102695710A (en) 2012-09-26
US20120238545A1 (en) 2012-09-20
CA2778174A1 (en) 2011-05-19
CN102695710B (en) 2015-08-19
AU2010317883B2 (en) 2015-08-06
CA2778174C (en) 2018-02-20
AU2010317883A1 (en) 2012-05-03
IL219602A0 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
EP2499146B1 (en) Tricyclic pyrazol amine derivatives
US9073892B2 (en) Indazolyl triazol derivatives
EP2440554B1 (en) Pyrazole oxadiazole derivatives as s1p1 agonists
US20110257170A1 (en) 4-morpholino-pyrido[3,2-d]pyrimidines
HUE029559T2 (en) Pyrimidine pyrazolyl derivatives
HUE028723T2 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
WO2020116662A1 (en) Cycloalkane-1,3-diamine derivative
ES2861382T3 (en) Pyrazolopyrimidine derivatives as CaM kinase inhibitors
EP2396322B9 (en) 2-Morpholino-pyrido[3,2-d]pyrimidines
TW202204342A (en) N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120605

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160114

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160506

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 830970

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161015

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010036607

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

Ref country code: NL

Ref legal event code: MP

Effective date: 20160921

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161221

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 830970

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160921

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161130

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170123

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161221

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170121

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010036607

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

26N No opposition filed

Effective date: 20170622

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161130

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20101112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161112

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160921

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230602

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240919

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240909

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240925

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20241010

Year of fee payment: 15

Ref country code: ES

Payment date: 20241204

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20241201

Year of fee payment: 15